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Abstract
This thesis covers work investigating the design, synthesis and evaluation of Combretastatin 
A-4 like chalcones and their analogues, and other anticancer agents.
The first two chapters are an introduction to cancer chemotherapy and the development of 
tubulin as a target for chemotherapy. Chapter one includes information on cancer 
epidemiology, the history of cancer and the development of important cancer chemotherapy 
agents. While the second chapter describes the role of tubulin in mitosis, and the 
development of anticancer agents that target tubulin.
The third chapter describes the background to the chalcone project, as well as the design and 
synthesis of new Combretastatin A-4 like chalcones and their analogues. To further the 
investigation of the substitution of the a-hydrogen of the chalcone with various groups, a 
series of a-arylchalcones was synthesized. The substitution of a-hydrogen with various aryl 
groups generally shows a significant increase in the anticancer activity of the chalcone. The 
effect of the conformation of the chalcone on its anticancer activity was also investigated by 
synthesizing two series of chalcone analogues which mimic the s-trans arrangement of 
chalcone, the indanones and indenones. Several of the indanones and indenones showed high 
levels of cytotoxicity with the CA-4 like indenone having an IC5o(K562) value of 0.019 pM.
MeO
MeO
OH
OMe
Chapter four looks at other chalcones with anticancer activity including the naturally 
occurring chalcone 4-hydroxyderricin, which has been isolated from the roots of Angelica 
keiskei and has shown to have anti-tumour promoting properties. As part of my PhD study the 
natural product 4-hydroxyderricin and a series of analogues was synthesized to investigate its 
anticancer activity.
In chapter five I synthesized the anticancer agent K.NK437 which has been shown to be a 
dose dependant inhibitor of the acquisition of thermotolerance in several different tumours. 
The study found that KNK437 sensitizes human leukaemia cells to the 17-allylamino- 
demethoxy geldanamycin induced apoptosis.
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Numbering System
a-ArylchalconeChalcone
5 '  5 ’
Dibenzylideneacetone
H02c .  2
Acrylic acid
5 4 -
Indanone/Indenone Flavanone
Benzylidene lactam Benzylidene rhodanine
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Abbreviations and
A
Ac
AcOH
AD
AKR
aq
Ar
BC
Bn
bp
br.
ca.
Celite
CIP
CML
-icm
8 (delta) 
d
dba
DBU
DCM
dd
ddt
DHFR
dm
DMBA
DMF
DMSO
DNA
dq
dt
eg-
ELISA
Glossary
Angstrom 
Acetyl 
Acetic acid
Anno domini (Latin: "in the year of our Lord")
Aldo keto reductase
Aqueous
Aryl
Before Christ 
Benzyl 
Boiling point 
Broad
Circa (Latin: “about”)
High-grade diatomaceous earth used as a filter aid 
Cahn Ingold Prelog 
Chronic myelogenous leukaemia 
Wavenumber
Chemical shift used in NMR (units are in ppm) 
Doublet
Dibenzylideneacetone
l,8-Diazobicyclo[4.3.0]undec-7-ene
Dichloromethane
Double doublet
Double doublet of triplets
Dihydrofolate reductase
Double multiplet
7,12-dimethylbenz[a]anthracene
Dimethylformamide
Dimethyl sulfoxide
Deoxyribonucleic acid
Double quartet
Double triplet
exempli gratia (Latin: “for example”) 
Enzyme-Linked ImmunoSorbent Assay
x
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eqv Equivalent, equivalents
et al. Et alia (Latin: “and others”)
GTP Guanosine 5’-triphosphate
HDM2 Human double minute 2
HRMS High resolution mass spectrometry
HSE Heat shock element
HSF Heat shock factor
HSP Heat shock protein
HUVEC Human umbilical vein endothelial cell
IC Inhibition concentration
in situ in the reaction mixture [Latin: “in its (original place)”]
in vacuo under vacuum [Latin: “empty space”]
in vitro [Latin: “in glass”]
in vivo [Latin: “in a living (thing)”]
ITP Inhibition of tubulin polymerization
kDa KiloDaltons
LLC Lewis lung carcinoma
m Multiplet
m Meta
MAP Microtubule associated proteins
MDM2 Mouse double minute 2
MDR Multidrug resistance
MOM Methoxymethyl
m.p. Melting point
MS Molecular sieves
MTOC Microtubules organising centres
MTT 3-(4,5-Dimethoxythiazol-2-yl)-2,5-diphenyl tetrazolium bromide
m/z Mass to charge ratio measured by mass spectroscopy
n Nano
NBS N-bromosuccinimide
NCI National Cancer Institute
0 Ortho
P Para
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffer solution
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PBSMT PBS + 5% nonfat dairy milk + 0.1% Tween 20
PBST PBS + 0.1 % Tween 20
PCC Pyridinium chlorochromate
per capita Latin: "for each head"
ppm Parts per million
q Quartet
R/  Retardation factor
s Singlet
SAR Structure-activity-relationship 
sp Septuplet
t Triplet
TBAF Tetra-w-butylammonium fluoride
TBDMS Tm-butyldimethylsilyl
td Triple doublet
tert Tertiary
TFA Trifluoroacetic acid
THF Tetrahydrofuran
t.l.c Thin-layer chromatography
tm Triple multiplet
TMS Trimethylsilyl
TPA 12-0-tetradecanoyl phorbol-13-acetate
pwave microwave
Angiogenesis growth of new blood vessels from existing vasculature.
Apoptosis death of individual cells within a tissue as a result of normal cell turnover within a
tissue or toxicity of an environmental agent.
Benign Not cancerous.
Cancer a malignant neoplasm.
Chromosome a structure within a cell nucleus of eukaryotes, consisting of DNA in
association with proteins and other molecules.
Cytostatic inhibiting or suppressing cellular growth and multiplication
Cytotoxic cell-killing
Denaturation a structural change in macromolecules caused by extreme conditions.
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Differentiation make or become different in the process of growth or development.
Enzyme an organic catalyst, usually a protein in nature, that catalyses chemical reactions 
while in most cases remaining chemically unchanged.
Epidemiology the study of the incidence and distribution of diseases and other factors 
relating to health
Hormone a chemical made by glands in the body which control the actions of certain cells or 
organs
Hyperthermia a type of treatment in which body tissue is exposed to high temperatures to 
damage and kill cancer cells or to make cancer cells more sensitive to the effects of radiation 
and certain anticancer drugs.
Hypoxia a condition in which there is a decrease in the oxygen supply to a tissue.
Leukaemia a cancer that starts in blood-forming tissue such as the bone marrow, and causes 
large numbers of blood cells to be produced and enter the bloodstream.
Malignant tending to invade normal tissue or to recur after removal
Metastasis the dissemination and/or growth of cells originating from a primary neoplasm at 
another site.
Microfilament the smallest o f  fibrous cytoskeletal elements, which have diametres 30-60 A, 
lack periodicity, and are chemically related to actins.
Microtubule a widely occurring cylindrical cytoplasmic element 200 to 270 A in diametre 
and of variable length, increasing in number during mitosis.
Mitosis process resulting in the replication of cells which contain the same number of 
chromosomes as the parent cell.
Mutation a change in the structure and/or expression of a gene that is perpetuated in 
subsequent progeny of the cells in which it first occurred.
Neoplasm a heritably altered, relatively autonomous growth of tissue.
Tumour an abnormal mass of tissue that results when cells divide more than they should or 
do not die when they should. Tumours may be benign, or malignant.
Chapter 1 - Cancer Chemotherapy
THE  KILLER
Cartoon booklet from the 1950s'
1.1 Introduction
In the late 19th century tuberculosis, also know as the “great destroyer” and the “white 
plague” was the most feared disease of its time. In 1900 it killed 200 Americans per 100,000 
of the population. But early on in the 20th century due to advances in medical treatment and 
understanding of the disease, the number of cases started to drop as the disease was brought 
under control. When this happened the number of cases of cancer and heart disease related 
deaths started to increase. This was especially apparent in the elderly population.
1.2 Social awareness and cancerphobia in modern society of the US.1
At the turn of the 20lh century cancer was a disease that was beyond the ability of 
contemporary medical science to treat or even understand. One theory at the time was that 
cancer may be caused by germs and that it could be contagious, while other theories also
1
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included that it could be heredity, or that it may be caused by luxurious living, depraved 
sexual acts or even depression and mental stress. It was an indiscriminating killer, striking at 
random, caring not of race, class or age. One US physician described cancer as a “Loathsome 
beast, which seized upon the breast, drove its long claws into the surrounding tissues, derived 
its sustenance by sucking out the juices of it victims, and never even relaxed its hold in 
death.” It became a social stigma, a disease that people would not talk about or see doctors if 
they suspected they had it, relatives of people who died of cancer often begged the coroner to 
record the death to be the cause of something else so the family would not be scandalized by 
it. Because of this, there was a general lack of hard evidence on the number of incidences 
and deaths each year. With such sentiments it is understandable why cancer became the new 
dread disease.
However by the mid 1930s the message of early detection and medical intervention was 
starting to spread, bringing a larger public interest. This led to several important news 
articles carried by Time, Life and Fortune and series of dedicated news reels shown in 
cinemas. In July 1937 a group of scientists and politicians secured $700,000 to support 
cancer research and a further $750,000 from the federal government, to build the National 
Cancer Institute in Bethesda, Maryland which would be a place to provide for and foster the 
continuous study of the cause, prevention, diagnosis and treatment of cancer. This action by 
the federal government strongly committed them to quest for the cure for cancer and further 
cancer research in the US.
By the late 1960s it was argued that the federal government needed to increase spending on 
cancer research. The price of scientific equipment was increasing faster than the increase in 
funds the government made to the NCI. The argument stated that in the 4 year course of the 
Vietnam War a total of 41,000 Americans had died, however in the last year over 320,000 
Americans had died of cancer, and due to the war less money was being spent on scientific 
research. One writer noted that in one year America spent $410 per capita on defense, $125 
on the war and only 89 cents on cancer research. With growing pressure and the chance to 
out flank one of his opponents, President Nixon made the following statement in his State of 
the Union message of January 1971 “The time has come when the same kind of concentrated 
effort that split the atom and took man to the moon should be turned towards conquering this 
dread disease. Let us make a total commitment to achieve this goal.” On the 23rd of 
December 1971 Nixon signed the National Cancer Act of 1971 into law; it stipulated that the 
NCI director was to be appointed directly by the president and to submit NCI financial 
requests to the budget office. Nixon also stated at the time that “I hope in years ahead we
2
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will be able to look back and see this action has been the most important action taken by this 
administration.” By 1973 NCI funding had increased to over $400 million, and by the end of 
the decade the funding had nearly reached a billion dollars.
13 Cancer Epidemiology
In the Western world cancer is the 2nd leading cause of death after heart disease (Figure 1). 
In 2003 cancer accounted for over a quarter of the deaths in the UK, with 154,547 people 
registered as dying from cancerous tumours.2 In the USA it is estimated that there will be 
570,280 deaths due to cancer in the year 2005, over 1500 deaths a day.2
■ Neoplasms ■  Diseases of the circulatory system
□  Diseases of the respiratory system □  Other
Figure 1: Mortality Statistics in England and Wales -  20032
It is estimated that 1 in every 3 people in the UK will develop some form of cancer during 
their life, with over quarter of a million new cases of cancer being diagnosed each year. Even 
though there are over 200 different types of cancer, only 4 of them account for over half the 
new cases, these are breast, lung, large bowel and prostate cancer (Figure 2). In recent years 
prostate cancer has overtaken lung cancer as the most commonly diagnosed cancer in UK 
male, with over 30,000 cases in 2001. The most prolific cancer in women is breast cancer, 
which is the highest occurring cancer in the British population, with over 40,000 in 2001. 
Children 14 years and younger count for less than 1% of total number of new cases of cancer 
each year. Nearly two thirds of all the new cases of cancer are diagnosed in those aged 65 
and older. With a growing elderly population due to increased life expectancy, it is predicted 
that by the year 2025, there will be an extra 100,000 incidences a year.2
3
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Figure 2: The 10 most commonly diagnosed cancers in the UK -  20012
In the UK cancer of the lungs, bowel, breast and prostate account for nearly half of all the 
cancer related deaths (Figure 3). Even with the decreasing number of annual incidences of 
lung cancer it is still accountable for over a fifth of the annual cancer deaths. More than 
three quarters of deaths due to cancer occur to persons aged 65 and over. However cancer 
accounts for over two fifths of the deaths in the population under 65 years old, and 
outnumbers the deaths due to circulatory systems including stroke and ischaemic heart 
disease.2
Despite the increasing number of incidents a year, the overall mortality rate from cancer is 
going down. From 1994 to 2003 the age standardized mortality rate from cancerous tumours 
has dropped by 13% for men and 10% for women. For instance there have been 1758 fewer 
deaths due to breast cancer in 2003 than 1994, even though there has been an increase in the 
number o f incidences for breast cancer.2
■  Female
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Figure 3: The 10 most common causes of death from cancer in the UK -  20032
As well as the previously mentioned drop in cancer related mortality rate, the 5-year survival 
rate for people diagnosed with cancer in the US has also increased from 50% in 1974 -  1976 
to 64% in 1995 - 2000. These 5-year survival rates vary greatly depending on the type of 
cancer, for instance the largest increase has been for prostate cancer, the 5-year survival rate 
was increased to 99% in 1995 - 2000 from 67% in 1974 1976. However there has been a
small decrease in the 5-year survival rates for cancers of the larynx and uterine corpus. 2
Tobacco smoking has been identified as the single most important cause of preventable 
cancer in the UK, and is linked to one third of the annual cancer related deaths.2 While in the 
US over one third of all cancer deaths are linked to nutrition, physical inactivity and 
weight/obesity, all of which are preventable.2 A study done on the factors that contribute to 
cancer in the US by R. Doll and R. Peto’ in 1981 {Figure 4) shows that a large percentage of 
these risks can be reduced by taking proper precautions. It has been suggested that pollution 
and occupation exposure to carcinogenic sources are relatively low risk factors when 
compared to our own lifestyle choices such as smoking, diet, alcohol consumption, sexual 
behaviour and exposure to sunlight.
■ Male
■ Female
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Figure 4: Proportions o f cancer deaths attributed to various different factors.3
Another way to lower the risks o f terminal cancer is early detection from regular 
screening/examination. If a cancer can be caught early treatment is likely to be far more 
successful. Screening can detect cancers of the breast, colon, rectum, cervix, prostate, oral 
cavity and skin.
1.4 The History of Cancer.4
Cancer is often thought of as a modem disease, however traces o f tumour have been found in 
fossil remains of dinosaurs from the 
Cretaceous period, 144 to 65 million years 
ago.5 The earliest recorded history of the 
treatment o f cancer is in the Ebers Papyrus 
(Figure 5). The Ebers Papyrus is ancient 
Egyptian medical scroll dating from around 
1500 BC; it is over 20 metres long and 
details over 700 medical magic's using 
different animal and plant extracts as well as 
surgery. The scrolls show evidence of 
Egyptian surgeons regularly identifying and 
removing tumours.6 There are also a 
number of tomb paintings showing evidence 
of tumours.
Figure 4: Frontispiece of the Ebers Papyrus.6
Hippocrates (460 BC -  380 BC) noted in his Aphorisms about the dangers of cancer 
spreading due to incomplete surgery. Also it was Hippocrates who described a tumour as
6
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being crab like due to the distended veins radiating from central lump, the Greek word for 
crabs being Karkinoma, which when translated to Latin becomes cancer.1
On a similar note the Roman physician Celsus (25 BC -  50 AD) also recommended surgery 
for early diagnosed tumours, claiming late intervention would aggravate the situation.
The Greek medical writer Galen (131 AD -  201 AD) provided exact instructions in his 
books, the therapeutic method on the removal of tumours. “When a tumour has risen to a 
noticeable size, there is no cure without surgery. The goal is to proceed with a round incision 
so that the entire tumour can be excised.” Galen’s medical views dominated European 
medicine for over a thousand years, cancer and all aliments were thought to be caused by an 
imbalance in the four body humours: blood, phlegm, black bile and yellow bile. The cause of 
cancer was said to be due to a concentration of black bile.
Cancer was a rare disease in Hippocrates and Galen’s time due to the average life span being 
much shorter then, 30 -  40 years, with modem day cancer happening most frequently to the 
people aged 65 and over. Physician and surgeons of this time were far more concerned with 
treatment of injuries from battles, sexually transmitted diseases and food poisoning. The true 
causes of cancer remained a mystery until the 19th century.
The Italian physician Bernardino Ramazzini, carried out the first study of cancer in the early 
18th century. He noted that nuns have a much higher incident rate of breast cancer compared 
to mothers who had breast fed their children. At the time no one knew of the importance of 
hormones and the development of breast cancer. Also in the 18th century an English physician 
John Hill7 commented on snuff users getting nasal cancer; this was probably the first link of 
cancer and tobacco. But it was Percivall Pott8 in 1775, who reported that boys who had 
worked as chimney sweeps, often developed scrotal cancer later on in life. This was first link 
between environmental carcinogens in this case, soot and cancer. Despite this warning, the 
practice of small boys cleaning chimney flues continued for a further hundred years before it 
became illegal, and even then it was due to humanitarian rights rather than health issues.
The discovery that organisms were made of cells which divide to replicate themselves in the 
1850s - 1860s by European scientists, especially the German Rudolf Virchow revolutionized 
medical theory. The idea that all cells come from pre-existing cells eliminated the accepted 
ideas of Galen’s theories on the bodies 4 humours. Virchow stated that cancer cells sprung 
from other cells in the body, just like any other cells. But unlike normal cells their growth 
was anarchic, invasive, metastatic and all too often disastrous. Later researchers disproved 
some of Virchow’s theories on the origins of some cancers; however no one was able to
7
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describe the reason why some cells became cancerous. This remained a mystery. Near the 
end of the 19th century a leading Philadelphia surgeon, Samuel Gross admitted that the basic 
questions of what cancers were and how they developed were simply beyond contemporary 
medical science.1
Virchow also speculated that cells that were exposed to certain irritants would be more prone 
to developing cancer cells. This helped to explain why some habits such as smoking tobacco 
seemed to provoke the disease. This idea also worked well to explain the link between 
chemical exposure and cancer. In the late 19th century these links became more apparent with 
increased cases of skin cancers in workers employed in the paraffin, tar and oil industry in the 
north of England and Scotland. Another case of exposure to hazardous materials occurred to 
German miners who were contracting lung cancer. The idea at the time was that mine dust 
was to blame, but the tumours were probably due to the presence of radioactive pitchblende, a 
mineral which contains radium.1
The first scientific proof between chemical exposure and cancer came from a study done by 
Yamagiwa & Ichikawa9 in 1915, where they had produced malignant tumours on the ears of 
rabbits by applying coal tar to them. Similar experiments were carried out on mice by 
Passey10 who smeared them with an extract of soot and reported the growth of malignant 
tumours.
1.5 How does a normal cell become a cancer cell?
The average adult is made up of 30 million million (3 * 1012) cells which can all undergo 
mitosis to produce two new cells which can replace dead or damaged cells. But during 
mitosis there are numerous points where a mistake can occur or where the delicate control 
mechanism can break down, this can lead to a number of events where a normal cell can be 
turned into a rogue cell and perhaps a cancer cell.
Two particular types of genes have the main responsibility of controlling the life cycle of a 
cell. These are the proto-oncogenes such as src protein and ras protein, the other being 
tumour suppressor genes like p53. The proto-oncogenes control the growth, differentiation 
(to change the function of a cell) and proliferation (rapid reproduction) of cells. While 
tumour suppressor genes code for the production of proteins that control DNA transcription, 
DNA repair, and are key components in biological pathways activated in response to DNA 
damage which will stop the cell from growing and undergo apoptosis. Damage to genes can 
occur through the effects of carcinogens, viruses and ionizing radiation and will disrupt their 
normal function. Proto-oncogenes when mutated will become an oncogene. Oncogenes are
8
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formed by a minor DNA sequence change to the proto-oncogenes; one amino acids difference 
will completely change the activity of the encoded enzyme and can ensure that the cell is 
constantly activated for growth and proliferation. In about half of tumours, tumour 
suppressors are found to be mutated. This ensures that the growth of the cell is uncontrolled 
and does not undergo apoptosis.
One of these mutations will not instantly cause tumour growth, normally half a dozen such 
mutations must accumulate before the tumour cell line is established. Even then the tumour 
may not be cancerous and will remain benign and localized; such tumours can be dealt with 
by surgery or destroyed via irradiation. For a tumour to become malignant it must undergo a 
process know as metastasis where it will become invasive and spread through out the body. 
To become invasive the localized tumour must overcome several more control systems and 
enter the bloodstream or lymphatic system. Once the tumour has become malignant it can 
only be treated with chemotherapy to stop the spread of the disease through out the body.
So how do cancer cells migrate when normal cells stay in the same place? Normal cells 
release adhesion molecules which bind them to their neighbours and the underlying structure 
of the body, the extracellular matrix. However in cancer cells these adhesion molecules are 
missing or have a higher affinity for the tissues that they came from, also cancer cells can 
avoid detection and therefore destruction by white blood cells. A better understanding of 
how these migrations take place will help in fight against cancer.
1.6 Cancer Chemotherapy
In the past 25 years there have been major advancements in surgery and radiotherapy in the 
treatment of cancer, but the most progress has been made in the field of chemotherapy. At 
the time of detection a tumour will probably weigh about a gram and be about one billion 
cells (1 x 109 cells). The overall strategy to deal with tumours is to eliminate 99.999% of it, 
leaving around ten thousand cells (1 x 104 cells) where hopefully the bodies immune system 
will destroy the remaining cells. However if a single cell remains it can reproduce itself 
again and start another tumour. The time taken for a tumour to double in size varies greatly, 
for instant people who have Hodgkin’s lymphoma will only have a short remission time 
because the tumour doubles in 3 - 4 days, while the remission time for breast cancer can be 
1 0 -1 5  years before a tumour re-emerges, this is due to the long doubling time of 80 -  100 
days. Anticancer drugs are most effective against cells that are going though mitosis, and 
therefore cancers with short remission times are the easiest to cure compared to ones with 
long remission time, this is because the cells are more frequently in the mitosis stage.
9
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1.6.1 The Mustard Gases
Mustard gas, bis(2-chloroethyl)sulfane (1), was first used by the Germans against the Allies 
in the 1st world war on the night of 12/13 July 1917. By the end of July it had claimed 15,000 
causalities, by the end of the war a further 125,000 casualities would be caused by the use of 
mustards. People who had been exposed suffered with severe eye irritation which could lead 
to blindness and would get a rash that turned to blisters. After 4 weeks, the blisters would 
burst and then if they became infected, it would take a further 5 to 6 weeks to heal. Also 
many of the exposed also suffered with inflamed throats and subsequent lung problems.4
However mustard gases were not made with the intention of killing, only to sow panic and 
confusion. Between the wars further research was done on the mustards to examine their 
properties." 12 Various nitrogen analogues of mustard gas was made. They were found to 
have similar blistering properties and were also found to be toxic to many cells of the body, 
especially cells going through mitosis.13
/ — \  / “ Cl 
Cl N—'
Research done at Yale University showed that mice bearing tumours that were treated with 
N-mustard analogues showed almost immediate effects and the tumours shrunk and 
eventually disappeared, only to reappear a month later. Subsequent treatments proved to be 
less successful; this was thought to be due to drug resistance.13
In August 1942 a man with terminal lymphoma whose tumours had stopped responding to 
radiotherapy was giving a 10 day treatment with the nitrogen mustard, tris(2- 
chloroethyl)amine (2). After 7 days the tumours which had covered his chest, neck and lower 
face had completely disappeared. However like the mice this was only temporary and he 
died 3 months later. Further clinical trials with 2 were done and another 5 people showed 
similar responses. A more widespread clinical trial took place with mechlorethamine (3) with 
over 150 patients and showed results against various lymphomas and leukaemias.13 It proved 
to be especially affective against Hodgkin’s lymphoma with one patient being in remission 
for 3 years upon being given periodic doses of 3.
Cl Cl Cl
1 2 3
4 5 6
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The side effects of the mustards include suppression of the bone marrow and therefore careful 
dosage due to the toxicity of the compounds was required. But they did not cause vomiting 
which is common with other anticancer drugs. In 1946 the first paper on this subject was 
released in Science, detailing the therapeutic results of 3. This was the first the public knew 
of this because until then all the research had be done in secret due to the war.13 The paper 
stated that only two nitrogen mustards had been tested so far, of literally hundreds of possible 
analogues. Over the next few years several improvements were made with drugs like 
Chlorambucil (4) and Melphalan (5) being water soluble and orally active. The most 
successful nitrogen mustard is Cyclophosphamide (6), which was designed as a prodrug to 
target prostate cancer. Designed to release 1, the actual mechanism of activation proved to be 
more complex. Cytochrome P-450, in the liver, is thought to oxidize C-4 of the prodrug 6 to 
give 4-hydroxycyclophosphamide (6a). This hemiaminal exists in equilibrium with the 
aldehyde 6b. The aldehyde then 
undergoes a retro-Michael reaction to give 
the true alkylating agent phosphoramide 
mustard (6c) and acrolein (6d) {Scheme 
/ ) .M I5 It was found to be highly active 
against a whole range of cancers. It can be 
taken orally and remains active in the body 
for up to 48 hours and has none of the 
adverse blistering effects that the early 
mustards had. Side effects from the 
mustards include bone marrow toxicity, 
hair loss and a reduction in fertility.
The mode of action of these compounds involves nucleic acid alkylation and they are 
therefore described as alkylating agents. DNA exists in a double helical structure and for a 
cell to replicate itself, the DNA strands needs to be unwound so that they can be copied. The 
nitrogen mustards and other related alkylating agents work by reacting with various groups 
on the DNA. When this takes place it changes the structure of the DNA, it also leads to the 
alkylating agents making inter and intra cross links on the DNA, which will prevent the DNA 
from being unwound. For example mechlorethamine (3) eliminates a chlorine anion by an 
internal nucleophilic attack to produce the reactive species 3a. The product can then react 
with the electron donor groups within DNA (7) such as the nitrogen 7 on guanine to form 
covalent bonds. The alkylated mustard can then form another azirdinium species which can 
then react with a further guanine to cross link the DNA {Scheme 2).
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1.6.2 Platinum Complexes
The next class of alkylating agent was found again by 
serendipity. In 1965, Prof. Bamett Rosenberg of the 
Biophysics Department at Michigan State University was 
investigating the effects of an electric current on cell division 
in cultures of Escherichia coli. He found that in the presence of platinum electrodes, 
ammonium chloride and oxygen that the bacteria cells did not undergo mitosis. He proposed 
that the acidified chloride salts attacked the platinum electrodes during electrolysis causing it 
to form a soluble platinum salt which could disrupt mitosis. Several experiments were then
carried out to prove this idea and it was 
reported that mitosis was prevented in the 
presence of PtCl6(NH4 )2  and several other 
transition metal salts.16 Further research 
showed PtCl6(NH4 )2 was unstable and that 
it was cis-diaminodichloroplatinate (8) 
(now known as cisplatin) which prevented 
mitosis at concentrations as low as 5 ppm.1 
Further research by Rosenberg’s coworker 
Loretta Van Camp showed that cisplatin (8) 
had anticancer activity on tumours in mice.
Figure 5: X-ray crystal structure of DNA containing a cross linked Cisplatin1*
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By 1973 preliminary results on humans with 8 had shown it to be highly effective at treating 
testicular cancer, and certain ovarian cancers. The side effects were high toxicity to the 
kidney and severe vomiting, but it had only a little toxicity to the bone marrow. By 1986 a 
new less toxic analogue of 8 was licensed for clinical use, known as carboplatin (9). The 
modes of action for these platinum complexes have been shown to be similar to that of the 
mustards and are also alkylating agents (Figure 5) where the nitrogen 7 on guanine (7) forms 
a covalent bond to the platinum complex, displacing a chlorine atom from 8. The X-ray 
crystal structure18 (Figure 5) shows two separate stands of DNA one in blue, the other in 
green which have been cross-linked by the platinum complex (shown in red) from the 
nitrogen at position 7 on guanines of each strand of DNA.
1.6.3 Antimetabolites and the cure for Leukaemia
Leukaemia is caused through uncontrolled proliferation of the white blood cells, it is a 
common childhood cancer. Fifty years ago, the life expectancy for patients with leukemia 
was 3 to 4 months. With modem treatments, nearly 80% of all children go on to survive for 5 
years, and most make a full recovery.
The breakthrough in the treatment of leukaemia started with the study of anti metabolites 
which disrupt cellular function due to the similarity of these compounds with cellular 
metabolites. Previous studies on leukaemia patients showed that the disease was accelerated 
when they were treated with folic acid (10) conjugates.19 This led Farber to believe that using 
antifolates (folic acid antagonists) might be effective in treating leukaemia cases. In 1947 
Farber found that 10 out 16 children with leukaemia responded favourably to the antifolate, 
aminopterin (11), going into full remission. However this remission was only temporary and 
repeated treatments with aminopterin had no effect.20 The use of aminopterin (11) caused 
ulceration to the mouth and left the patient at risk of infection due to their immune system 
being compromised. Aminopterin (11) was soon replaced with the safer drug methotrexate 
(12), which had first been synthesized by Seeger.21
13
Chapter 1 - Cancer Chemotherapy
Synthesis of the nucleotide thymidine (13) which is needed for the synthesis of DNA, 
requires the reduction of dihydrofolic acid (14) to tetrahydrofolic acid (15) by dihydrofolate 
reductase (DHFR) {Scheme 3). The antifolates aminopterin (11) and methotrexate (12) are 
dihydrofolate analogues which bind to DHFR and inhibits DHFR reduction of 14, this halts 
the synthesis of DNA by disrupting the synthesis of the nucleotide thymidine (13) and cause 
apoptosis."
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Scheme 3: The Folate Catalytic Cycle
The methylation mechanism of thymidylate synthase {Scheme 4) starts with the Michael 
attack of cysteine residue at the C6 position of the uridine (16) to form the enolate 17. The 
tetrahydrofolate (18) is then activated by iminium ion 19 formation via acid catalysis. The 
methylene group of the activated tetrahydrofolate iminium ion 19 then forms a bond with the 
enolate 17 at its C5 position, giving the methylene bridged product 20. The proton on the C5 
position of 20 is then deprotonated and the compound undergoes a ElcB elimination of 
tetrahydrofolic acid (15), via the enol 21, leaving the methylene group attached to C5 of 22. 
The methylene group of 22 is then reduced by the tetrahydrofolic acid (15) and releases the 
thioenzyme, giving the newly formed thymidine (13) and dihydrofolic acid (14) which is then 
recycled back tetrahydrofolate (18) again using the folate catalytic cycle {Scheme J).23
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Scheme 4 : The mechanism of Thymidylate Synthase
With the success of the antifolates, research was done into the other 2 antimetabolites, 
antipurines and antipyrimidines. Pioneering work on antipurines carried out by Elion and 
Hitchings in the late 1940s and early 1950s led to the initial development of antipurines as 
anticancer agents. 24 At this time the basic knowledge of the nucleic acids was rather 
rudimentary. Watson and Crick's publications on DNA were released in 1953.25 Hitching 
theorized that it might be possible to stop the growth of rapidly dividing cells with antipurines 
because they would interfere with nucleic acid synthesis. By 1948, 2,6-diaminopurine (23) 
was found to inhibit the growth of the microorganism Lactobacillus casei, the inhibition 
could be reversed by the addition of adenine (24). From this they deduced that adenine and 
2 ,6 -diaminopurine were anabolized by the same enzyme and somehow the diaminopurine 
interfered with purine interconversion. Further testing showed that 2,6-diaminopurine was a 
strong inhibitor of aldo keto reductase (AKR) mouse leukaemia. Unfortunately 2,6- 
diaminopurine proved to be too toxic for clinical trials, producing severe nausea and severe
15
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bone marrow depression. By 1951 over 100 purine analogues had been tested in the screen 
against Lactobacillus casei, the substitution of the oxygen by sulfur at the 6  position of 
guanine (25) produced 6 -mercaptopurine (26) and 6 -thioguanine (27) which proved to be 
active against a wide range of rodent tumours and leukaemias.
NH2 nh2 o  s h  SHfVN> 7 jtn'> ■jfV'v ifVN»
h 2 n A n A n ^ n«L-n h 2 n ^ n ^ - n  
23 24 25 26 27
In 1953 the Food and Drug Administration approved 6 -mercaptopurine (26) for general use, 
after clinical trials showed that it could induce complete remission in acute leukaemia in 
children, however most of the cases would eventually relapse. Today 6 -mercaptopurine (26) 
is used in combination chemotherapy with other drugs, including methotrexate (1 2 ) and
induces remission in nearly 80 % of all children with acute leukaemia. Hitchings and Elion
were awarded the Nobel Prize in 1988 for there advances in finding anticancer drugs.
Other purine and pyrimidine analogues have also shown anticancer activity. Prof 
Heidelberger at McArdle Memorial Labs at the University of Wisconsin in 1957 reported that 
the analogue of uracil (16), 5-fluorouracil (28) showed Q 0  0
tumour inhibitory properties. 26 5-Fluorouracil (28) was first HN^^ hn t F
7 l| 7 1) 7 I)
synthesized at Hoffmann-La Roche, Nutley, New Jersey in O N O N O N
H H H
1957.27 Heidelberger chose to make analogues of uracil 13 16 28
because he believed that uracil was a precursor to thymidine (13) which is a key component 
of DNA. His idea for replacing the hydrogen for fluorine, came from the difference between 
acetic acid and fluoroacetic acid (which is highly toxic), and that the same may be true of 
uracil. Clinical trials of 5-fluorouracil (28) have shown it to be highly effective at targeting 
colon and rectal cancers. It was also used in combination chemotherapy along with 
methotrexate to treat some cases of breast cancer in women. Fluorouracil (28) will become 
incorporated into the thymidylate synthase and will proceed normally like uracil (16). With 
the cysteine residue attacking the C6  position of fluorouracil (28), forming the enolate 29. 
The enolate 29 will then form a bond with the activated tetrahydrofolate iminium ion 19, 
giving the methylene bridged product 30. However the ElcB elimination of the linked 
tetrahydrofolic acid (15) is not possible, because the fluorine on the C5 position of 30 cannot 
be eliminated like the hydrogen in the same position of 2 0  through deprotonation, stopping 
the synthesis of 13 and thus disrupting DNA synthesis and inducing apoptosis (Scheme 5).
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Scheme 5: Mode of action for 5-fluorouracil (29)
Cytarabine or cytosine arabinosido (31) was original isolated from a 
Caribbean sea sponge, Cryptotethia crypta in 1951. Since then it has 
been found to have in vivo antitumour activity against leukaemia and
0
NH2
HO' OHa variety of transplanted rodent tumours as well as an effective agent ^
in the treatment of acute leukaemia in adults. 28 It is presently used 
against leukaemia and in combination chemotherapy.
1.6.4 Anticancer drugs from Nature
Man’s search for a cure to his ailments isn’t a new one. As previously mentioned, the Ebers 
Papyurus, an ancient Egyptian scroll from around 1500 BC details over 700 remedies using 
animal and plant extracts.6 Another ancient source of remedies using animal and plant 
extracts is Chinese Shennung herbal text from around 200 BC. Medical knowledge like this 
has been passed down the generations. In the 19th century scientists started to isolate and 
characterize compounds from these remedies. However many of the compounds proved to be 
too complex to be characterised until the 20th century. In the late 1940 scientists started a 
systematic search for novel natural products with interesting biological properties.4 These 
studies have given us several highly active anticancer drugs, such as vinblastine and 
vincristine.
In the Philippines the extract of the Madagascar periwinkle was used as a treatment of 
diabetes. The extract was also used in the same way in South Africa. In England the extract 
was sold as “Vin-q-lin” and was believed to reduce blood sugar. However experiments done 
by Ralph Noble29 at the University of Western Ontario, Canada, on rats showed that the 
extract did not lower their blood sugar level. All the rats tested died due to infections; more 
tests showed that the extract lowered the white blood cell count. With the help of an English 
chemist Charles Beer in 1958 they isolated a pure compound that depleted white blood cells 
and called it vincaleukoblastine, later known as vinblastine (32).30 At the same time Eli Lilly 
made similar discoveries and had found that the plant extract prolongs the life of mice 
carrying the leukaemia cell line P I534. They isolated a total of four vinca alkaloids that
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showed antileukaemia activity. Only 
Vinblastine (32) and Vincristine (33) 
went into clinical trials. 31 Vinblastine is 
now used in the treatment of Hodgkin’s 
lymphoma, testicular teratoma, and
bladder cancer. Vincristine is used in o^O M e
the treatment of Hodgkin’s lymphoma and a host of rare childhood cancers including Wilm’s 
tumour, neuroblastoma, rhabdomyosarcoma and Ewing’s sarcoma. Both compounds have 
serious adverse effects, Vinblastine leaves people susceptible to infection and depresses bone
marrow cell production, while use of Vincristine can cause loss of sensation in fingers and
toes, constipation and severe abdominal pain.
Another natural extract that has had anticancer activity was derived from OH
Podophyllum peltatum (Mayapple) (34). The Leech book of Bald, around 950 
AD, reports the use of wild chervils in the treatment of tumours, wild chervils 0  
are thought to be Myrrhis Odorata which is a source of a podophyllotoxin 
analogue. The NCI screening of natural compounds showed that
podophyllotoxin (34) isolated from the American Mayapple had antitumour 34
activity. However it proved to be too toxic in clinical trials.
Further studies done by the Swiss pharmaceutical company Sandoz, making semisynthetic 
glycosides analogues of podophyllotoxin, finally yielded two successful drugs Etoposide (35) 
and Teniposide (36). Etoposide is used as a less toxic replacement for Vinblastine (32) in
OMeMeO
OMe
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testicular cancer as well as small cell lung 
cancer. Teniposide (36) is used to treat acute 
lymphoblastic leukaemia and rare childhood 
cancers like neuroblastoma. They work by 
inhibiting the topoisomerase II enzyme, which 
is involved in the process of unwinding 
supercoiled DNA. Inhibition of topoisomerase II effects the S phase of the cell cycle and 
blocks the continuation to the G2/M phase and leads to apoptosis. 32
The natural product Camptothecin (37) was isolated from Carmptotheca acuminata, a tree 
native to China and Tibet which is used in traditional Chinese medicine, by Monroe Wall in 
1958.33 It was found to have potent antitumour activity against leukaemia L I210. The 
structure of Camptothecin (37) was determined in 1966.34 More water soluble analogues 
Topotecan (38) and Irinotecan (39) are used in the clinic for treatment of colon and ovarian
R
CH3
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cancers, respectively. 33 The mode of action of 
Camptothecin (37) was found in 1985,35 it 
inhibits the topoisomerase I enzyme which is 
needed in the S phase of the cell cycle to cause 
the DNA to unwind. 33
Since the discovery of penicillium in mould by 
Fleming in 1928,36 scientists have been studying 
the biological activities of microorganisms, this 
has led to hundreds of antibiotics and has also 
led to several antitumour agents.
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In 1960 Faber reported about the antitumour
properties o f actinomycin D (40) in treating
Wilm’s tumour in children. 37 Actinomycin D (40) » - ' D.Val »
) sy ^  NH
had been isolated from Streptomyces parvullus by 0 = j'' M6 *l!Thr i ~ 1=0 
Waksman in his studies of possible new 
antibiotics in 1954.38 The successes of 
actinomycin D led the way for a new class of 
anticancer drug into the clinic.
Mitomycin C (41) was first isolated from Streptomyces caespitosus 1958 by Wakaki. 39 It was 
also isolated from Streptomyces verticillatus and characterized by Lefemine and coworkers.40 
It proved to be highly toxic against a range of tumour cells as well as normal cells, causing 
severe side effects including vomiting, bone-marrow depression, alopecia, kidney and liver 
toxicity and heart damage. However it was widely used in Japan in the 1960s. Mitomycin C 
is bioreduced in vivo, producing reactive intermediates that are capable of forming covalent 
bonds to DNA, similar to the alkylating agents.41 The quinone of Mitomycin C (41) is 
reduced to the dihydroquinone 41a. The bioreduction of Mitomycin C 41, to the 
dihydroquinone 41a then triggers the loss of methanol (since the nitrogen lone pair is no 
longer delocalized) to give the conjugated electron rich system of leucoaziridinomitosene 
(41c). The hydroxy group on the C8  position of 41b then donates its electron pair causing 
the aziridine ring to open and give 41d (Scheme 6). The Cl position of 41d then undergoes 
nucleophilic attack from DNA to form the first DNA cross linking bond to give the 41e. 
Another nucleophilic group within DNA then attacks the CIO position of 41e and eliminates 
the carbamate group forming the second DNA covalent bond, and giving the alkylated DNA 
product 41 f 2 {Scheme 6)
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A more useful class of antitumour antibiotics is the anthracyclines. They were first isolated 
by the Arcamone group in the early 1960s and were found to strongly to inhibit the growth of 
a variety o f tumours. 43 Many hundreds of analogues have been made, including 
Daunorubicin (42) and Doxorubicin (43). Doxorubicin (42) has a broad spectrum of 
anticancer activity; it is used today for the treatment of solid tumours and childhood 
leukaemia. Daunorubicin (43) is one of the drugs of choice used against adult leukaemia. 
The flat aromatic unit of these
R
O OH R
42 Daunorubicin H
compounds slide between the DNA 
bases by intercalation so that the DNA 
can’t separate (Figure 6 ). They also 
inhibit the topoisomerases II enzyme. 
The other mode of action these
OMeO OH 6 ^ v ^ N H 2 43 Doxorubicin OH
'OH
compounds have is that they undergo a chemical reaction to form radicals, the radicals react 
with DNA and damage it. The main side effect of these drugs is damage to the heart muscle 
and cardiotoxicity.
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DNA strand 
DNA strand 
Doxorubicin (43)
Figure 6: X-ray crystal structure o f the intercalation of DNA base by Doxorubicin (43)44
Another area of development in anticancer drugs is the use of hormone mimics to treat 
cancer. In 1896 a Scottish surgeon George Beatson reported in Lancet that tumours o f 
women with breast cancer ceased growing and regressed after the removal of their ovaries 
and fallopian tubes.45 At the time nothing was known about hormones and this was inspired 
by the idea of the link between the mammary glands and the ovaries, which was shown that 
when a mother was breast feeding her menstrual cycle stopped. Since then it has been 
discovered that cell growth and differentiation is controlled by hormone signals, and that by 
switching off production of hormones or interfering with the receptor-hormone complex 
provides a means of cancer therapy.
In the 1930s Dodd and coworkers investigated hormone mimics of estrogen. They found that 
a dimer o f p-propenyl phenol 
(44) had potent oestrogenic 
activity. This led to a range of 
dimeric structures being 
synthesized, in 1938
diethylstilbestrol (45) was
reported to be 2-3 times more 
active than estrone.4* In 1944 
Haddow reported that some 
breast cancer patients could be helped by treating them with diethylstilbestrol (45). Further 
modification of diethylstilbestrol led to Tamoxifen (46) first made by ICI. This exists as two
OH HO
n
46a
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isomers, the Z-isomer (46a) having potent oestrogenic activity, the £-isomer (46) having 
potent antiestrogenic activity. Tamoxifen (46) acts in estrogen-dependent cancers by binding 
to the estrogen receptor in a tumour cell, blocking the attachment o f oestrogen, thus also 
preventing the activation of DNA and cell division. First used in clinical trail in 1971, it has 
proven to the drug of choice with post menopausal patients with breast cancer. Tamoxifen
(46) has been reported as leading to a 25% reduction in the recurrence of tumours after their 
removal and 17% reduction in the mortality rate in breast cancer.47 Raloxifene (47) was 
originally used in the treatment o f osteoporosis in postmenopausal women, but it was also 
found to be a potent antiestrogen, preventing rat mammary carcinogensis.4* Raloxifene (47) 
can be used if a woman with breast cancer becomes resistant to Tamoxifen (46).49 Raloxifene
(47) also binds in the estrogen receptor in cells {Figure 7).
Figure 7: X-ray crystal structure of Raloxifene (47) binding in the Estrogen receptor'
The early discoveries in the field o f chemotherapy were all unselective cytotoxic agents, 
many of which are still used today. However as our knowledge of cancer increases, modem 
chemotherapy is becoming more selective, with new anticancer agents seeking to target 
specific biological models to prevent oncogenesis.
In May 2001, Gleevec (48) was the first “target-based” cancer therapy to be approved by the 
FDA for the treatment o f chronic myelogenous leukaemia (CML).51 CML is associated with 
a specific chromosomal translocation, known as Philadelphia chromosome which is detected 
in 95% of patients with CML.'2 The result of this translocation is the creation of the BCR- 
ABL fusion protein, which is an activated form of tyrosine protein kinase.'1,53 The oncogenic 
properties of the BCR-ABL fusion protein were further demonstrated by several studies done
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in mice, where the introduction of the BCR-ABL fusion protein to healthy mice would induce
chronic myelogenous leukaemias.54^ 6   ^
H H r i i 1N 1 HTherefore the inhibition of BCR-
C O TABL tyrosine kinase activity in CML O
cells became an attractive drug target R'
H J, 48 49
for the treatment of the disease. ^
Extensive optimization of phenylamino-pyrimidines (49) by Zimmermann57 et al. yielded a 
highly potent (IC50 = 38 nM) and selective inhibitor o f BCR-ABL kinase, Gleevec (48).57 X- 
ray crystallography shows that 48 inhibits the BCR-ABL kinase activity, by binding with 
high specificity to the inactive form of the ABL kinase (Figure #).58
Treatment with Gleevec (48) results in remission in nearly 100% of newly diagnosed patients 
in the early stages o f CML.59 The side effects from the use of Gleevec have mainly been mild 
with adverse effects such as nausea, vomiting, oedema and muscle cramps being mostly 
reported, however on rarer occasions liver toxicity or fluid retention have also been 
reported.51 Even with these rarer serious side effects, treatment with Gleevec is far less toxic 
than the treatment of a more traditional chemotherapy.
Figure 8\ X-ray crystal structure of Gleevec (48) binding to inactive form of the ABL 
kinase.5*
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2.1 Developing Antimitotic Agents
Cancer chemotherapy agents are being designed to exploit the differences between normal 
and malignant cells. The ultimate goal is a drug that will only target cancer cells and destroy 
or render them benign, and not affect normal cells. The increased cell growth and division of 
cancer cells presents an attractive and achievable target for drug design by making them more 
selective to rapidly dividing cells. The biochemical target we are interested in is tubulin and 
the formation of microtubules, which plays a vital role in cell divison. The disruption of 
microtubule formation will impede the replication of the dividing cancer cells and will lead to 
cell death.
2.2 The Cell Cycle and Mitosis
Cell division is arguably one of the most complex and demanding process undertaken by the 
body. During this process the DNA of the cell will become unraveled and duplicated. The 
cell will then reorder the DNA strands into 2 new identical sets of chromosomes. The 2 new 
duplicate sets o f DNA will be moved to opposite sides o f the cell to make new nuclei, which 
will eventually separate into 2 new daughter cells.
G2
Cell
Death
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Differentiated
cel
GO
Figure 9: The Cell Cycle
The cell cycle is split into 5 different phases {Figure 9). The first is the Gi phase or 
intermitotic phase where the cell checks the DNA integrity, cell size, presence of nutrients 
and growth factors in preparation of cell division. This is followed by the S phase or DNA 
synthesis phase where replication of the DNA and chromosomes takes place. The cell cycle
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then enters the G2 phase or premitotic phase, where the integrity of new DNA is checked. 
These 3 stages are known as the interphase and it accounts for 95% of the time taken for a 
cell to divide. The M phase or mitosis stage is then entered, during which the chromosomes 
are segregated and the cell divides, this stage takes about an hour to complete. The fifth 
phase of the cell cycle can take place during the Gi phase if there is a lack of sufficent 
stimuli, it can become indefinite and the cells will become quiescent, this is known as the Go 
phase.60,61
Microtubules.
Centrozomes.
Chromosomes.
Prophase Prometaphase Metaphase
Telophase.
Figure 10: Stages of Mitosis62
The Mitosis phase is split into 5 separate stages (.Figure 10). Starting with the prophase 
where the microtubules start to form and grow towards the 2  sets of daughter chromosomes. 
The microtubules grow from the centrozomes which separate and move to opposite ends of 
the cell. The next phase is the prometaphase where the nuclear envelope around the nucleus 
disintegrates and the microtubules attach themselves to the centre point of the chromosomes 
known as the Kinetichore. The chromosomes gradually arrange themselves between the 2 
centrozomes. This is the metaphase. Once the chromosomes are accurately arranged 
between the 2 centrozomes, the cell abruptly enters the anaphase. The daughter 
chromosomes begin to separate and move towards the centrozomes as the microtubules
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attached to them begin to decay. Once the chromosomes reach other ends of the molecule a 
new nuclear envelope is formed around them. This is the end of mitosis with only the 
surrounding cytoplasm needing to divide in the process know as cytokinesis, giving 2  
identical daughter cells . 62
2.3 The formation of Microtubules from Tubulin62
As mentioned above microtubules play a vital role in cell divison and disruption of the 
microtubules can have a major effect on the cell. Tubulin exists as 2 spherical proteins, the a 
and p tubulin subunits, each with a molecular weight -50 kDa. The 2 subunits come together 
to make a heterodimer. In the presence of GTP and 37 °C, the heterodimers combine in a 
head to tail fashion to form protofilaments comprised of a long line of alternating a  and p- 
tubulin subunits. After several minutes of protofilament formation, 12 to 13 protofilaments 
will come together and form a protein sheet, that curls up into a C-shape to give the pipe-like 
structure of the microtubule. The external diametre of the microtubule is -24 nm and the 
internal diamter is -15 nm across (Figure 11). There are several types of proteins that are 
associated with the microtubules and their formation, which are known as microtubule 
associated proteins (MAPs). The presence of the MAPs increases the speed of microtubule 
formation and protect it from depolymerization agents like low temperature and Ca2+ ions. 
There are also the microtubules organising centres (MTOCs) or centrozomes, where the 
microtubule starts its growth. The 3rd type of protein involved in formation of microtubules 
is y-tubulin, which may bind to the centrozome, from there it may act as a site for nucleation 
for incoming a,p-tubulin heterodimers.
Once formed the microtubule maintains it shape by remaining in a dynamic equilibrium 
where heterodimers constantly add to one end of the microtubule (+ end) and leave from the 
other end of the microtubule (- end). This is a finely balanced equlibrium which controls the 
length and function of the microtubule. Disruption of this equlibrium will affect a number of 
cell functions including cellular divison.
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Figure 11: Polymization of Tubulin to Microtubules63
2.4 The Role and Dynamic Instability of Microtubules
As well as being vital to mitosis, microtubules are also key components of the cytoskeleton 
and are critical in the development of and maintenance of cell shape. They are also involved 
with the transport of vesicles, mitochondria and other components though out the cells, 
needed for cell signaling and mitosis.63 One o f the most remarkable features of microtubules 
is its dynamic instability, with it constantly growing or shrinking depending on the needs of 
the cell. The half life of a microtubule can range from several hours in the interphase when 
the cell is preparing itself for replication o f the DNA, to tens of seconds in the metaphase 
where the new strands of DNA are separated and moved to other ends of the cell so it can 
divide.61 If the equilibrium of formation of microtubules from tubulin can be disrupted by 
using an agent that will inhibit the decay of microtubles or the binding of tubulin to form 
microtubules, then the separation of chromosomes can be prevented and cell divison stopped. 
This makes microtubules and tubulin an interesting biological target.
2.5 Classes of Mitotic Spindle Poison61*63
Tubulin is the target o f several drugs used clinically in the treatment of cancer. These drugs 
can be classified by which site they bind to on Tubulin. These sites include the Colchine 
binding site, the Vinca Alkaloid binding site, the Rhizoxin/Maytansine binding site and the 
Taxane binding site. However some agents do not bind to any of these sites and instead have 
an affinity for reactive groups on tubulin like cysteine sulfhydryl groups.
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2.5.1 The Colchicine Binding Site
Colchicine (50) is considered to be the classic tubulin binding agent.64 
It was first isolated from the meadow saffron Colchicum autumnale 
and is a highly soluble alkaloid65 which is currently used as an 
effective treatment for gout. However it has proven to be too toxic to 
use in other therapies. It binds to a high affinity site on the tubulin 
heterodimer which causes a structural change and the partial unfolding of structure of p- 
tubulin. It is this change that disrupts the region needed for microtubule formation.66 Ravelli 
and coworkers have recently reported the structure of tubulin-colchicine complex, identifying 
the colchicine binding site on the P-tubulin subunit.67 The colchicine (50) binds at a location 
which curves the tubulin and prevents it adopting a straight structure, which is needed for the 
formation o f microtubules (Figure 72).67
—  a-tubulin
—  B-tubulin
—  colchicine (50)
Figure 12: X-ray crystal structure o f colchicine binding site to the p-tubulin subunit.67
Structural related analogues of Colchicine (50) that retain their 
binding affinity to the colchicine site of tubulin include 2- 
methoxy-5-(2’,3’,4,-trimethoxyphenyl)tropone (51), which 
prevented microtubule assembly at concentrations comparable to 
Colchicine (50) itself. However the analogue that has no 
methoxy groups on the B ring (52) is almost inactive.68
52
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Centauriedin (53) a natural flavone isolated from Polymnia 
fruticosa, prevents the binding of Colchicine (50) to tubulin 
and the formation of microtubules.69 Since the discovery that 
centauriedin (53) causes mitotic arrest by destabilizing the 
mitotic spindle, other flavones have shown tubulin inhibiting 
properties such as the flavone (54) isolated from both 
Zieridium pseudobtusifolium and Polansia dodecandra. 70,71
Chalcones. A series of chalcones, typified by 55 were 
synthesized by Edwards and co-workers and were shown to 
be potent cytotoxic agents. 72 Lawrence and co-workers 
revealed 56 as a potent anticancer agent73 with many other 
chalcones displaying high levels of cytotoxicity. Lawrence 
and co-workers have also used parallel synthesis to produced 
a library of over 600 chalcones, yielding 16 positive hits from 
their bioassay screening of the library, with the most active 
being chalcone 57 . 74 Such agents induce mitotic arrest, 
strongly binding to tubulin and preventing microtubule 
assembly. This will be discussed in more detail in chapter 3, 
since this forms the basis of the work described in this 
dissertation.
Combretastatins. The stilbene Combretastatin A-4 (58) is 
one of the most potent inhibitors of the colchicine binding 
site. 75 It was first isolated from the South African Willow, 
Combretum caffrum, along with the less active 
Combretastatin 59 and Combretastatin A-2 (60).76 These 
compounds are some of the simplest structures that show 
antimitotic effects by interaction with the colchicine binding 
site of tubulin. Combretastatin A-4 (58) has also generated 
lots of interest due to its effects on the inhibition of 
angiogenesis, the growth and development of blood vessels77 
as well as its antimitotic effects.78
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Due to the biological effects of the Combretastatin A-4 (58) there have been many structure- 
activity relationship (SAR) studies reported in recent years to try and maximize their 
biological properties. It has been generally accepted that A-ring of 58 must be kept as 3,4,5-
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trimethoxyphenyl for 
compound to maintain e ' 
its potent antimitotic 
effects. 79 However 
recent work reported X F Cl Br X N3 NH2 F Br NO2 X N CH
by Pettit80 has shown that the methoxy group on the C3 position of the A-ring can be replaced 
with a fluorine group in 61, chlorine group in 62 or bromine group in 63 and still retain the 
antimitotic effects of 58. The hydroxy group on C3 position of the B-ring of 58 can be 
replaced by several different groups including azido group in 64,81 amine groups in 65,798182 
fluorine groups in 6 6 , 83 and still maintain high levels of cytotoxicity comparable to 58. The 
hydroxy group on C3 position can also be replaced by bromine groups in 67,84 and nitro 
groups in 6 8 w or the whole B ring can be replaced with quinoline groups in 6985 or a 
napthalene group in 7086 87 and still retain good high levels of cytotoxicity, but not as high as 
58.
The SAR studies have also involved modification of the group that links the A and B rings. 
The c/s-ethene linker has been replaced with an ethane linker in 71,88and had an additional 
double bond in 7289 or triple bond in 7390 unit introduced to the linker as well. These changes 
to the linkers have all resulted in a general loss of cytotoxicty.
OH
MeO OMe 73 OMe
MeO
MeO
OMe
OMe
74 75 76 77 78
R Me Et CONH, NHC0 2 CN
X OH OH OH F NH2
The introduction of various alkyl groups in 74 -  75,91 R
acylamide groups in 76 -  I T 2 and other bulky groups799192 
attached to the ethene linker also gives CA4 analogues with 
reduced cytotoxicity. The nitrile group in 7879 appears to be 
largest group tolerated on the ethene cross linker with out 
causing a large loss cytotoxicity.
Various c/s-locked analogues of 58 have also been investigated, replacing the c/s-ethene 
linker with either an 1,2,-disubstituted five membered heterocycle such as imidazole 79 or 
oxazole 80 gave several compounds which inhibited tubulin polymerization more potently 
than 58 while still being less cytotoxic.93 The replacement of the cis-ethene linker with a 
furazan ring gave a compound 8194 that was 4 times more cytotoxic than Combretastatin A-4 
(58) and inhibited tubulin polymerization.
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Clinical trials of Combretastatin A-4 (58) have been hindered by its low water solubility, 
prompting research into Combretastatin analogues with enhanced solubility. Ohsumi and co­
workers synthesized a more water soluble analogue of Combretastatin A-4 (58) in which the 
phenol group of the B ring was replaced with an amino group, (AC-7739, 82).79 This 
analogue proved to have a more potent antitubulin activity than its parent molecule. 
Cushman and co-workers made a series of
solubility and bind to tubulin in a similar 
manner to Combretastatin A-4 (58).75
Other recent areas of Combretastatin research is the development of a chimeric compound 84
come multidrug resistance (MDR) protein induced by various alkylating agents. The chimeric 
compound 84 which is a cross between Chlorambucil (4) and Combretastatin A-4 (58) is 
reported to inhibit tubulin polymerization concentrations as low as would be expected for 58. 
At higher concentrations the nitrogen mustard alkylates tubulin and inhibit tubulin 
depolymerization much like Paclitaxel (85).95
Benzophenones. The benzophenone analogue of Combretastatin A-4 (58), Phenstatin (86) 
was isolated as a side product from the Jacobsen oxidation of 58.96 Phenstatin (86) proved to
is also highly cytotoxicity, but not as cytotoxic as 58.97 Several SAR studies96"99 have been 
carried out on the benzophenone scaffold, trying to improve the biological activity of the 
Combretastatin A-4 like benzophenone. Many of the compounds made have inhibition of
benzylamines hydrochlorides typified by 
83, these compounds displayed good water
iNn.HCI
bearing the Combretastatin and nitrogen mustard core to see if this combination could over
be a potent inhibitor of tubulin polymerization, comparable to Combretastatin A-4 (58).% It
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tubulin polymerization activity comparable to 58, many of them weren’t as cytotoxic as 58. 
However the 2-aminobenzophenones 87 and 8 8  proved to be as cytotoxic as Combretastatin 
A-4 (58).97
0  NH2
MeO
OMe MeO
OMe
OMe MeO
OMe
86 87
OMe OMe 
88
Further investigation showed that the 2-amino-4-methoxyphenyl ring of benzophenone 
analogue 87, can be replaced 3-amino-6-methylbenzo[b]thiophene to give 89 which proved to
be more active than 58 as an inhibitor of
MeO
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tubulin polymerization, however it wasn’t as 
cytotoxic. 100 The B ring of phenstatin (8 6 ) has MeO 
also been replaced by various heterocycles 
like 3-aroylindoles 90,101 benzo[b]thiophenes
benzo[b]furans 92,w or indoles 93,,<u M e 0  
many of which proved to be more potent  
inhibitors of tubulin polymerization than 
Combretastatin A-4 (58), however none of
them are as cytotoxic as 58. The replacement of the carbonyl linker group between the 2 aryl 
rings with a methylene group led to a complete lose of biological activity. " 104 The presence 
of 3,4,5-trimethoxyphenyl ring has also proved to be vital for biological activity.
Cornigerine (94) a natural product isolated from Colchicum 
cornigerum, resembles a hybrid of Colchicine (50), podophyllotoxin ^
(34) and steganacin (95). As would be expected from the similarity of 0
its structure, 62 displays a similar effect binding to the colchicine site 
with high affinity. 105
Steganacin76 (95) was isolated in 1973106107 from the stems and stem bark 
of the east African tree steganataenia araliacea Hochest, and was found to 
have in vivo antitumour activity against P388 leukaemia in mice and in 
vitro against human nasopharynx carcinoma cell line KB. 106 Steganacin 
(95) completely inhibits cleavage in fertilized sea urchin eggs at 
concentration of 0.3 pM by preventing the formation of mitotic 
apparatus. 108 Steganacin (95) shares structurally features with both Colchicine (50) and
OMe
••NH
MeO
94 OMe
MeO 95
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Podophyllotoxin (34), with all 3 compounds sharing a trimethoxybenzene ring. Like 
Podophyllotoxin109 (34), Steganacin (95) binds to tubulin with an affinity similar to 
Colchicine (50), and is, in fact, a competitive inhibitor of colchicine binding to tubulin. ,08-I,0-,I:3 
Steganacin (95) has also been shown to inhibit in vitro polymerization of microtubules, 108,110111 
with an IC50 value of 1.5 -  3.5 pM , 110,111 which makes it slightly less active than both 
Colchicine [50, IC5o(polymerization of microtubules) 2.5 pM]m and Podophyllotoxin [34, 
IC5o(polymerization of microtubules) 0.6 -  1.7 pM] 110111
Podophyllotoxin (34), Etoposide (35) and Teniposide (36). Podophyllotoxin (34) is isolated 
from the dried roots of the American mandrake Podophyllum peltatum. It has been used as a 
medical treatment for hundreds of years for conditions ranging from sclerosis of the liver 
through to constipation, rheumatism and cancer. Podophyllotoxin (34) has been shown to 
bind reversibly to at least part of the colchicine site of tubulin and binds as a competitive 
inhibitor. 109 However Podophyllotoxin (34) proved to be too toxic for clinical use in the 
treatment of cancer, so two less toxic semisynthetic analogues have been developed 
Etoposide (35) and Teniposide (36).114 Although both compounds bind to tubulin, it is 
thought now that they function predominantly by inhibition of DNA topoisomerases II, an 
enzyme involved in the unfolding of DNA in cell replication, rather than a microtubule 
interaction. 115
2.5.2 Vinca Alkaloid Binding Site.
The two vinca alkaloids Vinblastine (32) and Vincristine (33) were isolated from the 
Catharanthus roseus periwinkle. They are both used as clinical anticancer drugs for the
35 Etoposide
36 Teniposide
R
OMe
34
OH
treatment of leukaemias, 
lymphomas and some solid 
tumours. 116 Both these agents 
bind to a site on the p-tubulin 
subunit of the heterodimer117
32 Vinblastine Me OMe Ac
33 Vincristine CHO OMe Ac
r 1  O R2 96 Vindesine Me NH2 H
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with a high affinity for the protein118 and induce destabilization of polymerized tubulin. The 
destabilizing effect results from the stoichiometric endwise poisoning of the tubulin 
heterodimer, presumably preventing polymerization from occurring by blocking the region 
involved in heterodimer attachment. Due to the dynamic nature of microtubules constantly 
polymerizing and depolymerizing, a vinca alkaloid poisoned heterodimer can be easily 
introduced to the microtubule, thus preventing further growth. The incorporation of the vinca 
alkaloid onto the heterodimer is rapidly reversible and occurs at 2 sites per tubulin dimer. As 
well as the two natural products 32 and 33, a third effective alkaloid has also been produced 
by functional group transformation, Vindesine (96) and works by the same mechanism. 
Other Vinca Alkaloid binding site agents include halichondrin B (97), the hemiasterlins119 and 
the spongistatins, 120 all isolated from various marine sponges. Halichondrin B (97) has been 
isolated from several sponges Halichondria okadai,121 Axinella sp ,122 Phankellia carteri123 and 
Lissodendoryx sp,124 and have potent in vitro and in vivo activities against melanomas and 
leukaemias. 125 Halichondrin B (97) is extremely rare in the marine sponges, with only 12.5 
mg of 97 being isolated from 600 kg of Halichondria okadai,121 and would have limited the 
study of 97 as a viable tubulin targeting agent. Fortunately the complete synthesis of 97 was 
reported by Aicher and coworkers126 and further research into the structure has led to the 
structurally simpler analogs, ER-076349 (98) and ER-086526 (99) which still retain the 
biological activity of 97.125 The hemiasterlins are a family of cytotoxic and antimitotic 
tripeptides that have all been isolated from various marine sponges, such as Avletta sp 
[hemiasterlin (100), hemiasterlin A (101) and hemiasterlin C (102)]127 and Cymbastela sp 
[hemiasterlin A (101) and hemiasterlin B (103)].128 Despite their relatively simple structures 
the hemiasterlins A and B (101 and 103) are more potent in both cytotoxic and antimitotic 
activity than other microtubule agents such as Vinblastine (32) and Paclitaxel (85).119 
Spongistatins 1 -  9 129 are a group of macrocyclic lactones compounds130 which have been 
isolated from various marine sponges, Spongistatin 1 (104) was isolated from the Republic of 
Maldives Spongia sp. 131 The Spongistatins have all proven to be highly cytoxic, with 
Spongistatins 1 (104) having an I C 5 0  value of 0.03 nM for the inhibition of L 1 2 1 0  murine 
leukaemia cells . 129
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2.5.3 Rhizoxin/Maytansine (RZX/MAY) Binding Site.
RJiizoxin (105) was isolated from the fungus Rhizopus 
chinensis and is an antifungal agent which also acts as an 
antimitotic agent. Like many of the agents that bind to the 
RZX/MAY binding site, 105 was originally thought to be 
binding to the Vinca alkaloid binding site. However 
Rhizoxin (105) has been shown to have its own binding site 
that slightly overlaps with the Vinca alkaloid binding 
site. 132 Rhizoxin (105) is effective against hundreds of 
cancer cell lines and some vinca alkaloid resistance 
tumours, it also competively inhibits Maytansine (106) 
binding and exhibits similar effects.62 Maytansine (106) is 
isolated from various plants in the Maytenus family. It is 
the most potent of a family of highly cytotoxic 
macrolides. 133 Maytansine (106) binds to tubulin and in a 
reversible manner and can competitively inhibit the vinca alkaloids 32 and 33 . 134 Maytansine
HO,
OMe
105
Cl \
MeO.
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(106) binding to tubulin causes disassembly of the microtubules and prevents tubulin 
spiralization. 135 Other RZX/MAY binding site agents include Cryptophycin I , ' 36 the 
Dolastatins137 and Phomopsin A . 138
2.5.4 Taxane Binding Site.
Paclitaxel (Taxol™) (85) first isolated by Monroe Wall and Mansukh Wani in 1967 from the 
bark of a yew tree. 139 It was largely ignored as antimitotic agent, due to low availability and 
poor water solubility, until 1979 when the discovery that it stimulated microtubule 
polymerization, unlike the Vinca alkaloids which induce destabilization of polymerized 
tubulin. 140 Four groups have succeeded in the total synthesis141' 145 of Paclitaxel (85), and it is 
now used to treat breast and ovarian cancer as well as non-small-cell lung cancer and 
Kaposi’s sarcoma.63 The binding site of Paclitaxel (85) is on the p-subunit of tubulin and is 
on the inside of the surface of the microtubule, 146 and this binding stabilizes the microtubule 
and increases its polymerization. Taxotere (107) is a late stage intermediate in a synthesis of 
Paclitaxel (85) from a precursor readily obtained from needles from a yew tree. It displays a 
similar spectrum of activity as 85 but with a four fold increase in potency and improved water 
solubility. 147 It is currently used in clinical treatments of prostate, brain and lung tumours.63
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Discodermolide (108) is a potent immunosuppressive lactone isolated from Caribbean Sea 
sponge Discodermia dissolute. It also inhibits the dynamic nature of microtubules by binding 
to the microtubule and making it abnormally stable. Studies show that 108 shares the same 
binding site as Paclitaxel (85), has a greater affinity for this site. 148149 Discodermolide (108) is 
currently in phase I clinical trials.63 The Epothilones (e.g. 109 and 110) a family of 16 
membered macrolides isolated from the myxobacterium Sorangium cellulosum. Like 
Discodermolide (108) they are competitive inhibitors of the binding of Paclitaxel (85) to 
tubulin, exhibiting activity similar to 85 at the same concentrations. 150 It is thought that 
Paclitaxel (85) and the Epothilones may share a common pharmacophore and adopt similar 
conformations in vivo.151 The Epothilones are currently used clinically in the treatment of 
Paclitaxel-resistant tumours.63
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2.6 Antivascular effect 152.153
The tumour vasculature network is an important cancer therapy target. By disrupting the 
tumour vasculatures, the vital supply of oxygen and nutrients in blood that feeds the tumour 
will be cut off causing most tumours to starve and die. Antivascular agents inhibit tumour 
vascular function in 2  different ways; some inhibit the formation of new blood vessels, 
angiogenesis, 154 to tumours, while other compounds, especially tubulin targeting agents, have 
been shown to rapidly shut down existing tumour vasculatures. 152 Several Colchicine binding 
site agents are currently in clinical trials, including Combretastatin A-4 3-O-phosphate (CA- 
4-P) (111), Combretastatin A-1-phosphate (CA-l-P) (112), ZD6126 (113) and AVE8062A 
(114).152 Certain dolastatins like TZT-1027 are also in clinical trials for their antivascular 
effect, but target the vinca alkaloid binding site instead. 6 3 155
Combretastatin A-4 3-O-phosphate (CA-4-P) (111) has been shown 
to cause microtubules in endothelial cells to undergo rapidly 
depolymerization in a matter of minutes, which causes the cells to 
become round and the vasculature to become leaky, also known as 
blebbing. This eventually leads to secondary tumour cell death. 156 In M e 0  
vivo testing on P22 tumour in rats with CA-4-P (111) showed that MeO 
the blood flow rate to the interior of the P22 tumour dropped to <5 % 
of the starting value within a minute after the administration of 1 1 1 , 
and this value fell to almost zero after an hour. 157 MeO
Also importantly further in vivo studies on P22 tumour in rats with MeO 
1 1 1  showed that its antivascular effects are selective against tumour 
vasculature without causing significant harm to normal tissue. 158 The 
reason for the selective nature is not known, however it has been
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suggested that it may be due to the difference between mature MeO
normal vasculature and immature tumour vasculature. Normal 
vasculature can sustain more endothelial cell injury without the
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vascular collapse than the less developed cytoskeleton of the tumour vasculature. 157 The 
selectivity could also be due to the difference in blood flow rate of tumours and normal 
tissue, with tumour blood flow rate being far more slow than that of normal tissue, making 
the tumour more susceptible to CA-4-P (111).157 Also differences in tumour and normal 
tissue endothelial cells, like proliferation rate, 78 post-translational modifications of tubulin 
and the interaction of actin cytoskeleton and tubulin might also contribute to the specificity of 
vascular-targeting agents like CA-4-P (110).157
Many of the classic mitotic spindle poisons, such as Colchicine (50), Vincristine (33) and 
Vinblastine (34) induce similar deleterious effects on endothelial cells in culture and damage 
tumour vasculature in animals at high concentrations. However it has been shown that these 
new vascular targeting agents are effective at much lower concentrations, for instance 1 0  % 
o f its maximum tolerated dose of CA-4-P (111) has be shown to shut down tumour blood 
flow rate after 24 hours. 152 However at even lower concentrations 1 -  3 % of the maximum 
tolerated dose, similar reductions in tumour blood flow did occur but after 24 hours the blood 
flow rate had recovered, showing that the antivascular effects of the CA-4-P (111) are 
reversible at to low a concentration. The desired affects of microtubule targeting agents as 
either antiproliferative agents or as a vascular targeting agent may depend on its 
pharmacodynamics and pharmacokinetic characteristics, like the reversibility of the tubulin 
binding and its retention time in cells. Agents that can rapidly bind to tubulin/microtubules 
and cause microtubules to depolymerize and are rapidly metabolized by the body may act 
best as antivascular agents. While those agents are retained in cells and induce long term 
mitotic block might work best as antiproliferative agents causing apoptosis. 63
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3.1 History and dev elopment of the chalcone project.159
In 1994 our group launched a plant screening program160' 162 to investigate the cell growth
inhibitory properties of plant extracts from plants used in traditional Chinese medicine. The
dried whole plant of Scutellaria barbata D. Don (Labiatae)
(Figure 13) is used in traditional Chinese Medicine as an 
anti-inflammatory, anti-tumour agent and as a diuretic. 163 It 
is used clinically to treat cancers of the digestive system, 
lung, breast, liver. 163 Clinical studies have shown that 62% of 
patients suffering with primary liver cancer hepatoma were 
totally cured when treated with S. barbata.163 The book 
Anticancer Medicinal Herbs details the use of Scutellaria 
barbata in several different anti-cancer herbal therapies, for 
instance the ingredients for the treatment of ovarian cancer 
consists of Scutellaria barbata (50 g), Solani nigri (30 g),
Solani lyrati (30 g), Oldenlandia diffusa (30 g) and Carapax 
trionycis (30 g) . 164
The herb is known to contain several alkaloids and flavones, however the active anti-tumour 
ingredients of Scutellaria barbata were unknown. Bioassay guided fractionation of the 
methanol extract of Scutellaria barbata, using the MTT assay165 to determine the cytotoxicity 
of each fraction against the K562 human leukaemia cell line, led to the discovery of a fraction 
which had an IC50 (K562) of 7.5 pg/mL. 161 Further chromatography of the active fraction 
showed that the major component of this fraction was the a,p-unsaturated ketone £-l-(4’- 
hydroxyphenyl)-but-l-en-3-one (113) which displayed weak cell growth inhibitory 
properties, IC50 (K562) 60 pM.
Figure 13: Scutellaria barbata
113
IC50 (K562) 60 pM IC50 (K562) 1.9 pM
115
IC50 (K562) 2.6 pM
A library of over 30 /ram-phenylbutenones was then prepared and screened for its cell 
growth inhibitory properties. 166 It was found that the butenones processing electron 
withdrawing groups were the most active. For instance the pentafluorophenylbutenone 114
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was over 30 times more active than 113 and the nitrophenylbutenone 115 was over 20 times 
more active than 113.
Such findings prompted the investigation of replacing the methyl group of the trans-
phenylbutenone with substituted aryl groups to make chalcones to see what effect this
substitution had on its anti-cancer properties. The chalcone scaffold, 1,3-diary lprop-2-en-l- 
one, is commonly found throughout the plant kingdom. Chalcones 
have been shown to elicit various biological effects including anti- 
fungal, 167168 anti-inflammatory, 169170 anti-bacterial, 169171 anti- 
malarial, 172173 and anti-mutagenic174 175 properties. It was Edwards et 
al.72 who reported the anticancer activity of chalcones, with the 
chalcone MDL 27048 (55) being a very potent antimitotic agent.
Various substituted chalcones 116 -  J2773176177 were then prepared to further investigate the 
prerequisites needed for high cytotoxicity. The chalcones were prepared through the base 
catalysed Claisen-Schmidt aldol condensation178 of substituted benzaldehydes and substituted 
acetophencnes. It became apparent that the aryl ring substitution was again an important 
factor, as the anticancer activity of the chalcone may be improved or diminished depending 
on the arrangements selected (see fable 1).
O
Ar, X ^ A r2
116-127
Table 7: Cell growth inhibitory properties of substituted chalcones 116 -  127
Chalcone Ar1 Ar2 IC50(K562) pM
116 3,4,5-Trimethoxyphenyl 3,4-Dimethoxyphenyl 0.3
117 3,4,5-Trimethoxyphenyl 3-Hydroxy-4-methoxyphenyl 0.0043
118 3,4,5-Trimethoxyphenyl 4-Methoxyphenyl 0.3
119 3,4,5-T rimethoxypheny 1 Benzo[</|[ 1,3]dioxol-5-yl 0.3
1 2 0 3,4,5-Trimethoxyphenyl 2,3-Dihydrobenzo[b][ 1,4]dioxin-6-yl 0.08
1 2 1 3,4,5-Trimethoxyphenyl 2,4,6-T rimethoxyphenyl 0 .2
1 2 2 2,4,6-T rimethoxyphenyl 3,4,5-T rimethoxyphenyl 0.3
123 3,4-Dimethoxyphenyl 2,4,6-T rimethoxyphenyl 0.3
124 3,4-Dimethoxyphenyl 3-Hydroxy-4-methoxyphenyl 0 .6
125 3-Hydroxy-4-methoxyphenyl 3,4,5-T rimethoxyphenyl 0 .1 2
126 Thiophen-2-yl 3,4,5-Trimethoxyphenyl 1.2
127 2,5-Dimethylfuran-3-yl 3,4,5-Trimethoxyphenyl 2 .8
The Combretastatin A-4 (58) chalcone analog 117 was the most potent cell growth inhibitor 
prepared, with a cytotoxicity in the nanomolar region (117, IC50 4.3 nM). The introduction of
OMeO
NMe:
IC50 (HeLa) 12 nM
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the 3-hydroxy substitution on the B-ring greatly increases the cytotoxicity of chalcone 117, 
the chalcone 118 without the 3-hydroxy substitution is nearly 70 times less active than 117. 
The presence the 3,4,5-trimethoxyphenyl A-ring of chalcone 117 also appears vital to the 
cytotoxicity, which is shown when compared to the 3,4-dimethoxyphenyl analogue 124 
which is nearly a 140 times less active than 117.
The ease of the synthesis of chalcones provided an opportunity to make a large number of 
analogues. The Claisen-Schmidt condensation178 method is attractive because it 
predominantly generates the £-isomer, normally in high yields, from substituted 
benzaldehydes and acetophenones, a large number of both are commercially available and 
inexpensive. A 644-membered library of chalcones was prepared by parallel synthesis using 
the Claisen-Schmidt condensation178 of 23 substituted acetophenones and 28 substituted 
benzaldehydes all commercial available and selected randomly in a conventional 96-well 
tissue culture test-plate. 74 The cytotoxicity of these chalcones was conveniently determined 
upon the crude products directly in the 96-well tissue culture test-plate, at a concentration of 
5 pM, by conventional MTT assay165 Sixteen wells gave a positive bioassay response; a 
“success” rate 2.5 %. The 16 chalcones were then prepared conventionally on a 10 mmol 
scale, and the chalcones were indeed all active with an I C 5o ( K 562 )  less than 5 pM. Seven of 
these chalcones had an I C 5o ( K 562 )  less than 1 pM, with chalcones 57 and 128 being the most 
active. Chalcone 57 was also reported to cause cell cycle arrest at the G2/M point and binds 
to the colchicine binding site of tubulin, further testing shows that the chalcone inhibits the 
polymerization of tubulin with an I C 5 0  value of 1.5 pM which is comparable to 
Combretastatin A-4 (58, reported I C 5 0  for the inhibition of tubulin polymerization varies 
between 0.5179 -  2180 pM).
O O  O
NaOH
Assayed crude
OMeO Me
OMeMeO'
OMe 128
Me
HO.
OMeMeO'MeO
57
IC50 (K562) 30 nM IC50 (K562) 40 nM
Attention was then moved onto the effects of modifying the “bridge” linking the two aryl 
groups. The reduction of the carbon -  carbon double bond of chalcone 117 to the ketone 129
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resulted in a loss of activity, as did the subsequent reduction of the carbonyl functionality of 
129 to 130.m
OH
MeO. OH MeO OH MeO. OH
MeO' OMe MeO OMe MeO OMe
OMe OMe OMe117 129 130
1C50(K562) 4.3 nM IC50 (K562) 1 pM IC50 (K562) 1 pM
Changing the carbon-carbon double bond into an epoxide has been reported to increase the 
chalcones mutagenic properties by Rashid and co-workers. 182 This prompted the investigation 
of the effects of introducing an epoxide to see what effect this would have on cytotoxicity. 
Interestingly the results obtained showed no significant loss of activity and the chalcone 
oxide 131 of chalcone 132 displays a slight increase in activity.'177
MeO
MeO
OMe MeO
OMe MeO
OMe OMe
CL >H
132
IC50  (K562) 1.5 pM
OMe OMe131
IC50 (K562) 0.8 pM
The importance of the a,p-unsaturated ketone was shown again in a series of ester 133 and 
amide 134 chalcone derivatives where the a-carbon had been replaced with either an oxygen 
or a nitrogen respectively. Both linker changes caused significant lose in activity when 
compared to the equivalent chalcone 116.183
OMe MeO 
OMe MeO
OMe MeO 
OMe MeO
OMe 116
IC5 0  (K562) 0.3 pM
OMe 133
I C 5 0  (K562) 1 1  pM
OMe 134
IC50 (K562) 83 pM
It has been speculated that the importance of the a,p-unsaturated ketone to the activity of the 
compound is down to two possible reasons. The first is that the enone system could undergo 
nucleophilic attack via a Michael-type addition. Thus strong binding at the colchicine binding 
site may be the result of the enone system covalent binding to the tubulin. The second reason 
is that the role of the carbonyl and alkene group is to simply present the two aryl groups in a 
way that favours strong non-covalent binding to the tubulin.
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Edwards72 chalcone study showed that the presence of a methyl group on a-position to the 
carbonyl increased the cytotoxicty of the chalcone when compared to its 
a-hydrogen bearing chalcone equivalent. For instance the a- 
methylchalcone 55 is twice as active as chalcone 135. Edwards gave no 
explanation for this.
The paper72 also reports data on a selection of a-halogen bearing 
chalcones. It showed that the introduction of bromine group onto the ex­
position of the chalcone 136 increased its cytotoxicity, compared to the 
a-bearing chalcone equivalent 135. While the introduction of the 
chlorine group decreased the activity of the chalcone 137.
OMe NMe
IC50 (HeLa) 12 nM 
OMeO
OMe
NMe2
135
IC50 (HeLa) 24 nM
We then decided to investigate the introduction of various groups on the 
C-2 position of the chalcone to see the effects upon anticancer activity of 
the compounds and to try and account for the effects these groups have 
on the activity of the chalcone. It was suspected that the biological 
effects may be caused by the conformation that the chalcone adopts.
The a-methylchalcone of the CA-4 like chalcone 117 was quickly 
prepared. The £-isomer of the CA-4 like a-methyl chalcone 56 was 
isolated and had an exceptionally impressive IC50 value of 0 . 2 1  nM, a 2 0  
fold increase in activity over chalcone 117. While a (Z)-enriched 
mixture of 138 (£:Z, 1:5 determined by 'H NMR) gave an IC50 value of 
60 nM . 73
OMeO
OMe NMe136
IC50 (HeLa) 19 nM 
OMeO
OMe NMe
137
IC50 (HeLa) 43 nM
£-isomer
OMe
1 1 7
MeO.
OHMeO
OMe OMe
Z-isomer 
OMe
MeO
OMeMeO
OH
1 3 8
I C 5 0  (K562) 4.3 nM I C 5 0  (K562) 0 . 2 1  nM
Single crystals of chalcones 117 and 56 were obtained by careful diffusion crystallization and 
their structures determined by X-ray crystal structure analysis (Figure 14 and 75). The 
crystal structure of 56 confirmed the (£)-configuration of the carbon-carbon double bond.
The X-ray crystal structure of 117 and 56 revealed an interesting relationship between the 
conformation of the chalcone and its cytotoxicity. The structure of chalcone 117 shows that 
the carbon-oxygen double bond and the carbon-carbon double bond are positioned in a cis
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conformation relative to each other around the C1-C2 single bond (illustrated in the s-cis 
confomer Figure 14). While the more active a-methyl chalcone 56 structure shows that its 
carbon-oxygen double bond and the carbon-carbon double bond are positioned in a trans 
conformation relative to each other around its C1-C2 single bond (illustrated in the s-trans 
confomer Figure 15).
Figure 14: X-ray crystal structure of chalcone 117
s-trans
MeO.
.OHMeO'
OMe OMe
Figure 15: X-ray crystal structure of chalcone 56
These results were supported by a number of examples in the literature showing that the X- 
ray crystal structures of chalcones bearing hydrogen on the a-position to the carbonyl adopt 
the s-c/'s conformation. 184*187 A number of chalcones bearing various bulky groups at the ex­
position to the carbonyl, including methoxy, 188 azido189 and pyridinium190 groups, for which X- 
ray crystal structures have been determined, adopt the s-trans conformation.
The introduction of various alkoxy groups at the C-2 position of the chalcone has been 
investigated. 191 The CA-4 like a-methoxychalcone 139 showed the greatest anti-cancer 
activity of all of the a-alkoxychalcones, with an increase in cytotoxicity over the 
unsubstituted chalcone 117. However it proved to be less toxic than the a-methylchalcone 
56.
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The effects of varying the size of the alkoxy groups on the C-2 position showed that 
increasing the size of the alkoxy group led to a slight lose of activity. For example the a- 
methoxychalcone 1 4 0  was more active than the a-ethoxychalcone 1 4 1 ,  which in turn was 
more active than the a-propoxychalcone 1 4 2 .
The X-ray crystal structure of a-methoxychalcone chalcone 1 4 3  shows that a- 
alkoxychalcones adopt the s-trans conformation (Figure / 6 ) . 141
Figure 16: X-ray crystal structure of chalcone 1 4 3
A series of aurones 1 4 4  (conformationally-restricted analogues of the chalcones) was 
prepared and assessed for anti-cancer activity. 142 This was done to investigate the effects of 
the aryl ring orientation about the rotatable bonds a and c and their influence on the 
cytotoxicity of the molecule (Figure 17).
O O
IC50 (K562) 4.3 nM IC50 (K562) 0.21 nM IC50 (K562) 1.5 nM
IC50 (K.562) 3.7 nM IC50 (K562) 1 1 nM IC50 (K562) 20 nM
OMe 
1 4 3  T
MeO
MeO
OMe
R
5 6 144
Figure 17: Structure of aurones
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This study also provided a route for the total synthesis of the aurone 145 isolated from Uvaria 
hamiltonii by Wani and co-workers. 193 The 3’,4’-dihydroxy B-ring of extracted aurone 145 
and aurone 146 made both aurones fairly inactive, however the replacement of the 4’- 
hydroxy on the B-ring of 146 with a 4’-methoxy to give the CA-4 like aurone 147 causes the 
cytotoxicity to be significantly increased. The same replacement of the 4’-hydroxy group on 
145 with the 4’-methoxy group 148 decreases the cytotoxicity of the aurone. It seems to 
suggest that the 5,6,7-trimethoxy A-ring of 147 is vital for good cytotoxicity, while the 4,5,6- 
trimethoxy A-ring of 148 is detrimental to its activity. 192
OMe o
MeO
MeO'
OH
MeO.
MeO'
OHOMe
R R
145 R = OH, IC50 (K562) 12 pM 146 R = OH, IC50 (K562) 10 pM
148 R = OMe, IC50 (K562) 18 pM 147 R = OMe, IC50 (K562) 50 nM
Using the protocol developed by Wheeler and co-workers194 the aurones were transformed 
into their corresponding flavones by simply heating in the presence of KCN. The most active 
flavone was the CA-4 like flavone 149. Similar results to those of the aurones were found, 
with the CA-4 like 6,7,8-trimethoxy A-ring of 149 being vital to the cytotoxicity, and the 
5,6,7-trimethoxy A-ring of 150 having a detrimental effect on the activity of the molecule. 192
MeO.
.OHMeO
OMe OMe
.OHMeO 7
OMe
150 IC5o (K562) 22 pM 149 IC50 (K562) 40 nM
The activities of the aurones and flavones nevertheless show a significant decrease in activity 
compared to the chalcones 117 and 56, indicating the importance of rotational freedom 
around bond a (Figure 17).
Another group of conformationally-restricted chalcone analogues were prepared, the 
indanones 151.191 This was done to further investigate if the importance of the a,p~ 
unsaturated ketone to the activity of the compound. The indanones 151 were prepared via 
Nazarov cyclization by refluxing the precursor chalcone 152 in trifluoroacetic acid {Scheme 
7).195
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1 5 11 5 2
Scheme 7: a. TFA, reflux
The indanones show reasonable cytotoxicity. 191 However the CA-4 like indanone 153 is 
significantly less active than its precursor chalcone 117.191 This difference in activities isn’t 
really noticed in the fluoro indanone 154 and its precursor chalcone 155. The indanones 153 
and 154 both show modest inhibition of tubulin polymerization ( I T P )  with I C 5o ( I T P )  values 
of 1.9 pM and 4.0 pM respectively. 191 The IC5o(ITP) of 153 is comparable to that of 
Combretastatin A-4 (58, reported I C 5o ( I T P )  varies between 0.5179 -  2 180 fiM).
MeO.
MeO'
OMe
MeO.
MeO OMe
OMe
1 1 7  R = OH, I C 5 0  (K.562) 4.3 nM 1 5 3  R = OH, I C 5 0  (K562) 60 nM
1 5 5  R = F, I C 5 0  (K562) 0.3 pM 1 5 4  R = F, I C 5 0  (K562) 0.39 pM
The indanones were then reduced to give the indanols. The indanols show major loss in 
cytotoxicity, with the CA-4 like indanol 156 being 95 times less active than the precursor 
indanone 153.191
MeO.
MeO'
OMe
MeO.
MeO'
OH
OMe
1 5 7  1 5 6
I C 5 o  (K562) 2.1 pM I C 5 0  (K562) 5.7 pM
The biological properties of the indanols again show that the carbonyl group is vital to the 
cytotoxicity of the molecule. However while the indanones are less cytotoxic than their 
precursor chalcones, they still retain significant anti-cancer activity, supporting the idea that 
the purpose of the a,p-unsaturated ketone is to maintain the distance of the two aryl groups in 
a way that favours strong non-covalent binding to the tubulin. It appears that the ability of
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the enone system to undergo nucleophilic attack via a Michael-type is not an important 
determinant of biological activity.
3.2 a-Arylchalcones
Previous studies in our research group have investigated the substitution of the hydrogen on 
the C-2 of the chalcone with various other groups. This has given several active compounds 
including (£)-3-(3-hydroxy-4-methoxyphenyl)-1 -(3,4,5-trimethoxyphenyl)-2-methylprop-2- 
en-l-one (56), IC50 (K562) = 0.21 nM . 73 Other C-2 substitutions that have also been 
investigated include alkyl (158,159) or an alkoxy (139,160,161) groups. 177181191196
O
56 R = Me, 158 R = Et, 159 R = Pr 
139 R = OMe, 160 R = OEt, 161 R = OPr
To further the investigation into the effects of the substitution of the hydrogen on the C-2 of 
the chalcone, we set out to make a series of a-arylchalcones. The effects of this substitution 
upon the structure (especially the s-cis/s-trans preference) and the biological activity will 
feature highly in our study.
3.2.1 a-Arylchalcones - Synthesis, Results and Discussion
The approach to making the series of a-arylchalcones 162 we chose was the Suzuki coupling 
of an a-bromochalcone 163 and an arylboronic acid 164 to give the a-arylchalcone 162. This 
route was chosen due to the large number of commercially available arylboronic acids 
{Scheme 8).
.R
Me<X Br '  MeO,
MeO'
-ttR
- r  R
162
Scheme 8: a. Suzuki coupling conditions
The first step in the synthesis of the a-arylchalcones is the 
preparation of the chalcone (£)-l-(3 ,4 ,5 -trimethoxyphenyl)- 
3 -(4 -methoxyphenyl)prop-2 -en- 1 -one (165). The chalcone ^  R _ H ,C5o(K562) = 0  , , M 
165, was chosen over the more biological active chalcone 117 R = OH, IC50(K562) = 4.3 nM 
H 7 73 74 t 0  ease 0f  synthesis and no requirement of protecting groups later in the
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synthesis. With the chemistry validated we would return to the chalcone 117 later. The 
chalcone 165 was prepared in an excellent yield using the Claisen-Schmidt condensation178 of 
3,4,5,-trimethoxyacetophenone with p-anisaldehyde (Scheme 9). Inspection of the lH NMR 
spectrum clearly shows that the product chalcone is geometrically pure with only the trans 
isomer (Jh2-h3 15.6 Hz) being obtained.
MeO
MeO OMe
MeO
MeO OMe
OMe 165
O Br
MeO
MeO“ OMe
OMe
MeO
MeO
OMe “OMe167
Scheme 9: a. NaOH (2M) (aq), MeOH, r.t., overnight, 90%; b. Br2 (1M in CHCI3),
CHCI3, N2, 0  °C, 1 h, 99%; c. Et3N, CHC13, N2, 95 °C, 1 h, 60%.
A 1 molar solution of bromine in chloroform was then prepared; this solution was used to 
brominate the double bond of the chalcone 165. The bromine solution was added to the 
chalcone in chloroform at 0 °C {Scheme 9), giving a pink solid 166. The TLC of the product 
166 showed 2  spots, however the separation of these 2  products by column chromatography 
proved to be not trival. The 'H NMR spectrum of the crude product showed that it was 
approximately 90% pure {Figure 18) so it was used in the next step without purification.
JLLLjJL.  J wLl
7 4  7 2  7 0  6 t  6 6  6 *  6 2  6 0  5S 5 6  } 4  52  5
Figure 18: lH NMR spectrum of dibrominated chalcone 166
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We then needed to carry out a dehydrohalogenation reaction to give the a-bromochalcone 
167. This was first tried by treating 166 dissolved in chloroform, with DBU at room 
temperature for 30 minutes. This gave a mixture of E and Z isomers. We also performed the 
reaction at -30 °C for 2 hours and this also gave a mixture of isomers. Other a- 
bromochalcones have been made by treating the precursor dibrominated chalcone with 
triethylamine.197198 So the chalcone in chloroform was refluxed in excess triethylamine for 1 
hour. This procedure gave mainly one isomer; however it was noticed that the amount of the 
secondary isomer started to increase when the NMR sample was left out in the light. So it 
appeared that the product was light sensitive
The reaction was then repeated but wrapped in aluminium foil, purified by column 
chromatography and recrystallization from ethyl acetate and hexane, to give fine cream 
crystals of (Z)-2-bromo-1 -(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1 -one 
(167) in a reasonable yield (Scheme 9), that was geometrically OMeO
pure. The Z configuration of the compound was assigned by 
*H NMR spectral comparison to another (Z)-a-bromochalcone MeO 
168 reported by Bose197, the peak for the hydrogen attached to 
C3 of 168 was reported to occur at 7.72 ppm. The peak for the hydrogen attached to C3 of 
the geometrically pure 167 occurs at 7.69 ppm, looking at the crude mixture of the 2 isomers 
of 167 the peak for the hydrogen on C3 of the other isomer occurs at 7.31 ppm. Therefore we 
concluded that the pure isomer isolated was the Z-isomer due to the similarity of the 2 
spectral values. The structure was also conformed later by the X-ray crystals of several of the 
a-arylchalcones made from 167 (Figure 19 and 20).
The a-arylchalcone library was then to be synthesized by palladium-catalyzed Suzuki 
coupling of 167 and a selection of boronic acids.199 200 First, the palladium catalyst 
tris(dibenzylideneacetone)dipalladium(0).chloroform (169) had to be made as it is often most 
active when freshly prepared. The dibenzylideneacetone (170) was prepared by stirring 
acetone and benzaldehyde in the presence of sodium hydroxide in aqueous ethanol to give the 
Claisen-Schmidt condensation product as bright yellow crystals {Scheme 70).201 Only the 
trans isomer of dibenzylideneacetone (170) was obtained, this was clearly shown in ‘H NMR 
spectrum with 2 doublets at 7.09 and 7.75 ppm with a coupling constant of 16.2 Hz. 
Bis(dibenzylideneacetone)palladium(0) (171) was then prepared by heating a mixture of 170, 
sodium acetate and palladium chloride in methanol at 40 °C for 4 hours, forming a purple 
precipitate. This purple precipitate, bis(dibenzylideneacetone) palladium(O) (171), was then 
recrystallized from hot chloroform to give deep purple crystals of 169 {Scheme 10):202
50
Chapter 3 -  Combretastatin A-4 like chalcones and analogues. Results and Discussion
2 1
O O
170
b c
—► Pd(dba)2 ------► Pd2(dba)3 CHC1:
171 169
Scheme 10: a. 5M NaOH, ethanol, r.t. 1 hr, 50%; b. NaOAc, PdCl2, MeOH, 40 °C, 4 h, 
99%; c. CHCh, 74%.
The Suzuki coupling reaction of a-bromochalcone 167 and phenylboronic acid using the 
conditions described by Mull200 (Scheme 11) gave (£>l-(3,4,5-trimethoxyphenyl)-3-(4- 
methoxyphenyl)-2-phenylprop-2-en-l-one (172) isolated as cream fine needles after 
purification by chromatography and crystallization. Since this method proved successful a 
series of a-arylchalcones 173 -  177 was made from 167 using various substituted 
commercially available boronic acids.
MeOMeO
MeO MeO
OMe “OMe167
OMe172-177
Scheme 11: a. Pd2(dba)3.CHCl3 (2 mol%), PPh3 (4 mol%), Et2NH, Toluene, wPrOH, H20 , 
120 °C, 1 hr, yield (see table 2).
Table 2: a-Arylchalcones prepared by Suzuki coupling (see scheme 11).
R2 R3 R4 R6 Yield (%)
172 H H H H 43
173 H H OMe H 30
174 OMe H OMe H 37
175 H H NMe2 H 26
176 OMe OMe OMe H 61
111 OMe H H OMe 40
All the a-arylchalcones except 177 were isolated as a single isomer. X-ray crystal structures 
of the a-arylchalcones 173 (Figure 19) and 175 (Figure 20) show that these a-arylchalcones 
have the s-cis conformation around the C 1 -  C2 single bond. The X-ray crystal structures of 
the a-arylchalcones also show their carbon carbon double bond is of the E configuration.
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C(18)
C<») CO I
|C( 17)
C(13)S-CIS
'CO 6)14]IC<20)C<4> C(2SIMeO. K2)C(8j
* 2 1 )
OOl‘OMe C<22)
C(23)Me
OMe 0(8)
173
Figure 19: X-ray crystal structure of chalcone 173
lC(12) }C 0 7 )
kC(9)
•J16) 0 (5 )
CO )
kC(19)S-CIS
C(8l
>C(25)MeO.
C(21)l
MeO ‘OMe
OMe
(27)
C<2«7
Figure 20: X-ray crystal structure of chalcone 175
The 'H NMR spectrum of a-arylchalcone 177 shows that it is a mixture of the E and Z 
isomers. The 3:2 ratio favours for the Z-isomer. The 'H NMR signal of the hydrogen on C3, 
appears around 7.10 -  7.25 ppm in the other /T-conF/gi/rai a-arylchalcones. For 177 the 
olefinic signals occur at 7.13 ppm and 7.40 ppm {Figure 21).
MeO. Me
MeO.
MeO. ,OMe
M e0‘
M e0‘ MeOOMe
7.40 ppm
OMe
7.13 ppm 
177 £-isomer 177 Z-isomer
Figure 21: Structure of E and Z isomers of a-arylchalcone 177
We then decided to make another a-bromochalcone 178 bearing the unsubstituted phenyl 
group. The starting chalcone 179 was isolated as light yellow crystals after treating 3,4,5-
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trimethoxyacetophenone and freshly distilled benzaldehyde with the previously mentioned 
Claisen-Schmidt condensation conditions {Scheme 12). Inspection of the *H NMR spectrum 
of the chalcone 179 indicated that only the £-isomer had been isolated, shown by the alkene 
HH coupling (J 15.7 Hz). The chalcone was then brominated, giving the ketone 180 as a pale 
pink solid. The ketone 180 was then treated with triethylamine to give a-bromochalcone 178 
as brown crystals {Scheme 12) which after purification by chromatography and 
recrystallization from ethyl acetate and hexane gave a single isomer. The olefinic hydrogen 
of 178 occurred at 7.69 ppm in the *H NMR spectrum, which was comparable to the olefinic 
hydrogen peak of the Z-168 which is reported to occur at 7.72 ppm in the *H NMR 
spectrum. 197 Therefore we concluded that the pure isomer of 178 isolated was the Z-isomer 
due to the similarity of the spectral values.
178
Scheme 12: a. NaOH (2M) (aq), MeOH, r.t., overnight, 83%; b. Br2 (1M in CHCI3),
Suzuki coupling was then carried out with the a-bromochalcone 178 and phenylboronic acid 
as before {Scheme 13). The a-arylchalcone 181 was isolated as a yellow oil after purification
isomers was 1 :2.3. However due to complexity of the aromatic region of the spectrum of 181 
the assignment of the configuration of the two isomers by their olefinic hydrogens could not 
be made.
O O O
b
0 O Br
MeO
MeO
c
MeO
MeO
OMe 180
CHCI3 , N2, 0 °C, 1 h, 99%; c. Et3N, CHCI3 , N2, 95 °C, 1 h, 41%. 
by chromatography. The 'H NMR spectrum of the 181 showed a mixture of E and Z isomers. 
Inspection of the methoxy signals in the !H NMR spectrum indicated that the ratio of the
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O O
( H O ) 2 B H 0
MeO
MeO
OMe
178
MeO
MeO
Scheme 13: a. Pd2(dba)3.CHCl3 (2 mol%), PPh3 (4 mol%), Et2NH, Toluene, *PrOH, H20 , 
120 °C, 1 hr, 52 %
Only one a-arylchalcone was made from 178, the synthesis of other a-arylchalcone was then 
carried on by others in the group. The other a-arylchalcones were synthesized by the acid 
catalyzed condensation of l-(3,4,5-trimethoxyphenyl)-2-phenylethanone derivatives and 
various benzaldehydes (Scheme 14). This route proved to be easier for the synthesis of a 
larger library of a-arylchalcones. However it gave a mixture of E and Z-isomers as the 
product.
0
R MeO>  
a jr V i I
MeO
OMeOMe
Scheme 14: a. Piperidine, AcOH, EtOH, Ar, 110 °C, 4 days, 30%.
The a-methylchalcone analogue 182 of a-bromochalcone 167 was also synthesized so that its 
biological properties could be compared with those of the a-arylchalcones 172 -  177 and 
181. To make a-methylchalcone 182, we first needed to synthesise the propiophenone 183. 
One practical route to this compound was via a Grignard reaction to make the alcohol 184, 
followed by the oxidation with pyridinium chlorochromate (PCC) to give the desired 
propiophenone 183 in a good yield {Scheme 15).
MeO,
>X 5 ^ H
OMe
OH
• J v
OMe
184
„ . x r
OMe
183
Scheme 15: a. Magnesium turnings, bromoethane, THF, Ar, r.t., overnight, 97%; b. PCC, 
DCM, Ar, r.t., overnight, 76%.
The a-methylchalcone 182 was prepared using the acid-catalyzed condensation method 
described by Edwards and co-workers.72 The propiophenone 183 and p-anisaldehyde, 
dissolved in ethanol, were refluxed in the presence of glacial acetic acid and piperidine
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(Scheme 16). The water generated by the reaction was removed from the refluxing ethanol as 
it passed over activated 3-A molecular sieves packed in the condenser. After purification by 
column chromatography and recrystallization 182 was isolated in a moderate yield as clear 
white crystals. The reaction was repeated but using base catalyzed conditions, refluxing the 
propiophenone 183 and p-anisaldehyde in ethanol and the presence of sodium hydroxide for 2 
hours. After purification this method gave 182 in only 15% yield.
"*C l
a or b
OMe
183 OMe
Scheme 16. a. Piperidine, AcOH, EtOH, Ar, 110 °C, 4 days, 30%; b. NaOH, EtOH, Ar,
110 °C, 2 hours, 15%.
The 'H NMR spectrum of 182 showed that only a single isomer had been made, and after 
diffusion crystallisation form ethyl acetate and hexane, the X-ray structure of the crystals 
showed that the Zs-isomer had been isolated. The structure shown in Figure 22, clearly shows 
that the molecule adopts the s-trans configuration as we expected.
0 (4 )
|C<9) C(?o>
io7
'C ( I I )C(5]
rC(1)s -trans |C(2)C(4). .C( 18)
C(17)MeO C<8]
C (14)
0(5)
MeO‘ onT IC<19)
OMe OM e182
Figure 22: X-ray crystal structure of a-methylchalcone 182
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3.2.1.1 Biological results for a-substituted chalcones
MeO
MeO
OMe
Chalcone R R4” IC5o(K562)
165 H OMe 1.6 pM
167 Br OMe 3.4 pM
179 H H 9.4 pM
178 Br H 2.0 pM
182 Me OMe 10 nM
0 Br
MeOv
[ f ^ T I if
MeOxk J Br 11S ^ R 4"
OMe
Chalcone R4 IC50(K562)
166 OMe 3.3 pM
180 H 3.5 pM
R3'"
Chalcone R4” R2’” R3’” R4’” R6’” IC50(K562)
172 OMe H H H H 20 nM
173 OMe H H OMe H 40 nM
174 OMe OMe H OMe H 90 nM
175 OMe H H NMe2 H 150 nM
176 OMe OMe OMe H H 2.2 pM
177 OMe OMe H H OMe >10 pM
181 H H H H H 7.4 pM
The biological activity of the chalcone 165 had been previously reported as having an 
IC5o(K562) of 0.1 pM, however the experimental value this time proved to be significantly 
lower. The biological results show that the a-bromochalcone 167, and its precursor 166, are 
not as active as the original chalcone 165. The lack of the methoxy in the 4 position on the B 
ring of chalcone 179 decreases the activity of the chalcone compared to the chalcone 165 
which has a methoxy on the 4 position of its B ring. Therefore the presence of a methoxy in 
the 4 position on B ring increases the activity of the compound. The substitution of a-
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hydrogen with various substituted phenyl groups 1 7 2 -  177 does generally show a significant 
change in biological activity. The exceptions to this are 176 where there seems to be a slight 
decrease in activity and 177 which the 'H NMR shows as a mixture of E and Z isomers and 
has had a severe reduction in biological activity. The a-methylchalcone 182, as expected 
also showed a significant increase in biological activity, this increase appears to be more than 
the increase due to the addition of a-phenyl groups. The difference in activity of the 2 
compounds may be due to the favoured configuration around the C 1 -  C2 single bond, with 
the single isomer a-phenylchalcones favouring the s-cis conformation (Figures 19 and 20) 
and the a-methylchalcone 182 favouring the s-trans conformation around the Cl -  C2 single 
bond (Figure 22).
3.2.2 a-Benzylchalcones - Synthesis, Results and Discussion
Seeing thai the reaction to make the a-methylchalcone 182 from propiophenone 183 had 
worked, we decided to try the same reaction but with a chalcone that had been reduced at its 
carbon-carbon double bond, to make an a-benzylchalcone. We took the 2 chalcones that had 
already been prepared, 165 and 179 and reduced them using a hydrogenation method 
previously used in the Lawrence group by M. Woo. 203 The chalcone was dissolved in ethyl 
acetate, a catalytic amount of 1 0  % palladium on carbon was added and then the mixture was 
stirred under a hydrogen atmosphere for 3 hours at room temperature (Scheme 17). The 
reduced chalcones were then both purified via column chromatography in excellent yields. 
The *H NMR of the product showed that peaks for the alkene HH coupling were no longer 
present and that there were now 2 triplets both with an integration of 2 hydrogen’s in the 3.00 
-  3.30 region of the spectrum for the newly created methylene groups.
OMe OMe
165 & 179 185 - 186
Scheme 17: a. H2, 10% Pd/C, EtOAc, r.t., 3 hrs, yield (185, R4 = OMe, 82%; 186 R4" = 
H, 95%).
Both the acid catalyzed condensation72 and the base catalyzed condensation were attempted 
with the reduced chalcone and p-anisaldehyde {Scheme 18). Unfortunately neither of these 
conditions worked and the starting materials were recovered in both cases.
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R4"
MeO a or b Me<3H
OMe MeO MeO
OMe OMe OMe
187 R4 ' - OMe
188 R4 '-H
Scheme 18: a. Piperidine, AcOH, EtOH, Ar, 110 °C, 4 days, 0 %; b. NaOH, EtOH, Ar,
110 °C, 24 hours, 0 %.
Another route to the a-benzylchalcone 187 was then tried. This time we attempted the 
Suzuki coupling reaction of the a-bromochalcone 167 with 0.5 M 2?-benzyl-9-BBN in THF 
{Scheme 19). This reaction also didn’t work, the *H NMR spectrum of the crude product 
showed that it was mainly the a-bromochalcone 167, the spectrum also showed traces of the 
benzyl group in spectrum, with peaks at 4.69 ppm with an integration of two representing the 
methylene group of the benzyl compound and a multiplet at 7.33 -  7.39 ppm with an 
integration of five representing the phenyl group of the possible benzyl compound. The a- 
bromochalcone 167, was then recovered by column chromatography. The £-benzyl-9-BBN 
had probably been removed in the work up of the reaction, which would explain for the trace 
amounts of it in the *H NMR spectrum of the crude product.
MeOMeO
MeOMeO‘
OMeOMe OMeOMe 187167
Scheme 19: a. Pd2 (dba)3 .CHCl3 (2 mol%), PPh3 (4 mol%), Et2NH, Toluene, «PrOH, H2O, 
120 °C, 1 hr, 0%;
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3.2.2.1 Biological results for the reduced chalcones
185-186
Chalcone R4” IC50(K562) (pM)
185 OMe 2.5
186 H > 1 0
The effects on the biological activity of the chalcone by reducing its double bond to 185 and 
186 resulted in a fall in activity. Thus showing the importance of the double bond to the 
biological activity of the chalcone structure. The decrease in biological activity resulting 
from the reduction of the double bond has been previously reported in the group, with 
chalcones 117 and 56, being more active than their reduced analogues 129 and 189.181203
MeO OH MeO. OH
MeO OMe MeO' OMe
OMe OMe117 129
IC5o (K.562) 4.3 nM IC50 (K562) 1 pM 
0
MeO
MeO
OMe
189
IC5 0  (K562) 0.21 nM IC5 0  (K562) 30 nM
3.2.3 Another route to a-arylchalcones - Synthesis, Results and Discussion
As previously mentioned other members of the group made another series of a-arylchalcones 
by the acid catalyzed condensation of l-(3,4,5-trimethoxyphenyl)-2-phenylethanone 
derivatives and various benzaldehydes (Scheme 14). The most active compound of this series 
was the a-arylchalcone 190, IC5o(K562) 12 nM. However this chalcone was a mixture of E 
and Z isomers.
OMe
MeO
OHMeO'
OMe OMe
190
To try and prepare 190 as a single isomer we devised a new approach to the synthesis of the 
a-arylchalcones. The key steps in this new synthesis would be the synthesis of acrylic acid
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191 to give the B and C ring system and the converision of the acid 191 into the Weinreb 
amide 192. Finally we hoped that the reaction of 192 with the Grignard reagent 193 would 
introduce the A ring {Scheme 20).
O
HO
OMe
Cl!
195
OHH
OMe
194
OMe
HO
OH
191 OMe
OMe
MeO
OMe Me0 MgBr OMe
193MeO
OMe OPGOHMeO
192 OMeOMe
Scheme 20
The acrylic acid was synthesized by means of a Perkin reaction, 204 where isovanillin (194) 
and 4-methoxyphenylacetic acid (195) were heated in a mixture of triethylamine and acetic 
anhydride at 140 °C for 3 hours, the mixture was then left to cool to room temperature and 
then acidified with concentrated hydrochloric acid and stirred overnight causing the acrylic 
acid 191 to precipitate as a cream solid which was then purified by crystallization from hot 
ethanol and isolated in a moderate yield. The reaction was then repeated again, except this 
time in the microwave at 170 °C for 25 min and without the acid workup to see if the 
phenoxy acetate 196 could be isolated directly. The acetic anhydride and triethylamine were 
removed via vacuum distillation (Genevac), the product was then purified by chromatography 
and crystallization from hot ethanol to give the acetate of the corresponding acrylic acid 196 
in a moderate yield {Scheme 21).
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o f? 'Y 0Me
hojU J i
195
' V
194
OMe
OMe
HO'a or b OR
OMe
191 R = H
196 R = Ac
Scheme 21: a. i (CH3C0)20 , Et3N, 140 °C, 3 hr. ii. Cone. HC1. To give 191 37%; b.
(CH3C0 )2 0 , Et3N, 170 °C, 25 min, pwave. To give 196 39%.
By comparing the values of the ‘H NMR chemical shifts for hydrogen on C3 of the 2 acrylic 
acid obtained to similar compounds in literature it appears that we have isolated the desired E 
configured isomers. The E and Z isomers of 3-(4,-methoxy-3’-nitrophenyl)-2-(3” ,4” ,5” - 
trimethoxyphenyl)acrylic acids (197) were reported by Borrel204, and the lH NMNR chemical 
shift value for hydrogen on C3 for the E isomer appears at 7.70 ppm while the Z isomer 
appears at 7.10 ppm. The NMNR chemical shift value for hydrogen on C3 of 191 is 7.56 
ppm and 196 7.62 ppm, and both appear to be the E isomer when compared to the values of 
197 {Figure 23).
OMe OMe OMeOMe
HO' HO HO HO
OH OAc
7.10 ppmOMe MeO OMeOMe
191 196197
E isomer
197
Z isomer
7.70 ppm 7.62 ppm7.56 ppm
Figure 23: 'H NMR comparisons of 191 and 196 to 197
The protected acrylic acid 196 was then dissolved in chloroform and refluxed with thionyl 
chloride for 4 hours205 to give the acid chloride 198 in an excellent yield {Scheme 22). The 
Weinreb amide 199 was then obtained by treating the acid chloride 198 with N,0- 
dimethylhydroxyamine hydrochloride, in the presence of pyridine at 0 °C . 206 The amide 199 
was purified by chromatography as a pale yellow oil in good yield {Scheme 22).
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OMe
HO
OAc
196 OMe
OMe
Cl
OAc
198 OMe
OMe
OMe OAc
199 OMe
Scheme 22: a. SOCl2, CHC13, 75 °C, 4 hr, 93%; b. MeNHOMe.HCl, pyridine, CHC13, 0 
°C, 1 hr, 70%.
The Grignard reagent 193 was prepared in freshly distilled anhydrous THF, by gently heating 
magnesium turnings with 5-bromo-l,2,3-trimethoxybenzene (200) in the presence of a single 
iodine crystal, under an argon atmosphere. 99,207 When the reaction started the iodine 
discolouring disappeared and the mixture became clear, it was heated at 65 °C for an hour, 
and then stirred at room temperature for an hour (Scheme 23). The Weinreb amide 199 was 
then treated with a slight excess of the Grignard reagent 193 at 0 °C, and then left to stir at 
room temperature overnight (Scheme 23). The NMR spectrum of the crude reaction product 
showed that the reaction had not been successful and Weinreb amide 199 was recovered by 
chromatography, in a 6 6 % yield. The spectrum also showed the presence of the quenched 
Grignard reagent 201, with a triplet with an integration of one proton at 7.00 ppm and doublet 
with an integration of two protons at 6.59 ppm. The trimethoxy benzene 201 was not 
isolated.
M eO v^^^B r
j c ?
OMe
200
6.59 ppm 
7.00 ppm —
Xpr
OMe
193
OMe
OMe OAc
OMe
199
► H OMe
H OMe 
201
OMe
OAcOMe
OMe
199
Scheme 23: a. Mg, THF, I2, 65 °C, lhr; b. THF, 0 °C to r.t., overnight, 199 6 6 %.
The reaction was then attempted again, however this time the organolithium reagent 202 was 
used instead. The organolithium reagent 202 was prepared using the procedure reported by 
Chen208, where 5-bromo-l,2,3-trimethoxybenzene (200) dissolved in ether was added to
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solution of w-butyllithium in ether at -78 °C, and stirred for an hour at this temperature 
(Scheme 24). The Weinreb amide 199 was then dissolved in THF and chilled to -78 °C under 
an argon atmosphere, then 2.3 equivalents of the organolithium reagent 202 in ether was 
added to the mixture, and stirred at -78 °C for a further hour. The mixture was then stirred 
overnight at room temperature. Unfortunately this reaction did not work, and the !H NMR 
spectrum of the crude reaction mixture showed that the Weinreb amide 199 had become 
deprotected giving 203, which was isolated by chromatography {Scheme 24). It would have 
been deprotected by the excess amount of w-butyllithium used to make 202. The !H NMR 
spectrum of the crude product also showed the presence of the quenched organolithium 
reagent 201 as previously mentioned.
OMe
200
u J ?
OMe
202
OMe
OMe OAc
OMe
199
OMe
MeO.
OMe OH
MeO‘
OMe
203
Scheme 24\ a. «BuLi (2 eqv), ether, -78 °C, lhr; b. 202 (2.3 eqv), THF, -78 °C to r.t., 
overnight, 58%.
3.2.3.1 Biological results for the a-arylchalcones
.OMe
OMe
191, 196, 199, 203
Compound R 1 R3" IC50(K562) (pM)
191 OH OH > 1 0
196 OH OAc > 1 0
199 N(OMe)Me OAc > 1 0
203 N(OMe)Me OH 8.3
None of the above compounds proved to be particularly biologically active. The compounds 
are similar to Combretastatin A-4 (58), with a 4-methoxyphenyl A-ring instead of a 3,4,5- 
trimethoxyphenyl A-ring and a substituted group on the ethene linker. It has generally been 
accepted that A-ring of CA4 (58) must be 3,4,5-trimethoxyphenyl for the compound to 
maintain its cytotoxicity, 79 and the presence of a 4-methoxyphenyl A-ring may partially be 
the cause of the low biological activity of the compounds 191, 196, 199 and 203. Recent 
SAR studies of Combretastatin A-4 (58) has shown that introduction of alkyl groups91 and
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acylamide groups92 onto the ethene linker decreases the cytotoxicity of the CA4 analogues, 
this shows that the presence of various groups attached to the ethene linker of CA4 (58) will 
reduce its cytotoxicity. Therefore the low activity of 191, 196, 199 and 203 is also be due to 
the presence of the carboxylic acid group on 191 and 196 or the Weinreb amide on 199 and 
203 attached to the ethene linker.
CONH2
MeO
MeO
OMe OH
MeO. MeO
MeO' MeO
OMe OMeOH OH
OMe OMe OMe
IC50 (K562) 1 nM IC50 (K562) 0.04 pM IC50  (MCF-7) 1.13 pM 
IC50 (MCF-7) 69 nM
3 3  Indanones and Indenones
Research previously done by the group has shown that the s-trans conformation around the 
double bond of the chalcone 56 has proven important to its biological activity. 73 Therefore 
we have decided to investigate this effect, by making indanones 151 and indenones 204 as 
conformationally constrained analogs of the chalcones that mimic the s-trans arrangement.
MeO
OHMeO
OMe OMe
56 151 204
3.3.1 Indanones - Synthesis, Results and Discussion
The indanone scaffold can be constructed from chalcones through catalyzed Nazarov 
cyclization. 209'211 Literature shows that the preparation of indanones involves heating a 
chalcone in the presence of Lewis acids like aluminum chloride212 and boron trifloride213 or 
strong protic acids such as polyphosphonic acid214 or trifluoroacetic acid (TFA) . 195 The key 
step in this synthesis to make the indanones will be TFA catalyzed Nazarov cyclization of 
chalcones {Scheme 25).
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151152
Scheme 25: a. TFA, reflux
The chalcone 117 was prepared in a good yield using the Claisen-Schmidt condensation178 of 
3,4,5-trimethoxyacetophenone with isovanillin (Scheme 26). After an acid work up and 
recrystallization form aqueous methanol, the geometrically pure chalcone 117 was obtained, 
with the 'H NMR spectrum showing that only the trans isomer (Jh2-h3 15.4 Hz) was present.
MeO. OH
MeO OMe
OHMeO
MeO OMe
Scheme 26: a. NaOH (2M) (aq), MeOH, r.t., overnight, 69%.
Then using the conditions described by Rice and coworkers215 the indanones 205 and 153 
were prepared respectively from the chalcones 165 and 117 which were dissolved in neat 
TFA and heated at 120 °C for 4 hours in a sealed tube (Scheme 27).
MeO.
MeO
OMe
MeO
OMeMeO
OMe
165,117 205,153
Scheme 27: a. TFA, sealed tube, 120 °C, 4 hours, yield (205, R3 = H, 72%; 153 R3 = 
OH, 63%).
The indanones were then purified by column chromatography and characterised. The !H 
NMR spectrum of the indanone 153 (Figure 24) shows key diagnostic peaks of a classic 
ABX system that occur at 2.57 (lH a, dd, J2 .5 , 19.3 Hz, H-2a), 3.15 (lHb, dd, J7 .9 , 19.3 Hz, 
H-2b) and 4.50 (1 Hx, dd, J  2.5, 7.9 Hz, H-3) ppm.
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Figure 24: 1H NMR of indanone 153
We were then intrigued to see if the use of a microwave to heat the reaction would shorten 
the time of the reaction and give us a way of quickly producing a library of indanones. The 
use of microwave irradiation in organic synthesis has now become a widely adopted process 
as an alternative to traditional heating methods. The process of microwave irradiation often 
results in higher yields, shorter reaction time and less impurities, 216'220 and is more energy 
efficient than traditional heating. 221 It is also an operationally simple process. There is no 
need to set up an oil bath. The reactor also allows the reaction to be performed safely at 
temperatures well above the usual boiling point of the solvent.
The first attempt at using microwave irradiation instead of traditional heating was performed 
on chalcone 165 on a 600 mg scale. The chalcone was dissolved in TFA (0.7 mL) in a 
microwave reaction vessel and heated to 60 °C (power 50 W) for 5 minutes. Analysis of the 
resulting mixture by TLC showed that the reaction was still mainly starting material. Further 
heating at 70 °C (power 100 W) for 10 minutes showed that the resulted in an incomplete 
reaction; the indanone 205 was visible in the TLC plate. The mixture was then heated at 120 
°C (power 100 W) for 10 minutes and the TLC of reaction showed that the reaction had gone 
to completion. The indanone was then isolated by column chromatography in a 50% yield. 
The reaction was then repeated using the following conditions, 900 mg scale, TFA (1 mL), 
120 °C (power 100 W) for 20 minutes, after purification by column chromatography the 
indanone was obtained in a 60% yield (Scheme 28).
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OMe
OMe
MeO.
MeO'
OMe
165 205
Scheme 28: a. TFA, pwave, 120 °C (100 W), 20 mins, 60%.
A series of chalcones 155, 206 220, were then prepared using the Claisen-Schmidt
condensation178 of 3,4,5-trimethoxyacetophenone and various substituted benzaldehydes 
{Scheme 29). The chalcones, which precipitate from the reaction mixture were filtered off 
and purified by recrystallization from methanol. The 'H NMR spectra of the obtained 
chalcones showed that they had all been isolated as the geometrically pure E isomer, shown 
by the alkene coupling ~ 15 -  16 Hz. Whilst this assignment was not in doubt the X-ray 
crystal structures of chalcone 209 further showed that the E isomer had been obtained {Figure 
24).
0(3) 0(5)
C(2) S*J) C(15X.fcC(14)
0(1)
COL
yc(8)
1  Xc(9) 1 C O D C(13j#
^ K ( 4 )  1ttcm ^C(12)
> 0(4)
C(18)
Figure 24: X-ray crystal structure of chalcone 209
O O 
Me° Y ^ A  H^Ar’ a
MeOv
OMe OMe
155, 206 - 220
Scheme 29: a. NaOH (2M) (aq), MeOH, r.t., overnight, yields (see table J).
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Table 3: Yields of chalcones 155, 206 -  221 (see scheme 29).
Chalcone Arl Yield (%)
155 3-Fluoro-4-methoxyphenyl 87 e
206 4-Chlorophenyl 55
207 3-Bromo-4-methoxyphenyl 75
208 3,4-Dichlorophenyl 50
209 Benzo[c/][ 1,3]dioxol-5-yl 73
210 4-Bromophenyl 88
211 Phenyl-4-oxyacetic acid 52
212 2,3,4-Trimethoxyphenyl 78
213 2,6-Dichlorophenyl 92
214 2,4-Dichlorophenyl 83
215 3-Nitro-4-methoxyphenyl 68 e
216 4-(Benzyloxy)phenyl 42
217 2,3-Dihydrobenzo[b][ 1,4]dioxin-6-yl 96 t
218 3,4,5-T rimethoxypheny 1 83
219 2,4-Dimethoxyphenyl 73
220 3,5-Dimethoxyphenyl 83
e Prepared by Dr. B. Greedy, Post doctoral research assistant, Cardiff, 2003 
t  Prepared by S. Ducki, PhD Student, UMIST, 1997 
The benzaldehyde 221 used to make chalcone 216 was prepared by heating 4-hydroxy 
benzaldehyde in DMF with benzyl bromide and potassium carbonate at 90 °C for 2 hours. 
After column chromatography 4-(benzyloxy)benzaldehyde (221)222 was isolated as a pale 
yellow solid in an excellent yield (Scheme 30). The benzaldehyde had to be protected 
because of the electron-donating effect of the hydroxy group (deprotonated under the 
reaction conditions) significantly reduces the electrophilicity of the carbonyl group.
H C r ^
H
221
MeO
OBnMeO
OMe 216
Scheme 30: a. K2C 0 3, DMF, 90 °C, 2 hours, 96%; b. 3,4,5-trimethoxyacetophenone, 
NaOH (2M) (aq), MeOH, r.t., overnight, 42%.
The indanones 153, 154, 222 -  234 were all then prepared using the microwave method, on a 
250 mg scale in TFA (0.3 mL) {Scheme 31). They were all isolated after purification by 
column chromatography in poor to good yields {Table 4). The TFA promoted Nazarov 
cyclization of the benzyl protected chalcone 216 cleaves the benzyl group giving the 
unprotected indanone 235, but only in a poor yield. The chalcones 218 -  220 were also used 
in the microwave synthesis of the indanones, however there reactions failed and were not
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further investigated. These examples have electron rich B-rings which generally reduce the 
efficiency of the Nazarov cyclization (see later).
O
M e O ^ A ^ A r '
M e C r^ f 
OMe
117, 155, 179, 206 - 220 153, 154,222 - 234
Scheme 31: a. TFA, pwave, 120 °C (100 W), 20 mins, yield (see table 4).
Table 4: Yields of indanones 153, 154, 222 - 234 via microwave assisted Nazarov 
reaction (see scheme 31).
Indanone Ar1 Yield (%)
153 3-Hydroxy-4-methoxyphenyl 56
154 3-Fluoro-4-methoxyphenyl 37
222 4-Chlorophenyl 53
223 3-Bromo-4-methoxyphenyl 59
224 3,4-Dichloropheny 1 69
225 Benzo(//][l,3]dioxol-5-yl 54
226 4-Bromophenyl 33
227 Phenyl-4-oxyacetic acid 26
228 2,3,4-Trimethoxyphenyl 25
229 2,6-Dichlorophenyl 95
230 2,4-Dichlorophenyl 83
231 Phenyl 23
232 3 -N itro-4-methoxypheny 1 39
233 4-Hydroxyphenyl 15
234 2,3-Dihydrobenzo[b][l,4]dioxin-6-yl 52
Two of the indanones (228 and 230) NMR spectra (.Figure 26 and Figure 27) showed line
broadening for peaks on the B ring and hydrogens H-2 and H-3 of the indanone due to bulky 
groups on the B ring causing steric hindrance and inhibiting its ffee rotation around the C-3 
C-T bond (Figure 25). While the 2 bulky chlorine groups on C-2’ and C-6’ of the B ring of 
indanone 229 allow for no rotation at all (or at least slow rotation on the NMR timescale) and 
gives three signals for the hydrogen’s on the B ring, since H3” and H5” are no longer 
equivalent (Figure 28). All three indaones 228 -  230 have the hydrogen H-3 signal shifted 
slightly down field due to the bulky effect of the groups on there C-2’ and C-6’. The degree 
of shielding from the B ring is dependent on its rotation around the C-3 -  C -l’ bond. The 
shielding effect on the H-3 hydrogen from the B ring attached to C-3 is reduced due to the 
orientation the B ring is forced to take by its bulky ortho group. The decreased shielding 
effect causes the signal for the hydrogen H-3 signal to be shifted further downfield.
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The degree of shielding from the B ring is dependent 
on the rotation around the bond C-3 - C-T.
Bulky ortho groups attached to the B ring will force 
it into a more static orientation, decreasing its 
shielding effect on the H-3, by impeding the rotation 
of the aromatic group around the C-3 - C-T bond.
Figure 25: Steric hindrance inhibiting free rotation around C-3 C -l” bond.
 JL_i__
a  /  b
Figure 26: 'H NMR of indanone 228
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Figure 27 \ x H NMR of indanone 230
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Figure 28: NMR of indanone 229
A small series of chalcones 235 -  244 were made from 3,4-dimethoxyacetophenone and 
various benzaldehydes using the Claisen-Schmidt condensation178 (Scheme 32). All of the 
chalcones were isolated as the E isomers after recrystallization from methanol. The geometry 
of the chalcones was as usual determined by the alkene coupling value ~ 15 -  16 Hz in the 'H 
NMR spectra of the chalcones.
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M e C V ^ A  A r '
MeO
^  MeO
MeO
235 - 244
Scheme 32: a. NaOH (2M) (aq), MeOH, r.t., overnight, yield (see table 5). 
Table 5: Yields of chalcones 235 -  244(see scheme 32).
Chalcone Ar1 Yield (%)
235 4-Methoxyphenyl 67
236 4-Bromophenyl 76
237 4-Chlorophenyl 76
238 2,6-Dichlorophenyl 77
239 3,4,5 -T rimethoxypheny 1 90
240 3,4-Dichloropheny 1 57
241 2,4,6-Trimethoxyphenyl 61
242 2,4-Dimethoxyphenyl 79
243 3,5-Dimethoxyphenyl 62
244 2,6-Dimethoxyphenyl 61
The dimethoxyindanones 245 -  250 were then prepared from their precursor chalcones 235 -  
240 using the same microwave conditions as previously described (Scheme 33) and isolated 
by column chromatography. The 3,4-dimethoxychalcones 241 -  244 were also used in the 
microwave synthesis of the dimethoxyindanones, however these four reactions failed and 
were not further investigated. Again these examples have electron rich B-rings (see later).
-  z o } '
Ar
235 - 240 245 - 250
Scheme 33: a. TFA, pwave, 120 °C (100 W), 20 mins, yield (see table 6).
Table 6: Yields of indanones 245 -  250 via microwave assisted reaction (see scheme 33).
Indanone Arl Yield (%)
245 4-Methoxyphenyl 7
246 4-Bromophenyl 52
247 4-Chlorophenyl 34
248 2,6-Dichlorophenyl 71
249 3,4,5 -T rimethoxypheny 1 41
250 3,4-Dichloropheny 1 13
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The !H NMR spectra of the indanones 245 -  247 and 249 -  250 all showed the key peaks and 
coupling patterns for the H-2 and H-3 atoms as previously described for indanone 153. 
However the indanone 248 2,6-dichlorophenyl B ring inhibited the free rotation of the phenyl 
around the C-3-C-1”  bond, again causing the hydrogens at position H-3’ and H-5’ on the B 
ring to become non equivalent. The ‘H NMR spectrum of indanone 248 shows that one of 
the hydrogens at position H-3’ or H-5’ occurs at 7.43 (1H, dd, J  1.4, 7.8 Hz) 
ppm the other signal for the hydrogen at position H-3’ or H-5’ occurs under 
the multiplet at 7.16 -  7.23 ppm (Figure 29). Also the hydrogen H-3 has its 
peak shifted down field from around 4.50 ppm to 5.43 ppm by reduced 
shielding effect of the bulky 2,6-dichlorophenyl B ring of 248, similar to
248
same affect seen in the hindered indanones 228 -  230.
i
J L  i(i
Figure 29: !H NMR of indanone 248
Inspection of the tables 4 and 6 show that the Nazarov cyclization works best for the 
electron-deficient B-ring systems like 229, 230 and 248. The presence of an electron 
donating /7-alkoxy group on the B-ring like 227, 228 and 245 has a detrimental effect on the 
yield of the indanone. The detrimental effect on the indanone formation of electron donating 
/?-alkoxy group on the B-ring was further shown in the failed indanone formations from 
chalcones 2 1 8 - 2 1 9  and 241 -  243. This is expected because the Nazarov cyclization is an 
electrophilic substitution process which requires an electron-rich A-ring system which can 
donate electrons to an electron deficient enone reaction partner (Scheme 34). So the methoxy 
groups on the A ring are not only necessary for good tubulin binding properties but also 
increase the precursor chalcone reactivity in the cyclization.
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H+
OH + 0  0
H*  ^ T Y \  
MeO Ar
MeO
MeO
MeO OMe Ar
Scheme 34: The mechanism of the Nazarov cyclization of electron-rich A-ring chalcones
It was found that the TFA used in the microwave reaction should ideally be anhydrous. We 
found that the synthesis of indanone 249 using TFA as supplied was problematic. The !H 
NMR spectrum of the crude product of 249 showed the formation of a 2.5:1 mixture of 3,4- 
dimethoxyacetophenone and 249. It appeared that the presence of water in the TFA had 
caused the precursor chalcone 249 to undergo a water promoted retro-Michael retro-aldol 
process to give the 3,4-dimethoxyacetophenone. The TFA was then dried over phosphorus 
pentoxide for 12 hours under an atmosphere of argon followed by distillation (bp 74 -  75 
°C/1 atm . ) . 223 When the reaction to make indanone 249 was repeated with anhydrous TFA, 
the crude *H NMR showed no trace of 3,4-dimethoxyacetophenone and 249 was isolated in a 
41% yield.
Chalcones can also be prepared by acid-catalyzed conditions. 224 With this in mind we tried a 
one-pot reaction using 3,4,5-trimethoxyacetophenone with/7-anisaldehyde in TFA in the hope 
that the acid conditions would affect both the aldol condensation to give the chalcone 165, 
which would then undergo the Nazarov reaction to give indanone 205 (Scheme 35). After 
purification by chromatography the indanone was isolated in a 31 % yield, however the NMR 
of the product showed it to be a mixture of the indanone 205 and 3,4,5,- 
trimethoxyacetophenone in a ratio of 1:2.3 respectively. Further purification of the indanone 
was not trivial and this method was not investigated any further. For comparison the two step 
synthesis of indanone 205 give an overall yield of 54%, 90% for the chalcone formation and 
60% for the Nazarov cyclization.
MeO.
MeO‘
OMe
OMe
M e O y ^  
OMe
OMe
205 : acetophenone 
1 : 2.3
Scheme 35: a. TFA, pwave, 120 °C (100 W), 20 mins, 31%.
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3.3.1.1 Biological results for the indanones and precursor chalcones
MeO
MeO
Chalcone R5 Ar1 IC50(K562) (pM)
117 OMe 3-Hydroxy-4-methoxyphenyl 0.26
155 OMe 3-Fluoro-4-methoxyphenyl 0.30e
165 OMe 4-Methoxyphenyl 1 . 6
179 OMe Phenyl 9.4
206 OMe 4-Chlorophenyl > 1 0
207 OMe 3-Bromo-4-methoxyphenyl 6.57
208 OMe 3,4-Dichlorophenyl 7.0
209 OMe Benzo[W][l,3]dioxol-5-yl 1.48
210 OMe 4-Bromophenyl > 1 0
211 OMe Phenyl-4-oxyacetic acid > 1 0
212 OMe 2,3,4-Trimethoxyphenyl 3.67
213 OMe 2,6-Dichlorophenyl 4.3
214 OMe 2,4-Dichlorophenyl 6.71
215 OMe 3-Nitro-4-methoxyphenyl 4.0 0
216 OMe 4-(Benzyloxy)phenyl > 1 0
217 OMe 2,3-Dihydrobenzo[b][ 1,4]dioxin-6-yl 0.08 t
218 OMe 3,4,5-T rimethoxypheny 1 > 1 0
219 OMe 2,4-Dimethoxyphenyl 1 . 6 6
220 OMe 3,5-Dimethoxyphenyl 0.64
235 H 4-Methoxyphenyl > 1 0
236 H 4-Bromophenyl > 1 0
237 H 4-Chlorophenyl 8.9
238 H 2,6-Dichlorophenyl 1 . 2
239 H 3,4,5-Trimethoxyphenyl 5.0
240 H 3,4-Dichlorophenyl > 1 0
241 H 2,4,6-Trimethoxyphenyl 1.94
242 H 2,4-Dimethoxyphenyl 9.76
243 H 3,5-Dimethoxyphenyl 6.31
244 H 2,6-Dimethoxyphenyl 4.64
e Prepared by Dr. B. Greedy, Post doctoral research assistant, Cardiff, 2003
t  Prepared by S. Ducki, PhD Student, UMIST, 1997
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MeO
MeO
Indanone R4 Ar1 IC50(K562) (pM)
153 OMe 3-Hydroxy-4-methoxyphenyl 0.13
154 OMe 3-Fluoro-4-methoxyphenyl 0.105
205 OMe 4-Methoxyphenyl 0.49
222 OMe 4-Chlorophenyl 30
223 OMe 3-Bromo-4-methoxyphenyl 1 . 2
224 OMe 3,4-Dichlorophenyl 24
225 OMe Benzo[*/][ 1,3]dioxol-5-yl 2.41
226 OMe 4-Bromophenyl 1.85
227 OMe Phenyl-4-oxyacetic acid > 1 0
228 OMe 2,3,4-T rimethoxypheny 1 2.78
229 OMe 2,6-Dichlorophenyl 7.37
230 OMe 2,4-Dichlorophenyl 1.97
231 OMe Phenyl > 1 0
232 OMe 3-Nitro-4-methoxyphenyl 0.081
233 OMe 4-Hydroxyphenyl > 1 0
234 OMe 2,3-Dihydrobenzo[b][ 1,4]dioxin-6-yl 0 . 2 2
245 H 4-Methoxyphenyl 0.17
246 H 4-Bromophenyl 5.35
247 H 4-Chlorophenyl > 1 0
248 H 2,6-Dichlorophenyl > 1 0
249 H 3,4,5 -T rimethoxypheny 1 34
250 H 3,4-Dichloropheny 1 > 1 0
Generally the chalcones with the 3,4,5-trimethoxyphenyl A  rings tend to show more 
biological activity against the leukaemia cell line K562 than their 3,4-dimethoxyphenyl A  
ring analogues. For instance looking at the two chalcones with 4-methoxyphenyl B ring 165 
and 235, the 3,4,5-trimethoxyphenyl A  ring chalcone 165 has much higher I C s o ( K 5 6 2 )  value 
of 1 . 6  pM, compared to the 3,4-dimethoxyphenyl A  ring chalcone 235, which has an 
IC5o(K 5 6 2 )  value of >10 pM. This shows that the presence of the 3,4,5-trimethoxyphenyl A  
ring is an important feature of the overall cytotoxicity of the chalcone. However the 3,4- 
dimethoxyphenyl A  ring chalcones with either a 4-chlorophenyl B  ring 237 [ I C 5 o ( K 5 6 2 )  =  8 . 9  
pM] or a 2,6-dichlorophenyl B ring 238 [ I C s o ( K 5 6 2 )  = 1.2 pM] show a higher biological 
activity than their 3,4,5-trimethoxyphenyl A  ring chalcone equivalents with a 4-chlorophenyl 
B ring 206 [ I C s o ( K 5 6 2 )  > 10 pM] and 2,6-dichlorophenyl B ring 213 [ I C s o ( K 5 6 2 )  = 4.3 pM].
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In some cases the indanones show increased biological activity over their precursor 
chalcones. For instance the indanones 232 [ I C s o ( K 5 6 2 )  0 . 0 8 1  pM] and 245 [ I C s o ( K 5 6 2 )  0 . 1 7  
pM] show a significant increase in biological activity compared to their precursor chalcones 
215 [IC5o(K562) 4 . 0  pM] and 235 [ I C 5 o ( K 5 6 2 )  > 1 0  pM]. However this is not always the 
case. The indanones 225 [ I C 5 0 ( K 5 6 2 )  2 . 4 1  pM] and 234 [ I C 5 0 ( K 5 6 2 )  0 . 2 2  pM] both show a 
decrease in the biological activity when compared to there precursor chalcones 209 
[ I C 5 0 ( K 5 6 2 )  1 . 4 8  pM] and 217 [ I C 5 0 ( K 5 6 2 )  0 . 0 8  pM].
The biological results of the indanones 153, 154, 205, 232, 234 and 245, show that they are 
all potent inhibitors of K562 cell growth with IC50 values less than 0.5 pM.
3.3.2 Indenones - Synthesis, Results and Discussion
The indenone scaffold is another conformationally constrained analog of the CA-4 like 
chalcones locked in the s-tram arrangement. It retains an a,p-unsaturated enone and lacks 
the indanone stereogenic centre and is therefore worthy of study. Clark and co-workers used 
an internal Heck reaction to form the Indenone scaffold from a 2’-bromochalcone.225 Using 
the same idea the key step in making the CA-4 like Indenone scaffold will be the preparation 
of the precursor chalcone and the internal Heck reaction of a 2’-bromo chalcone {Scheme 36).
To make the 2’-bromochalcone precursors we first had to prepare the 2’- 
bromoacetophenone 251. We set about doing this by first refluxing 3,4,5- 
trimethoxybenzaldehyde with jV-bromo succinimide (NBS) in chloroform for 4 hours to 
give the 2-bromo-3,4,5-timethoxybenzaldehyde (252), which was isolated after column 
chromatography in a good yield {Scheme 37).226 We then used commercially available 3 
molar methylmagnesium chloride in THF to carry out the Grignard reaction on 252 to give 
the secondary alcohol 253 as pale yellow oil in an excellent yield {Scheme 37). We 
originally tried to make the Grignard reagent insitu by reacting iodomethane with 
magnesium turnings in anhydrous THF, however this caused a grey precipitate to form. 
Since methylchloride is a gas we thought the preparation of methylmagnesium chloride 
would be troublesome. The alcohol 253 was then oxidized with pyridinium chlorochromate 
(PCC) to give the desired acetophenone 251 in a good yield {Scheme 37). The PCC 
oxidation was carried out in the presence of silica gel (5 times the mass of PCC) too stop
O n
Scheme 36
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the reaction from becoming to viscous, by providing a support upon which reduced 
chromium species can precipitate. The reaction work-up is also convenient as the solvent 
can simply be removed to provide the crude reaction product supported on silica for use 
directly on a chromatography column.
O O OH O
M e O y y t , ,  a M e C L ^ A H MeOv^ A v c M e C L ^ J ^
M e C T '- f^ B r  M e O ^ j ^ B r  M e O 'y ' ^ B r
DMe OMe OMe
252 253 251
Scheme 37: a. NBS, CHCI3, 75 °C, 4 hours, 83%; b. MeMgCl (3M in THF), THF, 0 °C 
to r.t., 12 hours, 99%; c. PCC, DCM, r.t., 12 hours, 83%.
The two chalcones 254 and 255 were prepared using the Claisen-Schmidt condensation178 of 
251 and their corresponding benzaldehyde, and purified by recrystallization from methanol 
{Scheme 38). The chalcones were only isolated as E isomers, as shown by the usual alkene 
coupling value ~ 15 -  16 Hz in the *H NMR spectra.
MeO
MeO OMe
OMe
251 254 R = H, 74%
255 R = OH, 77%
Scheme 38: a. NaOH (2M) (aq), MeOH, r.t., overnight.
Then using the conditions described by Clark225 the internal Heck reaction was carried out on 
1 mmol scale of chalcone 254 {Scheme 39). After purification by chromatography and 
recrystallization from ethyl acetate and hexane the indenone 256 was isolated in a high yield 
as bright red crystals. The key diagnostic peak of the indenone 256 is singlet at 5.73 ppm for 
the alkene hydrogen H-2 {Figure 30). The reaction was repeated using chalcone 255, 
however no indenone was isolated and only starting material was recovered. This prompted 
us to investigate the use of various protecting groups to mask the phenol group, which we 
believe was the cause of the failure to make the indenone.
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MeO.
MeO OMe
OMe
MeO.
MeO‘
OMe
Scheme 39: a. PdCl2 (2.5 mol%), PPh3 (7.5 mol%), K2C 03, DMF, 1 10 °C, 30 mins, 8 8 %.
72 66 6 4 6 2 50 40
Figure 30: !H NMR spectrum of indenone 256
Several protected chalcones 257 -  260 were prepared. The chalcone 255 was protected with 
/er/-butylchlorodimethylsilane chloride (TBDMSC1), by reaction with TBDMSC1 for 3 days 
at room temperature. The protected chalcone 257 was isolated via column chromatography 
in a good yield as a pale yellow oil that eventually solidified (Scheme 40).
MeO. OH
MeO OMe
OMe
MeO. OR
MeO OMe
OMe
255 257 R = TBDMS
Scheme 40: a. TBDMSC1, imidazole, DMF, r.t., 3 days, 89%;
The intramolecular Heck reaction225 of the TBDMS protected chalcones 257 was then carried 
out {Scheme 42). Unfortunately the preparation of the protected indenone 261 failed and the 
unprotected chalcone 255 was recovered. Clearly the TBDMS group is not suitable as a 
phenol protecting group for the reaction conditions used.
Other protected chalcones were therefore required. Three protected versions of the 
isovanillin starting material were prepared, benzyl protected222 262, isopropyl protected227 263
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and methoxymethyl (MOM) protected228 264 {Scheme 41). These protected benzaldehydes 
were then reacted with 251 using the Claisen-Schmidt condensation178 to make the protected 
chalcones 258 -  260. Chalcones 258 -  260 were all isolated as pure E isomers after 
recrystallization from methanol.
OR 262 R = Bn
263 R = CH(CH3 ) 2 
OMe 264 R = CH2OCH3
OH
OMe
MeO OR MeO OR
MeO OMe MeO OMe
OMe
251 262 R = Bn
263 R = CH(CH3 ) 2
264 R = CH2 OCH3
OMe
258 R = Bn, 84%
259 R = CH(CH3)2, 74%
260 R = CH2OCH3, 69%
Scheme 41: a. Benzyl bromide, K2 CO3 , DMF, 90 °C, 2 hours, 99%; b. Isopropyl 
bromide, K2C 0 3, DMF, r.t. 2 days, 8 8 %; c. MOMC1, NaH, DMF, 0 °C to r.t., 8 8 %; d. 
NaOH (2M) (aq), MeOH, r.t., overnight.
After heating the MOM protected chalcone 260 in the previous conditions used for the 
intramolecular Heck reaction225 for 30 minutes the reaction had not gone to completion 
{Scheme 42). So the mixture was heated at 110 °C for 8  hours, however after this time the 
reaction still had not gone to completion and the NMR spectrum of the crude product 
showed that it was a 1:1 mix of chalcone 260 and indenone 265. The separation of 260 and 
265 by column chromatography proved to be hard because the 2 compounds co-spotted on 
the TLC plate.
OMe
257 R = TBDMS
258 R = Bn
259 R = CH(CH3 ) 2
260 R = CH2OCH3
MeO
MeO
OR
OMe
261 R = TBDMS 0%
266 R = Bn 62%
267 R = CH(CH3 ) 2 48% 
265 R = CH2OCH3 0%
Scheme 42\ a. PdCl2 (2.5 mol%), PPh3 (7.5 mol%), K2C 03, DMF, 1 10 °C, 30 mins;
The benzyl protected indenone was prepared from 258 using the intramolecular Heck 
reaction225 previously described as a red solid which was isolated via chromatography in a
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good yield (Scheme 42). To remove the benzyl group from the indenone 266 
hydrogenation with 10% palladium on carbon and hydrogen was attempted (Scheme 43). 
Unfortunately this reaction failed and the starting indenone 266 was recovered. We then 
tried using trimethylsilyl iodide229 to cleave the benzyl ether. After ten minutes the reaction 
was quenched with methanol and was worked up. Unfortunately the NMR spectrum 
showed that the compound had decomposed and neither starting material nor product could 
be recovered from the mixture (Scheme 43). Trimethylsilyl iodide cleaves ether groups, so 
it may have reacted with the methoxy groups on the indenone as well as the benzyl ether.
MeO. MeO.
MeO a or b M e 0
OH
266 268OMe OMe
Scheme 43: a. H2 , 10% Pd/C, EtOAc, r.t., 30 mins; b. Me3 SiI, CHCI3 , r.t., 10 mins.
The intramolecular Heck reaction225 was carried out on the isopropyl protected chalcone 259 
to prepare the isopropyl-protected indenone 267 in a moderate yield as red crystals after 
recrystallization from ethyl acetate and hexane (Scheme 42). We then tried to deprotect the 
isopropyl-protected indenone 267 by treating it with 1M boron trichloride in heptane (Scheme 
44).227 Unfortunately the reaction caused the compound 267 to decompose and no phenol 
could be recovered from the resulting reaction product.
MeO.
MeO
OH
268 OMe
MeO.
MeO‘
267 OMe
Scheme 44: a. 1M BCI3 in heptane, EtOAc, 0 °C, 6  hrs.
The preparation of the MOM-protected indenone 265 was then attempted again, this time 
using microwave irradiation instead of traditional heating, to see if the reaction could be 
pushed to completion. The reaction was performed in a microwave vessel at 160 °C, 150 W, 
for 15 minutes (Scheme 45). The reaction proved to be capricious, one attempt on a 100 mg 
scale gave a 91% crude yield of 265 and another time using the same conditions but on a 
larger scale of 260 mg the reaction did not go to completion. After careful column 
chromatography using the Flashmaster system only 19% of the indenone 265 was isolated
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from the chalcone 260/indenone 265 mix. More indenone could possibly have been isolated 
from the mixture by repeat chromatography {Scheme 45). Maybe if the reaction was repeated 
for a longer time on a 260 mg scale the reaction would have gone to completion.
0 MeO.
f Y °
^ * S ) M e
OMe
260
MeO
MeO MeO
OMe
265
Scheme 45: a. PdCl2 (2.5 mol%), PPh3 (7.5 mol%), K2C 03, DMF, pwave, 160 °C (150
W), 15 mins, 100 mg scale crude 91%, 260 mg scale 19%.
The deprotection of the MOM-protected indenone 265 was carried out by refluxing the 
compound in methanol and in the presence of 3 M hydrochloric acid for 45 minutes {Scheme 
46).230 This deprotection method gave only a 12% yield of indenone 268, however it also 
gave the side product 269 in a 30% yield corresponding to the addition of methanol across the 
C2-C3 double bond. The !H NMR spectrum of 269 showed the presence of an extra methoxy 
signal, also the key diagnostic peak of the alkene hydrogen H-2 of the indenone 268 which 
appears at 5.73 ppm was no longer present in the spectrum of 269 indicating that the alkene 
bond was no longer present in the molecule. The signal at 51.73 ppm in the l3C NMR and 
DEPT spectrum of 269 showed that the molecule possesses a methylene group, this was 
further confirmed by the key diagnostic peaks of a AB system that occur at 5 2.92 (lH a, d, J
19.2 Hz, H-2a), 3.17 (lHb, d, J  19.2 Hz, H-2b) ppm in the !H NMR spectrum. The HRMS of 
269 also showed the molecular weight for the [MH]+ ion to be 375.14396, HRMS which 
confirms that the molecule has undergone the addition of methanol, when compared to 
HRMS 268 found [MH]+ 343.11840 for C 19H 19O6 , where the difference in weight is 36 
(CH3OH).
MeO.
MeO MeO
OMe
MeO.MeO
OMeMeOMeO
OHOH
OMeOMe
265 268 269
Scheme 46: a. 3M HC1 (aq), MeOH, 75 °C, 45 mins, 268 12%, 269 30%;
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Seeing that the microwave assisted Heck reaction of the MOM-protected chalcone 260 was 
successful we then attempted the same reaction but with the TBDMS protected chalcone 257. 
Using these Heck reaction conditions, the chalcone 257 was heated in a microwave reactor at 
160 °C (150 W) for 15mins, giving a 81% crude yield of indenone 261 which was then taken 
without any further purification to be deprotected (Scheme 47).
The indenone 261 was fully characterised with API ES+ MS showing a molecular ion [MH+] 
at m/z 457, corresponding to a molecular formula of C2sH3 3 0 6 Si. 'H NMR spectroscopy 
further supported the formation of the indenone 261 with the key indenone diagnostic peak 
appearing at 8  5.71 (1H, s, H-2) ppm.
OMe
OMe OMe
257 261
Scheme 47: a. PdCb (2.5 mol%), PPI13 (7.5 mol%), K2CO3 , DMF, pwave, 160 °C (150 
W), 15 mins, crude 81 %.
This transformation of 257 into 261 also proved to be capricious. When it was repeated on a 
slightly larger scale of 160 mg the results varied dramatically from the original reaction. After 
purification, in this case by column chromatography only a 24% yield of the TBDMS 
protected indenone 261 was isolated, however the unprotected indenone 268 was also isolated 
in a 25% yield.
The TBDMS-protected indenone 261 was then treated with tetrabutylammonium fluoride 
(TBAF) in THF at 0 °C to give the unprotected indenone 268 in a good yield {Scheme 48). 
The indenone 268 was fully characterised with API ES+ MS showing a molecular ion [MH+] 
at m/z 343, corresponding to a molecular formula of C 19H 19O6 . 'H NMR spectrum further 
supported the formation of the indenone 261 with the key indenone diagnostic peak appearing 
at 8  5.73 (1H, s, H-2) ppm.
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MeO
MeO
OH
OMeOMe
261 268
Scheme 48: a. 1M TBAF in THF, THF, 0 °C, 30 mins, 6 6 %.
A small series of 2’-bromochalcones 270 -  275 were prepared to make a small library of 
compounds with the indenone scaffold. They were prepared using the typical Claisen- 
Schmidt condensation178 method previous mentioned and isolated in good yields as crystals 
afler recrystallization from methanol {Scheme 49). The *H NMR spectra of the compounds 
showed that they were isolated as the pure E isomer by their alkene coupling value ~ 15 -  16 
Hz. The fluoro chalcone 271 *H NMR spectrum showed a more complex coupling pattern 
due to the fluorine hydrogen coupling on its aromatic B ring {Figure 31), with with !H NMR 
signals at 6.97 (1H, d, J  8.4 Hz, H-5” ), 7.29 -  7.33 (1H, dm, J  9.0 Hz, H-6 ” ) and 7.36 (1H, 
dd, J2 .0  Hz, J12.0
Hz, H-2” ) ppm.
OMe
251
Scheme 49: a.
Br
OMe 
270 - 275 
Ar'CHO, NaOH (2M) (aq),
MeOH, r.t., overnight.
Chalcone Ar1 %
270 3 -Nitro-4-methoxypheny 1 70
271 3-Fluoro-4-methoxyphenyl 84
272 Phenyl 71
273 3,5-Dimethoxyphenyl 73
274 3,4,5 -T rimethoxypheny 1 79
275 3,4-Dichloropheny 1 71
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Figure 31: x H NMR of chalcone 271 
To make chalcone 270 the 4-methoxy-3-nitrobenzaldehyde (276) was prepared from p-
(iScheme 50). The benzaldehyde 276 was isolated after an hour by pouring the reaction into ice 
cold water. The benzaldehyde 276 that precipitated as a light brown solid was then filtered off, 
recrystallized from ethanol and then dried in vacuo. This benzaldehyde was then used to 
prepare chalcone 270.
276
Scheme 50: a. HNO3 , H2SO4 , -15 °C, 1 hour, 69%.
Each of the 2’-bromochalcones 270 -  275 were then treated with the conditions described by 
Clark225 for the intramolecular Heck reaction, on a 1 mmol scale {Scheme 51, route a). This 
route worked well for all the chalcones, except for nitro chalcone 270 and dichloro chalcone 
275. The indenones 277 -  280 were isolated pure after column chromatography and 
recrystallization from EtOAc and hexane. The formation of the dichloro indenone 281 was 
problematic because the reaction did not go to completion and the XU NMR spectrum of the 
crude product showed that it was a mixture of the starting chalcone 275 and the indenone 
281. Unfortunately both chalcone 275 and indenone 281 were not resolved by TLC, however 
we did manage to isolate the indenone by recrystallization from ethyl acetate and hexane in a 
31% yield of peach coloured fluffy crystals. The reaction to make the nitro indenone 282 via 
traditional heating techniques did not work and the starting chalcone was recovered. We next 
tried the microwave conditions used to make the MOM and TBDMS protected indenone 265
anisaldehyde by nitration with concentrated nitric acid and concentrated sulfuric acid at -15 °C
O O
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and 261 on the chalcone 270 {Scheme 51, route b). The indenone 282 was prepared running 
the experiment on a 100 mg scale of the chalcone 270 five times and then combining the 
crude mixtures and working them up together. After recrystallization from ethyl acetate and 
hexane 282 was isolated as red crystals in a 31 % yield.
270 - 275 277 - 282
Scheme 51. a. PdCl2 (2.5 mol%), PPh3 (7.5 mol%), K2C 03, DMF, 1 10 °C, 30 mins, yield 
(see table 7); b. PdCl2 (2.5 mol%), PPh3 (7.5 mol%), K2C 03, DMF, pwave, 160 °C (150 
W), 15 mins, yield (see table 7).
Table 7: Yields of indenones 277 -  282 (see scheme 51).
Indenones Route Ar1 %
277 a 3 -Fluoro-4-methoxyphenyl 70
278 a Phenyl 65
279 a 3,5-Dimethoxyphenyl 54
280 a 3,4,5-Trimethoxyphenyl 63
281 a 3,4-Dichloropheny 1 32
282 b 3 -N itro-4-methoxypheny 1 31
We then wanted to investigate the effects of replacing the a-hydrogen with a methyl on the 
indenone scaffold, due to the marked improvement of the biological activity of chalcones 
such as 182. The 2’-bromopropiophenone 283 was prepared via the Grignard addition of 
commercially available ethylmagnesium chloride in THF to the 2-bromobenzaldehyde 252 to 
make the secondary alcohol 284. This alcohol was oxidized with PCC to give the desired 2’- 
bromo propiophenone 283 in a good yield {Scheme 52).
O OH O
OMe OMe OMe
252 284 283
Scheme 52: a. EtMgCl (2M in THF), THF, 0 °C to r.t., 12 hours, 99%; b. PCC, DCM, 
r.t., 12 hours, 89%.
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The a-methylchalcone 285 was then prepared via the acid-catalyzed condensation method 
described by Edwards, 72 by refluxing 2’-bromopropiophenone 283 and p-anisaldehyde in 
ethanol, glacial acetic acid and piperidine {Scheme 53). The reaction generates water which 
was removed from the reaction as the refluxing reaction condenses in the condenser tube 
packed with activated 3-A molecular sieves. The reaction was then worked up and purified 
by chromatography. However the desired chalcone was isolated with /?-anisaldehyde which 
co-eluted on the TLC plate. The !H NMR spectrum showed the ratio of a-methylchalcone 
285 to p-anisaldehyde was 2.9:1. To remove the p-anisaldehyde from the desired a- 
methylchalcone 285 the mixture was shaken in deuterated chloroform in the presence of the 
scavenger agent PS-trisamine (286) at room temperature for 2
hours. PS-trisamine (286) can scavenge a range of compounds231 __yN H 2
including acid chlorides, aldehydes, epoxides and isocyanates. To ~ \ i h 2
scavenge benzaldehydes the primary amine groups of PS-trisamine 286
(286) react with the carbonyl of the benzaldehyde forming imines. Deuterated chloroform 
was used as the solvent so that the reaction can monitored by taking ]H NMR spectra 
periodically. After which time the mixture was passed through a filter to remove the PS- 
trisamine to give the pure a-methylchalcone 285 as a yellow oil in a fair yield {Scheme 53).
The a-methylchalcone 285 was fully characterised with AP+ mass spectrometry showing a 
molecular ion [MH+] at m/z 421, corresponding to the molecular formula C20H22B1O 5. The *H 
NMR spectrum also supports the formation of the a-methylchalcone 285, the key diagnostic 
peak being the p-H of the enone system appearing at 8  7.09 (1H, s, H-3) ppm. Similar a- 
methylchalcone 56,177,191 287 and 28836 prepared previously our group and the a- 
methylchalcone x23 were all isolated as the £-isomer with the P-H appearing 7.08 -7 .17  ppm 
{Figure 32). The p-H signal of the a-methylchalcone 285 appears at 5 7.09 ppm suggesting 
that the E-isomer of 285 has also been isolated.
n
0 O
M e C f y ^ r  ^ ^ O M e
OMe
283
Scheme 53: a. Piperidine, AcOH, EtOH, Ar, 110 °C, 7 days; b. PS-trisamine 286, 
CHCI3 , r.t., 2 hours, 61% over 2 steps.
MeO
b
^  MeO
OMe OMe
285
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MeO MeO MeO
OHMeO MeO MeO
OMe1 OMeOMe “OMe “OMe
56 7.11 ppm 287 7.08 ppm 288 7.08 ppm
O0 MeO
MeO
MeO
MeO MeO BriiOMe OMe
1 8 2  7. 7 ppm 285 7.09 ppm
Figure 32: *H NMR signals for the p-H of the a-methylchalcone chalcones
The Clark indenone formation technique,225 as previously described, was then applied to a- 
methylchalcone 285. Unfortunately this reaction did not work and the a-methylchalcone 285 
was recovered. The microwave indenone technique was then also tried, this reaction also 
failed and the starting material was recovered {Scheme 54).
MeO
a or b
OMe
MeO.
MeO'
OMe “OMe
285
Scheme 54: a. PdCl2 (2.5 mol%), PPh3 (7.5 mol%), K2C 03, DMF, 110 °C, 1 hour; b.
PdCl2 (2.5 mol%), PPh3 (7.5 mol%), K2C 03, DMF, pwave, 160 °C (150 W), 15 mins.
One possible reason why the internal Heck reaction of a-methylchalcone 285 failed, may be 
due to the difficulty in forming the carbometallation intermediate 293 {Scheme 55). The 
carbometallation intermediate of a-methylchalcone 285, 295 {Figure 33) has two bulky 
groups attached to the C-2 position, the methyl group and the palladium (II) species, these 
will make the formation of this intermediate unfavourable due to steric hindrance of these 
groups. This is not a problem for the formation for indenones from the 2,-bromochalcones 
which only have a hydrogen on the a-position instead of a methyl group, because this gives a 
carbometallation intermediate 296 {Figure 33) has less steric hindrance from the interaction 
of the hydrogen and the palladium (II) species attached to the C-2 position which makes its 
formation more favourable than the formation of 295 {Figure 33).
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MeO.
Oxidative
additionreductive B.HBr elimination \
MeO'
MeO
290
MeO.PdL2 Pd(ll)
Pd(II)
MeO'
MeO
Pd(II) 291B-hydride
eliminaton MeO.
MeO. carbometallationMeO'
MeO
293MeOMeO
294
Scheme 55: The internal Heck reaction mechanism for the formation of the indenones.
MeO
MeO Pa
MeO
MeO
MeO
295
more steric 
hindered intermeidate
hd8
MeO
296
less steric 
hindered intermeidate
Figure 33: The steric hindrance of the carbometallation intermediate.
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3.3.2.1 Biological results for the indenones and the precursor 2’-bromochalcones
MeO
MeO
OMe
Indanone R2 At' IC50(K562) (pM)
254 H 4-Methoxyphenyl 4.25
255 H 3-Hydroxy-4-methoxyphenyl 0.32
257 H 3-/£r/-Butyldimethylsilyloxy-4-methoxyphenyl 4.1
258 H 3-(Benzyloxy)-4-methoxyphenyl >10
259 H 3-Isopropoxy-4-methoxyphenyl 3.2
260 H 4-Methoxy-3-(methoxymethoxy)phenyl 6.15
270 H 3 -N itro-4-methoxypheny 1 5.5
271 H 3-Fluoro-4-methoxyphenyl 7.6
272 H Phenyl 8.1
273 H 3,5-Dimethoxyphenyl 7.4
274 H 3,4,5-Trimethoxyphenyl >10
275 H 3,4-Dichloropheny 1 >10
285 Me 4-Methoxyphenyl 0.24
I W1 . .  Ar1OMe
Indenone Ar1 IC50(K562) (pM)
256 4-Methoxyphenyl 0.090
261 3-terf-Butyldimethylsilyloxy-4-methoxyphenyl 1.86
266 3 -(Benzy loxy )-4-methoxypheny 1 2.0
267 3-Isopropoxy-4-methoxyphenyl 3.32
265 4-Methoxy-3-(methoxymethoxy)phenyl 2.21
268 3 -Hydroxy-4-methoxypheny 1 0.019
282 3 -Nitro-4-methoxypheny 1 0.44
277 3-Fluoro-4-methoxyphenyl 0.037
278 Phenyl 7.6
279 3,5-Dimethoxyphenyl > 10
280 3,4,5-Trimethoxyphenyl 1.4
281 3,4-Dichlorophenyl 0.6
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269 0.024
The biological results show that the addition of a bromine on the C 2  position of the A ring of 
the chalcone generally decreases the biological activity against leukaemia cell line K 5 6 2 ,  for 
instance the a-methylchalcone 285 [ I C 5 o ( K 5 6 2 )  = 0.24 pM] with the bromine on the C 2  
position of its A ring is much less effective against K 5 6 2  than the a-methylchalcone 182 
[IC5o(K562) = 0.010 pM] without the bromine. The conformationally s-trans locked 
indenones generally show an increased activity against K 5 6 2  when compared against their 2 ’ -  
bromochalcone precursors. This activity is also an improvement on their conformationally 
flexible chalcone analogues, for instance the activity of chalcone 165 [ I C s o ( K 5 6 2 )  =  1 . 6  pM] 
is considerably increased when compared to its indenone 256 [ I C s o ( K 5 6 2 )  = 0.090 pM]. As 
is expected from previous biological results the indenone 268 with the CA-4 like 3-hydroxy- 
4-methoxyphenyl B ring is the most active indenone prepared [ I C 5 o ( K 5 6 2 )  = 0.019 pM] and 
is a potent inhibitor of K 5 6 2  cells. It is a shame that the a-methyl indenone 289 could not be 
prepared because the addition of the methyl group alpha to the carbonyl of chalcones has 
shown a vast improvement on their biological activity,73 and it would be interesting to see if 
this improvement also takes place on the indenones. The side product 269 from the 
deprotection of the MOM protected indenone 265 also has a high biological activity against 
K 5 6 2  [IC5o(K562) = 0.024 pM] and further investigation into this product may lead to other 
compounds of interest, one area specifically that may give interesting results on this 
compound is the investigation of the separation of the two enantiomers of 269 to see what 
effects they have on its biological activity.
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4.1 The Development of other Cytotoxic Chalcones232
The biological properties of the chalcone scaffold have been widely investigated and have 
shown a diverse range of pharmacological activities including cytotoxicity,232 antitumour,232 
antiinflammatory,170233 234 antiplasmodial,235 and antioxidant236 properties. There has been 
sustained interest in the cytotoxic properties of chalcones and in recent years a number of 
cytotoxic chalcones have been reported
Nam237238 and co-workers prepared a 50+ library of 2’,5’-dihydroxychalcones developed from 
the active extracts of the Vietnamese medicinal plant Notopterygium incisum.239240 These 
chalcones were then tested against a variety of tumour cell lines including B16 murine 
melanoma, HCT 116 human colon cancer and A31 human epidermoid carcinoma to 
investigate there cytotoxicity. The majority of the 2’,5’-dihydroxychalcones proved to have 
potent cytotoxicity against these cell lines, with the 2-chloro substituted B
OH O
ring chalcone 297 being one of the most cytotoxic chalcone prepared.
Several of the chalcones prepared also had strong angiogenesis inhibitory 
properties, especially 297 [The IC50 for growth inhibition of human OH 
umbilical vein endothelial cells (HUVEC) was 0.11 pM].237
The 2’-oxygenated chalcones have previously shown anticancer 
activity including the inhibition of the growth of the MCF-7 human 
breast cancer cells.241 Rao and co-workers242 decided to synthesis ten 
2’-oxygenated chalcones to further investigate their cytotoxic effects 
against the Jurkat and U937 human tumour cell lines, as well as 
against normal peripheral blood mononuclear cells (PBMCs), to 
explore their potential clinical application. The 2’-oxygenated 
chalcone 298 proved to be selectively toxic to Jurkat cells, I C 50  
(Jurkat) 3.2 pM, but showed little cytotoxicity to U937 cancer cells,
IC50 (U937) 16.0 pM or the normal cells, IC50 (PBMCs) 39.8 pM.
The 2’-oxygenated chalcones 299 -  301 also showed good 
cytotoxicity to both Jurkat and U937 cells with I C 50  <7 pM, however 
they were all fairly cytotoxic to the normal cell line PBMC as well 
with I C 50  <11 pM.
The 2’-amino chalcone analogues of structurally rigid 2-phenyl-4-quinolones243 were shown 
to possess potent cytotoxic activity to a panel of human tumour cells, with the 2’-amino 
chalcone 302 being the most potent.244 The presence of the 2’-amino group was shown to be
L'f 1
MeO
OH O
298 OMe
MeO O
MeO OMe
299
MeO'
OH O OMe
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vital to the activity of the chalcone, with 303 being 40 fold less 
active than the T -amino chalcone 302. ^
Dimmock et al.224 investigated the cytotoxicity of various Mannich 
base chalcones, many of which displayed a significant cytotoxicity 
towards murine P388, L1210 leukaemia cells and a number of  ^
human tumour cells as well. The idea that caused these Mannich 
base chalcones to be investigated for possible cytotoxicity is that a number of a,p-unsaturated 
ketones have demonstrated reactivity towards soft nucleophiles like thiols245 246 instead of hard 
nucleophiles like hydroxy or amino groups, and therefore avoid the problems of mutagenicity 
and carcinogenicity associated with a number of alkylating agents used in cancer 
chemotherapy.247 The Mannich base should also be able to alkylate the thiol as well, causing 
the compound to be more cytotoxic than the normal chalcone
0(Scheme 57). The chalcone 304 may alkylate the common HQ C02H
A a l t n l n r  n l n f n t U i r v n a  / ^ A C \  t r v  n u r a  t U a  — L J
NH: H 
305
cellular thiol glutathione (GSH, 305) to give the adduct 306 
(Scheme 56). This could also happen to the Mannich base 
chalcone 307 to give the thiol adduct 308, the Mannich base of 308 could then form the 
intermediate enone 309 which could then undergo further thiol alkylation to give the thiol 
bisadduct 310 (Scheme 57).
GSH
0  GSGSH
304 ^
O GS
Scheme 56: The mechanism of the thiol alkylation of chalcone 304 
O NMe2 0  GS NMe;
GSH
0 GS O GS
GSH
309
Scheme 57: The mechanism of thiol alkylation of Mannich base chalcone 307
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Biological testing of the Mannich base chalcone 311 showed that 
in a buffered solution it was stable and it did not react with the 
excess GSH (305). However the chalcone 311 did react with GSH 
(305) when it was in the presence of glutathione ^-transferase.
Therefore under these biological conditions the chalcones may 
undergo thiol alkylation. 224
The most promising lead molecule found in Dimmock study was 
the Mannich base chalcone 312 which displayed potent cytotoxicity to the L1210 
[1C5o(L1 2 1 0 ) 2.5 pM] and human tumour cells[IC5o(Molt 4/C8) 7.0 pM, IC5o(CEM) 2.5 
pM ] . 224
The 4’,4” -hydroxychalcone RVC-588 (313) has also been shown recently to be cytotoxic to 
the human myeloid HL-60 leukaemia cell line (IC50 2 pM ) . 248 The mode of action of 313 is 
not known, however a previous study236 has shown that hydroxy O
substituted compounds were found to be the most potent anti-
oxidant and cytotoxic in tumour cells, and it may be the hydroxy ^H
groups that play a role in the cytotoxicity of RVC-588 (313). It was also proposed that the 
cytotoxicity of RVC-588 (313) could be attributed in part to the thiol alkylating ability of the 
a,p-unsaturated carbonyl system in the chalcone.224
OH O
OH 0
MeO 315
Hexane extracts of the common northeastern Brazilian plant 
Lonchocarpus sericeus, were found to be cytotoxic against the 
C E M  leukemic cell line, IC50 17.6 pgmL*1.249 The main 
components of the extract were Lonchocapin (314) [ I C s o ( C E M )
33.9 pM] and Derricin (315) [ I C 5o ( C E M )  40.3 pM] in roughly 
equal amounts. Derricin (315) proved to be the most potent of 
the two chalcone isolated causing a maximum inhibition of C E M
cells of 96%, while Lonchocapin (314) maximum inhibition of the CEM cells was 77%. 
Further testing of the prenylated chalcone Derricin (315) showed that it disrupted the 
development of fertilized eggs of sea urchins by disrupting the cell cycle. Further testing 
suggested that the cytotoxicity of the two chalcones 314 and 315 was not due to microtubule 
disruption.249
Two similar chalcones have been recently isolated from the Japanese plant Angelica keiskei 
Koizumi, xanthoangelol (316)250 and 4-hydroxyderricin (317).251 Xanthoangelol (316)250 and 
4-hydroxyderricin (317)251 were both shown to inhibit the growth of Lewis lung carcinoma 
(LLC) tumours and have antimetastatic properties. It was proposed that the mechanism for
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the antitumour and antimetastatic actions of 316 might involve the inhibition of DNA 
synthesis in LLC cells and inhibition of tumour induced angiogenesis.250 However it was 
found that 317 did not inhibit DNA synthesis and its mechanism of antitumour and 
antimetastatic actives of 317 may be associated with the inhibition of the reduction of the 
immune system and tumour-induced angiogenesis.251
OH O . OH O
The human homolog of MDM2 (mouse double minute 2) oncogene is over expressed in 
human breast cancer, and it binds to the tumour suppressor protein p53 at its transactivation 
site, inhibiting p53’s ability to initiate apoptosis and leading to deregulation of the cell cycle. 
This makes disruption of the p53/HDM2 complex an attractive target for cancer therapy. 
Stoll252 and co workers found that chalcones with carboxylic acid substituents bound to the 
tryptophan pocket of the p53 binding site of MDM2 and promote dissociation of the 
p53/MDM2 complex. The most active carboxylic acid chalcone 318 inhibited MDM2 
binding to p53 with an IC50 value of 49 pM. The o
Ci
carboxylic acid chalcone 318 was shown by jj* 
multidimensional NMR spectroscopy to dock in the Cl ^ 318 ^ ^ ^ 0 '^ C 0 2H
tryptophan subsite of human MDM2 p53 binding site and disrupt the MDM2/p53 protein 
complex. The carboxylic acid is thought to be important to the activity of 318 by disrupting
the salt bridge between lysine51 and glutamic acid 54 in the tryptophan subsite of human
MDM2 bound P53.
The replacement of the carboxylic acid group with a boronic acid was further investigated by 
Kumar et al. 253 The boronic acids are weaker acids pKa 9-10 and will be largely non-ionized 
at physiological pH and are therefore unlikely to form a salt bridge with lysine51. However it 
was proposed that they may form a covalent bond to the amino of lysine51 instead, resulting 
in a stronger interaction with p53 binding site of MDM2. o
The carboxylic acid chalcone 318 was not selectively 
toxic to cancer cell lines, with I C 50  values ranging from 319 B(OH)2
1 3 - 1 8  pM for the human breast cancer cell lines and I C 50  values ranging from 1 2 - 2 8  pM 
for the normal human breast cell lines, however the boronic acid chalcones showed a greater 
selectivity to cancer cells. For example the iodo derivative boronic acid 319 had the highest 
selective cytotoxicity against human breast cancer cell lines I C 50  9 . 5 - 1 8  pM, compared to 
the normal human breast cell line I C 50  3 8 -  100 pM.253
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4.2 The total synthesis of 4-hydroxyderricin (317) and analogues.
The hardy Japanese plant Angelica keiskei Koizumi (Japanese name “Ashitaba”, belonging to 
the Umbelliferae family) is found mainly on the Pacific coast of Japan. The Umbellifers are 
used in traditional Chinese medicines,254 Angelica keiskei Koizumi has traditionally been used 
as a diuretic, laxative, analeptic and galactagogue.255 The plant has also shown beneficial 
effects such as the suppression of gastric acid secretion,256 antithrombotic effects,257 reduction 
of blood pressure,258 suppression of histamine release and the promotion of blood 
circulation.259 The roots and herbs of A. keiskei are also thought to have preventive effects 
against coronary heart disease, hypertension and cancer, however the basis for this is 
unclear.250,251
In a study of the anti-tumour-promoting activities of the Umbelliferae family, Okuyama254 
and co-workers reported the potent anti-tumour activity of the nonpolar extracts of the root of 
Angelica keiskei. Eight compounds were isolated from the nonpolar extract including three 
chalcones xanthoangelol (316), 4-hydroxyderricin (317) and the novel ashitaba-chalcone 
(320). The chalcones xanthoangelol (316) and 4-hydroxyderricin (317) proved to have anti- 
tumour promoting activity in mouse skin carcinogenesis that had been induced by exposure to 
the carcinogen 7,12-dimethylbenz[a]anthracene (DMBA, 321) plus 12-Otetradecanoyl 
phorbol-13-acetate (TPA, 322).254
OH O
316 321HO OH
OH OOH 0
HO OHHOO
322320317 OHMeO”OHMeO
Akihisa260 and co-workers have recently reported the isolation of seventeen different 
compounds from the ethyl acetate extract of the stems of Angelica keiskei including two of 
the previously reported chalcones 316 and 317, as well as three other chalcones 
xanthoangelol F (323), xanthoangelol H (324), isobavachalcone (325). All 5 of the chalcones 
isolated showed potent antitumour inhibition of the induction of Epstein-Barr virus early 
antigen (EBV-EA) by TP A (322), with the chalcones 317 and 325 being the most potent 
inhibitors.260
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In another recent study by Kimura and co-workers the two chalcones xanthoangelol (316)250 
and 4-hydroxyderricin (317)251 were isolated from Angelica keiskei. Both of the chalcones 
316 and 317 were shown to inhibit the growth of Lewis lung carcinoma (LLC) tumours, and 
were also reported to have antimetastatic properties. It was proposed that the mechanism for 
the antitumour and antimetastatic actions of 316 might involve the inhibition of DNA 
synthesis in LLC cells and inhibition of tumour induced angiogenesis.250 However when 4- 
hydroxyderricin (317) was further investigated it did not inhibit DNA synthesis. The 
mechanism of antitumour and antimetastatic actives of 317 are now proposed to be associated 
with the inhibition of the reduction of the immune system and tumour-induced 
angiogenesis.251 The chalcone 4-hydroxyderricin (317) has been shown to exert a beneficial 
effect on the prevention of strokes in mice.261
So we have chosen to further investigate the total synthesis of 4-hydroxyderricin (317) and 
then create a small library of similar compounds to assess their biological activity.
4.2.1 The synthesis of 4-hydroxyderricin (317).
Our idea for the synthesis of 4-hydroxyderricin (317) was the preparation of the 3’- 
allylacetophenone 326 from 2-hydroxy-4-methoxyacetophenone (327), followed by the 
Claisen-Schmidt condensation178 with 4’-hydroxybenzaldehyde (328) to give the 3’- 
allylchalcone 329. Metathesis of the 3’-allylchalcone 329 would then hopefully provide the 
prenylated chalcone 4-hydroxyderricin (317) {Scheme 58).
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Scheme 58
Using the method described by Anjaneyulu262 et al., the hydroxy group of 2’-hydroxy-4’- 
methoxyacetophenone (327) was allylated by refluxing 327 in acetone with allyl bromide 
and potassium carbonate at 75 °C for 12 hours {Scheme 59). The mixture was then allowed 
to cool to room temperature, the potassium carbonate was then removed by filtration and 
then the acetone was removed in vacuo. The crude product was then dissolved in ethyl 
acetate and the base washed with 5% sodium hydroxide solution to remove any remaining 
327, the allyl ether acetophenone 330 was then isolated in an excellent yield as a white 
solid.
The allyl ether acetophenone 330 was then dissolved in AVV-dimethylaniline, and heated at 
210 °C for 12 hours to cause the allyl group to undergo a [3,3]-sigmatropic Claisen 
rearrangement to give the 3’-allylacetophenone 326 {Scheme 59)262 as yellow crystals in a 
moderate yield.
MeO
330
OH Ob or c
MeO
326
MeO
327
Scheme 59: a. allyl bromide, K2CO3 , acetone, 75 °C, 12 hours, 99 %; b. A.A-dimethyl 
aniline, 210 °C, 6  hours, 326 58%; c. A.A-dimethylaniline, pwave, 260 °C, 200 W, 12 
mins, 326 6 6 %.
The key diagnostic peaks of the *H NMR spectrum of 3’-allylacetophenone 326 are the 
peaks for the allyl group which appear at 3.42 (2H, dt, J  6.1, 1.7 Hz, H -l” ), 4.93 -  4.98 
(1H, dm, J  10.1 Hz, cis-H-3” ), 4.97 -  5.04 (1H, dm, J  17.0 Hz, trans-H-3” ) and 5.95 (1H,
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ddt, J  10.1, 17.0 and 6.1 Hz, H-2” ) ppm (Figure 34). The !H NMR spectrum of 326 
corresponds to the literature values reported by Anjaneyulu262 et al.
6 00 
ppm (f1)
5  5 0 5 0 0 4  5 0 4  0 0 3 5 0
Figure 34: !H NMR spectra signals for the allyl group of 326
The Claisen rearrangement of the allyl ether acetophenone 330 to prepare the 3’-allyl 
acetophenone 326 {Scheme 59) was tried again. However instead of heating this reaction 
conventionally we used the microwave reactor to see if we could reduce the reaction time.
It is generally expected that each time the temperature of a reaction is increased in the 
microwave reactor by 10 °C the time taken for the reaction is halved. Therefore the Claisen 
rearrangement was attempted at 260 °C for 12 minutes, after which time the TLC showed 
that the reaction had gone to completion {Scheme 59, route c). The 3’-allyl acetophenone 
326 was then isolated by column chromatography as a yellow solid in a moderate yield.
The 2’-hydroxy group of 326 had to be protected before the acetophenone 326 could be used 
to prepare a chalcone, to prevent the in situ formation of the possible flavanone side product 
from the 2’-hydroxychalcone under the basic conditions needed for the Claisen-Schmidt 
condensation. 232
We first attempted the MOM protection of 326 using the conditions that had previous worked 
for protecting isovanillin in chapter 3. 228 A solution of 326 in DMF was treated with 1.2 
equivalents of sodium hydride, followed by 1.2 equivalents of methoxymethyl chloride. This 
technique for MOM protection did not work well and only gave a low yield of 28% of 331, 
and 70% of the starting acetophenone 326 {Scheme 60).
We then tried using a modified version of the MOM protecting strategy described recently by 
Romano263 and coworkers for the protection of 2,4-dihydroxybenzaldehyde. In this protocol a
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slightly larger excess of sodium hydride and MOMC1 is used. But the significant change is 
the reaction temperature (65 °C for 18 hours). The MOM protected acetophenone 331 was 
isolated after column chromatography in a moderate yield of 43%. The starting acetophenone 
326 was also recovered from the column chromatography in a 42% yield {Scheme 60).
OH 0 ^ 0 ^ 0  O
MeO
326
a or b
MeO
331
Scheme 60: a. M0MC1 (1.2 eqv), NaH (1.2 eqv), DMF, 0 °C to r.t., 12 hrs, 28%; b. 
MOMC1 (1.5 eqv), NaH (1.5 eqv), THF, 0 °C to 65 °C, 18 hrs, 43%.
Before the chalcone 329 could be made the 4-hydroxybenzaldehyde 328 had to be protected 
because of the electron-donating effect of the hydroxy group (deprotonated under the reaction 
conditions) significantly reduces the electrophilicity of the carbonyl group. Therefore we 
MOM protected the 4-hydroxybenzaldehyde 328 using the conditions described for the MOM 
protection of isovanillin in chapter 3 (Scheme 61). This gave the MOM protected 
benzaldehyde 332 in a high yield of 94% as a pale yellow oil.
0 O
H
332
H
OH
328
Scheme 61: a. M0MC1, NaH, DMF, 0 °C to r.t., 12 hrs, 94%.
The MOM protected acetophenone 331 was then treated sodium hydroxide and the 
benzaldehydes 332 and 333 using the typical Claisen-Schmidt condensation178 conditions to 
give the MOM protected chalcones 334 and 335. The *H NMR spectrum of crude products 
of 334 and 335 showed that they were a mixture of the desired chalcone and their precursor 
benzaldehyde. Neither of the chalcones were isolated and instead they were deprotected, by 
refluxing the mixtures in methanol in the presence of 3 M hydrochloric acid for 45 minutes 
{Scheme 62) . 230 The two chalcones 329 and 336 were then both isolated after column 
chromatography in good yields. Both chalcones were isolated as their E isomer and were 
fully characterised.
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'0 0 o
M e O ^ 5^ OR
R
331 332 MOM
333 Me
MeO OR
334 MOM
335 Me
329
336
Scheme 62: a. 2M NaOH (aq), MeOH, r.t., overnight; b. 3M HC1 (aq), MeOH, 75 °C, 45 
mins, 329 81%, 336 72%.
The API ES+ mass spectrometry of 3’-allylchalcone 329 showed the expected molecular ion 
[MH+] at m/z 311. The key diagnostic peaks in the NMR spectrum of 329 were the 
hydrogen signals of the enone system appearing at 8  7.47 (1H, d, J  15.0 Hz, H-2) and 7.84 
(1H, d, J  15.0 Hz, H-3) ppm proving that the chalcone 329 was isolated as its £-isomer. The 
hydrogen signals for the allyl group which appear at 3.45 (2H, dt, J  62  and 1.8 Hz, H -l’” ),
4.95 -  5.00 (1H, dm, J  10.0 Hz, cis-H-3’” ), 5.00 -  5.07 (1H, dm, J  17.1 Hz, trans-H-3’” ), 
5.98 (1H, ddt, J  10.0 Hz, 17.1, 6.2 Hz, H-2’” ) ppm (Figure 35).
J U J U __
7 0 5 0 4  0130 12 0 11 0 10 0 9 0 8 0 6 0
ppm (f1)
Figure 35: H NMR spectrum of 3’-allylchalcone 329
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Olefin metathesis is a powerful method of making carbon-carbon double bonds264'266 and its
use in small molecule synthesis has become widely used in recent years due to the 
commercial availability of the Schrock catalyst (337)267'269 and Grubbs first generation catalyst 
(338),270'272 especially in ring-closing metathesis reactions. The development of Grubbs 
second generation catalyst (339)273,274 has led to the development of new intermolecular olefin 
cross-metathesis techniques. 275'278 The cross-metathesis of 2-methyl-2-butene (340) with allyl 
groups to give prenyl groups has recently been reported (<Scheme 63).276,279
Scheme 63: a. 2-methylbut-2-ene (340), 339 (1 mol%), 23 °C, 12 hrs, 99% ; 276 b. 2- 
methylbut-2-ene (340), 339 (5 mol%), DCM, 50 °C, 12 hrs, 100% . 279
64.216 The reaction pathway is driven forward by the synthesis of volatile propene (345) 
which will boil off and be removed from the reaction mixture (Scheme 64).
(F3C)2I
(F3C)2I
337
PCy3
339338 340
TBDMSO TBDMSO
The proposed 2-methyl-2-butene (340) cross-metathesis reaction pathway is shown in scheme
R
Scheme 64: 2-methyl-2-butene (340) cross-metathesis reaction pathway276
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Using Grubbs second generation catalyst (339) the cross metathesis of the 3’-allylchalcone 
329 and 2-methylbut-2-ene (340) was carried out in anhydrous DCM under an argon 
atmosphere in a Schlenk tube at 50 °C for 12 hours.279 After column chromatography the 3’- 
prenylchalcone 4-hydroxyderricin (317) was isolated in a 6 6 % yield as a yellow solid 
{Scheme 65).
OH O OH O
MeO
329 317
Scheme 65: a. 2-methylbut-2-ene (340), 339 (2 mol%), DCM, 50 °C, 12 hrs, 6 6 %.
OH 0
The 3’-prenylchalcone 317 was characterised and deemed 
to be identical to the 4-hydroxyderricin (317) isolated by 
Baba et al2*0 and Okuyama et aP54 from the plant Angelica M eO^i^^6' 
keiskei Koizumi. The melting point of 317 was recorded 317
at 133 -  134 °C (literature m.p. 134- 135 °C254) and the ‘H and 13C NMR spectra {Table 8) of 
317 support the formation of 4-hydroxyderricin (317). The key diagnostic peaks in the ‘H 
NMR spectrum of 317 are the hydrogen signals of the enone system appearing at 6  7.47 (1H, 
d, J  15.4 Hz, H-2) and 7.83 (1H, d, J  15.4 Hz, H-3) ppm proving that the chalcone 317 was 
isolated as its is-isomer {Figure 36). The hydrogen signals for the prenyl group which appear 
at 1.68 (3H, s, H-5” ’), 1.80 (3H, s, H-4’” ), 3.36 (2H, broad d, J6 .5  Hz, H -l’” ), 5.23 (1H, 
broad t, J  6.5 Hz, H-2’” ) ppm, showing that the 2-methylbut-2-ene (340) cross-metathesis 
reaction gave the desired prenylated product {Figure 36).
2 03 05 0 4 08 0 7 0 6 011 0 10 0 9 013 0 12 0
ppm (11)
Figure 36: *H NMR spectrum of 4-hydroxyderricin (317)
103
Chapter 4 -  Other Cytotoxic Chalcones. Results and Discussion
Table 8: !H NMR and 13C NMR Spectral data for 4-hydroxyderricin (317) and literature 
comparison
'H N M R  (ppm) l3C N M R (ppm)
Position
Synthetic product  
(CDC13)
Natural product 2 8 0  
(CDC13)
Synthetic product 
(C D C I 3 )
Natural
product 2 8 0
(C DC I 3 )
1 - - 192.56 193.39
2 7 .47  (1H , d, J 15.4 Hz) 7 .48  (1H, d, J 15.4 Hz) 118.45 118.26
3 7 .83  (1H , d, J 15.4 Hz) 7 .84  (1H, d, J 15.4 Hz) 144.15 145.04
r - - 114.89 115.07
2 ' - - 163.23 163.51
3' - - 117.81 118.02
4' - - 163.47 164.04
5' 6 .5 0  (1H , d, J 9 .2  Hz) 6 .50  (1H, d, J 9 .0  Hz) 102.31 102.77
6 ' 7 .7 9  (1H , d, J 9 .2  Hz) 7 .80  (1H, d, J 9 .0  Hz) 129.35 129.90
1 " - - 128.07 127.81
2 " 7 .56  (2H , d, 7  8 .2  Hz) 7 .57 (2H, d, J 8.5 Hz) 130.75 131.16
3" 6 . 8 8  (2H , d, 7  8 .2 Hz) 6 .89  (2H, d, J 8.5 Hz) 116.22 116.58
4" - - 158.13 159.20
5" 6 . 8 8  (2H , d, 7  8 .2 Hz) 6 .89  (2H, d, J 8.5 Hz) 116.22 116.58
6 " 7 .5 6  (2 H , d, 7  8 .2 Hz) 7 .57  (2H, d, J 8.5 Hz) 130.75 131.16
1 "' 3 .36  (2H , br.d, 7 6 . 5  Hz) 3 .40  (2H, d, J 7 .6  Hz) 2 1 .9 6 2 1 .94
2 '" 5 .23 (1H , br.t, 7 6 . 5  Hz,) 5.23 (1H, t, J 7 .6 Hz) 122.25 122.53
3'" - - 132.17 132.57
4"' 1.80 (3H , s) 1.80 (3H , s) 2 6 .0 5 2 6 .03
5’" 1.68 (3H , s) 1.69 (3H, s) 18.05 18.03
2'-OH 13.46 (1H , s) 13.50 (1H, s) - -
4'-O M e 3.91 (3H , s) 3 .92  (3H , s) 56.01 (not reported)
4"-OH 5.41 (1H , bd.s) 5 .78 (1H, s) - -
We then decided to make a small library of similar 3’-allychalcones and 3’-prenylchalcones.
We methylated the 2’-hydroxy group on the acetophenone 326 to make the synthesis of the 
chalcone library easier by eliminating the requirement of protecting and deprotecting this 
hydroxy group. The 2’-hydroxy group was methylated by treating 326 in THF with sodium 
hydride at 0 °C under an argon atmosphere and then adding 1M solution of dimethyl sulfate 
in THF and then refluxing the mixture for 18 hours at 65 °C (Scheme 66) . 263 This gave the 
methylated acetophenone 346 which was isolated by column chromatography in an excellent 
yield as a yellow oil. The NMR spectrum of 346 showed that the 2-hydroxy group of the 
acetophenone 326 had been methylated by the presence of a new methoxy signal at 3.75 ppm, 
and the signal for the 2’-hydroxy group which appears at 12.77 ppm in the NMR spectrum 
of 326 was no longer present. The acetophenome 346 was then subjected to the cross­
metathesis reaction279 with 2-methylbut-2-ene (340) to give the prenylated acetophenone 347 
which was isolated in an excellent yield as a light brown oil after column chromatography 
{Scheme 66).
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OH O MeO O MeO 0
MeO
347
MeO MeO
326 346
Scheme 66: a. 1M (Me0)2S0 2 in THF, NaH, THF, 0 °C to 65 °C, 18 hrs, 96%; b. 2- 
methylbut-2-ene (340), 339 (2 mol%), DCM, 50 °C, 12 hrs, 98%.
A small library of chalcones 348 -  363, were then prepared from the two acetophenones 346 
and 347 and various substituted benzaldehydes using the Claisen-Schmidt condensation178 
conditions (Scheme 67). The chalcones 350 -  352 and 358 were purified by recrystallization 
from methanol, while the other chalcones were purified by column chromatography. All of 
the chalcones were isolated as the £-isomer as shown by their *H NMR spectra.
R1 MeO 0  0  R1 MeO O
,2' ^ x ^ L A .  HA Ar,
^  Y ^ T  ^  H' ' A f i  »  R2^  'Ar1
M e o A ^  M e O ^ ^
346R' = R2=H 348 - 355 R1 = R2 = H
347 R1 = R2 = Me 356 - 363 R1 = R2 = Me
Scheme 67: a. 2M NaOH (aq), MeOH, r.t., overnight, yields see table 9.
Table 9: Yields of the 3’-allychalcones 348 -  355 and 3’-prenylchalcones 356 -  363.
Chalcone R1 R2 Ar1 Yield (%)
348 H H 4-Methoxyphenyl 62
349 H H 3-Fluoro-4-methoxyphenyl 84
350 H H Phenyl-4-oxyacetic acid 71
351 H H 3,4-Dichloropheny 1 69
352 H H 2,4-Dichlorophenyl 82
353 H H 4-(Methoxymethoxy)phenyl 77
354 H H 3-Methoxy-4-(methoxymethoxy)phenyl 89
355 H H 4-Methoxy-3-(methoxymethoxy)phenyl 73
356 Me Me 4-Methoxyphenyl 54
357 Me Me 3-Fluoro-4-methoxyphenyl 75
358 Me Me Phenyl-4-oxyacetic acid 85
359 Me Me 3,4-Dichloropheny 1 25
360 Me Me 2,4-Dichlorophenyl 89
361 Me Me 4-(Methoxymethoxy)phenyl 8 6
362 Me Me 3-Methoxy-4-(methoxymethoxy)phenyl 85
363 Me Me 4-Methoxy-3-(methoxymethoxy)phenyl 91
Before the chalcones 354 and 362 could be prepared the 4-hydroxy group of vanillin (364) 
had to be protected, otherwise the electrophilicity of the carbonyl group of 364 would have
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been significantly reduced by the electron-donating effects of the 4-hydroxy group 
(deprotonated under the reaction conditions). The MOM protected benzaldehyde 365 was 
prepared from vanillin (364) using the same conditions as previously described for 264 and 
332 {Scheme 68).228 This gave the MOM protected benzaldehyde 365 as a pale yellow oil 
which was isolated in a 80% yield after column chromatography.
spectrum showed the presence of the MOM protected B-ring of the chalcone 355 with the
6.95 (1H, J  15.8 Hz, H-2) and 7.67 (1H, J  15.8 Hz, H-3) ppm. The l3C NMR spectrum of the 
side product showed the presence of 1 2  non-equivalent carbons, with the presence of a 
carbonyl signal at 188.92 (s, C-l) ppm. Finally the API-ES+ mass spectrometry of the side 
product gave a molecular ion [MH+] at m/z 415, corresponding to the molecular formula 
C23H27O7 . We therefore decided that the side product must be 366, therefore the reaction 
mixture must have been contaminated with acetone, which had most probably been used to 
clean the reaction flask before hand. So that the acetone and benzaldehyde undergo Claisen- 
Schmidt condensation to give 366 {Scheme 69).
O 0 R1 MeO O
H ■OMe a
OH
364 365 346R' = R2 = H 
347 R1 = R2 = Me
R1 MeO 0
354 R1 = R2 = H
362 R1 = R2 = Me
Scheme 68: a. MOMC1, NaH, DMF, 0 °C to r.t., 12 hrs, 80%; b. 2M NaOH (aq), MeOH, 
r.t., overnight, 354 89%, 362 85%.
From the column of the isolation of the 3’-allylchalcone 355 a side product was also isolated. 
The side product was a yellow solid which had a melting point of 105 - 107 °C, the NMR
signals at 3.56 (3H, s, CH2OCH3), 3.94 (3H, s, OCH3), 5.30 (2H, s, OCH2O), 6.92 (1H, d, J  
8.4 Hz, H-5’), 7.27 (1H, dd, J  1.9 Hz, J  8.4 Hz, H-6 ’), 7.47 (1H, d, J  1.9 Hz, H-2’) ppm. The 
*H NMR spectrum also showed the presence of an £-isomer enone system with signals at
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O MeO 0  O
^ T ) M e
264
M e O "^ ^  
346
O^^OMe M eO ^.O o
MeO 355 'OMe MeO
0 . .OMe
Scheme 69: a. 2M NaOH (aq), MeOH, r.t., overnight, 355 73%, 366 17%.
The 6 MOM protected chalcones 353 -  355 and 361 -  363 were then deprotected by 
refluxing the chalcones in methanol and in the presence of 3 M hydrochloric acid for 45 
minutes {Scheme 70).™ The chalcones 367 -  370 were isolated by column chromatography 
in excellent yields, and the chalcones 371 and 372 were crystallized from methanol.
MeO
0 OMeMeO'
353 R 1 = R2 = H
MeO
OHMeO
367 R1 = R2 = H
361 R 1 = R2 = Me 
MeO O
MeO
370 R = R -  Me
MeO
354 R 1 = R2 = H 
362 R1 = R2 = Me
368 R 1 = R2 = H 
371 R1 = R2 = Me
OMe
MeO MeO
355 R1 = R2 = H 
363 R1 = R2 = Me
369 R 1 = R2 = H 
372 R1 = R2 = Me
Scheme 70: a. 3M HC1 (aq), MeOH, 75 °C, 45 mins, 367 95%, 368 99%, 369 98%, 370 
89%, 371 72%, 372 59%.
We also prepared the 2’-hydroxychalcone 373 without the 3’-allyl or 3’-prenyl group to test 
for biological activity, because several 2’-hydroxychalcones have been reported in the 
literature as being cytotoxic agents241,242 and we wanted to investigate the importance of the 
allyl/prenyl group. The 2’-hydroxy group of the acetophenone 327 was MOM protected by
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treating it with sodium hydride and MOMC1 in THF at 65 °C for 18 hrs. This gave 374 as a 
pale yellow oil in a moderate yield after chromatography {Scheme 71).263 The MOM 
protected acetophenone 374 and MOM protected benzaldehyde 332 were then treated with 
aqueous sodium hydroxide in the typical Claisen-Schmidt condensation178 conditions, 
yielding the MOM protected chalcone 375 as a yellow oil which was isolated via column 
chromatography {Scheme 71). The MOM protected chalcone 375 was then deprotected by 
refluxing it in methanol and 3 molar hydrochloric acid for 45 minutes {Scheme 71). This 
MOM deprotection led to 2 separate products which were isolated by chromatography, the 
first being the desired 2’-hydroxychalcone 373 in a moderate yield as a yellow solid and the 
flavanone side product 376 as yellow crystals. The 2’-hydroxychalcone 373 was isolated as 
the £-isomer as which was shown in the NMR spectrum by its alkene coupling of 15.4 
Hz. The *H NMR spectrum of the flavanone 376 corresponds to literature values given by 
Pouget et a/,281 with the key signals in the spectrum being the signals for the classic ABX 
system of the flavanone 376 which appear at 2.81 (lH a, dd, J2 .9  Hz, J  16.9 Hz, H-3a), 3.06
(lH b, dd, J  13.2 Hz, J  16.9 Hz, H-3b) and 5.41 (1HX, dd, J2 .9  Hz, J  13.2 Hz, H-2) ppm.
OH O MeO^O O MeO O O
a b
327 374 375
Scheme 71: a. MOMC1, NaH, THF, 0 °C to 65 °C, 18 hrs, 66%; b. 332, 2M NaOH (aq), 
MeOH, r.t., overnight 62%; c. 3M HC1 (aq), MeOH, 75 °C, 45 mins, 373 41%, 376 34%.
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4.2.2 Biological results for the 4-hydroxyderricin (317) and similar chalcone 
derivatives.
OH O OH O
MeO MeO
3 2 9  &  3 3 6 3 1 7
Chalcone Ar1 IC50(K562) (pM)
329 4-Hydroxyphenyl >10
336 4-Methoxyphenyl >10
317 4-Hydroxyphenyl >10
MeO 0
MeO
3 4 8  -  3 5 5  &  3 6 7  -  3 6 9
Chalcone Ar1 IC50(K562) (pM)
348 4-Methoxyphenyl 7.9
349 3-Fluoro-4-methoxyphenyl 4.2
350 Phenyl-4-oxyacetic acid >10
351 3,4-Dichloropheny 1 >10
352 2,4-Dichlorophenyl >10
353 4-(Methoxymethoxy)phenyl >10
354 3-Methoxy-4-(methoxymethoxy)phenyl 7.5
355 4-Methoxy-3-(methoxymethoxy)phenyl 8.4
367 4-Hydroxyphenyl >10
368 4-Hydroxy-3-methoxyphenyl >10
369 3-Hydroxy-4-methoxyphenyl 0.2
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356 - 363 & 370 - 372
Chalcone Ar1 IC50(K562) (pM)
356 4-Methoxyphenyl >10
357 3-Fluoro-4-methoxyphenyl >10
358 Phenyl-4-oxyacetic acid >10
359 3,4-Dichloropheny 1 >10
360 2,4-Dichlorophenyl >10
361 4-(Methoxymethoxy)phenyl >10
362 3-Methoxy-4-(methoxymethoxy)phenyl >10
363 4-Methoxy-3-(methoxymethoxy)phenyl >10
370 4-Hydroxyphenyl >10
371 4-Hydroxy-3-methoxyphenyl >10
372 3-Hydroxy-4-methoxyphenyl 8.4
O OH O
MeO^O^.
M if f[V W iII
MeO ^ ^ O M e  MeO
366 IC50(K562) 3.9 pM 373 IC50(K562) >10 pM
O
MeO O O
1 1 1
r V ^ Y ^ l
MeO ^ T ^ O M e ^ O H
375 IC50(K562) >10 pM 376 IC50(K562) >10 pM
The 4-hydroxyderricin (317) and chalcone derivatives generally show low cytotoxicity 
towards the human leukaemia cell line K562. Only 7 of the compounds prepared show 
cytotoxicity below 10 pM.
The most active of these compounds is the chalcone (£)-l-(3-allyl-2,4-dimethoxyphenyl)-3- 
(3-hydroxy-4-methoxyphenyl)prop-2-en-l-one (369) which displays an IC50 value of 0.2 pM. 
Our studies of the CA-4 like chalcones (see chapter 3) have shown that chalcones which bear 
the 3-hydroxy-4-methoxyphenyl 5-ring display potent cytotoxicity towards the K562 cell 
line and the activity of 369 may be due to presence of its 3-hydroxy-4-methoxyphenyl B- 
ring.
The prenylated version of 369, (£)-3-(3-hydroxy-4-methoxyphenyl)-l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)prop-2-en-l-one (372) has an I C 50  value of 8.4 pM, shows that the
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addition of the two methyl groups on the allyl group to make the prenyl group cause a 40 fold 
decrease in activity of this chalcone.
The side product (l£ ,4£)-l,5 -b is(4-m ethoxy-3-(m ethoxym ethoxy)phenyl)penta-l,4 -d ien-3- 
one (366) is the second most active com pound isolated, w ith an IC 50 value o f  3.9 pM. The 
deprotected version o f  this com pound may have been proven to be more active, and may 
prove interesting for future studies. Several sim ilar com pounds have been reported by Artico 
and co-w orkers282 for having anti-HIV activity.
4.3 p53-MDM2 complex disrupting chalcones283,284
The tumour suppressor p53 is a key player in the prevention of cancer. When a cell is 
exposed to oncogenic stress, p53 in the cell nucleus acts as a transcription factor capable of 
activating multiple target genes, leading to cell cycle arrest, apoptosis and senescence as well 
as enhancing DNA repair.285'287 Therefore p53 ensures that cells carrying cancer promoting 
alterations such as damaged genomes are either fixed or permanently deleted. In normal cells 
the p53 is tightly regulated by the oncoprotein HDM2, which binds to p53 and promotes p53 
ubiquitination, causing the degradation of p53 within the nucleus and prevents it causing cell 
death in normal cells.288 However amplification of the HDM2 protein has been observed in 
several human tumours,283,289'292 inhibiting the ability of p53 to initiate apoptosis of cancer 
cells. This makes disruption of the p53/HDM2 complex an attractive target for cancer 
therapy.
However due to the nature of proteins-protein interactions, with their relatively large and flat 
interacting surfaces they are often viewed as high-risk targets because they are not easily 
disrupted by small drug like molecules.293 The crystal structure of a p53 bound to HDM2 
revealed that the interaction of the two proteins is due to the projection of three amino acid 
residues (Phenylalanine 19, Tryptophan23 and Leucine26) from p53 into the deep 
hydrophobic binding pocket on the surface of MDM2 {Figure 3 7).294 This realization has 
raised the hope that finding a pharmacological inhibitor of this interaction may be possible.
I l l
Chapter 4 -  Other Cytotoxic Chalcones. Results and Discussion
Phenylalanine 19
Tryptophan23
Leucme26
Figure 37: The p53 helix binding to the hydrophobic binding pocket on the surface of 
MDM2.294
Stoll et al.2i2 reported chalcones are HDM2 antagonists. They found that chalcones with 
carboxylic acid substituents could disrupt the MDM2 binding of p53 with ELISA (Enzyme- 
Linked Immunosorbent Assay) data giving IC50 values of 49 -  250 pM for the disruption of 
p53/HDM2 complex (Figure 38).
O
379 IC50 117 pM 378 IC50 2 50 pM
Figure 38: Inhibition of MDM2 binding to p53 measured by ELISA252
The chalcones were then tested to see if they could dissociate preincubated p53/MDM2 
complexes and release p53 active for DNA-binding in a electrophoretic gel mobility shift 
assay (EMSA). The EMSA showed that the carboxylated chalcones 377 and 378 did not 
release active p53, while chalcones 318 and 379 removed MDM2 from the complex with 
p53, with 379 fully removing HDM2.252
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Multidimensional NM R spectroscopy experiments with the carboxylic acid chalcones 318 
and 377 -  379 showed that the chalcones dock in the tryptophan-binding subsite o f human 
HDM2 p53 binding site and disrupt the HDM2/p53 protein complex. The carboxylic acid 
groups are thought to be important to the activity o f  the chalcones by disrupting the salt 
bridge between lysine51 and glutamic acid 54 in the tryptophan subsite o f human HDM2 
bound p53.252
Kumar et al investigated the effects o f replacing the carboxylic acid group o f these chalcones 
with a boronic acid.253 The boronic acids are weaker acids pKa 9-10 and will be largely non­
ionized at physiological pH, they are therefore unlikely to form a salt bridge with lysine51, 
however it was proposed that they may form a covalent bond to the amino group o f lysine51 
instead, resulting in a stronger interaction with p53 binding site o f HDM2.
The MTT assay showed that the carboxylic acid chalcones 318 and 379 were not selectively 
toxic to cancer cell lines, with IC50 values ranging from 9 - 1 8  pM for the human breast 
cancer cell lines and IC 50 values ranging from 1 2 - 2 8  pM for the normal human breast cell 
lines, however several o f  the boronic acid chalcones 319 and 380 showed a greater selectivity 
to cancer cells with IC 50 values ranging from 7 - 1 8  pM for the human breast cancer cell lines 
and IC50 values ranging from 38 -  100 pM for the normal human breast cell lines, {Figure 
59).253
co2h ho2c
318 379
IC50(breast cancer cell lines) 13-18 pM IC50(breast cancer cell lines) 9-13 pM 
IC5o(normal breast cell lines) 12-28 pM IC50(normal breast cell lines) 13-15 pM
(HO)2B (HO)2B
380 319
IC50(breast cancer cell lines) 7.0-10 pM IC50(breast cancer cell lines) 9.5-18 pM
IC5o(normal breast cell lines) 63-75 pM IC50(normal breast cell lines) 38-100 pM
Figure 39: IC50 values o f carboxylic acid chalcones 318 & 379 compared against boronic 
acid chalcones 380 & 319 against human breast cancer cell lines (MDA-MB-435, MDA- 
MB-231 & Wt-MCF7) and normal beast cell lines (MCF-10A & MCF-12A)253
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However multidimensional NMR spectroscopy experiments 
carried out by D’Silva295 and co-workers recently, show that 
the boronic chalcone 381 does not dissociate the p53-HDM2 ^ 0 ) 2B 
complex, but 381 does bind to the tryptophan-binding subsite 
of human MDM2 p53-binding cleft, and that they may be 
extremely weak inhibitors of the MDM2/p53 interaction.
4.3.1 Synthesis of the 3’,4’-dichlorochalcones
We decided to make a small series of 3’,4’-dichlorochalcones without the carboxylic acid 
group to see if it was a requirement for disrupting the HDM2/p53 interaction. The chalcones 
were be prepared by the Claisen-Schmidt condensation178 of the 3’4’-dichloroacetophenone 
(382) and various substituted benzaldehydes (Scheme 72).
Cl
382
Scheme 72: a. 2M NaOH (aq), MeOH, r.t., overnight
The 3 \4 ’-dichlorochalcones were prepared by treating 3’4’-dichloroacetophenone (382) and 
a substituted benzaldehyde in methanol with 2M sodium hydroxide. The product chalcone 
was left overnight to precipitate out of the methanol solution. They were then filtered off and 
recrystallized from methanol {Scheme 73).
Cl
Cl
382
Cl
383 - 390
Chalcone Ar1 Yield (%)
383 4-Chlorophenyl 66
384 3,4-Dichloropheny 1 83
385 2,6-Dichlorophenyl 66
386 4-Bromophenyl 56
387 2,4-Dimethoxyphenyl 72
388 3,5-Dimethoxyphenyl 70
389 2,3,4-Trimethoxyphenyl 90
390 3,4,5 -T rimethoxypheny 1 48
Scheme 73: a. Ar CHO, 2M NaOH (aq), MeOH, r.t., overnight.
The 3’,4’-dichlorochalcones 383 -  390 were all isolated in moderate to excellent yields as the 
£-isomers as shown by their !H NMR spectra.
We then tried to prepare (£)-l-(3,,4’-dichlorophenyl)-3-(4” -hydroxyphenyl)prop-2-en-l-one 
(391) via the basic Claisen-Schmidt condensation178 of the 3’4’-dichloroacetophenone (382)
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and 4-hydroxybenzaldehyde (328) This reaction failed due to the reduced electrophilicity of 
the carbonyl group of 328 because the electron donating effect of the deprotonated 4-hydroxy 
group. The starting materials were recovered. We attempted the acidic Claisen-Schmidt 
condensation of the 3’4’-dichloroacetophenone (382) and 4-hydroxybenzaldehyde (328) 
reported by Dimmock224 et al, whereby chalcone was prepared by bubbling hydrogen 
chloride though a solution of 382 and 328 in ethanol, the mixture turned red and was left 
stirring at room temperature overnight. However this reaction also failed and the 3’4 ’- 
dichloroacetophenone (382) was recovered. We then prepared the MOM protected chalcone 
392 from the MOM protected benzaldehyde 332 and the acetophenone 382 {Scheme 74). 
The MOM protected chalcone 392 was then deprotected by refluxing the chalcone in 
methanol and in the presence of 3 M hydrochloric acid for 45 minutes {Scheme 74)P° This 
gave 391 as yellow solid in an excellent yield, as the £-isomer shown by inspection of its *H 
NMR spectrum (Jho,p 15.4 Hz).
Cl
Cl' ■ hA C l ,
382 332
O OMe
Cl
O OMeCl
392b
391
Scheme 74: a. 2M NaOH (aq), MeOH, r.t., overnight, 65%; b. 3M HC1 (aq), MeOH, 75 
°C, 45 mins, 99%.
We also prepared the carboxylic acid chalcone 318 so we could directly compare the 
biological results of the 3’,4’-dichlorochalcones with and without the carboxylic acid group. 
The chalcone 318 was prepared using the Claisen-Schmidt condensation178 of the 3’4’- 
dichloroacetophenone (382) and 4-formylphenoxyacetic acid (393) in methanol under basic 
conditions {Scheme 75). The chalcone was isolated by ethyl acetate extraction and 
recrystallization from methanol to give 318 in good yield as yellow crystals.
115
Chapter 4 -  Other Cytotoxic Chalcones. Results and Discussion 
H ° o  c o 2h
382 393
Cl
Cl
318
o  c o 2h
Scheme 75: a. 2M NaOH (aq), MeOH, r.t., overnight, 66%.
The key diagnostic peak of the JH NMR spectrum of carboxylic acid chalcone 318 are the 
peak for the methylene group which appears at 4.76 (2H, s, H-2’” )ppm and the peaks for 
enone system of 318 at 7.74 (1H, d, J  15.4 Hz, H-2) and 7.83 (1H, d, J  15.4 Hz, H-3) ppm 
showing that chalcone was isolated as the £-isomer {Figure 40). The *H NMR spectrum of 
318 corresponds to the literature values reported by Kumar253 et al.
8 50  8 33 8 17 8 00 7 83  7 67 7 50 7 33 7 17 7 00 6 83  6 67 6 50 6 33  6 17 6  00  5 83 5 67 5 50 5 33 5 17 5 00 4  83  4 67
p p m ( f l )
Figure 40: JH NMR spectrum of the carboxylic acid chalcone 318
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4.3.2 Biological activities of 3’,4’-dichlorochalcones
O
318, 383 -392
Chalcone Ar1 IC50(p53-MDMX) (pM)
318 Phenyl-4-oxyacetic acid 250
383 4-Chlorophenyl >300
384 3,4-Dichlorophenyl >300
385 2,6-Dichlorophenyl >300
386 4-Bromophenyl >300
387 2,4-Dimethoxyphenyl >300
388 3,5-Dimethoxyphenyl >300
389 2,3,4-T rimethoxyphenyl >300
390 3,4,5 -T rimethoxyphenyl >300
391 4-Hydroxyphenyl >300
392 4-(Methoxymethoxy)phenyl >300
Our chalcones were tested for their ability to disrupt the p53-MDMX complex. The 
chalcones were screened in an ELISA (Enzyme-Linked ImmunoSorbent Assay) assay296 using 
p53 and MDMX proteins purified from E. coli. This ELISA assay measures the binding of 
the MDMX protein to the p53 protein which is immobilized on the surface of the ELISA 
plate, by looking at the absorbance of the plate at a wavelength of 450 nm. The ELISA plates 
are first treated with p53 and incubated in PBS (phosphate buffered saline) for 16 hours, so 
the p53 can bind to the ELISA plate. The plate was then washed with PBST (PBS + 0.1% 
Tween 20), and then blocked with PBSMT (PBS + 5% nonfat dairy milk + 0.1% Tween 20) 
for 30 minutes. The chalcones were then dissolved in DMSO. The MDMX (5 pg/ml) was 
then mixed with the DMSO dissolved chalcone (at various concentrations) in PBSMT. The 
MDMX/chalcone mixture was then added to the wells of the plate. The plate was then 
incubated for an hour and then washed with PBST. The antibody 5B10 in PBSMT was then 
added to the plates for 1 hour, followed by washing and incubation with horseradish 
peroxidase-rabbit anti-mouse immunoglobulin antibody for an hour. The antibody 5B10 is 
used to detect the MDMX binding to P53. The plate was then developed by incubation with 
tetramethyl benzidine peroxides substrate and measured by absorbance at 450 nm .296
MDMX is a protein related to MDM2 and shares several regions of homology with MDM2 
including the p53 binding site.297 The only chalcone to show any activity below a 
concentration of 300 pM, was the chalcone 318 with an IC5o(p53-MDMX) of 250 pM. This
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shows that the presence of the carboxylic acid group on 3,4-dichalcone 318 plays an 
important role in the disruption of the HDM2/p53 interaction.
The chalcone 394 which was prepared by another member of the our group exhibited an IC50 
value of 80 pM for the inhibition of the p53-MDMX interaction, however further testing 
showed that 394 had no effect on p53-MDM2 interaction, up to a concentration of 500 pM. 
While the chalcone 319 shows a weak activity at inhibiting both the p53-MDMX and p53- 
MDM2 interaction. This makes 394 a good lead structure for the optimization of potency of 
a selective p53-MDMX inhibitor. Presently the crystal structure of MDMX is unknown, so a 
model of the p53 binding site, based on the MDM2 model will be constructed by the 
computer modelers, which can be used cautiously for structure-based design for the 
optimization of 394. Traditional QSAR (quantitative structure-activity relationships) studies 
will also be used in the optimization of 394 as a selective p53-MDMX inhibitor.
394
IC50(p53-MDMX) 80 pM 
IC50(p53-MDM2) >500 pM
318
IC50(p53-MDMX) 250 pM 
IC50(p53-MDM2) 250 pM
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5.1 Hyperthermia and the prevention of thermotolerance via drug like compounds
Hyperthermia is a type of cancer treatment in which body tissue is exposed to high 
temperatures, 40 -  44 °C. In vivo tests show that hyperthermia treatment selectively kills 
tumour cells at temperatures between 40 -  44 °C,298 while normal tissues are undamaged at 
exposure to these temperatures.299 Tumour tissue is more sensitive to hyperthermia because 
of the chaotic architecture of the tumour vasculature in solid tumours, which result in regions 
of the tumour tissue which have low pH and suffer from hypoxia.298 300 These environmental 
differences make tumour cells more sensitive to hyperthermia treatment. The main 
mechanism for cell death is thought to be caused by protein denaturation, which is observed 
at temperatures >40 °C, this can lead to the alteration of cellular structures like the 
cytoskeleton and membranes, and changes in enzyme complexes used for DNA synthesis and 
repair.301
The use of hyperthermia in conjunction with radiotherapy302'306 or chemotherapy307 has been 
shown to increase the anticancer effects of both therapies. However one of the major 
problems with hyperthermia is the development of thermotolerance, which is a transient 
resistance to the effects of hyperthermia induced by prior exposure to heat treatment.308 309 
When cells are exposed to heat they respond by synthesizing a group of proteins called the 
heat shock proteins (HSPs)310 which are involved in the acquisition of thermotolerance in 
cells.311,312 The HSPs bind to denatured proteins caused by cellular stress such as heat shock 
and renature them or bring them to degradation pathways.302 Several studies312'314 have shown 
the relationship between the level of thermotolerance and cellular content of the HSPs, one 
study showed that the introduction of HSP72 specific antibodies to fibroblast cells made them 
more sensitive to thermal stress.315 These studies suggest that a strong relationship between 
the induction of stress proteins in the prevention of apoptosis.302
The regulation of the synthesis of the HSP is mediated by the interaction of the heat shock 
factor (HSF1) with the heat shock elements (HSEs) in the heat shock protein gene promoter 
region.316,317 HSF1 exists in unstressed cells in an inactive form and is rapidly activated after 
heat shock.302
It is critical for the further development of hyperthermia as a cancer therapy to find drug like 
compounds that can specifically inhibit the induction of HSPs in cancer cells after their first 
heat treatment to help improve the effects of fractionated hyperthermia.302,318
The flavonoid quercetin (395) has been shown to inhibit the synthesis of several HSPs 
(including HSP70) induced by heat shock on 2 human cancer cell lines, HeLa and COLO
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320DM.319 In vivo and in vitro tests show that the quercetin (395) 
inhibits the induction of the HSP by suppressing the activation of the 
HSF1, or the interaction of the HSF1 with the HSEs.320 HO
OH O
OH
OH
In vitro testing of the novel benzylidene lactam compound KNK437
(396) by Yokota302 and co-workers showed that it was a dose dependant inhibitor of the
acquisition of thermotolerance in COLO 320DM (human colon carcinoma) cells and in HeLa 
S3 cells after fractionated heat treatment. Further testing showed that 396 inhibits the
Further in vivo testing of KNK437 (396) by Koishi318 and co-workers,  ^
showed that KNK437 (396) inhibited the induction of thermotolerance at a 
concentration of 200 mg/kg when administrated 6 hours before initial
2.9 days longer than that for tumours that had been heat shocked without the '
KNK437.318 Showing that KNK437 had contributed to the inhibition of the synthesis of HSP 
in vivo. They also found that the KNK437 (396) was metabolized to KNK423 (397) which 
was observed by HPLC at high levels in tumours that had been administered with KNK437 
(396).318
The effects of KNK 437 (396) proved to be cytostatic and reversible over time, rather than 
being cytotoxic.302 Further testing showed that KNK 437 (396) was a very weakly toxic drug, 
with tumour free mice recovering the lost body weight by 2 days after treatment of 396 at 
concentrations up to 400mg/kg.318
It is thought that the inhibitory mechanism of KNK437 may be attributed to the inhibition of 
the HSF1, or the interaction of the HSF1 with the HSEs, as reported for the bioflavonoid 
Quercetin.302,320
5.2 Synthesis of KNK437 and similar analogues.
Our route for the synthesis of KNK 437 (396) involved the aldol condensation of 1- 
acetylpyrrolidin-2-one (398) and piperonal (399) to give KNK423 (397)321 (Scheme 76). 
KNK 437 (396) would then be obtained via the formylation of the amine on the 2- 
pyrrolidinone ring of 397 {Scheme 76).322
synthesis of various HSPs including HSP70, HSP40 and HSP 105.302 O
heating. The time taken for the tumour to triple in volume was on average
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399 398 397
Scheme 76
Before we carried out the aldol condensation of piperonal (399) and l-acetylpyrrolidin-2-one 
(398), the l-acetylpyrrolidin-2-one (398) had to be prepared by acetylating the nitrogen of 2- 
pyrrolidinone (400) (Scheme 77). Using the procedure described by Sasaki323 and coworkers 
1 -acetylpyrrolidin-2-one (398) was prepared by adding acetyl chloride to a mixture of 
triethylamine and 2-pyrrolidinone in THF at 0 °C {Scheme 77, route a). The isolation of 398 
as described by Sasaki323 was done by distillation, however after collecting the distillate at 
152 -  155 °C the *H NMR spectrum showed that the distillate was an 1:1 mixture of the 
starting pyrrolidinone (400) and desired acetylated product 398. The acetylated product 398 
was then isolated from 400 by column chromatography in a moderate yield.
It was also found by other members of the group that the acetylation of 400 can be achieved 
by treating the 2-pyrrolidinone (400) in anhydrous THF with 2.5 M w-butyl lithium in hexanes 
at -20 °C and then by adding acetyl chloride to a mixture and then leaving the mixture stirring 
overnight {Scheme 77, route b). The acetylated product 398 was then isolated by 
chromatography in a good yield.
400 398
Scheme 77: a. acetyl chloride, triethylamine, THF, 0 °C -  r.t., lhr, 52%; b. i. «BuLi,
THF, -20 °C, ii. acetyl chloride, THF, -20 °C to r.t., overnight, 71%.
Then using the technique described by Zimmer321 et al. the benzylidene lactam compound 
KNK423 (397) was prepared by treating 1 -acetylpyrrolidin-2-one (398) and piperonal (399) 
in anhydrous THF at 0 °C with sodium hydride {Scheme 78). After an hour the reaction was 
quenched by treating the mixture with methanol, and then tipped into 6M H2 SO4 . The 
product was then extracted with chloroform, and was recrystallized from /so-propyl alcohol 
as a fine cream powder in a low yield. However, this provides sufficient material for the 
biological studies.
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~  0 0 ^  “
399 398 397
Scheme 78: a. NaH, THF, 0 °C, lhr, 27%; b. formic acid, 105 °C, 18hrs, 55%.
The KNK 423 (397) was fully characterised; the HRMS of 397 gave a molecular ion [MH+] 
of m/z 218.0812 which corresponds to the expected formula C 12H 12O3N. The key diagnostic 
peaks in the *H NMR spectrum of 397 are two signals for the 2-pyrrolidinone ring 3.12 (2H, 
td, J  6.5 Hz, J  2.8 Hz, H-4) and 3.56 (2H, t, J  6.5 Hz, H-5) ppm and the signal for methylene 
proton at 7.28 (1H, t, J 2.8 Hz, H -l’) ppm {Figure 41).
7 30
3  6 0
7 0 6 0 5 0 4  0 3  0
ppm (f 1)
Figure 41:' H NMR spectrum of KNK423 (397)
Using the procedure described by Rigo322 et al. 397 was formylated by heating in neat
refluxing formic acid for 18 hrs {Scheme 78). After which time the reaction mixture was a
1:1.9 ratio of the starting KNK423 (397) to the product KNK437 (396). The KNK437 (396) 
was then isolated via column chromatography as a white solid in a moderate yield.
The KNK 437 (396) was fully characterised; the HRMS of 396 
gave a molecular ion [MH+] of m/z 246.0758 which 
corresponds to the required C 13H12O4N formula. The key 
diagnostic peaks in the 'H NMR spectrum of 396 is the loss of 
the signal for the 397 amine proton of at 6.45 (1H, br. s, NH-1) 
ppm {Figure 41) and introduction of the signal for the formyl 
group at 9.24 (1H, s, H -l’” ) ppm {Figure 42).
396
7.06 ppm
:\ 3.09 ppm
7.00 ppm
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Figure 42: ‘H NMR spectrum of KNK437 (396)
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Figure 43: NOESY NMR spectrum of KNK437 (396) showing the nOe correlations 
between the signals of H-4 and H-7” , and H-4 and H-5’’proving the ^-geometry of 396.
The geometry of double bond of K.NK437 (396) was determined by a NOESY NMR 
experiment (Figure 43). The NOESY experiment of 396, shows nOe correlations between 
the signals for the H-4 hydrogens at 3.09 ppm to the H-7” hydrogen at 7.00 ppm, as well as
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the H-5” hydrogen at 7.06 ppm proving that the £-isomer of KNK437 (396) was isolated 
from the reaction.
One of the main problems with KNK437 (396) and KNK423 (397) is their poor solubility in 
DMSO, KNK437 (396) solubility in DMSO ~ 25 mg/ml, while KNK423 (397) solubility in 
DMSO ~20 mg/ml.
We therefore decide to investigate producing a more soluble version of the KNK compounds. 
To do this we decided to use rhodanine (401) instead of 1-acetylpyrrolidin-2-one (398) in the 
synthesis. The introduction of the rhodanine (401) into the KNK structure gives the molecule 
an extra sulfide group and thioamide group, which should improve the solubility of the 
molecule. The heteroatom should increase the number of hydrogen bonds that the KNK 
rhodanine analogues can make with a polar solvent, thus enhancing the overall solubility of 
these compounds in polar solvents.
The rhodanine analogue 402 of KNK423 (397) was prepared using the same conditions for 
the synthesis of KNK423 (397)321 (Scheme 79).
3 05 06 0 4 O9 0 8 0 7 01 1 0 10 01 2  013 0
ppm  (11)
Figure 44: *H NMR spectrum of rhodanine analogue 402 of KNK423
The key diagnostic peak of the 1H NMR spectrum of rhodanine analogue r  .0
402 of KNK423 (397) are the signals for the aromatic hydrogens which 2-( || I \ NH3
appear at 7.08 (1H, d, J  8.0 Hz, H-4” ), 7.11 (1H, d, J  1.9 Hz, H-7” ) and 3- 4 " i 's
402
7.15 (1H, dd, J  1.9 Hz, J  8.0 Hz, H-5” ) ppm, and the olefinic proton at 
7.56 (1H, s, H -l’) ppm (Figure 44).
It was found that we could dissolve up to 35 mg of 402 in 1 ml of DMSO. This made it more 
soluble than KNK423 (397) (ca. 20 mg could be dissolved in 1 ml of DMSO).
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We then made a small series of other KNK like rhodanine analogues using various 
substituted benzaldehydes to investigate the effects of changing the aromatic group on the 
biological properties of the molecule. Another six KNK rhodanine analogues 403 -  408 were 
prepared using the same method as previously described {Scheme 79).
P P
j A  a Ar
SV H S^ NHS S
401 402 - 408
Scheme 79: a. Ar'CHO, 
NaH, THF, 0 °C, lhr.
KNK analogues Ar1 Yield (%)
402 Benzo[*/][l,3]dioxol-5-yl 65
403 2,4-Dichlorophenyl 44
404 5-Bromo-2-methoxyphenyl 52
405 4-Methoxyphenyl 66
406 3,5-Dimethoxyphenyl 63
407 3,4,5-Trimethoxyphenyl 40
408 2,4,6-Trimethoxyphenyl 81
The NMR spectrum of the KNK rhodanine analogue 405 corresponded to Z-isomer of 405 
which had been previously prepared by Khodair,324 therefore the Z-isomer of 405 had been 
prepared. This is the same geometrical sense as for the KNK437 (396), but 405 is labeled Z, 
since the CIP rankings have changed.
Others members of our group continued the investigation into developing a more soluble 
version of the KNK compounds.
5.3 Biological results of KNK437 and its analogues
A number of proteins associated with leukaemia require interaction
H
with HSP90 to maintain a mature and functional 
conformation.325,326 The semi-synthetic derivative 17-allylamino- 
demethoxygeldananycin (17-AGG, 409) has been shown to inhibit v 
the function of HSP90,327 and leads to the degradation of its HSP90 MeO*
associated proteins.325,326 17-AGG (409) is currently being 
investigated in phase 1 and 2 clinical trials, administered alone or 
in combination with other anticancer agents.328 329
The HSP90 also binds HSF1 .330 When 17-AGG (409) binds to HSP90, it displaces bound 
HSF1. This increased level of HSF1 led to the up-regulation of the antiapoptotic HSP72.330'332 
Therefore the question arises, whether the elimination of the antiapoptotic HSP72 by co- 
treating with KNK437 (396) will further sensitize the human leukaemia (HL-60) cells to 17- 
AGG (409) treatment?333
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Figure 45: The effect on apoptosis of HL-60 cells after being pretreated with KNK437 
(396) for an hour, followed by 17-AAG (409) + KNK437 (396) for 72 hours.333
The KNK437 (396) we made was then used in a study by Guo333 et al. The study found that 
KNK437 (396) sensitizes human leukaemia (HL-60) cells to 17-AGG (409) induced 
apoptosis {Figure 45).n3 For instance treating the HL-60 cells with only 2.0 pM 17-AGG 
(409) caused apoptosis in about 40% of the HL-60 cells after 72 hours, while treatment with 
2.0 pM 17-AGG (409) and 100 pM KNK437 (396) increased apoptosis to about 55%. 
Treating the HL-60 cells with 2.0 pM 17-AGG (409) and 400 pM KNK437 (396) increased 
the apoptosis again to 65% of the HL-60 cells {Figure 45)?n
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General Experimental Information
Nuclear Magnetic Resonance Spectrometry
*H NMR and 13C NMR were carried out on a Bruker 400 MHz spectrometre and Varian 400 
MHz spectrometre; chemical shifts for *H NMR are referenced to tetramethylsilane (TMS) as 
an internal standard, and chemical shifts for ,3C NMR are referenced to the solvent used.
Infra-red Spectroscopy
IR spectras were obtained for the compounds using a Perkin Elmer 1600 series FTIR 
instrument, Perkin-Elmer Spectrum One FTIR Spectrometre and JASCO FT/IR 4100 
Spectrometre
Mass Spectrometry
Low resolution mass spectra were determined using a Fisons VG Platform II Quadrupole 
instrument and Agilent Technologies LC/MSD VL instrument. High resolution mass 
spectroscopy was carried out by the EPSRC national mass spectrometry service centre at 
Swansea University, as well as on an Agilent Technologies LC/MSD TOF instrument at the 
University of South Florida.
Elemental Analysis and Melting Point
Elemental analyses were performed by Warwick Analytical Services Ltd. Melting points 
were determined using Electrothermal Mel-Temp* manual melting point apparatus and 
Electrothermal Digital melting point apparatus model 9100, they were not corrected.
Chromatography and Solvents
Column chromatography was performed using silica gel 60, 220-440 mesh (Apollo in the UK 
and Fisher in the US). Automated flash chromatography was conducted using a Flashmaster 
II system (Argonaut-Biotage), using Biotage silica cartridges. Thin layer chromatography 
was performed using silica gel 60 F254 plates (Apollo in the UK and Fisher in the US), with 
observation under UV when necessary. Anhydrous solvents were obtained as follows: 
dichloromethane (anhydrous, 99.8%, contains 50-150 ppm hydrocarbon as stabilizer from 
Aldrich), dimethyl formamide (anhydrous, 99.8% from Aldrich), tetrahydrofuran (distilled 
over sodium/benzophenone under nitrogen as required).
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Protocol A
To a stirring solution of substituted acetophenone and substituted benzaldehyde in methanol 
was added a quantity of an aqueous solution of sodium hydroxide and the mixture stirred at 
room temperature overnight allowing the chalone to precipitate. The precipitate was then 
filtered off and washed with cold aqueous methanol (4:1 Me0 H:H2 0 ). Purified by 
recrystallization from methanol.
(E)-l-(3,4,5-Trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 165334335
O
MeO
MeO
OMe
165
The chalcone 165 was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(8.65 g, 41.1 mmol), p-anisaldehyde (5.0 cm3, 41.1 mmol) and aqueous sodium hydroxide 
solution (6.9 cm3, 12M) in methanol (25 cm3). Recrystallization from methanol afforded 165 
as cream crystals (12.1 g, 37.0 mmol, 90%); m.p. 98 -  99 °C; R/0.73 (SiC>2 , hexaneiethyl 
acetate 1:1); v^X cm '1) 3007, 2941, 2843, 1655, 1591, 1567, 1505, 1459, 1447, 1420, 1411, 
1345, 1308, 1248, 1153, 1121, 998, 979, 812, 824, 709; 6  ‘H NMR (400 MHz; CDC13; ppm) 
3.87 (3H, s, OCH3), 3.94 (3H, s, OCH3), 3.95 (6 H, s, OCH3), 6.95 (2H, d, J  8 . 8  Hz, H-3” & 
H-5” ), 7.27 (2H, s, H-2’ & H-6 ’), 7.37 (1H, d, J 15.6 Hz, H-2), 7.62 (2H, d, J 8 . 8  Hz, H-2” 
& H-6 ” ), 7.80 (1H, d, J 15.6 Hz, H-3); 6  ,3C NMR (100 MHz; CDC13; ppm) 55.46 (s, 
OCH3), 56.39 (s, OCH3), 61.02 (s, OCH3), 105.90 (s, CH), 114.44 (s, CH), 119.37 (s, CH),
127.59 (s, C), 130.28 (s, CH), 133.85 (s, C), 142.19 (s, C), 144.68 (s, CH), 153.12 (s, C),
161.70 (s, C), 189.32 (s, CO); m/z(AP+) 329 (MH+, 100%); HRMS found [MH]+ 329.1385 
for C 19H21O5, C 19H21O5 requires [MH]+ 329.1384; CHN found C 69.16%, H 6.14%, CHN 
requires C 69.50%, H 6.14%.
2,3-Dibromo-l-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)propan-l-one 166334
O Br
OMe
166
To a stirring solution of (£)-l-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l- 
one 165 (0.92 g, 2.8 mmol), in chloroform (15cm3) at 0 °C under nitrogen, was added a 
solution of bromine in chloroform (2.8 cm3, 1M). The mixture was then stirred at 0 °C for
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one hour. The chloroform was then removed in vacuo to give the crude product 166 as a light 
pink solid (1.35 g, 2.8 mmol, 99%); m.p. 129 - 130 °C; Rf 0.85 & 0.66 (Si02, ethyl 
acetate:hexane 1:1); vmax(cm ‘) 3006, 2941,2841, 1663, 1607, 1580, 1515, 1504, 1455, 1414, 
1332, 1244, 1123, 991, 767; 8  'H NMR (400 MHz; CDC13; ppm) 3.77 (3H, s, OCH3), 3.89 
(3H, s, OCH3), 3.90 (6 H, s, OCH3), 5.59 (1H, d, J  11.3 Hz, H-3), 5.69 (1H, d, J  11.3 Hz, H-
2), 6 . 8 8  (2H, d, J  8.7 Hz, H-3” & H-5” ), 7.27 (2H, s, H-2’ & H-6 ’), 7.40 (2H, d, J  8.7Hz, H- 
2”  & H-6 ” ); 8  13C NMR (100 MHz; CDC13; ppm) 47.04 (s, CHBr), 50.42 (s, CHBr), 55.39 
(s, OCH3), 56.52 (s, OCH3), 61.08 (s, OCH3), 106.52 (s, CH), 114.24 (s, CH), 129.43 (s, C),
129.71 (s, CH), 130.23 (s, C), 143.69 (s, C), 153.33 (s, C), 160.17 (s, C), 190.17 (s, C=0).
(Z)-2-Bromo-l-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 167
O
MeO
OMe OMe167
Triethylamine (50 cm3) was slowly added to a stirring solution of (2,3-dibromo-l-(3,4,5- 
trimethoxyphenyl)-3-(4-methoxyphenyl)propan-l-one 166 (2.44 g, 5.0 mmol), in chloroform 
(5cm3) at 0 °C under nitrogen. The mixture was then stirred overnight at room temperature, 
and then heated to 95 °C for 1 hour. The triethylamine was then evaporated in vacuo, the 
crude compound was then dissolved in chloroform (30 cm3) and washed with water (3 x 20 
cm ) and saturated sodium bicarbonate solution (2 x 20 cm ). The organic fraction was then 
dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo. Recrystallization 
from ethyl acetate and hexane afforded 167 as fine cream crystals (1.22g, 3.0 mmol, 60%) 
m.p. 111-112 °C; R/ 0.64 (Si02, hexane:ethyl acetate 1:1); Vmaxfcm'1) 2935, 2837, 1642, 
1581, 1504, 1461, 1448, 1411, 1327, 1249, 1121, 1099, 1028, 827, 712; 6  'H NMR (400 
MHz; CDC13; ppm) 3.87 (3H, s, OCH3), 3.89 (6 H, s, OCH3), 3.94 (3H, s, OCH3) 6.97 (2H, d, 
J8 .9  Hz, H-3” & H-5” ), 7.03 (2H, s, H-2’ & H-6 ’), 7.69 (1H, s, H-3), 7.92 (2H, d, J8 .9  Hz, 
H-2” & H-6 ” ); 6  ,3C NMR (100 MHz; CDC13; ppm) 55.47 (s, OCH3), 56.38 (s, OCH3), 
61.05 (s, OCH3), 107.14 (s, CH), 114.04 (s, CH), 119.77 (s, C), 126.02 (s, CBr), 131.89 (s, 
C), 132.55 (s, CH), 141.81 (s, C), 142.47 (s, CH), 152.96 (s, C), 161.47 (s, C), 190.89 (s, 
C=0); m/z(AP+) 407 (MH+, 80%), 409 (MH+, 100%); HRMS found [MH]+ 407.0489 for 
C,9H2o05Br, C,9 H2o05Br requires [MH]+ 407.0489; CHN found C 56.05%, H 4.78%, CHN 
requires C 56.03%, H 4.70%.
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(1E,4 E)-1,5-Diphenylpenta-1,4-dien-3-one 170336
O
170
The method adopted was that of Shoppee201 et al. To a stirring solution of acetone (3.7 cm3, 
50.4 mmol) and benzaldehyde (10.3 cm3, 101.3 mmol), in ethanol (80 cm3) was added an 
aqueous sodium hydroxide solution (100 cm3, 2.5 M). The reaction was then allowed to 
stand for 1 hour, allowing the bright yellow solid to precipitate. The yellow solid was then 
filtered off and washed with water (3 * 25 cm3). Recrystallization from ethyl acetate 
afforded 170 as bright yellow crystals (5.90 g, 25.2 mmol, 50%); m.p. 107 - 108 °C; Rf 0.32 
(SiC>2 , ethyl acetate:hexane 1 :1 ); VmaxXcm'1) 3054, 3026, 1649, 1626, 1589, 1574, 1495, 
1447, 1342, 1192, 980, 883, 760; 6  'H NMR (400 MHz; CDC13; ppm) 7.09 (2H, d, J  16.2 Hz, 
H-2), 7.39 -  7.44 (6 H, m, H-3’, H-4’ & H-5’), 7.60 -  7.65 (4H, m, H-2’ & H-6 ’), 7.75 (2H, d, 
J  16.2 Hz, H-3); 8  I3C NMR (100 MHz; CDC13; ppm) 125.66 (s, CH), 128.64 (s, CH),
129.21 (s, CH), 130.74 (s, CH), 135.04 (s, C), 143.55 (s, CH), 189.16 (s, CO).
Bis(dibenzylideneacetone)palladium(0) 171 and tris(dibenzylideneacetone)dipalladium(0) 
chloroform 169202
Pd(dba) 2 Pd2 (dba) 3 CHC13
171 169
The method adopted was that of Hegedus. 202 To a stirring solution of (1£,4£)-1,5- 
diphenylpenta-l,4-dien-3-one 170 (4.60 g, 19.7 mmol) and sodium acetate (3.90 g, 47.5 
mmol) in methanol (150 cm3) under argon at 50 °C, was added palladium chloride (1.00 g,
5.6 mmol). The reaction was then cooled to 40 °C and stirred at this temperature for 4 hours. 
The mixture was then left to cool to room temperature and allow the product to precipitate. 
The purple precipitate was then collected by filtration and washed with water (10 cm3) and 
acetone (10 cm3). The purple precipitate was then dried in vacuo and afforded 171 as a 
purple precipitate (3.21 g, 5.6 mmol, 99%). Z?/s(dibenzylideneacetone)palladium(0) 171 
(2.42 g, 4.2 mmol) was then dissolved in hot chloroform (90 cm3) and filtered to give a deep 
purple solution. Diethyl ether (120 cm3) was then slowly added to the purple solution and the 
mixture was then left to crystallize over night. The crystals were then filtered and dried in 
vacuo to afford 169 as deep purple crystals (1.61 g, 1. 6  mmol, 74%).
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Protocol B
The method adopted was that of Mull200 et al. In a Schlenk tube a mixture of the a-bromo 
chalcone ( 1 . 0  mmol), boronic acid ( 1 . 2  mmol), tris(dibenzylideneactone)dipalladium(0 ) 
chloroform 169 (0.023g, 0.02 mmol) and triphenylphosphine (0.011 g, 0.04 mmol) was 
dissolved in toluene ( 6  cm3) and rt-propanol (2 cm3), and then degassed by evacuation. After 
stirring for lOmins, diethylamine (0.13 cm3, 1.3 mmol) and H2O (1.6 cm3) were added to the 
reaction. The mixture was degassed a second time, refluxed for a 1 hour at 100 °C, then 
cooled to room temperature. The reaction was then poured into ethyl acetate (100 cm3) and 
washed with aqueous sodium hydroxide solution (30 cm3, 0.2 M), aqueous hydrochloric acid 
(30 cm3,0.05 M) and water (2 x30 cm3). The organic fraction was then dried over anhydrous 
magnesium sulfate, filtered and evaporated in vacuo. The product chalcone was then purified 
by means of column chromatography and/or recrystallization.
(E)-l-(3,4,5-Trimethoxyphenyl)-3-(4-methoxyphenyl)-2-phenylprop-2-en-l-one 172
O
OMe
The a-arylchalcone 172 was obtained following Protocol B. Using (Z)-2-bromo-l-(3,4,5- 
trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 167 (0.407 g, 1.0 mmol),
phenylboronic acid (0.147 g, 1.2 mmol). Recrystallization from ethyl acetate and hexane 
afforded 172 as cream fine needles (0.172 g, 0.42 mmol, 43%) m.p. 136-137°C; R /0.75 
(SiC>2 , hexanerethyl acetate 1 :1 ); VmaxXcm'1) 2936, 1642, 1580, 1505, 1459, 1411, 1328, 
1249, 1170, 1028, 827, 712; 6  ‘H NMR (400 MHz; CDC13; ppm) 3.70 (3H, s, OCH3), 3.75 
(6 H, s, OCH3), 3.83 (3H, s, OCH3), 6.65 (2H, d, J  8 . 8  Hz, H-3” & H-5” ), 6.98 (2H, s, H-2’ 
& H-6 ’), 6.99 (2H, d, J 8 . 8  Hz, H-2” & H-6 ” ), 7.19-7.31 (6 H, m, H-3 & H-2’” to H-6 ” ’); 6  
13C NMR (100 MHz; CDC13; ppm) 55.28 (s, OCH3), 56.21 (s, OCH3), 60.97 (s, OCH3), 
107.31 (s, CH), 113.77 (s, CH), 127.33 (s, C), 127.86 (s, CH), 128.98 (s, CH), 129.74 (s, 
CH), 132.22 (s, CH), 133.31 (s, C), 137.33 (s, C), 138.58 (s, C), 140.02 (s, CH), 141.37 (s, 
C), 152.71 (s, C), 160.27 (s, C), 196.17 (s, C=0); m/z{AP+) 405 (MH+, 100%), HRMS found 
[MH]+ 405.1697 for C2 5H25O5 , C25H25O5 requires [MH]+ 405.1697; CHN found C 73.65%, H 
5.97%, CHN requires C 74.24%, H 5.98%.
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(E)-l-(3,4,5-Trimethoxyphenyl)-2,3-bis(4-methoxyphenyl)prop-2-en-l-one 173
OMeMeO
OMe
OMe
173
The a-arylchalcone 173 was obtained following Protocol B. Using (Z)-2-bromo-l-(3,4,5- 
trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 167 (0.407 g, 1.0 mmol), 4- 
methoxyphenylboronic acid (0.182 g, 1.2 mmol). Column chromatography (SiC>2 , ethyl 
acetate:hexane 1:3) followed by recrystallization from ethyl acetate and hexane afforded 173 
as yellow solid (0.131 g, 0.30 mmol 30%) m.p. 112-114°C; R/0.19 (SiC>2 , hexane:ethyl 
acetate 3:1); vmm(cm'‘) 2937, 2838, 1644, 1602, 1578, 1555, 1504, 1453, 1413, 1329, 1253, 
1120, 1029, 1004, 823; 8 ‘H NMR (400 MHz; CDC13; ppm) 3.71 (3H, s, OCH3), 3.75 (6H, s, 
OCH3), 3.76 (3H, s, OCH3), 3.83 (3H, s, OCH3), 6.66 (2H, d, J  8.8 Hz, H-3” & H-5” ), 6.83 
(2H, d, J  8.7 Hz, H-3’”  & H-5’” ), 6.98 (2H, s, H-2’ & H-6’), 7.03 (2H, d, J  8.8 Hz, H-2” & 
H-6” ), 7.13 (2H, d, J  8.7 Hz, H-2’” & H-6’” ), 7.16 (H, s, H-3); 5 l3C NMR (100 MHz; 
CDC13; ppm) 55.27 (s, OCH3), 56.21 (s, OCH3), 60.96 (s, OCH3), 107.29 (s, CH), 113.76 (s, 
CH), 114.40 (s, CH), 127.56 (s, C), 129.40 (s, C), 130.95 (s, CH), 132.11 (s, CH), 133.40 (s, 
C), 138.26 (s, C), 139.43 (s, CH), 141.32 (s, C), 152.70 (s, C), 159.19 (s, C), 160.14 (s, C),
196.61 (s, C=0); m/z(AP+) 435 (MH\ 100%); HRMS found [MH]+ 435.1799 for C26H27O6 , 
C26H27 0 6 requires [MH]+ 435.1802; CHN found C 71.46%, H 6.04%, CHN requires C 
71.87%, H 6.03%.
(E)-2-(2,4-Dimethoxyphenyl)-l-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-J- 
one 174
MeOv v
MeO
MeO
OMe
174
The a-arylchalcone 174 was obtained following Protocol B. Using (Z)-2-bromo-l-(3,4,5- 
trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 167 (0.407 g, 1.0 mmol), 2,4- 
dimethoxyphenylboronic acid (0.219 g, 1.2 mmol). Column chromatography (SiC>2 , ethyl 
acetate:hexane 1:3) followed by recrystallization from ethyl acetate and hexane afforded 174
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as cream crystals (0.171 g, 0.37 mmol, 37%); m.p. 124 -  126 °C; R/ 0 . 1 2  (SiC>2, 
hexane:ethyl acetate 3:1); VmaxXcm'1) 2935, 2835, 1651, 1580, 1503, 1463, 1439, 1412, 1328, 
1303, 1208, 1155, 1121, 1008, 830, 766; 6  *H NMR (400 MHz; CDC13; ppm) 3.59 (3H, s, 
OCH3), 3.78 (3H, s, OCH3), 3.81 (6 H, s, OCH3), 3.83 (3H, s, OCH3), 3.89 (3H, s, OCH3), 
6.44 -  6.51 (2H, m, H-3’” & H-5’” ), 6.73 (2H, d, J 8 . 6  Hz, H-3” & H-5” ), 7.07 (2H, s, H-2’ 
& H-6 ’), 7.10 ( 1 H, d, J  8.0 Hz, H-6 ” ’), 7.14 (2H, d, J 8 . 6  Hz, H-2” & H-6 ” ), 7.23 (H, s, H-
3); 8  13C NMR ( 1 0 0  MHz; CDC13; ppm) 55.25 (s, OCH3), 55.39 (s, OCH3), 55.49 (s, OCH3), 
56.15 (s, OCH3), 60.93 (s, OCH3), 99.07 (s, CH), 105.23 (s, CH), 106.96 (s, CH), 113.63 (s, 
CH), 119.44 (s, C), 128.04 (s, C), 131.69 (s, CH), 131.75 (s, CH), 133.87 (s, C), 135.42 (s, 
C), 139.68 (s, CH), 141.00 (s, C), 152.52 (s, C), 158.05 (s, C), 159.98 (s, C), 161.08 (s, C),
197.09 (s, CO); m/z{AP+) 465 (MH\ 100%); HRMS found [MH]+ 465.1901 for C2 7H29O7 , 
C27H29O7 requires [MH]+ 465.1908; CHN found C 69.45%, H 6.06%, CHN requires C 
69.81%, H 6.08%.
(E)-2-(4-(Dimethylamino)phenyl)-l-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en- 
1-one 175
O
OMeMeO‘
OMe
NMe2
1 7 5
The a-arylchalcone 175 was obtained following Protocol B. Using (Z)-2-bromo-l-(3,4,5- 
trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 167 (0.407 g, 1.0 mmol), 4- 
(dimethylamino)phenylboronic acid (0.198 g, 1 . 2  mmol). Column chromatography (SiC>2 , 
ethyl acetate:hexane 1:3) followed by recrystallization from ethyl acetate and hexane afforded 
175 as yellow crystals (0.116 g, 0.26 mmol, 26%); m.p. 129 -  131 °C; R/ 0.20 (SiC>2 , 
hexane:ethyl acetate 3:1); vmax(cm ‘) 2945, 1642, 1604, 1576, 1526, 1507, 1465, 1412, 1326, 
1119, 997, 764; 6  'H NMR (400 MHz; CDC13; ppm) 2.97 (6 H, s, N(CH3)2), 3.78 (3H, s, 
OCH3), 3.80 (6 H, s, OCHj), 3.89 (3H, s, OCH3), 6 . 6 8  (2 H, d, J  8 . 8  Hz, H-3” & H-5” ), 6.74 
(2H, d, J 8 . 8  Hz, H-3’”  & H-5’” ), 7.07 (2H, s, H-2’ & H-6 ’), 7.10 -  7.14 (3H, m, H-3 & H- 
2’”  & H-6 ’” ), 7.18 (2H, d , . / 8 . 8  Hz, H-2”  & H-6 ” ); 8  l3C NMR (100 MHz; CDC13; ppm) 
40.79(s, N(CH3)2), 55.62 (s, OCH3), 56.55 (s, OCH3), 61.30 (s, OCH3), 107.76 (s, CH),
112.97 (s, CH), 114.04 (s, CH), 125.07 (s, C), 128.52 (s, C), 130.89 (s, CH), 132.32 (s, CH),
133.82 (s, C), 137.82 (s, CH), 139.41 (s, C), 150.32(s, C), 152.98 (s, C), 153.43 (s, C-N),
160.19 (s, C), 197.36 (s, CO); m/z(AP+) 447 (M, 100%) 448 (MH+, 30%); HRMS found
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[MH]+ 448.2112 for C27H30NO5, C2 7H30NO5 requires [MH]+ 448.2118; CHN found C 
71.82%, H 6.59%, N 2.94%, CHN requires C 72.46%, H 6.53%, N 3.13%.
(E)-2-(2,3,4-Trimethoxyphenyl)-l-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l- 
one 176
MeO
MeO
MeO OMe
176
The a-arylchalcone 176 was obtained following Protocol B. Using (Z)-2-bromo-l-(3,4,5- 
trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 167 (0.407 g, 1.0 mmol), 2,3,4- 
trimethoxyphenylboronic acid (0.255 g, 1 . 2  mmol). Column chromatography (SiC>2 , ethyl 
acetateihexane 1:3) afforded 176 as brown oil (0.30 g, 0.61 mmol, 61%); Rf 0.18 (SiC>2 , ethyl 
acetateihexane 1:3); v^X cm '1) 2938 , 1649, 1581, 1509, 1493, 1460, 1409, 1327, 1254, 
1122, 1026, 1005, 798; 6  ‘H NMR (400 MHz; CDC13; ppm) 3.63 (3H, s, OCH3), 3.71 (3H, s, 
OCH3), 3.78 (6 H, s, OCH3), 3.78 (3H, s, OCH3), 3.82 (3H, s, OCH3), 3.84 (3H, s, OCH3),
6.59 (H, d, J  8 . 6  Hz, H-5’” ), 6.67 (2H, d, J  8.9 Hz, H-3” & H-5” ), 6.82 (H, d, J  8 . 6  Hz, H- 
6 ” ’), 7.04 (2H, d, J  8.9 Hz, H-2” & H-6 ” ), 7.05 (2H, s, H-2’ & H-6 ’), 7.15(H, s, H-3); 6  13C 
NMR (100 MHz; CDC13; ppm) 55.26 (s, OCH3), 55.98 (s, OCH3), 56.21 (s, OCH3), 60.69 (s, 
OCH3), 60.91 (s, OCH3), 60.93 (s, OCH3), 107.15 (s, CH), 107.61 (s, CH), 113.61 (s, CH),
124.43 (s, C), 125.45 (s, CH), 127.56 (s, C), 131.86 (s, CH), 133.82 (s, C), 135.38 (s, C),
140.39 (s, CH), 141.20 (s, C), 142.42 (s, C), 151.45 (s, C), 152.64 (s, C), 153.94 (s, C), 
160.17 (s, C), 197.07 (s, CO); m/z(AP+) 117 (Mfragment, 100%), 495 (MH+, 50%); HRMS 
found [MH]+ 495.2008 for C,9H,80 6, C,9 H1806 requires [MH]+ 495.2013.
(E & Z)-2-(2,6-Dimethoxyphenyl)-l-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl) prop-2- 
en-l-one 111
OMe
MeO
MeO
MeO,
r  JpMeMeO
MeO
177
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The a-arylchalcone 177 was obtained following Protocol B. Using (Z)-2-bromo-l-(3,4,5- 
trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 167 (0.407 g, 1.0 mmol), 2,6- 
dimethoxyphenylboronic acid (0.219 g, 1 . 2  mmol). Column chromatography (SiC>2 , ethyl 
acetateihexane 1:3) afforded 177 as a mixture of E and Z isomers as a light brown solid 
(0.186 g, 0.40 mmol, 40%); m.p. 123 - 124 °C; Rf 0.19 (SiC>2 , ethyl acetateihexane 1:3); 
VmaxXcm'1) 2938, 1662, 1644, 1582, 1501, 1474, 1414, 1327, 1254, 1157, 1023, 998, 810, 
773, 739; 8  'H NMR (400 MHz; CDC13; ppm) 3.57 (9H, s, OCH3), 3.69 (6 H, s, OCH3, £), 
3.73 (3H, s, OCH3, £), 3.75 (6 H, s, OCH3, £), 3.77 (4.5H, s, OCH3, Z), 3.78 (9H, s, OCH3, 
Z), 3.83 (3H, s, OCH3, £), 3.87 (4.5H, s, OCH3, Z), 6.52 -  6.58 (5H, m, H-3’” & H-5’” , E & 
Z), 6 . 6 8  (2H, d, J  9.2 Hz, H-3” & H-5” , £), 6.69 (3H, d, J  8 . 8  Hz, H-2” & H-6 ” , Z), 7.05 
(3H, s, H-2’ & H-6 ’, Z), 7.12 (3H, d, J 8 . 8  Hz, H-2” & H-6 ” , Z), 7.13 (1H, s, H-3, £), 7.16 
(2H, d, J 9.2 Hz, H-2”  & H-6 ” , £), 7.21 (1H, t, J 8 . 6  Hz, H-4’” , E), 7.24 (2H, s, H-2’ & H- 
6 ’, £), 7.27 (1.5 H, t, J  8.4 Hz, H-4’” , Z) 7.40 (1.5H, s, H-3, Z); 513C NMR (100 MHz; 
CDC13; ppm) 55.22 (s, OCH3), 55.73 (s, OCH3), 55.84 (s, OCH3), 56.04 (s, OCH3), 60.85 (s, 
OCH3), 60.90 (s, OCH3), 104.37 (s, CH), 104.49 (s, CH), 106.52 (s, CH), 106.79 (s, CH),
113.43 (s, CH), 115.82 (s, C), 118.88 (s, C), 128.87 (s, C), 129.02 (s, C), 129.28 (s, CH),
129.96 (s, CH), 130.67 (s, CH), 130.79 (s, C), 131.06 (s, CH), 131.14 (s, C), 132.65 (s, C),
134.09 (s, C), 138.59 (s, CH), 140.73 (s, C), 141.03 (s, CH), 141.38 (s, C), 152.42 (s, C),
157.70 (s, C), 158.08 (s, C), 159.26 (s, C), 160.06 (s, C), 197.12 (s, CO), 197.41 (s, CO); 
m/z(API-ES) 465 (MH+, 100%); HRMS found [MH]+ 465.19053 for C27H29O7, C27H29O7 
requires [MH]+ 465.19078.
(E)-l-(3,4,5-Trimethoxyphenyl)-3-phenylprop-2-en-l-one 17972,337
O
MeO
MeO
OMe l / y
The chalcone 179 was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(3.15 g, 15.0 mmol), freshly distilled benzaldehyde (1.6 cm3, 15.7 mmol) and aqueous 
sodium hydroxide solution (2.5 cm , 12M) in methanol (9 cm ). Recrystallization from 
methanol afforded 179 as light yellow crystals (3.71 g, 12.4 mmol, 83%); m.p. 75 -  77 °C; 
R f 0.38 (SiC>2, ethyl acetate:hexane 1:3); Vmaxfcm'1) 2941, 1656, 1573, 1501, 1451, 1412, 
1337, 1156, 991, 763; 8  'H NMR (400 MHz; CDC13; ppm) 3.94 (3H, s, OCH3), 3.96 (6 H, s, 
OCHj), 7.28 (2H, s, H-2’ & H-6 ’), 7.41 -  7.46 (3H, m, H-3” , H-4”  & H-5” ), 7.49 (1H, d, J
15.7 Hz, H-2), 7.63 -  7.68 (2H, m, H-2”  & H-6 ” ), 7.82 (1H, d, ^715.7 Hz, H-3); 8  13C NMR 
(100 MHz; CDC13; ppm) 56.41 (s, OCH3), 61.04 (s, OCH3), 106.03 (s, CH), 121.77 (s, CH),
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128.48 (s, CH), 129.01 (s, CH), 130.61 (s, CH), 133.52 (s, C), 134.89 (s, C), 142.44 (s, C),
144.82 (s, CH), 153.17 (s, C), 189.30 (s, CO).
2,3-Dibromo-l-(3,4,5-trimethoxyphenyl)-3-phenylpropan-l-one 180
O Br
3 "
4 "
OMe 180
To a stirring solution of (£)-l-(3,4,5-trimethoxyphenyl)-3-phenylprop-2-en-l-one 179 (3.05
g, 10.2 mmol), in chloroform (45cm3) at 0 °C under nitrogen, was added a solution of
■*>
bromine in chloroform (5.2 cm , 2M). The mixture was then stirred at 0 °C for one hour. 
The chloroform was then removed in vacuo to give the crude product 180 as a pale pink solid 
(4.66 g, 10.2 mmol, 99%); m.p. 128 -134 °C; R f  0.31 (SiC>2 , ethyl acetateihexane 1:3); 
Vmaxfcrn'1) 2937, 1682, 1579, 1504, 1454, 1412, 1335, 997, 696; 6  lU NMR (400 MHz; 
CDC13; ppm) 3.90 (3H, s, OCH3), 3.91 (6 H, s, OCH3), 5.58 ( 1 H, d, J  11.26 Hz, H-3), 5.69 
(1H, d, J  11.26 Hz, H-2), 7.27 (2H, s, H-2’ & H-6 ’), 7.32 -  7.40 (3H, m, H-3” , H-4” & H- 
5” ), 7.46 -  7.49 (2H, m, H-2” & H-6 ” ); 6  ,3C NMR (100 MHz; CDC13; ppm) 46.71 (s, CH), 
50.35 (s, CH), 56.90 (s, OCH3), 61.47 (s, OCH3), 106.90 (s, CH), 128.80 (s, CH), 129.28 (s, 
CH), 129.75 (s, CH), 138.57 (s, C), 144.11 (s, C), 153.72 (s, C), 190.44(s, CO); m/z(AP+) 
299 (MH+-Br2, 100%), 377(M-Br, 30%), 379(M-Br, 40%), 457 (MH+, 25%), 459 (MH+, 
40%), 461(MH\ 25%).
(Z)-2-Bromo-l-(3,4,5-trimethoxyphenyl)-3-phenylprop-2-en-l-one 178
O
MeO
OMe
178 5 -
Triethylamine (35 cm3) was slowly added to a stirring solution of 2,3-dibromo-l-(3,4,5- 
trimethoxyphenyl)-3-phenylpropan-l-one 180 (1.60 g, 3.5 mmol), in chloroform (3cm ) at 0 
°C under nitrogen. The mixture was then stirred overnight at room temperature, and then 
heated to 95 °C for 1 hour. The triethylamine was then evaporated in vacuo, the crude 
compound was then dissolved in chloroform (30 cm3) and washed with water (3 * 20 cm3) 
and saturated sodium bicarbonate solution (2 x 20 cm3). The organic fraction was then dried 
over anhydrous magnesium sulfate, filtered and evaporated in vacuo. Recrystallization from 
ethyl acetate and hexane afforded 178 as brown crystals (0.54 g, 1.4 mmol, 41%); m.p. 108 -
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110 °C; Rf0.35 (Si02, ethyl acetate:hexane 1:3); VmaxXcm'1) 2975, 1651, 1582, 1505, 1488, 
1463, 1443, 1411, 1334, 1245, 1100, 1005, 770, 692; 6  'H NMR (400 MHz; CDC13; ppm)
3.83 (6 H, s, OCH3), 3.88 (3H, s, OCH3), 7.02 (2H, s, H-2’ & H-6 ’), 7.36 -  7.41 (3H, m, H- 
3” , H-4” & H-5” ), 7.62 (1H, s, H-3), 7.78 -  7.82 (2H, m, H-2” & H-6 ” ); 6  13C NMR (100 
MHz; CDC13; ppm) 56.39 (s, OCH3), 61.06 (s, OCH3), 107.34 (s, CH), 121.74 (s, C), 128.60 
(s, CH), 130.23 (s, CH), 130.41 (s, CH), 131.21 (s, C), 133.59 (s, C), 141.66 (s, CH), 142.23 
(s, C), 153.00 (s, C), 190.69 (s, CO); m/z(AP+) 377 (MH+, 100%) 379 (MH+, 100%); HRMS 
found [MH]+ 377.0389 for Ci9Hi80 6, Ci9 H180 6 requires [MH]+ 377.0383.
(E & Z)-l-(3,4,5-Trimethoxyphenyl)-2,3-diphenylprop-2-en-l-one 181
MeO MeO
OMe,
181
The a-arylchalcone 181 was obtained following Protocol B. Using (Z)-2-bromo-l-(3,4,5- 
trimethoxyphenyl)-3-phenylprop-2-en-l-one 178 (0.337 g, 1.0 mmol), phenylboronic acid 
(0.147 g, 1.2 mmol). Column chromatography (Si0 2 , ethyl acetate:hexane 1:3) afforded 181 
as a mixture of E and Z isomers as yellow oil (0.194 g, 0.52 mmol, 52%); Rf 0.44 (Si02, 
ethyl acetate:hexane 1:3); VmaxXcm'1) 2936, 1651, 1578, 1499, 1447, 1412, 1323, 1154, 1000, 
764, 692; 6  *H NMR (400 MHz; CDC13; ppm) 3.77 (14H, s, OCH3), 3.81 (6 H, s, OCH3), 3.86 
(7H, s, OCH3), 3.90 (3H, s, OCH3), 7.09 -  7.47 (42 H, m, Ar-H); 6  ,3C NMR (100 MHz; 
CDC13; ppm) 56.15 (s, OCH3), 56.22 (s, OCH3), 60.92 (s, OCH3), 60.98 (s, OCH3), 107.02 (s, 
CH), 107.45 (s, CH), 126.38 (s, CH), 128.02 (s, CH), 128.17 (s, CH), 128.28 (s, CH), 128.31 
(s, CH), 128.58 (s, CH), 128.79 (s, CH),128.92 (s, CH), 128.94 (s, CH), 129.61 (s, CH),
130.27 (s, CH), 130.33 (s, CH), 131.32 (s, C), 132.71 (s, C), 134.87 (s, C), 135.51 (s, C),
136.85 (s, C), 138.40 (s, C), 138.87 (s, CH), 140.70 (s, C), 140.76 (s, C), 142.93 (s, C),
152.77 (s, C), 153.10 (s, C), 196.11 (s, CO), 198.17 (s, CO); m/z(API-ES) 375 (MH+, 
100%); HRMS found [MH]+ 375.15914 for C24H230 4, C24H230 4 requires [MH]+ 465.19078.
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(E)-l-(3,4,5-Trimethoxyphenyl)-3-(4-methoxyphenyl)-2-methylprop-2-en-l-one 182
O
MeO‘
OMe OMe182
The method adopted was that of Edwards72 et al. A solution of 1-(3,4,5- 
trimethoxyphenyl)propan-l-one 183 (2.73 g, 12.2 mmol), p-anisaldehyde (1.5 cm3, 12.3 
mmol), piperidine (7 cm3) and acetic acid (3.5 cm3) in ethanol (13 cm3) was heated at reflux 
at 110 °C under argon for 4 days. The mixture was then cooled to room temperature and 
diluted with dichloromethane (60 cm3) and washed with water (3 x 20 cm3). The aqueous 
fraction was then extracted with dichloromethane (4 * 50 cm3). The organic fractions were 
then combined and dried over anhydrous magnesium sulfate, filtered and evaporated in 
vacuo. Recrystallization from ethyl acetate and hexane afforded 182 as clear white crystals 
(1.24 g, 3.7 mmol, 30%); mp 119 -  121 °C; Rf 0.38 (SiC>2 , ethyl acetate:hexane 1:3); 
VmaxXcm'1) 2996, 2936, 2825, 1632, 1604, 1582, 1502, 1458, 1412, 1331, 1175, 1031, 1015, 
821, 771; 5 'H NMR (400 MHz; CDC13; ppm) 2.28 (3H, d, J  1.3 Hz, H -l’” ), 3.85 (3H, s, 
OCH3), 3.89 (6 H, s, OCH3), 3.92 (3H, s, OCH3), 6.95 (2 H, d, 7  8 . 8  Hz, H-3” & H-5” ), 6.99 
(2H, s, H-2’ & H-6 ’), 7.17 (1H, br. s, H-3), 7.42 (2H, d, 78.8 Hz, H-2” & H-6 ” ); 8  13C NMR 
(100 MHz; CDC13; ppm) 14.72 (s, CH3), 55.38 (s, OCH3), 56.30 (s, OCH3), 60.99 (s, OCH3),
106.94 (s, CH), 114.03 (s, CH), 128.33 (s, C), 131.60 (s, CH), 133.91 (s, C), 134.56 (s, C),
141.06 (s, C), 141.85 (s, CH), 152.80 (s, C), 159.99 (s, C), 198.70 (s, CO); m/z(AP+) 343 
(MH+, 100%); HRMS found [MH]+ 343.1544 for C2 0H23O5, C2oH230 5 requires [MH]+ 
343.1540; CHN found C 70.22%, H 6.49% CHN requires C 70.16%, H 6.48%.
l-(3,4,5-Trimethoxyphenyl)propan-l-ol 184338,339
OH
MeO>3>£pJSs2 / 3
M e O ' ^ f 6'
OMe
184
A solution of bromoethane (3.7 cm3, 49.6 mmol) in anhydrous tetrahydrofuran (40 cm3) was 
slowly added to a stirred mixture of magnesium turnings (1.46 g, 60.1 mmol) in anhydrous 
tetrahydrofuran (40 cm3) under argon. On consumption of the magnesium a solution of 3,4,5- 
trimethoxybenzaldehyde (7.85 g, 40.0 mmol) in anhydrous tetrahydrofuran (40 cm ) was 
added over 30 minutes. The mixture was stirred at room temperature under argon overnight
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and quenched by pouring carefully onto a mixture of ice and aqueous hydrochloric acid (70 
cm3, 1 M). The mixture was extracted with ethyl acetate (5 x 60 cm3) The organic fraction 
was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to give 184 as 
a yellow oil (8.77 g, 38.8 mmol, 97%); Rf 0.14 (Si02, ethyl acetate:hexane 1:3); Vmaxfcrn'1) 
3448, 2937, 2811, 2823, 1590, 1507, 1456, 1417, 1326, 1121, 1004, 830; 6  'H NMR (400 
MHz; CDC13; ppm) 0.91 (3H, t, J1.6  Hz, H-3), 1.61 -  1.86 (2H, m, H-2), 2.09 (1H, s, OH-1), 
3.81 (3H, s, OCH3), 3.84 (6 H, s, OCH3), 4.50 (1H, t, J  6.1 Hz, H-l), 6.54 (2H, s, H-2’ & H- 
6 ’); 6  ,3C NMR (100 MHz; CDC13; ppm) 10.30 (s, CH3), 31.96 (s, CH2), 56.04 (s, OCH3), 
60.83 (s, OCH3), 76.18 (s, CH(OH)), 102.67 (s, CH), 136.94 (s, C), 140.58 (s, C), 153.13 (s, 
C); m/z(AP+) 209 (M(-H20)H+, 100%).
J-(3,4,5-Trimethoxyphenyl)propan-l-one 183338
O
OMe
183
Pyridinium chlorochromate (12.93 g, 60 mmol) was added to a stirred solution of 1 -(3,4,5- 
trimethoxyphenyl)propan-l-ol 184 (8.70 g, 38.5 mmol) in dichloromethane (100 cm3). The 
reaction was then put under argon gas and stirred at room temperature under argon overnight. 
It was then filtered through Celite®, dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. Column chromatography (Si02, ethyl acetate:hexane 1:3) afforded 183 
as a pale cream solid (6.55 g, 29.3 mmol, 76%); mp 64 -  6 6  °C; Rf 0.32 (Si02, ethyl 
acetate:hexane 1:3); v^X cm '1) 3004, 2968, 2939, 2839, 1673, 1586, 1505, 1454, 1411, 
1309, 1157, 1123, 857, 799; 5 lH NMR (400 MHz; CDC13; ppm) 1.21 (3H, t, J  7.2 Hz, H-3),
2.97 (2H, q, J  7.2 Hz, H-2), 3.90 (3H, s, OCH3), 3.91 (6 H, s, OCH3), 7.21 (2H, s, H-2’ & H- 
6 ’); 6  ,3C NMR (100 MHz; CDC13; ppm) 8.44 (s, CH3), 31.59 (s, CH2), 56.28 (s, OCH3),
60.96 (s, OCH3), 105.40 (s, CH), 132.24 (s, C), 142.33 (s, C), 153.04 (s, C), 199.65 (s, CO); 
m/z(AP+) 225 (MH+, 100%).
l-(3,4,5-Trimethoxyphenyl)-3-(4-methoxyphenyl)propan-l-one 185
O
OMe
185
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(£)-l-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 165 (2.09 g, 6.4 mmol) 
in ethyl acetate (40 cm3) was added to a stirring activated suspension of 10% Pd/C (1 spatula) 
in ethyl acetate (10 cm3). The mixture was stirred at room temperature under a hydrogen 
atmosphere for 3 hours, filtered through celite and evaporated in vacuo. Purification by 
column chromatography (SiC>2 hexane:ethyl acetate 3:1) afforded 185 as white crystals (1.72 
g, 5.2 mmol,82%); m.p. 8 8  -  90 °C; R f  0.46 (Si02, ethyl acetate:hexane 1:3); VmaxXcm'1) 
3006, 2964, 2939, 2834, 1673,1615, 1585, 1514, 1503, 1482, 1451, 1411, 1323, 1247, 1151, 
1033, 1007, 816, 762; 6  *H NMR (400 MHz; CDC13; ppm) 3.00 (2H, t, J  7.6 Hz, H-3), 3.23 
(2H, t, J 7.6 Hz, H-2), 3.79 (3H, s, OCH3), 3.89 (6 H, s, OCH3), 3.91 (3H, s, OCH3), 6.85 (2H, 
d, J8 .5  Hz, H-3” & H-5” ), 7.18 (2H, d ,J8 .5  Hz, H-2” & H-6 ” ), 7.20 (2H, s, H-2’ & H-6 ’); 
5 13C NMR (100 MHz; CDC13; ppm) 29.50 (s, CH2), 40.67 (s, CH2), 55.30 (s, OCH3), 56.29 
(s, OCH3), 60.98 (s, OCH3), 105.42 (s, CH), 113.96 (s, CH), 129.43 (s, CH), 132.19 (s, C),
133.33 (s, C), 142.44 (s, C), 153.05 (s, C), 158.03 (s, C), 198.19 (s, CO); m/z(AP+) 331 
(MH+, 100%); HRMS found [MH]+ 331.1537 for C 19H230 5, Ci9 H230 5 requires [MH]+ 
331.1540.
l-(3,4,5-Trimethoxyphenyl)-3-phenylpropan-l-one 186
O
MeO.
MeO
OMe
186
(£)-l-(3,4,5-trimethoxyphenyl)-3-phenylprop-2-en-l-one 179 (3.00 g, 10.1 mmol) in ethyl 
acetate (50 cm3) was added to a stirring activated suspension of 10% Pd/C (1 spatula) in ethyl 
acetate (10 cm3). The mixture was stirred at room temperature under a hydrogen atmosphere 
for 3 hours, filtered through celite and evaporated in vacuo. Purification by column 
chromatography (Si0 2  hexane:ethyl acetate 3:1) afforded 186 as an off white solid (2.87 g,
9.6 mmol, 95%); m.p. 90 -  91 °C; R f  0.45 (Si02 hexane:ethyl acetate 3:1 v/v); VmaxXcrn'1) 
2998, 2940, 2839, 1674, 1583, 1501, 1465, 1452, 1411, 1324, 1001, 712; 6  'H NMR (400 
MHz; CDC13; ppm) 3.06 (2H, t, J  7.6 Hz, H-3), 3.27 (2H, t, J  7.6 Hz, H-2), 3.89 (6 H, s, 
OCH3), 3.91 (3H, s, OCH3), 7.20 (2H, s, H-2’ & H-6 ’), 7.21 -  7.34 (5H, m, H-2” to H-6 ” ); 
S13C (100MHz; CDC13; ppm), 30.36 (s, CH2), 40.42 (s, CH2), 56.30 (s, OCH3), 60.99 (s, 
OCH3), 105.40 (s, CH), 126.23 (s, CH), 128.52 (s, CH), 128.60 (s, CH), 132.14 (s, C), 141.35 
(s, C), 142.45 (s, C), 153.06 (s, C), 198.04 (s, CO); m/z(AP+) 301 (MH+, 100%); HRMS 
found [MH]+ 301.14398 for Ci8H210 4, Ci8H2 ,0 4 requires [MH]+ 301.14344.
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(E)-3-(3-Hydroxy-4-methoxyphenyl)-2-(4-methoxyphenyl)acrylic acid 191
HO i
OMe
191
The method adopted was that of Borrel92 et al. A mixture of 4-methoxyphenylacetic acid 
(1.66 g, 10.0 mmol), 3-hydroxy-4-methoxybenzaldehyde (0.76 g, 5.0 mmol) and 
tnethylamine (2.3 cm , 16.5 mmol) in acetic anhydride (4.5 cm ) under argon was heated to 
140 °C for 3 hours. The mixture was then cooled to room temperature and was acidified with 
concentrated hydrochloric acid (6.9 cm ). The mixture was then stirred overnight at room 
temperature allowing the product to precipitate. The cream precipitate was then filtered off 
and recrystallization from ethanol afforded 191 as cream crystals (0.56 g, 1.9 mmol, 37%); 
m.p. 207 -  209 °C; R f  0.16 (SiC>2 , ethyl acetate:hexane 1 :1 ); VmaxXcrn'1) 3323, 2939, 2847, 
1661, 1598, 1509, 1434, 1268, 1241, 1133, 800; 6  *H NMR (400 MHz; d6 -DMSO; ppm)
3.71 (3H, s, OCH3), 3.77 (3H, s, OCH3), 6.48 ( 1 H, d, J  1.7 Hz, H-2” ), 6.55 (2H, d, J  1.7, 8.7 
Hz, H-6 ” ), 6.76 (1H, d, J  8.7 Hz, H-5” ), 6.92 (2H, d, J  9.0 Hz, H-3’ & H-5’), 7.05 (2H, d, J  
9.0 Hz, H-2’ & H-6 ’), 7.56 (1H, s, H-3), 8.91 (1H, s, OH-3” ), 12.41 (1H, s, C 0 2H-1); 5 ,3C 
NMR (100 MHz; d6 -DMSO; ppm) 55.71 (s, OCH3), 56.17 (s, OCH3), 122.22 (s, CH), 114.63 
(s, CH), 117.84 (s, CH), 123.41 (s, CH), 128.01 (s, C), 129.29 (s, C), 130.86 (s, C), 131.41 (s, 
CH), 139.66 (s, CH), 146.54 (s, C), 149.36 (s, C), 159.20 (s, C), 169.57 (s, C 0 2H); m/z(API- 
ES +) 301 ([MH]+, 100%); HRMS found [MH]+ 301.10765 for CnHpOs, CpHnOs requires 
[MH]+ 301.10705.
5-((E)-2-(Chlorocarbonyl)-2-(4-methoxyphenyl)vinyl)-2-methoxyphenyl acetate 198
4>OMe
OMe
198
The method adopted was that of Hosoda 205 et al. To a stirred suspension of (£)-3-(3-acetoxy-
4-methoxyphenyl)-2-(4-methoxyphenyl)acrylic acid 196 (0.38 g, 1.1 mmol) in dry 
chloroform and anhydrous dimethyl formamide ( 1  drop) under argon was added thionyl 
chloride (0.1 cm3, 1.4 mmol). The mixture was then heated to reflux at 75 °C for 4 hours.
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The solvent was then removed at evaporated in vacuo at 80 °C to afford 198 as a thick yellow 
brown oil (0.37g, 1 . 0  mmol, 93%); Rf 0.17 (SiC>2, ethyl acetate:hexane 1 :1 ); Vmaxfcm'1) 
2937, 2841, 1765, 1735, 1601, 1571, 1508, 1462, 1439, 1274, 1195, 1071, 1020, 813; 6  
NMR (400 MHz; CDC13; ppm) 2.26 (3H, s, H-2’” ), 3.81 (3H, s, OCH3), 3.86 (3H, s, OCH3),
6.79 (1H, d, J8 .4  Hz, H-5” ), 6.80 (1H, d, J2 .3  Hz, H-2” ), 6.96 (2H, d, J9 .2  Hz, H-3’ & H- 
5’), 6.98 (1H, dd, J2 .3 , 8.4 Hz, H-6 ’), 7.14 (2H, d, J9 .2  Hz, H-2’ & H-6 ’), 7.99 (1H, s, H-3); 
6  ,3C NMR (100 MHz; CDC13; ppm) 20.55 (s, CH3), 55.33 (s, OCH3), 55.95 (s, OCH3),
111.98 (s, CH), 114.73 (s, CH), 126.08 (s, CH), 126.56 (s, C), 126.78 (s, C), 130.82 (s, CH), 
131.02 (s, CH), 134.09 (s, C), 139.42 (s, C), 146.57 (s, CH), 153.10 (s, C), 159.88 (s, C),
168.63 (s, CO), 169.40 (s, CO).
(E)-3-(3-Acetoxy-4-methoxyphenyl)-2-(4-methoxyphenyl)acrylic acid 196
4>OMe
HO
OMe
196
A mixture of 4-methoxyphenylacetic acid (1.66 g, 10.0 mmol), 3-hydroxy-4- 
methoxybenzaldehyde (0.76 g, 5.0 mmol) and triethylamine (2.3 cm3, 16.5 mmol) in acetic 
anhydride (4.5 cm3) was sealed in a pressure-rated reaction vial (10 cm3). The reaction vial 
was then irradiated in a self-tuming single-mode CEM Discovery™ Focused Synthesizer. 
The reaction was maintained at 170 °C (power: 200 W) for 25 minutes. The mixture was then 
rapidly cooled to room temperature. The solvent was evaporated in vacuo using a gene vac. 
The residue was then dissolved in ethyl acetate (50 cm3), washed with water (3 x 20 cm3), 
dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. Column 
chromatography (SiC>2 , ethyl acetate:hexane 1:9 to 1 :1 ) followed by recrystallization from 
ethyl acetate and hexane afforded 196 as white crystals (0.67 g, 1.9 mmol, 39%); m.p. 163 -  
165 °C; Rf 0.26 (SiC>2 , ethyl acetate:hexane 1 :1 ); VmaxXcrn'1) 2967, 2933, 2837, 2624, 1769, 
1734, 1687, 1666, 1606, 1575, 1504, 1468, 1431, 1244, 1201, 1173, 1123, 1031,815, 772; 6  
'H NMR (400 MHz; d6 -DMSO; ppm) 2.17 (3H, s, H-2’” ), 3.70 (3H, s, OCH3), 3.76 (3H, s, 
OCH3), 6.78 (1H, d, J  1.9 Hz, H-2” ), 6.91 (1H, dd, J  1.9, 9.1 Hz, H-6 ” ), 6.93 (2H, d, J  8 . 6  
Hz, H-3’ & H-5’), 6.96 (1H, d, J  9.1 Hz, H-5” ), 7.06 (2H, d, J  8 . 6  Hz, H-2’ & H-6 ’), 7.62 
(1H, s, H-3), 12.52 (1H, br. s, C 0 2H-1); 6  ,3C NMR (100 MHz; d6 -DMSO; ppm) 20.94 (s, 
CH3), 55.79 (s, OCH3), 56.58 (s, OCH3), 113.19 (s, CH), 114.80 (s, CH), 125.43 (s, CH),
128.01 (s, C), 128.96 (s, C), 129.72 (s, CH), 131.35 (s, CH), 132.12 (s, C), 138.32 (s, CH),
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139.49 (s, C), 152.08 (s, C), 159.38 (s, C), 168.94 (s, C 0 2H), 169.31 (s, CO); m/z(API-ES +) 
342 ([MH]\ 100%); HRMS found [MH]+ 343.11800 for Ci9Hi90 6, Ci9Hi90 6 requires [MH]+ 
343.11761.
5-((E)-2-(N-Methoxy-N-methylcarbamoyl)-2-(4-methoxyphenyl)vinyl)-2-methoxyphenyl 
acetate 199
The method adopted was that of Nahm206 et al. To a stirred mixture of 5-((£)-2- 
(chlorocarbonyl)-2-(4-methoxyphenyl)vinyl)-2-methoxyphenyl acetate 198 (0.36 g, 1.0 
mmol) and A,Odimethylhydroxyamine hydrochloride (0 . 1 1  g, 1 . 2  mmol) in dry chloroform
at room temperature for 1 hour. The solvent was then evaporated in vacuo, the residue as
were then combined, then dried over anhydrous sodium sulfate, filtered and evaporated in 
vacuo. Column chromatography (Si02, ethyl acetateihexane 1:1) afforded 199 as a pale 
yellow oil (0.27 g, 0.7 mmol, 70%); R f  0.30 (Si02, ethyl acetate:hexane 1:1); Vmaxfcrn'1)
C), 169.01 (s, CO), 172.31 (s, CO); m/z{API-ES +) 386 ([M H]\ 100%);HRMS found [MH]+ 
386.16039 for C2 iH240 6N, C2 ,H240 6N requires [MH]+ 386.15981.
3 ’
199
(10 cm3) under argon at 0 °C was added pyridine (0.2 cm3, 2.6 mmol). The mixture was then
then dissolved in dichloromethane (10 cm ) and washed with water (3 x 10 cm ). The 
aqueous faction was then extracted with dichloromethane (2 * 1 0  cm3), the organic fractions
2936, 2840, 1765, 1643, 1607, 1573, 1508, 1460, 1442, 1268, 1246, 1175, 1124, 1109, 1020, 
836; 6  'H NMR (400 MHz; CDC13; ppm) 2.25 (3H, s, H-2’” ), 3.20 (3H, s, NOCH3 - l ” ” ),
3.30 (3H, s, NCH3-1” ” ), 3.78 (3H, s, OCH3), 3.82 (3H, s, OCH3), 6.75 (1H, d, J8 .5  Hz, H- 
5” ), 6.79 (1H, d, J  2.0 Hz, H-2” ), 6.81 (1H, s, H-3), 6 . 8 6  (2H, d, J  8 . 8  Hz, H-3’ & H-5’), 
6.95 (1H, dd, J  2.0, 8.5 Hz, H-6 ” ), 7.23 (2H, d, J  8 . 8  Hz, H-2’ & H-6 ’); 6  13C NMR (100 
MHz; CDC13; ppm) 20.85 (s, CH3), 33.75(s, NCH3), 55.47(s, OCH3), 56.03(s, OCH3), 
60.85(s, OCH3), 112.00 (s, CH), 114.34 (s, CH), 124.34 (s, CH), 128.45, 128.55, 128.67 (s, 
CH), 130.50 (s, CH), 130.94 (s, CH), 136.03 (s, C), 139.41 (s, C), 150.98 (s, C), 159.42 (s,
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(E)-3-(3-Hydroxy-4-methoxyphenyl)-N-methoxy-2-(4-methoxyphenyl)-N-methylacrylamide
203
.4>OMe
OMe
203
A mixture 5-bromo-l,2,3-trimethoxybenzene (0.500 g, 2.02 mmol) in anhydrous ether (4 
cm3) was slowly added to n-butyllithium in hexane (2.5 cm3, 1.6 M) in anhydrous ether (30 
cm3) under argon at -78 °C. The mixture was then stirred for an hour at -78 °C, to make a 
milky white solution of 3,4,5-trimethoxyphenyl lithium. A portion of the 3,4,5- 
trimethoxyphenyl lithium in ether (20 cm3) was then added slowly to a mixture of 5-((£)-2- 
(N-methoxy-N-methylcarbamoyl)-2-(4-methoxyphenyl)vinyl)-2-methoxyphenyl acetate 199 
(0.183 g, 0.47 mmol) in anhydrous tetrahydrofuran (10 cm ) under argon at -78 °C. The 
reaction was then stirred at -78 °C for 1 hour, before being allowed to warm to room 
temperature and being stirred overnight. Any excess lithium reagent was then quenched by 
adding methanol (0.5 cm3) to the mixture. The mixture was then washed with water (3><10 
cm ) and the aqueous layer was extracted with ethyl acetate (4 x 20 cm ). The organic 
fractions were then combined, dried over anhydrous sodium sulfate, filtered and evaporated 
in vacuo. Column chromatography (SiC>2 , ethyl acetate:hexane 1:19 to 1 :1 ) afforded 203 as a 
yellow residue (0.094 g, 0.27 mmol, 58%); m.p. 54 -  55 °C; R f  0.30 (SiC>2, ethyl 
acetate:hexane 1:1); vmax(cm’') 3352, 2961, 2935, 1631, 1606, 1578, 1508, 1459, 1440, 
1415, 1275, 1244, 1175, 1022, 836, 797, 762; 6  'H NMR (400 MHz; CDC13; ppm) 3.20 (3H, 
s, NOCH3- I ’” ), 3.30 (3H, s, NCH3- I ’” ), 3.82 (3H, s, OCH3), 3.85 (3H, s, OCH3), 5.44 (1H, 
s, OH-3” ), 6.63 (1H, dd, J  1.7, 8.5 Hz, H-6 ” ), 6 . 6 6  (1H, d, J  8.5 Hz, H-5” ), 6.71 ( 1 H, d, J
1.7 Hz, H-2” ), 6.82 (1H, s, H-3), 6.85 (2H, d, J  8 . 6  Hz, H-3’ & H-5’), 7.23 (2H, d, J  8 . 6  Hz, 
H-2’ & H-6 ’); 8  l3C NMR (100 MHz; CDCI3 ; ppm) 33.81 (s, NCH3), 55.41 (s, OCH3), 56.03 
(s, OCH3), 60.79 (s, OCH3), 110.42 (s, CH), 114.24 (s, CH), 115.94 (s, CH), 122.55 (s, CH),
128.70 (s, C), 129.00 (s, C), 130.53 (s, CH), 132.06 (s, CH), 135.41 (s, C), 145.28 (s, C),
146.74 (s, C), 159.33 (s, C), 172.55 (s, CO); m/r( API-ES +) 344 ([M H]\ 100%); HRMS 
found [MH]+ 344.15096 for C 19H22O5N, C 19H22O5N requires [MH]+ 344.14925.
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(E)-3-(3-Hydroxy-4-methoxyphenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 11773
0
OMe
1 1 7
To a stirring mixture of 3,4,5-trimethoxyacetophenone (2.51 g, 11.9 mmol) and 3-hydroxy-4- 
methoxybenzaldehyde (1.81 g, 11.9 mmol) in methanol (10 cm3) was added an aqueous 
sodium hydroxide solution (4.0 cm , 12M). The mixture was then stirred overnight at room 
temperature forming a red solution; the mixture was then acidified with aqueous hydrochloric 
acid (1 M) till the pH ~ 5 -  6 , solution turns yellow. The mixture was then extracted with 
chloroform (4 * 25 cm3), the organic fraction was then dried over anhydrous magnesium 
sulfate, filtered and evaporated in vacuo. Recrystallization from methanol afforded 117 as 
yellow crystals (2.83 g, 8.2 mmol, 69%); mp 150 -  151 °C; Rf 0.32 (SiC>2 , ethyl 
acetateihexane 1:1); VmaxXcrn'1) 3398, 3003, 2935, 2837, 1652, 1571, 1507, 1453, 1414, 
1244, 1233, 1127, 990, 813; 6  *H NMR (400 MHz; CDC13; ppm) 3.92 (6 H, s, OCH3), 3.94 
(6 H, s, OCH3), 5.81 (1H, s, OH-3” ), 6 . 8 6  (1H, d, J8 .2  Hz, H-5” ), 7.12 (1H, J2 .0 , 8.2 Hz, H- 
6 ” ), 7.26 (2H, s, H-2’& H-6 ’), 7.30 (1H, d, J  2.0 Hz, H-2” ), 7.34 (1H, d, J 15.4 Hz, H-2),
7.74 (1H, d, J 15.4 Hz, H-3); 6  13C NMR (100 MHz; CDC13; ppm) 56.06 (s, OCH3), 56.38 (s, 
OCH3), 61.02 (s, OCH3), 105.87 (s, CH), 110.57 (s, CH), 112.70 (s, CH), 119.80 (s, CH),
123.10 (s, CH), 128.52 (s, C), 133.76 (s, C), 142.24 (s, C), 144.73 (s, CH), 145.89 (s, C),
148.86 (s, C), 153.13 (s, C), 189.15 (s, CO); CHN found C 66.17%, H 5.88%, CHN requires 
C 66.27%, H 5.85%.
Anhydrous Trifluoroacetic acid
The method adopted was that of Armarego223 et al. Trifluoroacetic acid (25 cm3) stirred over 
phosphorus pentoxide (5.2 g) for 12 hours under an atmosphere of argon, followed by 
distillation (bp 7 4 - 7 5  °C/1 atm.).
Protocol C
The chalcone was dissolved in anhydrous trifluoroacetic acid and sealed in a pressure-rated 
reaction vial (10 cm3). The reaction tube was irradiated in a self-turning single-mode CEM 
Discovery™ Focused Synthesizer. The reaction was maintained at 120 °C (power: 100 W) 
for 20 minutes. The mixture was then rapidly cooled to room temperature and poured into 
water, extracted with ethyl acetate. The organic fraction was then washed with saturated
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aqueous sodium bicarbonate solution, dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. The crude indanone was purified by means of column chromatography.
2,3-Dihydro-4,5,6-trimethoxy-3-(4-methoxyphenyl)inden-l-one 205
MeO‘
6 ’ \  \ \ 3 '
OMe
205
The method adopted was that of Rice215 et al. In a sealed tube (£)-l-(3,4,5- 
trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 165 (2.25 g, 6.9 mmol) was 
dissolved in anhydrous trifluoroacetic acid (13 cm3). The sealed tube is then heated to 120 
°C for 4 hours. Once the reaction had cooled to room temperature it was tipped into cold 
water (30 cm3), and then extracted with ethyl acetate (5 * 30 cm3). The organic fraction was 
then washed with saturated aqueous sodium bicarbonate solution (30 cm ), brine (30 cm ), 
dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo. Column 
chromatography (Si0 2 , ethyl acetate:hexane 1:3) afforded 205 as a cream solid (1.63 g, 5.0 
mmol, 72%.
The indanone 205 was obtained following Protocol C. Using (£)-l-(3,4,5-trimethoxyphenyl)-
3-(4-methoxyphenyl)prop-2-en-l-one 165 (0.99 g, 6.9 mmol) in anhydrous trifluoroacetic 
acid (1 cm3). Tipped into water (10 cm3), extracted with ethyl acetate (2><10 cm3) washed 
with saturated aqueous sodium bicarbonate solution (10 cm3). Column chromatography 
(SiC>2 , ethyl acetate:hexane 1:3) afforded 205 as a cream solid (0.59 g, 1 . 8  mmol, 60%); m.p. 
6 6  - 67 °C; R f  0.35 (SiC>2 , ethyl acetate:hexane 1:3); v^X cm '1) 2967, 2938, 2836, 1706, 
1610, 1594, 1512, 1470, 1456, 1417, 1429, 1417, 1340, 1303, 1248, 1177, 1125, 1091, 1025, 
830; 6  'H NMR (400 MHz; CDC13; ppm) 2.59 (1H, dd, J2 .4 , 19.2 Hz, H-2), 3.19 (1H, dd, J  
7.6, 19.2 Hz, H-2), 3.35 (3H, s, OCH3), 3.77 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.91 (3H, s, 
OCH3), 4.54 (1H, dd, J2 .4 , 7.6 Hz, H-3), 6.81 (2H, d , J 8 . 8  Hz, H-3’ & H-5’), 7.02 (2H, d, J
8 . 8  Hz, H-2’ & H-6 ’), 7.08 (1H, s, H-7); 6  13C NMR (100 MHz; CDC13; ppm) 40.89 (s, CH),
47.33 (s, CH2), 55.26 (s, OCH3), 56.25 (s, OCH3), 60.14 (s, OCH3), 60.92 (s, OCH3), 100.31 
(s, CH), 113.97 (s, CH), 128.23 (s, CH), 132.00 (s, C), 136.27 (s, C), 145.17 (s, C), 148.98 (s, 
C), 150.35 (s, C), 154.86 (s, C), 158.27 (s, C), 206.19 (s, CO); m/z(AP+) 329 (MH+, 100%); 
HRMS found [MH]+ 329.13853 for C,9H2 i0 5, Q 9H21O5 requires [MH]+ 329.13835.
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2,3-Dihydro-3-(3-hydroxy-4-methoxyphenyl)-4,5,6-trimethoxyinden-l-one 153
Me0^6
The indanone 1 5 3  was obtained following Protocol C. Using (£)-3-(3-hydroxy-4- 
methoxyphenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 1 1 7  (0.92 g, 2.7 mmol) in 
anhydrous trifluoroacetic acid (1 cm3). Tipped into water (10 cm3), extracted with ethyl 
acetate (2><15 cm3) washed with saturated aqueous sodium bicarbonate solution (10 cm3). 
Column chromatography (SiC>2 , ethyl acetate:hexane 1:3) afforded 1 5 3  as brown solid (0.51 
g, 1.5 mmol, 56%); m.p. 116-117 °C; R f  0.36 (SiC>2 , ethyl acetate:hexane 1:1); Vmax^cm'1) 
3253, 2959, 2835, 1693, 1586, 1509, 1463, 1417, 1270, 1215, 1130, 1096, 1024, 806; 6  'H 
NMR (400 MHz; CDC13; ppm) 2.57 (1H, dd, J2 .5 , 19.3 Hz, H-2), 3.15 (1H, dd, J7 .9 , 19.3 
Hz, H-2), 3.42 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.91 (3H, s, OCH3), 
4.50 (1H, dd, J2 .5 , 7.9 Hz, H-3), 5.56 (1H, s, OH-3’), 6.61 (1H, dd, J2 .0 , 8.3 Hz, H-6 ’), 6.63 
(1H, d, J  2.0 Hz, H-2’), 6.75 (1H, d, J  8.3 Hz, H-5’), 7.07 (1H, s, H-7) ; 6  ,3C NMR (100 
MHz; CDC13; ppm) 41.04 (s, CH), 47.32 (s, CH2), 55.95 (s, OCH3), 56.27 (s, OCH3), 60.18 
(s, OCH3), 60.94 (s, OCH3), 100.26 (s, CH), 110.55 (s, CH), 113.32 (s, CH), 118.72 (s, CH),
132.19 (s, C), 137.69 (s, C), 144.66 (s, C), 145.23 (s, C), 145.66 (s, C), 148.79 (s, C), 150.40 
(s, C), 154.85 (s, C), 205.54 (s, C=0); m/z (AP+) 345 (MH+, 100%); HRMS found [MH]+ 
345.13353 for C 19H21O6 , C 19H21O6 requires [MH]+ 345.13326.
(E)-3-(4-Chlorophenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 2 0 6
0
2 0 6
The chalcone 2 0 6  was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(2.10 g, 10.0 mmol), 4-chlorobenzaldehyde (1.41 g, 10.0 mmol) and aqueous sodium 
hydroxide solution (1.7 cm3, 12M) in methanol (5 cm3). Recrystallization from methanol 
afforded 5 1  as light yellow crystals (1.87 g, 5.6 mmol, 55%); m.p. 115-116 °C; R f  0.50 (SiC>2 , 
ethyl acetate:hexane 1:3); Vmaxfcrn'1) 2936, 2837, 1655, 1579, 1505, 1490, 1455, 1410, 1323,
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1157, 1090, 1001, 809; 5 !H NMR (400 MHz; CDC13; ppm) 3.87 (3H, s, OCH3), 3.89 (6H, s, 
OCH3), 7.20 (2H, s, H-2’ & H-6’), 7.33 (2H, d, J  8.5 Hz, H-3” & H-5” ), 7.39 (1H, d, J  15.6 
Hz, H-2), 7.52 (2H, d, J  8.5 Hz, H-2” & H-6” ), 7.70 (1H, d, J  15.6 Hz, H-3); 6 ,3C NMR 
(100 MHz; CDC13; ppm) 56.43 (s, OCH3), 61.05 (s, OCH3), 106.04 (s, CH), 122.08 (s, CH),
129.28 (s, CH), 129.64 (s, CH), 133.32 (s, C), 133.36 (s, C), 136.47 (s, C), 142.57 (s, C),
143.30 (s, CH), 153.19 (s, C), 188.94 (s, CO); m/z (AP+) 333 (MH+, 100%), 335 (MH+, 
25%); HRMS found [MH]+ 333.0887 for C18H180 4C1, C18H,80 4C1 requires [MH]+ 333.0888; 
CHN found C 64.88%, H 5.11% CHN requires C 64.97%, H 5.15%.
(E)-3-(3-Bromo-4-methoxyphenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 207
OMeMeO'
OMe
207
The chalcone 207 was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(1.07 g, 5.1 mmol), 3-bromo-4-methoxybenzaldehyde (1.09 g, 5.1 mmol) and aqueous 
sodium hydroxide solution (1.7 cm3, 12M) in methanol (20 cm3). Recrystallization from 
methanol afforded 207 as light yellow crystals (1.55 g, 3.8 mmol, 75%); mp 108-110 °C; Rf 
0.28 (Si02, ethyl acetate:hexane 1:3); VmaxXcnT1) 2939, 1654, 1575, 1494, 1453, 1412, 1341, 
1306, 1263, 1157, 1126, 807; 6 *H NMR (400 MHz; CDC13; ppm) 3.88 (3H, s, OCH3), 3.89 
(3H, s, OCH3), 3.90 (6H, s, OCH3), 6.87 (1H, d, J  8.5 Hz, H-5” ), 7.20 (2H, s, H-2’ & H-6’), 
7.29 (1H, d, J  15.6 Hz, H-2), 7.48 (1H, dd, J 2 2 ,  8.5 Hz, H-6” ), 7.66 (1H, d, J  15.6 Hz, H-3),
7.84 (1H, d, J2 .2  Hz, H-2” ); 6 13C NMR (100 MHz; CDC13; ppm) 56.24 (s, OCH3), 56.45 (s, 
OCH3), 61.04 (s, OCH3), 105.96 (s, CH), 111.85 (s, CH), 112.41 (s, C), 120.43 (s, CH),
128.94 (s, C), 130.00 (s, CH), 132.57 (s, CH), 133.54 (s, C), 142.43 (s, C), 143.06 (s, CH),
153.16 (s, C), 157.63 (s, C), 188.91 (s, C=0); m/z (C1+) 407 (MH+, 70%), 409 (MH+, 100%); 
HRMS found [MH]+ 407.0487 for C,9H2oBr05, C ^ o B rO s  requires [MH]+ 407.0489; CHN 
found 55.10%, H 4.80% CHN requires C 56.03%, H 4.70%.
(E)~3-(3,4-Dichlorophenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 208
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The chalcone 2 0 8  was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(1.03 g, 4.9 mmol), 3,4-dichlorobenzaldehyde (0.89 g, 5.1 mmol) and aqueous sodium 
hydroxide solution (1 cm3, 10M) in methanol (2.5 cm3). Recrystallization from methanol 
afforded 2 0 8  as light yellow crystals (1.17 g, 3.2 mmol, 65%); mp 137 -  139 °C; Rf 0.78 
(Si02, ethyl acetate:hexane 1:1); vmax(cm'‘) 2943, 2833, 1664, 1607, 1577, 1505, 1467, 
1413, 1337, 1125, 996, 812; 6 *H NMR (400 MHz; CDC13; ppm) 3.88 (3H, s, OCH3), 3.90 
(3H, s, OCH3), 7.20 (2H, s, H-2’ & H-6’), 7.36-7.42 (2H, m, H-2 & H-6” ), 7.44 (1H, d, J8 .5  
Hz, H-5” ), 7.64 (1H, d, J  15.6 Hz, H-3), 7.67 (1H, d, J  2.0 Hz, H-2” ); 6 ,3C NMR (100 
MHz; CDC13; ppm) 56.46 (s, OCH3), 61.05 (s, OCH3), 106.08 (s, CH), 123.10 (s, CH),
127.63 (s, CH), 129.73 (s, CH), 130.98 (s, CH), 133.05 (s, C), 133.31 (s, C), 134.41 (s, C), 
134.93 (s, C), 141.88 (s, CH), 142.76 (s, C), 153.22 (s, C=0), 188.52 (s, C=0); m/z (AP+) 
366 (MH+, 100%), (368 MH+, 60%); HRMS found [MH]+ 367.0499 for Ci8H,7 0 4 C12, 
C 18H17O4 CI2 requires [MH]+ 367.0498; CHN found C 57.67%, H 4.29% CHN requires C 
58.87%, H 4.39%.
(E)-3-(Benzo[d][l,3]dioxol-5-yl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 2 0 9 340
O
OMe
2 0 9
The chalcone 2 0 9  was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(0.64 g, 3.0 mmol), piperonal (0.45 g, 3.0 mmol) and aqueous sodium hydroxide solution (1 
cm3, 6M) in methanol (3.0 cm3). Recrystallization from methanol afforded 2 0 9  as light 
yellow needle (0.75 g, 2.2 mmol, 73%); m.p. 133-135 °C; R f  0.48 (Si02, ethyl acetate:hexane 
1:1); vmax (cm"1) 2944, 1655, 1576, 1492, 1464, 1444, 1410, 1328, 1240, 1157, 1121, 992, 
724; 6 ‘H NMR (400 MHz; CDC13; ppm) 3.95 (3H, s, OCH3), 3.97 (6H, s, OCH3), 6.06 (2H, 
s, H-2” ), 6.87 (1H, d, J  8.0 Hz, H-4” ), 7.15 (1H, dd, J  8.0, 1.6 Hz, H-5” ), 7.20 (1H, d, J  1.6 
Hz, H-7” ), 7.28 (2H, s, H-2” & H-6” ), 7.34 (1H, d, J  15.5 Hz, H-2), 7.76 (1H, d, J  15.5 Hz, 
H-3); 6 ,3C NMR (100 MHz; CDC13; ppm) 56.39 (s, OCH3), 61.02 (s, OCH3), 101.70 (s, 
CH2), 105.89 (s, CH), 106.62 (s, CH), 108.73 (s, CH), 119.67 (s, CH), 125.35 (s, CH), 129.33 
(s, C), 133.72 (s, C), 142.27 (s, C), 144.66 (s, CH), 148.41 (s, C), 149.95 (s, C), 153.13 (s, C),
189.11 (s, CO); m/z (AP+) 343 (MH+, 100%); HRMS found [MH]+ 343.1175 for C,9Hi806, 
Ci9H,806 requires [MH]+ 343.1176; CHN found C 66.55%, H 5.28% CHN requires C 
66.66%, H 5.30%.
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(E)-3-(4-Bromophenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 21072
MeO.
MeO'
OMe
210
The chalcone 210 was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(0.41 g, 1.9 mmol), 4-bromobenzaldehyde (0.37 g, 2.0 mmol) and aqueous sodium hydroxide 
solution (2.0 cm3, 2M) in methanol (3 cm3). Recrystallization from methanol afforded 210 as 
fluffy white crystals (0.62 g, 1.6 mmol, 84%); m.p. 124 -  125 °C; R f  0.64 (SiC>2 , ethyl 
acetate:hexane 1:1); v^Xcm*1) 2933, 2836, 1668, 1610, 1580, 1506, 1485, 1461, 1451, 
1435, 1415, 1336, 1160, 1063, 996, 802, 730; 8  'H NMR (400 MHz; CDC13; ppm) 3.94 (3H, 
s, OCH3), 3.95 (6 H, s, OCH3), 7.27 (2H, s, H-2’ & H-6 ’), 7.47 (1H, d, J  15.6 Hz, H-2), 7.51 
(2H, d, J  8 . 6  Hz, H-3”  & H-5” ), 7.56 (2H, d, J  8 . 6  Hz, H-2” & H-6 ” ), 7.75 (1H, d, J  15.6 
Hz, H-3); 513C (100MHz; CDC13; ppm) 56.65 (s, OCH3), 61.23 (s, OCH3), 106.35 (s, CH),
122.44 (s, CH), 125.03 (s, C), 130.02 (s, CH), 132.45 (s, CH), 133.51 (s, C), 134.03 (s, C),
142.89 (s, C), 143.51 (s, C), 153.42 (s, CH), 189.10 (s, CO); m/z(API ES+) 377 (MH+, 
100%), 379 (M H \ 90%).
(E)-3-(4-Carboxymethoxyphenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 211
MeO'
OMe
211
To a stirring mixture of 3,4,5-trimethoxyacetophenone (0.50 g, 2.4 mmol) and 4- 
formylphenoxyacetic acid (0.43 g, 2.4 mmol) in methanol (2.5 cm3) was added an aqueous 
sodium hydroxide solution (1.2 cm3, 4 M). The mixture was then stirred overnight at room 
temperature; the mixture was then acidified with aqueous hydrochloric acid (1 M) till the pH 
~ 5 -  6 , causing the product to precipitate.. Recrystallization from methanol afforded 211 as a 
pale yellow solid (0.46 g, 1 . 2  mmol, 52%); m.p. 148 — 151 °C; R f  0.46 (SiC>2, ethyl 
acetate:methanol 9:1); VmaxXcm'1) 3489, 3001, 2943, 2833, 1718, 1652, 1596, 1575, 1455, 
1423, 1412, 1336, 1253, 1159, 992, 826; 8  *H NMR (400 MHz; CDC13; ppm) 3.94 (3H, s, 
OCH3), 3.94 (6 H, s, OCH3), 4.74 (2H, s, H-2” ’), 6.96 (2H, d, J 8 . 8  Hz, H-3” & H-5” ), 7.26 
(2H, s, H-2’ & H-6 ’), 7.38 (1H, d, J  15.8 Hz, H-2), 7.61 (2H, d, J  8 . 8  Hz, H-2” & H-6 ” ),
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7.79 (1H, d, J  15.8 Hz, H-3); 8 I3C (100MHz; CDC13; ppm) 56.64 (s, OCH3), 61.23 (s, OCH3), 
64.90 (s, CH2), 106.36 (s, CH), 115.28 (s, CH), 120.39 (s, CH), 129.11 (s, C), 130.55 (s, CH),
133.77 (s, C), 142.73 (s, C), 144.59 (s, CH), 153.36 (s, C), 159.60 (s, C), 172.49 (s, C 0 2H),
189.79 (s, CO); m/z(API ES+) 373 (MH+, 100%); HRMS found [MH]+ 373.12852 for 
C20H2 iO7, C20H2 |O 7 requires [MH]+ 373.12818.
(E)-3-(2,3,4-Trimethoxyphenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 212
O OMe
>
OMe 5
212
The chalcone 212 was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(0.51 g, 2.4 mmol), 2,3,4-trimethoxybenzaldehyde (0.47 g, 2.4 mmol) and aqueous sodium 
hydroxide solution (1.2 cm , 4M) in methanol (2.5 cm ). Recrystallization from methanol 
afforded 212 as yellow crystals (0.72 g, 1.9 mmol, 78%); m.p. 118 -  120 °C; R f  0.36 (SiC>2 , 
ethyl acetate:hexane 1:1); VmaxXcm'1) 2935, 2833, 1651, 1568, 1494, 1465, 1416, 1343, 1296, 
1162, 1123, 993, 804; 6  'H NMR (400 MHz; CDC13; ppm) 3.88 (3H, s, OCH3), 3.90 (3H, s, 
OCH3), 3.92 (3H, s, OCH3), 3.93 (6 H, s, OCH3), 3.94 (3H, s, OCH3), 6.72 (1H, d, J  8 . 6  Hz, 
H-5” ), 7.26 (2H, s, H-2’ & H-6 ’), 7.37 (1H, d, J 8 . 6  Hz, H-6 ” ), 7.50 (1H, d, J  15.8 Hz, H-2),
7.97 (1H, d, J  15.8 Hz, H-3); 8 13C (100MHz; CDC13; ppm) 56.32 (s, OCH3), 56.56 (s, OCH3),
61.16 (s, OCH3), 61.19 (s, OCH3), 61.60 (s, OCH3), 106.24 (s, CH), 107.83 (s, CH), 121.44 
(s, CH), 122.22 (s, C), 124.22 (s, CH), 134.11 (s, C), 140.34 (s, CH), 142.40 (s, C), 142.70 (s, 
C), 153.31 (s, C), 153.99 (s, C), 156.04 (s, C), 189.97 (s, CO); m/z(API ES+) 389 (MH+, 
100%); HRMS found [MH]+ 389.16097 for C21H25O7, C21H25O7 requires [MH]+ 389.15948.
(E)~3-(2,6-Dichlorophenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 213
O Cl
MeO 5.
The chalcone 213 was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(0.50 g, 2.4 mmol), 2,6-dichlorobenzaldehyde (0.42 g, 2.4 mmol) and aqueous sodium
7  7
hydroxide solution (1.2 cm , 4M) in methanol (2.5 cm ). Recrystallization from methanol 
afforded 213 as fluffy white crystals (0.72 g, 1.9 mmol, 82%); m.p. 100 -  101 °C; R f  0.64
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(SiC>2, ethyl acetate:hexane 1:1); Vm^cm'1) 2936, 2839, 1671, 1621, 1582, 1507, 1459, 
1429, 1411, 1340, 1160, 991, 963, 771; 5 ‘H NMR (400 MHz; CDC13; ppm) 3.95 (9H, 
OCHj), 7.22 (1H, t, J  8.0 Hz, H-4” ), 7.29 (2H, s, H-2’ & H-6’), 7.39 (2H, d, J  8.0 Hz, H-3” 
& H-5” ), 7.59 (1H, d, J  16.2 Hz, H-2), 7.81 (1H, d, 7 16.2 Hz, H-3); 8I3C (100MHz; CDC13; 
ppm) 56.55 (s, OCH3), 61.23 (s, OCH3), 106.50 (s, CH), 129.09 (s, CH), 130.08 (s, CH),
130.86 (s, CH), 133.00 (s, C), 133.07 (s, C), 135.33 (s, C), 137.79 (s, CH), 142.94 (s, C), 
153.41 (s, C), 189.33 (s, CO); m/z{API ES+) 367 (MH+, 100%), 369 (M H\ 60%); HRMS 
found [MH]+ 367.05060 forCisHnC^Ch, C 18H17O4 CI2 requires [MH]+ 367.04984.
(E)-3-(2,4-Dichlorophenyl)-I-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 214
0 Cl
f | | 3"
6 ' Cl
OMe
5
214
The chalcone 2 1 4  was obtained following Protocol A .  Using 3,4,5-trimethoxyacetophenone 
(0.63 g, 3.0 mmol), 2,4-dichlorobenzaldehyde (0.52 g, 3.0 mmol) and aqueous sodium 
hydroxide solution (1.0 cm , 6M) in methanol (3 cm ). Recrystallization from methanol 
afforded 2 1 4  as yellow crystals (0.91 g, 2.5 mmol, 83%); m.p. 151-153 °C; R f  0.63 (Si02, 
ethyl acetate:hexane 1:1); v ^ c m * 1) 3090, 2939, 1657, 1597, 1572, 1504, 1451, 1413, 1341, 
1314, 1159, 986, 815; 5*H NMR (400 MHz; CDC13; ppm) 3.96 (9H, s, OCH3), 7.27 (2H, s, 
H-2’ & H-6’), 7.32 (1H, dd, J8.4, 2.1 Hz, H-5” ), 7.40 (1H, d, J  15.8 Hz, H-2), 7.44 (1H, d, 
J  2.1 Hz, H-3” ), 7.70 (1H, d, J  8.4 Hz, H-6” ), 8.09 (1H, d, J  15.8 Hz, H-3’); 5 ,3C NMR 
(100 MHz; CDC13; ppm) 56.40 (s, OCH3), 61.05 (s, OCH3), 106.19 (s, CH), 125.05 (s, CH),
127.61 (s, CH), 128.55 (s, CH), 130.14 (s, CH), 131.88 (s, C), 132.95 (s, C), 135.99 (s, C),
136.49 (s, C), 139.32 (s, CH), 142.64 (s, C), 153.1 (s, C), 189.18 (s, CO); m/z (API-ES+) 
367 (MH+, 100%), 369 (MH+, 65%); HRMS found [MH]+ 367.4966 for C 18H17C12 0 4 , 
C 18H,7C120 4  requires [MH]+ 367.04984; CHN found C 58.74%, H 4.33% CHN requires C 
58.87%, H 4.39%.
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(E)-3-(4-(Benzyloxy)phenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 216
MeO 5.
OMe
216
The chalcone 216 was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(0.63 g, 3.0 mmol), 4-(benzyloxy)benzaldehyde x64 (0.64 g, 3.0 mmol) and aqueous sodium 
hydroxide solution (1.0 cm3, 6M) in methanol (3 cm3). Recrystallization from methanol 
afforded 216 as yellow needles (0.50 g, 1.2 mmol, 42%); m.p. 90-93 °C; Rf0.52 (SiC>2 , ethyl 
acetaterhexane 1:1); VmaxXcrn'1) 2937, 2835, 1649, 1571, 1504, 1463, 1424, 1410, 1326, 1250, 
1157, 1009, 980, 812; 8!H NMR (400 MHz; CDC13; ppm) 3.94 (3H, s, OCH3), 3.95 (6H, s, 
OCH3), 5.13 (2H, s, H-2’” ), 7.02 (2H, d, J8 .8  Hz, H-3” & H-5” ), 7.27 (2H, s, H-2’ & H- 
6’)7.33 -  7.46 (6H, m, H-2 & H-2” ” -  H-6” ” ), 7.61 (2H, d, J  8.8 Hz, H-2” & H-6” ), 7.80 
(1H, d, J  15.6 Hz, H-3); 8 13C NMR (100 MHz; CDC13; ppm) 56.39 (s, OCH3), 61.03 (s, 
OCH3), 70.12 (s, CH2), 105.91 (s, CH), 115.31 (s, CH), 119.48 (s CH), 127.52 (s, CH),
127.82 (s, C), 128.24 (s, CH), 128.73 (s, CH), 130.30 (s, CH), 133.83 (s, C), 136.36 (s, C)
142.21 (s, C), 144.62 (s, CH), 153.12 (s, C), 160.85 (s, C), 189.30 (s, CO); m/z (AP+) 405 
(MH+, 100%), 406 (MH+, 30%); HRMS found [MH]+ 405.1695 for C25H24O5, C2 5H24O5 
requires [MH]+ 405.1697; CHN found C 74.10%, H 5.99% CHN requires C 74.24%, H 
5.98%.
(E)-1,3-Bis(3,4,5-trimethoxyphenyl)prop-2-en- 1-one 218341
0
MeCU 2'
5"I OMe 
OMe
218
The chalcone 218 was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(2.10 g, 10.0 mmol), 3,4,5-trimethoxybenzaldehyde (1.96 g, 10.0 mmol) and aqueous sodium 
hydroxide solution (2.0 cm3, 10M) in methanol (10 cm3). Recrystallization from methanol 
afforded 218 as pale yellow crystals (3.61 g, 8.3 mmol, 83%); m.p. 125-128 °C; R f  0.08 
(SiC>2 , ethyl acetaterhexane 1:3); VmaxXcrn*1) 2936, 2833, 1677, 1662, 1579, 1503, 1465, 
1451, 1412, 1326, 1243, 1227, 994, 972, 813; 8 !H NMR (400 MHz; CDC13; ppm) 3.90 (3H, 
s, OCH3), 3.92 (6H, s, OCH3), 3.94 (3H, s, OCH3), 3.95 (6H, s, OCH3), 6.86 (2H, s, H-2” &
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H-6” ), 7.25 (2H, s, H-2’ & H-6’), 7.33 (1H, d, J  15.6 Hz, H-2), 7.72 (1H, d, J  15.6 Hz, H-3); 
6  13C NMR (100 MHz; CDC13; ppm) 56.29 (s, OCH3), 56.51 (s, OCH3), 61.04 (s, OCH3),
61.06 (s, OCH3), 105.71 (s, CH), 106.21 (s, CH), 121.33 (s, CH), 130.39 (s, C), 133.64 (s, C), 
140.47 (s, C), 142.49 (s, C), 145.03 (s, CH), 153.16 (s, C), 153.51 (s, C), 189.50 (s, CO); 
m/z{AP+) 389 (MH+, 100%); HRMS found [MH]+ 389.1596 for C21H25O7, C21H25O7 
requires [MH]+ 389.1595; CHN found C 64.55%, H 6.22% CHN requires C 64.94%, H 
6.23%.
(E)-3-(2,4-Dimethoxyphenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 219
5OMe
219
The chalcone 219 was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(0.51 g, 2.4 mmol), 2,4-dimethoxybenzaldehyde (0.40 g, 2.4 mmol) and aqueous sodium 
hydroxide solution (1.2 cm3, 4M) in methanol (2.5 cm3). Recrystallization from methanol 
afforded 219 as yellow crystals (0.63 g, 1.8 mmol, 73%); m.p. 129 -  130 °C; Rf 0.43 (Si02, 
ethyl acetaterhexane 1:1); VmaxXcrn'1) 2941, 2837, 1647, 1604, 1568, 1502, 1468, 1455, 
1439, 1409, 1323, 1299, 1274, 1157, 1104, 1027, 1003,828; 6 *H NMR (400 MHz; CDC13; 
ppm) 3.85 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.94 (6H, s, OCH3), 6.47 
(1H, d, J  2.4 Hz, H-3” ), 6.54 (1H, dd, J2 .4 , 8.7 Hz, H-5” ), 7.26 (2H, s, H-2’ & H-6’), 7.47 
(1H, d, J  15.6 Hz, H-2), 7.57 (1H, d, J  8.7 Hz, H-6” ), 8.04 (1H, d, J  15.6 Hz, H-6” ); SI3C 
(100MHz; CDC13; ppm) 55.74 (s, OCH3), 55.77 (s, OCH3), 56.54 (s, OCH3), 61.18 (s, 
OCH3), 98.67 (s, CH), 105.67 (s, CH), 106.24 (s, CH), 117.35 (s, C), 120.52 (s, CH), 131.05 
(s, CH), 134.40 (s, C), 140.68 (s, CH), 142.21 (s, C), 153.25 (s, C), 160.57 (s, C), 163.28 (s, 
C), 190.32 (s, CO); m/z(API ES+) 359 (MH+, 100%); HRMS found [MH]+ 359.1493 for 
C2oH230 6, C20H23O6 requires [MH]+ 359.1489.
(E)-l-(3,4,5-Trimethoxyphenyl)-3-(3,5-dimethoxyphenyl)prop-2-en-l-one 220
O
OMe
OMe OMe
220
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The chalcone 2 2 0  was obtained following Protocol A. Using 3,4,5-trimethoxyacetophenone 
(0.51 g, 2.4 mmol), 3,5-dimethoxybenzaldehyde (0.42 g, 2.4 mmol) and aqueous sodium 
hydroxide solution (1.2 cm3, 4M) in methanol (2.5 cm3). Recrystallization from methanol 
afforded 2 2 0  as yellow crystals (0.72 g, 2.0 mmol, 83%); m.p. 107 -  109 °C; R f  0.50 (SiC>2 , 
ethyl acetate:hexane 1:1); VmaxXcrn'1) 2947, 2839, 1648, 1589, 1570, 1507, 1461, 1416, 1334, 
1160, 827; 6  ‘H NMR (400 MHz; CDC13; ppm) 3.83 (6 H, s, OCH3), 3.93 (3H, s, OCH3),
3.94 (6 H, s, OCH3), 6.52 (1H, t, J  2.3 Hz, H-4), 6.77 (2H, d, J  23  Hz, H-2” & H-6 ” ), 7.25 
(2H, s, H-2’ & H-6 ’), 7.41 (1H, d, J  15.6 Hz, H-2), 7.71 (1H, d, J  15.6 Hz, H-3); 8 13C 
(100MHz; CDC13; ppm) 55.72 (s, OCH3), 56.65 (s, OCH3), 61.22 (s, OCH3), 102.68 (s, CH),
106.39 (s, CH), 106.69 (s, CH), 122.59 (s, CH), 133.65 (s, C), 137.02 (s, C), 142.77 (s, C),
144.98 (s, CH), 153.38 (s, C), 161.29 (s, C), 189.54 (s, CO); m/z{API ES+) 359 (MH+, 
100%); HRMS found [MH]+ 359.15056 for C2oH2306, C2oH2306 requires [MH]+ 359.14891.
4-(Benzyloxy)benzaldehyde 2 2 1 342
221
To a stirring mixture of 4-hydroxybenzaldehyde (1.00 g, 8.2 mmol) and potassium carbonate 
(4.53 g, 32.7 mmol) in dimethyl formamide (40 cm3) was added benzyl bromide (1.2 cm3,
10.1 mmol). The mixture was then put under argon and heated to 90 °C for 2 hours. The 
dimethyl formamide was then evaporated in vacuo. The crude product was then dissolved in 
chloroform (120 cm3) and filtered through celite, and washed with water (3 x 40 cm3). The 
organic fraction was then dried over anhydrous magnesium sulfate, filtered and evaporated in 
vacuo. Purification by column chromatography (Si02, ethyl acetate:hexane 1:1) afforded 2 2 1  
as a pale yellow solid (1.67 g, 7.9 mmol, 96%); m.p. 73 -  74 °C; R f  0.76 (Si02, ethyl 
acetate:hexane 1:1); vmax (cm'1) 2829, 2745, 1685, 1598, 1574, 1509, 1462, 1452, 1425, 1259, 
1163, 1018, 829; 6  'H NMR (400 MHz; CDC13; ppm) 5.15 (2H, s, H -l” ), 7.08 (2H, d , J 8 . 8  
Hz, H-3’ & H-5’), 7.33 -  7.47 (5H, m, H-2’” -  H-6 ’” ), 7.84 (2H, d , , / 8 . 8  Hz, H-2’ & H-6 ’),
9.89 (1H, s, H-l); 8 I3C (100MHz; CDC13; ppm) 70.28 (s, OCH20), 115.16 (s, CH), 127.54 (s, 
CH), 128.39 (s, CH), 128.78 (s, CH), 130.09 (s, C), 132.07 (s, CH), 135.94 (s, C), 163.76 (s, 
C), 190.92 (s, CHO).
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3-(4-Chlorophenyl)-2,3-dihydro-4,5,6-trimethoxyinden-l -one 222
The indanone 222 was obtained following Protocol C. Using (£)-3-(4-chlorophenyl)-l-(3,4,5- 
trimethoxyphenyl)prop-2-en-l-one 206 (0.24 g, 0.72 mmol) in anhydrous trifluoroacetic acid 
(0.3 cm3). Tipped into water (5 cm3), extracted with ethyl acetate (2><5 cm3) washed with 
saturated aqueous sodium bicarbonate solution (5 cm3). Column chromatography (SiC>2 , 
ethyl acetaterhexane 1:3) afforded 222 as yellow solid (0.13 g, 0.39 mmol, 53%); m.p. 74-75 
°C; R f  0.50 (SiC>2 , ethyl acetaterhexane 1:3); v^X cm '1) 2960, 2840, 1703, 1598, 1491, 1469, 
1431, 1417, 1341, 1306, 1127, 1090, 1014, 793; 5 *H NMR (400 MHz; CDC13; ppm) 2.49 
(1H, dd, J  2.8, 19.3 Hz, H-2), 3.12 (1H, dd, J  8.0, 19.3 Hz, H-2) 3.33 (3H, s, OCH3), 3.83 
(3H, s, OCH3), 3.85 (3H, s, OCH3), 4.48 (1H, dd, J  2.8, 8.0 Hz, H-3), 6.98 (2H, d, J  8.5 Hz, 
H-3’ & H-5’), 7.01 (1H, s, H-7), 7.19 (2H, d, J8 .5  Hz, H-2’ & H-6 ’); 6  13C NMR (100 MHz; 
CDC13; ppm) 40.97 (s, CH), 47.01 (s, CH2), 56.28 (s, OCH3), 60.11 (s, OCH3), 60.93 (s, 
OCH3), 100.29 (s, CH), 128.63 (s, CH), 128.76 (s, CH), 132.17 (s, C), 132.33 (s, C), 142.93 
(s, C), 144.02 (s, C), 148.73 (s, C), 150.27 (s, C), 155.10 (s, C), 204.93 (s, C=0); m/z (AP+) 
333 (M H\ 100%), 335 (MH+, 30%); HRMS found [MH]+ 333.0890 for Ci8Hi80 4C1, 
C,8H,80 4C1 requires [MH]+ 333.088.
3-(3-Bromo-4-methoxyphenyl)-2,3-dihydro-4,5,6-trimethoxyinden-l-one 223
The indanone 223 was obtained following Protocol C. Using (£)-3-(3-bromo-4- 
methoxyphenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 207 (0.26 g, 0.64 mmol) in 
anhydrous trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted with ethyl 
acetate (2><5 cm3) washed with saturated aqueous sodium bicarbonate solution (5 cm3). 
Column chromatography (SiC>2 , ethyl acetaterhexane 1:3) afforded 223 as brown solid (0.15 
g, 0.37 mmol, 59%); m.p. 128-129 °C; R f  0.39 (SiC>2 , ethyl acetaterhexane 1:3); VmaxXcrn'1) 
2956, 2834, 1699, 1601, 1497, 1462, 1442, 1419, 1342, 1281, 1092, 1021, 814; 6  'H N M R
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(400 MHz; CDC13; ppm) 2.51 (1H, dd, .72.6, 19.3 Hz, H-2), 3.10 (1H, dd, J8 .0 , 19.3 Hz, H- 
2) 3.36 (3H, s, OCH3), 3.80 (3H, s, OCH3), 3.84 (3H, s, OCH3), 3.85 (3H, s, OCH3), 4.44 
(1H, dd, J2 .6 , 8.0 Hz, H-3), 6.74 (1H, d, J  8.5 Hz, H-5’), 6.94 (1H, dd, J  2.3, 8.5 Hz, H-6 ’),
7.01 (1H, s, H-7), 7.22 (1H, d, J 2.3 Hz, H-2’);S l3C NMR (100 MHz; CDC13; ppm) 40.46 (s, 
CH), 47.06 (s, CH2), 56.26 (s, OCH3), 56.28 (s, OCH3), 60.20 (s, OCH3), 60.94 (s, OCH3),
100.31 (s, CH), 111.61 (s, CBr), 111.88 (s, CH), 127.17 (s, CH), 132.06 (s, CH), 132.12 (s, 
C), 137.93 (s, C), 144.76 (s, C), 148.76 (s, C), 150.29 (s, C), 154.53(s, C), 155.06 (s, C),
205.01 (s, C=0); m/z (AP+) 407 (MH+, 100%), 409 (MH+, 70%); HRMS found [MH]+ 
407.0495 for Ci9 H2o05Br, Ci9H2o05Br requires [MH]* 407.0489.
3-(3,4-Dichlorophenyl)-2,3-dihydro-4,5,6-trimethoxyinden-1 -one 224
The indanone 224 was obtained following Protocol C. Using (£)-3-(3,4-dichlorophenyl)-l- 
(3,4,5-trimethoxyphenyl)prop-2-en-l-one 208 (0.25 g, 0.68 mmol) in anhydrous 
trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted with ethyl acetate (2><5 
cm ) washed with saturated aqueous sodium bicarbonate solution (5 cm ). Column 
chromatography (SiC>2 , ethyl acetate:hexane 1:3) afforded 224 as light brown solid (0.17 g, 
0.46 mmol, 69%); m.p. 129 - 132°C; R f  0.32 (SiC>2 , ethyl acetaterhexane 1:3); v^X cm '1) 
2941, 2898, 2834, 1710, 1601, 1557, 1471, 1431, 1417, 1346, 1316, 1121, 1095, 832; 8  *H 
NMR (400 MHz; CDCl3; ppm) 2.73 (1H, dd, J  2.8, 19.3 Hz, H-2), 3.11 (1H, dd, J  8.0, 19.3 
Hz, H-2), 3.41 (3H, s, OCH3), 3.84 (3H, s, OCH3), 3.86 (3H, s, OCH3), 4.46 (1H, dd, J  2.8,
8.0 Hz, H-3), 6.87 (H, dd, J2 .3 , 8.3 Hz, H-6 ’), 7.02 (H, s, H-7), 7.14 (H, d, J2 .3  Hz, H-2’), 
7.29 (H, d, J  8.3 Hz, H-5’); 8  ,3C NMR (100 MHz; CDC13; ppm) 40.72 (s, CH), 46.72 (s, 
CH2), 56.31 (s, OCH3), 60.20 (s, OCH3), 60.97 (s, OCH3), 100.36 (s, CH), 126.62 (s, CH),
129.27 (s, CH), 130.58 (s, CH), 132.17 (s, C), 132.57 (s, C), 143.11 (s, C), 144.68 (s, C),
148.65 (s, C), 150.18 (s, C), 155.31 (s, C), 204.34 (s, C=0); m/z (AP+) 367 (MH+, 100%), 
369 (M H\ 60%); HRMS found [MH]+ 367.0501 for C ig H ^ C b , QgHnC^Cb requires 
[MH]+ 367.0498.
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3-(Benzo[d][1,3]dioxol-5-yl)-2,3-dihydro-4,5,6-trimethoxyinden-l-one 225
MeO'
7'^<
225
r
The indanone 225 was obtained following Protocol C. Using (£)-3-(benzo[i/][l,3]dioxol-5- 
yl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 209 (0.26 g, 0.76 mmol) in anhydrous 
trifluoroacetic acid (0.3 cm ). Tipped into water (5 cm ), extracted with ethyl acetate ( 2 x 5  
cm ) washed with saturated aqueous sodium bicarbonate solution (5 cm ). Column 
chromatography (SiC>2 , ethyl acetaterhexane 1:3) afforded 225 as light brown solid (0.14 g, 
.41 mmol, 54%); m.p. 105-107 °C; R f  0.62 (SiC>2 , ethyl acetaterhexane 1 r 1); VmaxXcrn'1) 
2973, 2938, 2837, 1706, 1593, 1506, 1487, 1478, 1468, 1456, 1444, 1431, 1417, 1340, 1308, 
1246, 1127, 1036, 1021, 923, 875, 858; 5 ’H NMR (400 MHz; CDC13; ppm) 2.48 (1H, dd, J  
2.5, 19.1 Hz, H-2), 3.09 (1H, dd, J  8.0, 19.1 Hz, H-2), 3.39 (3H, s, OCH3), 3.84 (3H, s, 
OCH3), 3.85 (3H, s, OCH3), 4.45 (1H, dd, J 2.5, 8.0 Hz, H-3), 5.85 (2H, dd, J  1.5, 4.1 Hz, H- 
2’), 6.45 (1H, d, J  1.8 Hz, H-4’), 6.54 (1H, dd, J  1.8, 8.0 Hz, H-6 ’), 6.66(1H, d, J8 .0  Hz, H- 
7’), 7.01 (1H, s, H-7); 5 ,3C NMR (100 MHz; CDC13; ppm) 41.33 (s, CH), 47.30 (s, CH2), 
56.27 (s, OCH3), 60.20 (s, OCH3), 60.94 (s, OCH3), 100.28 (s, CH), 101.00 (s, OCH20),
107.49 (s, CH), 108.27 (s, CH), 120.36 (s, CH), 132.18 (s, C), 138.29 (s, C), 144.44 (s, C), 
146.19 (s, C), 147.84 (s, C), 148.80 (s, C), 150.37 (s, C), 154.94 (s, C), 205.28 (s, C=0); m/z 
(API-ES+) 343 (MH+, 100%); HRMS found [MH]+ 343.11762 for C19H,906, C,9H,9 0 6 
requires [MH]+ 343.11761.
3-(4-Bromophenyl)-2,3-dihydro-4,5,6-trimethoxyinden-l-one 226
MeO
226
The indanone 226 was obtained following Protocol C. Using (£)-3-(4-bromophenyl)-l- 
(3,4,5-trimethoxyphenyl)prop-2-en-l-one 210 (0.22 g, 0.58 mmol) in anhydrous
trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted with ethyl acetate (2 x 5  
cm3) washed with saturated aqueous sodium bicarbonate solution (5 cm3). Column
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chromatography (SiC>2, ethyl acetate:hexane 1 :3) afforded 226 as a pale yellow oil (0.07 g, 
0.19 mmol, 33%); R f  0.34 (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcrn'1) 2938, 2837, 1702, 
1599, 1468, 1417, 1340, 1309, 1125, 1009, 825; 6  *H NMR (400 MHz; CDC13; ppm) 2.55 
(1H, dd, J  2.5, 19.3 Hz, CH2), 3.18 (1H, dd, J  7.8, 19.3 Hz, CH2), 3.41 (3H, s, OCH3), 3.90 
(3H, s, OCH3), 3.92 (3H, s, OCH3), 4.54 (1H, dd, J2 .4 , 7.8 Hz, H-3), 6.99 (2H, d, J S 2  Hz, 
H-2’ & H-6 ’), 7.08 (1H, s, H-7), 7.41 (2H, d, J  8.2 Hz, H-3’ & H-5’); 5,3C NMR (100MHz; 
CDC13; ppm) 41.25 (s, CH), 47.16 (s, CH2), 56.48 (s, OCH3), 60.32 (s, OCH3), 61.12 (s, 
OCH3), 100.52 (s, CH), 120.56 (s, C), 129.21 (s, CH), 131.91 (s, CH), 132.39 (s, C), 143.69 
(s, C), 144.06 (s, C), 148.92 (s, C), 150.48 (s, C), 155.34 (s, C), 204.97 (s, CO); m/z(API 
ES+) 377 (MH+, 100%), 379 (MH+, 100%); HRMS found [MH]+ 377.03851 for Ci8H 180 4Br, 
C,8Hi80 4Br requires [MH]+ 377.03830.
2,3-Dihydro-3-(4-carboxymethoxyphenyl)-4,5,6-trimethoxyinden-l-one 227
7 ,9
M e O ^ f r ^ ,
OMe^S?
6\ / '
227 h L c ° 2H
1"  2 "
The indanone 227 was obtained following Protocol C. Using (£)-3-(4- 
carboxymethoxyphenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 211 (0.24 g, 0.64 mmol) 
in anhydrous trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted with ethyl 
acetate (2 x 5 cm3) washed with saturated aqueous sodium bicarbonate solution (5 cm3). 
Aqueous layer then washed acidified aqueous hydrochloric acid (1 M) till the pH ~ 5 -  6 , 
then extracted with ethyl acetate (2 x 10 cm3). Column chromatography (SiC>2 , ethyl 
acetate:methanol 49:1) afforded 227 as a cream solid (0.06 g, 0.16 mmol, 26%); m.p. 169 -  
171 °C; R f  0.63 (SiC>2 , ethyl acetate:methanol 49:1); Vmaxfcrn’1) 2930, 2726, 2668, 1740, 
1667, 1599, 1512, 1468, 1439, 1416, 1344, 1101, 830; 6  *H NMR (400 MHz; CDC13; ppm)
2.57 (1H, dd, c/2.7 Hz, J  19.2 Hz, H-2), 3.18 (1H, dd, J8.1 Hz, J  19.2 Hz, H-2), 3.36 (3H, s, 
OCH3), 3.90 (3H, s, OCH3), 3.91 (3H, s, OCH3), 4.55 (1H, dd, J2 .7  Hz, J8.1 Hz, H-3), 4.65 
(2H, s, H-2” ), 6.85 (2H, d , J 8 . 8  Hz, H-3’ & H-5’), 7.05 (2H, d, J 8 . 8  Hz, H-2’ & H-6 ’), 7.08 
(1H, s, H-7); 8 ,3C NMR (100MHz; D6-DMSO; ppm) 47.62 (s, CH2), 56.81 (s, OCH3), 60.51 
(s, OCH3), 61.22 (s, OCH3), 65.18 (s, CH2), 100.94 (s, CH), 115.13 (s, CH), 128.72 (s, CH),
132.41 (s, C), 137.52 (s, C), 144.56 (s, C), 148.73 (s, C), 150.61 (s, C), 155.17 (s, C), 156.95 
(s, C), 170.87 (s, C 0 2H), 204.81 (s, CO); m/z(API ES+) 373 (MH+, 100%); HRMS found 
[MH]+ 373.12851 for C20H21O7, C2oH2 i0 7Br requires [MH]+ 373.12818.
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2,3-Dihydro-4,5,6-trimethoxy-3-(2,3,4-trimethoxyphenyl) inden-1 -one 228
The indanone 228 was obtained following Protocol C. Using (£)-3-(2,3,4-trimethoxyphenyl)- 
l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 212 (0.23 g, 0.59 mmol) in anhydrous 
trifluoroacetic acid (0.3 cm ). Tipped into water (5 cm ), extracted with ethyl acetate (2><5 
cm3) washed with saturated aqueous sodium bicarbonate solution (5 cm3). Column 
chromatography (SiC>2 , ethyl acetaterhexane 1 :3) afforded 228 as a pale brown solid (0.06g, 
0.15 mmol, 25%); m.p. 115 -  117 °C; R f  0.31 (SiC>2 , ethyl acetaterhexane lr3); v^X cm '1) 
2932, 2838, 1699, 1597, 1497, 1469, 1434, 1418, 1337, 850; 6  *H NMR (400 MHz; CDC13; 
ppm) 2.59 (1H, broad d, J20 .8  Hz, H-2), 3.13 (1H, dd, J  8.2, 19.0 Hz, H-2), 3.39 (3H, s, 
OCH3), 3.71 (3H, br. s, OCH3), 3.82 (3H, s, OCH3), 3.86 (3H, s, OCH3), 3.90 (3H, s, OCH3),
3.92 (3H, s, OCH3), 4.78 (1H, d, J5 .6  Hz, H-3), 6.56 (1H, d, J8 .4  Hz, H-5’), 6.60 (1H, br. s, 
H-6 ’), 7.10 (1H, s, H-7); 8 13C NMR (100MHz; CDC13; ppm) 36.41 (broad s, CH), 46.61 (s, 
CH2), 56.15 (s, OCH3), 56.44 (s, OCH3), 60.25 (s, OCH3), 60.75 (broad s, OCH3), 60.93 (s, 
OCH3), 61.11 (s, OCH3), 100.56 (s, CH), 107.37 (s, CH), 122.75 (broad s, CH), 130.09 
(broad s, C), 132.83 (s, C), 142.54 (s, C), 144.67 (s, C), 148.77 (s, C), 150.50 (s, C), 151.80 
(s, C), 152.76 (s, C), 154.81 (s, C), 205.99 (s, CO); m/z(API ES+) 389 (MH+, 100%); HRMS 
found [MH]+ 389.16112 for C21H25O7, C21H25O7 requires [MH]+ 389.15948.
3-(2,6-Dichlorophenyl)-2,3-dihydro-4,5,6-trimethoxyinden-l-one 229
MeO.
MeO‘
OMe r = X
229 5 4
The indanone 229 was obtained following Protocol C. Using (£>3-(2,6-dichlorophenyl)-l- 
(3,4,5-trimethoxyphenyl)prop-2-en-l-one 213 (0.24 g, 0.65 mmol) in anhydrous
trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted with ethyl acetate (2 x 5  
cm ) washed with saturated aqueous sodium bicarbonate solution (5 cm ). Column 
chromatography (SiC>2 , ethyl acetaterhexane 1 :3) afforded 229 as a pink solid (0.23 g, 0.63 
mmol, 95%); m.p. 98 -  102 °C; R f  0.46 (SiC>2 , ethyl acetaterhexane lr3); VmaxXcrn'1) 2999,
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2974, 2938, 2831, 1706, 1598, 1582, 1561, 1470, 1459, 1435, 1414, 1340, 1308, 1124, 1096, 
1044, 1006, 848, 753; 5 'H NMR (400 MHz; CDC13; ppm) 2.91 (1H, dd, J 4.0, 19.1 Hz, H- 
2), 3.11 (1H, dd, J  8.1, 19.1 Hz, H-2), 3.41 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.91 (3H, s, 
OCH3), 5.48 (1H, dd, J4 .0 , 8.1 Hz, H-3), 7.09 (1H, s, H-7), 7.14 (1H, d, J7 .9  Hz, H-4’), 7.18 
(1H, dd, J  1.5, 7.9 Hz, H-3’ or H-5’), 7.42 (1H, dd, J  1.5, 7.9 Hz, H-3’ or H-5’); 513C NMR 
(100MHz; CDC13; ppm) 37.85 (s, CH), 42.59 (s, CH2), 56.38 (s, OCH3), 60.32 (s, OCH3),
61.05 (s, OCH3), 100.99 (s, CH), 128.50 (s, CH), 128.55 (s, CH), 130.08 (s, CH), 133.22 (s, 
C), 134.84 (s, C), 136.49 (s, C), 137.25 (s, C), 142.68 (s, C), 148.41 (s, C), 150.31 (s, C),
154.87 (s, C), 204.31 (s, CO); m/z(API ES+) 367 (MH+, 100%), 369 (MH+, 60%); HRMS 
found [MH]+ 367.05008 for Ci8H17Cl20 4, Ci8H17C120 4 requires [MH]+ 367.04984.
3-(2,4-Dichlorophenyl)-2,3-dihydro-4,5,6-trimethoxyinden-l-one 2 3 0
7 ,?
1 JLv2MeO ^pT \ L. Cl 
O M e^^2'
2 3 « W
The indanone 2 3 0  was obtained following Protocol C. Using (£)-3-(2,4-dichlorophenyl)-l- 
(3,4,5-trimethoxyphenyl)prop-2-en-l-one 2 1 4  (0.25 g, 0.68 mmol) in anhydrous
trifluoroacetic acid (0.3 cm ). Tipped into water (5 cm ), extracted with ethyl acetate (2><5 
cm3) washed with saturated aqueous sodium bicarbonate solution (5 cm3). Column 
chromatography (Si02, ethyl acetate:hexane 1:3) afforded 2 3 0  as a light brown solid (0.21 g, 
0.57 mmol, 83%); m.p. 103 -  105 °C; R f  0.48 (Si02, ethyl acetate:hexane 1:3); VmaxXcrn'1) 
2945, 1703, 1603, 1587, 1559, 1469, 1417, 1346, 1317, 1157, 830; 5 *H NMR (400 MHz; 
CDC13; ppm) 2.45 (1H, br. d, J  15.2 Hz, H-2), 3.24 (1H, dd, J8 .0 , 19.2 Hz, H-2), 3.56 (3H, s, 
OCH3), 3.91 (3H, s, OCH3), 3.92 (3H, s, OCH3), 5.03 (1H, br. s, H-3), 6.67 (1H, br s, H-6 ’),
7.09 (1H, s, H-7), 7.11 (1H, br. s, H-5’), 7.42 (1H, br. s, H-3’); 8 ,3C NMR (100MHz; CDC13; 
ppm) 37.60 (broad s, CH), 45.92 (broad s, CH2), 56.45 (s, OCH3), 60.38 (s, OCH3), 61.14 (s, 
OCH3), 100.60 (s, CH), 127.57 (s, CH), 128.67 (broad s, CH), 129.46 (s, C), 132.93 (s, C),
133.00 (s, C), 134.37 (s, C), 140.57 (broad s, CH), 142.49 (s, C), 148.65 (s, C), 150.29 (s, C), 
155.44 (s, C), 204.27 (s, CO); m/z(API ES+) 367 (MH+, 100%), 369 (MH+, 60%); HRMS 
found [MH]+ 367.05035 for C 18Hi7 0 4Cl2, Ci8H 170 4C12 requires [MH]+ 367.04984.
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2.3-Dihydro-4,5,6-trimethoxy-3-phenylinden-1 -one 231
MeO 
MeO
231
The indanone 231 was obtained following Protocol C. Using (£)-l-(3,4,5-trimethoxyphenyl)- 
3-phenylprop-2-en-l-one 179 (0.23 g, 0.77 mmol) in anhydrous trifluoroacetic acid (0.3 cm3). 
Tipped into water (5 cm ), extracted with ethyl acetate (2><5 cm ) washed with saturated 
aqueous sodium bicarbonate solution (5 cm3). Column chromatography (SiC>2 , ethyl 
acetaterhexane 1:3) afforded 231 as a yellow oil (0.05 g, 1.7 mmol, 23%); Rf 0.36 (SiC>2 , 
ethyl acetateihexane 1:3); v^X cm '1) 2938, 2837, 1702, 1600, 1493, 1467, 1417, 1339, 1309, 
1125, 699; 6  *H NMR (400 MHz; CDC13; ppm) 2.62 (1H, dd, J2 .6 , 19.2 Hz, H-2), 3.19 (1H, 
dd, J  8.0, 19.2 Hz, H-3), 3.31 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.92 (3H, s, OCH3), 4.57 
(1H, dd, J2 .6 , 8.0 Hz, H-3), 7.09 -  7.13 (3H, m, H-7, H-2’ & H-6 ’), 7.16 -  7.23 (1H, m, H- 
4’), 7.26 -  7.31 (2H, m, H-3’ & H-5’); 8 13C NMR (100MHz; CDC13; ppm) 41.84 (s, CH), 
47.40 (s, CH2), 56.46 (s, OCH3), 60.19 (s, OCH3), 61.08 (s, OCH3), 100.50 (s, CH), 126.86 
(s, CH), 127.51 (s, CH), 128.83 (s, CH), 132.45 (s, C), 144.61 (s, C), 144.92 (s, C), 149.01 (s, 
C), 150.62 (s, C), 155.14 (s, C), 205.55 (s, CO); m/z(API ES+) 299 (MH+, 100%); HRMS 
found [MH]+ 299.12893 for CI8H190 4, Ci8H190 4 requires [MH]+ 299.12779.
2.3-Dihydro-4,5,6-trimethoxy-3-(4-methoxy-3-nitrophenyl)inden-1 -one 232
232 oMe
The indanone 232 was obtained following Protocol C. Using (£)-3-(4-methoxy-3- 
nitrophenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 215 (0.25 g, 0.67 mmol) in 
anhydrous trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted with ethyl 
acetate (2 x 5 c m  ) washed with saturated aqueous sodium bicarbonate solution (5 cm ). 
Column chromatography (SiC>2 , ethyl acetate:hexane 1:3) afforded 232 as a yellow solid 
(0.10 g, 0.27 mmol, 39%); m.p. 136 -  137 °C; R f  0.14 (SiC>2 , ethyl acetate:hexane 1:3); 
Vmax.(cm ') 2999, 2926, 2837, 1696, 1623, 1596, 1570, 1525, 1461, 1422, 1342, 1275, 1248, 
1093, 1004, 824; 5 'H NMR (400 MHz; CDC13; ppm) 2.55 (1H, dd, 7 2.8 Hz, J  19.3 Hz, H-
162
Chapter 6 -  Experimental
2), 3.21 (1H, dd, J  8.1 Hz, J  19.3 Hz, H-2), 3.50 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.93 
(3H, s, OCH3), 3.93 (3H, s, OCH3), 4.58 (1H, dd, J 2 .8  Hz, J  8.1 Hz, H-3), 7.01 (1H, d, J  9.1 
Hz, H-5’), 7.09 (1H, s, H-7), 7.26 (1H, dd, J  2.4, 9.1 Hz, H-6 ’), 7.64 (1H, d, J 2 .4  Hz, H-2’); 
S13C NMR (100MHz; CDC13; ppm) 40.53 (s, CH), 46.89 (s, CH2), 56.49 (s, OCH3), 56.80 (s, 
OCH3), 60.41 (s, OCH3), 61.16 (s, OCH3), 100.61 (s, CH), 114.03 (s, CH), 124.61 (s, CH), 
132.36 (s, C), 132.93 (s, CH), 136.96 (s, C), 139.67 (s, C), 143.09 (s, C), 148.84 (s, C), 
150.38 (s, C), 151.83 (s, C), 155.56 (s, C), 204.34 (s, CO); m/z{API ES+) 374 (MH+, 100%), 
396 (M N a\ 40%); HRMS found [MH]+ 374.12469 for C 19H20O 7N, C 19H20O7N requires 
[M H f 374.12343.
3-(3-Fluoro-4-methoxyphenyl)-2i3-dihydro-4,5,6-trimethoxyinden-1 -one 154
154 0Me
The indanone 154 was obtained following Protocol C. Using (£)-3-(3-fluoro-4- 
methoxyphenyl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 155 (0.24 g, 0.69 mmol) in 
anhydrous trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted with ethyl 
acetate (2 x 5  Cm3) washed with saturated aqueous sodium bicarbonate solution (5 cm3). 
Column chromatography (SiC>2, ethyl acetaterhexane 1:3) afforded 154 as a yellow solid 
(0.09g, 0.26 mmol, 37%); m.p. I l l  -  114 °C; R f  0.31 (SiC>2, ethyl acetaterhexane 1:3); 
VmaxXcrn'1) 3008, 2927, 2853, 1705, 1625, 1586, 1518, 1455, 1430, 1415, 1290, 1263, 1092, 
1025, 1006, 760; 6  *H NMR (400 MHz; CDC13; ppm) 2.55 (1H, dd, J 2 .3 ,  19.1 Hz, H-2),
3.16 (1H, dd, J  7.8, 19.1 Hz, H-2), 3.44 (3H, s, OCH3), 3.86 (3H, s, OCH3), 3.90 (3H, s, 
OCH3), 3.92 (3H, s, OCH3), 4.52 (1H, dd, J2 .3 , 7.8 Hz, H-3), 6.79 -  6.90 (3H, m, H-2’, H -5’ 
& H-6 ’), 7.08 (1H, s, H-7); S13C NMR (100MHz; CDC13; ppm) 40.90 (s, CH), 47.29 (s, 
CH2), 56.45 (s, OCH3), 56.49 (s, OCH3), 60.34 (s, OCH3), 61.11 (s, OCH3), 100.51 (s, CH), 
100.51 (s, CH), 113.68 (d, J 2 .1  Hz, CH), 115.14 (d, J  18.3 Hz, CH), 122.97 (d, J  3.7 Hz, 
CH), 132.34, (s, C), 137.67 (d, J5 .1  Hz, CH), 144.15 (s, C), 146.44 (d, J  10.2 Hz, C), 148.95 
(s, C), 150.53 (s, C), 152.54 (d, J 244.7 Hz, CF), 155.27 (s, C), 205.06 (s, CO); m/z(API ES+) 
374 (MH+, 100%); HRMS found [MH]+ 347.13028 for C 19H20O 5F, C 19H2o0 5F requires 
[MH]+ 347.12893.
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2,3-Dihydro-3 - (4-hydr oxyphenyl)-4,5,6-trimethoxyinden-l -one 233
MeO
233 OH
The indanone 233 was obtained following Protocol C. Using (£)-3-(4-(benzyloxy)phenyl)-l- 
(3,4,5-trimethoxyphenyl)prop-2-en-l-one 216 (0.22 g, 0.56 mmol) in anhydrous
trifluoroacetic acid (0.3 cm ). Tipped into water (5 cm ), extracted with ethyl acetate ( 2 x 5  
cm3) washed with saturated aqueous sodium bicarbonate solution (5 cm3). Column 
chromatography (SiC>2 , ethyl acetate:hexane 1:3) afforded 233 as a Brown gum (0.03g, 0 . 1 0  
mmol, 15%); R f  0.44 (SiC>2 , ethyl acetate:hexane 1 :1 ); VmaxXcm*1) 3299 (broad m), 2938 (m), 
1682 (s), 1596 (s), 1514 (s), 1468 (s), 1418 (s), 1340 (s), 1311 (s), 1207 (s), 1127 (s), 834 (s); 
6  'H NMR (400 MHz; CDC13; ppm) 2.58 (1H, dd, J  2.7, 19.3 Hz, H-2), 3.17 (1H, dd, J  7.6, 
19.3 Hz, H-2), 3.36 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.91 (3H, s, OCH3), 4.53 (1H, dd, J  
2.7, 7.6 Hz, H-3), 4.75 (1H, broad s, OH-4’), 6.75 (2H, d, J 8 . 6  Hz, H-3’ & H-5’), 6.98 (2H, 
d, J  8 . 6  Hz, H-2’ & H-6 ’), 7.08 (1H, s, H-7); 513C NMR (100MHz; CDC13; ppm) 41.10 (s, 
CH), 47.59 (s, CH2), 56.45 (s, OCH3), 60.34 (s, OCH3), 61.11 (s, OCH3), 100.52 (s, CH),
115.73 (s, CH), 128.56 (s, CH), 132.26 (s, C), 136.18 (s, C), 141.34 (s, C), 149.13 (s, C), 
150.59 (s, C), 155.06 (s, C), 162.98 (s, C), 206.20 (s, CO); m/z{API ES+) 315 (MH+, 100%); 
HRMS found [MH]+ 279.15910 for C,8H190 5 , CigH^Os requires [MH]+ 279.14602.
2,3-Dihydro-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4,5,6-trimethoxyinden-l-one 234
MeO"
234
r 2'
The indanone 234 was obtained following Protocol C. Using (£)-3-(2,3-
dihydrobenzo[b][l,4]dioxin-6-yl)-l-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 217 (0.27 g, 
0.76 mmol) in anhydrous trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted 
with ethyl acetate (2 x 5  cm3) washed with saturated aqueous sodium bicarbonate solution (5 
cm3). Column chromatography (SiC>2 , ethyl acetate:hexane 1:3) afforded 234 as a brown 
solid (0.14 g, 0.39 mmol, 52%); m.p. 93 -  96 °C; R f  0.26 (SiC>2 , ethyl acetate:hexane 1:3);
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VnaxXcm-') 2931 (m), 1705 (s), 1587 (s), 1505 (s), 1466 (s), 1427 (s), 1414 (s), 1281 (s), 1125 
(s), 1100 (s), 841 (s), 810 (s); 6  [H NMR (400 MHz; CDC13; ppm) 2.57 (1H, dd, J  2.7, 19.2 
Hz, H-2), 3.15 (1H, dd, J7 .9 , 19.2 Hz, H-2), 3.45 (3H, s, OCH3), 3.91 (3H, s, OCH3), 3.91 
(3H, s, OCH3), 4.22 (4H, s, H-2’ & H-3’), 4.47 (1H, dd, J  2.7, 7.9 Hz, H-3), 6.57 -  6.61 (2H, 
m, H-5’ & H-7’), 6.77 (1H, d, J  8.4 Hz, H-8 ’), 7.07 (1H, s, H-7); 5I3C NMR (100MHz; 
CDC13; ppm) 41.12 (s, CH), 47.46 (s, CH2), 56.42 (s, OCH3), 60.34 (s, OCH3), 61.08 (s, 
OCH3), 64.48 (s, OCH2CH20), 64.55 (s, 0CH 2CH20), 100.46 (s, CH), 116.05 (s, CH),
117.43 (s, CH), 120.34 (s, CH), 132.35 (s, C), 137.89 (s, C), 142.37 (s, C), 143.69 (s, C),
144.70 (s, C), 148.95 (s, C), 150.57 (s, C), 155.06 (s, C), 205.52 (s, CO); m/z(API ES+) 357 
(MH+, 100%); HRMS found [MH]+ 357.13332 for C2 0H21O6, C20H2 ,O6 requires [MH]+ 
357.13326.
(E)-l-(3,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 235343
O
235
The chalcone 235 was obtained following Protocol A. Using 3,4-dimethoxyacetophenone 
(0.36 g, 2.0 mmol), /?-anisaldehyde (0.25 cm3, 2.0 mmol) and aqueous sodium hydroxide 
solution (1.0 cm3, 4M) in methanol (2.0 cm3). Recrystallization from methanol afforded 235 
as light yellow crystals (0.40 g, 1.3 mmol, 67%); m.p. 8 1 - 8 3  °C; R f  0.54 (SiC>2 , ethyl 
acetate:hexane 1:1); v^Xcm*1) 3055, 3007, 2931, 2836, 1648, 1592, 1568, 1508, 1452, 
1439, 1422, 1240, 1161, 1148, 1025, 995, 822; 6  !H NMR (400 MHz; CDC13; ppm) 3.86 
(3H, s, OCH3), 3.97 (3H, s, OCH3), 3.98 (3H, s, OCH3), 6.93 (1H, d, J  8.5 Hz, H-5’), 6.94 
(2H, d, J  8.4 Hz, H-3” & H-5” ), 7.45 (1H, d, J  15.6 Hz, H-2), 7.61 (2H, d, J8 .4  Hz, H-2” 
& H-6 ” ), 7.62 (1H, d, J  1.5 Hz, H-2’), 7.68 (1H, dd, J  1.5, 8.5 Hz, H-6 ’), 7.79 (1H, d, J 15.6 
Hz, H-3); 8 ,3C NMR (100MHz; CDC13; ppm) 55.62 (s, OCH3), 56.26 (s, OCH3), 56.30 (s, 
OCH3), 110.19 (s, CH), 111.01 (s, CH), 114.61 (s, CH), 119.56 (s, CH), 123.05 (s, CH), 
128.02 (s, C), 130.34 (s, CH), 131.80 (s, C), 144.03 (s, CH), 149.42 (s, C), 153.31 (s, C),
161.75 (s, C), 188.82 (s, CO); m/z{API ES+) 299 (MH+, 100%).
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(E)-3-(4-Bromophenyl)-l-(3,4-dimethoxyphenyl)prop-2-en-1 -one 236
0
236
The chalcone 236 was obtained following Protocol A. Using 3,4-dimethoxyacetophenone 
(0.36 g, 2.0 mmol), 4-bromobenzaldehyde (0.37 g, 2.0 mmol) and aqueous sodium hydroxide 
solution (2.0 cm , 2M) in methanol (3.0 cm ). Recrystallization from methanol afforded 236 
as yellow crystals (0.52 g, 1.5 mmol, 75%); m.p. 130 -  132 °C; R f  0.63 (SiC>2 , ethyl 
acetate:hexane 1:3); vmax(cm‘‘) 3003, 2941, 2844, 1654, 1599, 1577, 1561, 1511, 1485, 
1451, 1417, 1256, 1239, 1157, 1144, 1018, 993, 757; 8  'H NMR (400 MHz; CDC13; ppm) 
3.97 (6 H, s, OCH3), 6.93 (1H, d, J  8.5 Hz, H-5’), 7.49 -  7.57 (5H, m, H-2, H-2” , H-3” , H- 
5” & H-6 ” ), 7.62 (1H, d, J2.Q Hz, H-2’), 7.68 (1H, dd,./2.0, 8.5 Hz, H-6 ’), 7.74 (1H, J  15.6 
Hz, H-3); 8 i3C NMR (100MHz; CDCI3; ppm) 56.28 (s, OCH3), 56.34 (s, OCH3), 110.19 (s, 
CH), 110.96 (s, CH), 122.37 (s, CH), 123.30 (s, CH), 124.77 (s, C), 129.95 (s, CH), 131.34 
(s, C), 132.38 (s, CH), 134.2 (s, C)l, 142.71 (s, CH), 149.53 (s, C), 153.64 (s, C), 188.43 (s, 
CO); m/z(API ES+) 347 (MH+, 100%), 349 (MH+, 100%); HRMS found [MH]+ 347.02896 
for Ci7Hi6 0 3 Br, Ci7Hi6 0 3 Br requires [MH]+ 347.02773.
(E)-3-(4-Chlorophenyl)-J-(3,4-dimethoxyphenyl)prop-2-en-l -one 237
O
237
The chalcone 237 was obtained following Protocol A. Using 3,4-dimethoxyacetophenone 
(0.36 g, 2.0 mmol), 4-chlorobenzaldehyde (0.28 g, 2.0 mmol) and aqueous sodium hydroxide 
solution (1.0 cm3, 4M) in methanol (2.0 cm3). Recrystallization from methanol afforded 237 
as white crystal (0.47 g, 1.5 mmol, 76%); m.p. 123 -  125 °C; R f  0.63 (SiC>2 , ethyl 
acetate:hexane 1:1); VmaxXcm'1) 3078, 2933, 2837, 1651, 1600, 1575, 1566, 1513, 1490, 
1459, 1446, 1417, 1255, 1240, 1148, 1018, 760; 6  'H NMR (400 MHz; CDC13; ppm) 3.96 
(3H, s, OCH3), 3.96 (3H, s, OCH3), 6.92 (1H, d, J 8 . 8  Hz, H-5’), 7.38 (2H, d, J 8 . 6  Hz, H-3” 
& H-5” ), 7.51 (1H, d, J  15.6 Hz, H-2), 7.56 (2H, d, J  8 . 6  Hz, H-2” & H-6 ” ), 7.61 (1H, d, J
2.0 Hz, H-2’), 7.67 (1H, dd, J2 .0 , 8 . 8  Hz, H-6 ’), 7.74 (1H, d, J  15.6 Hz, H-3); 8 13C NMR 
(100MHz; CDC13; ppm) 56.28 (s, OCH3), 56.33 (s, OCH3), 110.22 (s, CH), 111.02 (s, CH),
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122.32 (s, CH), 123.28 (s, CH), 129.42 (s, CH), 129.73 (s, CH), 131.38 (s, C), 133.81 (s, C), 
136.42 (s, C), 142.66 (s, CH), 149.55 (s, C), 153.65 (s, C), 188.47 (s, CO); m/z(A?l ES+) 303 
(MH+, 100%), 305 (MH+, 30%); HRMS found [MH]+ 303.07929 for C,7H 160 3C1, 
C 17H160 3C1 requires [MH]+ 303.07825.
(E)-3-(2,6-Dichlorophenyl)-l-(3,4-dimethoxyphenyl)prop-2-en-l-one 2 3 8
O
MeCL3^L
2 3 8
The chalcone 2 3 8  was obtained following Protocol A. Using 3,4-dimethoxyacetophenone 
(0.36 g, 2.0 mmol), 2,6-dichlorobenzaldehyde (0.35 g, 2.0 mmol) and aqueous sodium 
hydroxide solution (1.0 cm3, 4M) in methanol (2.0 cm3). Recrystallization from methanol 
afforded 2 3 8  as yellow crystals (0.52 g, 1.5 mmol, 77%); m.p. 131 -  133 °C; R f  0.71 (Si02, 
ethyl acetate:hexane 1:1); VmaxXcm*1) 3057, 2937, 1652, 1599, 1575, 1554, 1513, 1451, 
1439, 1420, 1304, 1265, 1256, 1242, 1161, 1141, 1022, 760; 6  *H NMR (400 MHz; CDC13; 
ppm) 3.96 (3H, s, OCH3), 3.96 (3H, s, OCH3), 6.93 ( 1 H, d, J8.4  Hz, H-5’), 7.19 ( 1 H, t, J8 .3  
Hz, H-4” ), 7.37 (2H, d, J  8.3 Hz, H-3” & H-5” ), 7.62 -  7.69 (3H, m, H-2, H-2’ & H-6 ’),
7.83 (1H, d, J  16.0 Hz, H-3); 8 13C NMR (100MHz; CDC13; ppm) 56.26 (s, OCH3), 56.34 (s, 
OCH3), 110.28 (s, CH), 111.04 (s, CH), 123.71 (s, CH), 129.06 (s, CH), 129.93 (s, CH),
130.53 (s, CH), 131.06 (s, C), 133.09 (s, C), 135.37 (s, C), 137.18 (s, CH), 149.52 (s, C),
153.76 (s, C), 188.57 (s, CO); m/z{API ES+) 337 (MH+, 100%), 339 (MH+, 60%); HRMS 
found [M H f 337.04008 for Ci7H150 3C12, C,7H150 3Cl2 requires [MH]+ 337.03928.
(E)-3-(3,4,5-Trimethoxyphenyl)-l-(3,4-dimethoxyphenyl)prop-2-en-l-one 2 3 9
O
2" OMe
4M OMe 
OMe 
2 3 9
The chalcone 2 3 9  was obtained following Protocol A. Using 3,4-dimethoxyacetophenone 
(0.36 g, 2.0 mmol), 3,4,5-trimethoxybenzaldehyde (0.39 g, 2.0 mmol) and aqueous sodium
'X "Xhydroxide solution (2.0 cm , 2M) in methanol (3.0 cm ). Recrystallization from methanol 
afforded 2 3 9  as light yellow crystals (0.65 g, 1.8 mmol, 91%); m.p. 125 -  126 °C; R f  0.43 
(Si02, ethyl acetate:hexane 1:1); VmaxXcrn'1) 2999, 2949, 2832, 1656, 1605, 1582, 1505, 
1470, 1450, 1418, 1262, 1244, 1000, 981, 817; 6  *H NMR (400 MHz; CDC13; ppm) 3.89
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(3H, s, OCH3), 3.92 (6 H, s, OCH3), 3.96 (3H, s, OCH3), 3.96 (3H, s, OCH3), 6 . 8 6  (2H, s, H- 
2” & H-6 ” ), 6.92 (1H, d, J  8.4 Hz, H-5’), 7.42 (1H, J  15.6 Hz, H-2), 7.61 (1H, d, J  2.0 Hz, 
H-2’), 7.68 (1H, dd, J  2.0, 8.4 Hz, H-6 ’), 7.71 (1H, J  15.6 Hz, H-3); 8 13C NMR (100MHz; 
CDCb; ppm) 56.31 (s, OCH3), 56.32 (s, OCH3), 56.46 (s, OCH3), 61.22 (s, OCH3), 105.82 (s, 
CH), 110.14 (s, CH), 111.05 (s, CH), 121.28 (s, CH), 123.22 (s, CH), 130.80 (s, C), 131.59 
(s, C), 140.51 (s, C), 144.36 (s, CH), 149.52 (s, C), 153.48 (s, C), 153.69 (s, C), 188.79 (s, 
CO); m/z{API ES+) 359 (MH+, 100%).
(E)-3-(3,4-Dichlorophenyl)-l-(3,4-dimethoxyphenyl)prop-2-en-l-one 2402'5
0
240
The chalcone 240 was obtained following Protocol A. Using 3,4-dimethoxyacetophenone 
(0.90 g, 5.0 mmol), 3,4,-dichlorobenzaldehyde (0.88 g, 5.0 mmol) and aqueous potassium 
hydroxide solution (6.0 cm3, 3M) in ethanol (13.0 cm3). Recrystallization from ethanol 
afforded 240 as cream crystals (0.96 g, 2.8 mmol, 57%); mp 119 -  121 °C; Rf 0.36 (SiC>2 , 
ethyl acetate:hexane 1:3); v^Xcm '1) 2953, 2832, 1661, 1599, 1583, 1514, 1472, 1417, 1261, 
1242, 1165, 1150, 1027, 766; 8  *H NMR (400 MHz; CDC13; ppm) 3.98 (6 H, s, OCH3),6.94 
(1H, d, J  8.4 Hz, H-5’), 7.46 (1H, dd, J  1.8, 8.4 Hz, H-6 ’), 7.49 (1H, d, J  8.3 Hz, H-5” ), 7.53 
(1H, d, J  15.6 Hz, H-2), 7.62 (1H, d, J 2.0 Hz, H-2” ), 7.66 -  7.72 (2H, m, H-3 & H-6 ” ), 7.73 
(1H, d, J  1.8 Hz, H-2’); 8  13C NMR (100 MHz; CDC13; ppm) 56.10 (s, OCH3), 56.17 (s, 
OCH3), 109.94 (s, CH), 110.65 (s, CH), 123.09 (s, CH), 123.21 (s, CH), 127.54 (s, CH),
129.65 (s, CH), 130.91 (s, C), 130.94 (s, CH), 133.26 (s, C), 134.17 (s, C), 135.14 (s, C),
141.09 (s, CH), 149.36 (s, C), 153.56 (s, C), 187.89 (s, CO); m/z(AP+) 337 (MH+, 100%) 339 
(M H \ 60%).
(E)-3-(2,4,6-Trimethoxyphenyl)-]-(3,4-dimethoxyphenyl)prop-2-en-l-one 241344
O OMe
OMe 
241
The chalcone 241 was obtained following Protocol A. Using 3,4-dimethoxyacetophenone 
(0.55 g, 3.0 mmol), 2,4,6-trimethoxybenzaldehyde (0.59 g, 3.0 mmol) and aqueous sodium 
hydroxide solution (1.0 cm3, 6 M) in methanol (3.0 cm3). Recrystallization from methanol
MeO
M e O j ^ ' A ^  1-I 3 
4'il J  6"
6' MeO 5^ 4 "'
5' 5
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afforded 241 as yellow plates (0.65 g, 1.8 mmol, 61%); m.p. 171-173°C; Rf 0.30 (Si0 2 , ethyl 
acetate:hexane 1:1); vmax(cm'') 2983, 2840, 1637, 1597, 1555, 1515, 1464, 1417, 1319, 
1258, 1235, 1154, 1022, 819; 6  'H NMR (400 MHz; CDC13; ppm) 3.88 (3H, s, OCH3), 3.93 
(6 H, s, OCH3), 3.97 (3H, s, OCH3), 3.99 (3H, s, OCH3), 6.16 (2H, s, H-3” & H-5” ), 6.95 
(1H, d, J  8.4 Hz, H-5’), 7.65 (1H, d, J  1.9 Hz, H-2’), 7.68 (1H, dd, J  8.4, 1.9 Hz, H-6 ’), 7.92 
(1H, d, J  15.9 Hz, H-2), 8.25 (1H, d, J  15.9 Hz, H-3); 5 13C NMR (100 MHz; CDC13; ppm) 
55.43 (s, OCH3), 55.83 (s, OCH3), 55.98 (s, OCH3), 56.05 (s, OCH3), 90.50 (s, CH), 106.60 
(s, C), 109.88 (s, CH), 110.91 (s, CH), 121.73 (s, CH), 122.70 (s, CH), 132.35 (s, C), 135.27 
(s, CH), 148.90 (s, C), 152.52 (s, C), 161.62 (s, C), 162.95 (s, C), 190.48 (s, CO); m/z (AP+) 
359 (M H \ 100%); HRMS found [M Hf 359.1490 for C20H22O6) C2 0H22O6 requires [M H f 
359.1489; CHN found C 66.97%, H 6.19% CHN requires C 67.03%, H 6.19%.
(E)-3-(2,4-Dimethoxyphenyl)-l-(3,4-dimethoxyphenyl)prop-2-en-l-one 242
O OMe
OMe
J
242
The chalcone 242 was obtained following Protocol A. Using 3,4-dimethoxyacetophenone 
(0.37 g, 3.0 mmol), 2,4,-dimethoxybenzaldehyde (0.33 g, 2.0 mmol) and aqueous sodium 
hydroxide solution (1.0 cm3, 4M) in methanol (2.0 cm3). Recrystallization from methanol 
afforded 242 as yellow crystals (0.51 g, 1.6 mmol, 79%); m.p. I l l  — 112 °C; Rf 0.42 (Si0 2 , 
ethyl acetate:hexane 1:1); VmaxXcm'1) 2999, 2938, 2836, 1646, 1592, 1578, 1554, 1506, 1468, 
1454, 1437, 1417, 1307, 1242, 1210, 1151, 1025, 1009, 838, 786, 745; 6  'H NMR (400 
MHz; CDC13; ppm) 3.85 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.95 (3H, s, OCH3), 3.96 (3H, s, 
OCH3), 6.47 (1H, d, J  1.7 Hz, H-3” ), 6.53 (1H, dd, J  1.7, 8 . 6  Hz, H-5” ), 6.92 (1H, d, J  8.4 
Hz, H-5’), 7.56 (1H, d, J  15.7 Hz, H-2), 7.57 (1H, d, J 8 . 6  Hz, H-6 ” ), 7.62 (1H, d, J  1.9 Hz, 
H-2’), 7.66 (1H, dd, J  1.9, 8.4 Hz, H-6 ’), 8.04 (1H, d, J  15.7 Hz, H-3); 5,3C (100MHz; 
CDC13; ppm) 55.71 (s, OCH3), 55.77 (s, OCH3), 56.23 (s, OCH3), 56.28 (s, OCH3), 98.68 (s, 
CH), 105.59 (s, CH), 110.18 (s, CH), 111.13 (s, CH), 117.53 (s, C), 120.36 (s, CH), 122.99 
(s, CH), 131.05 (s, CH), 132.15 (s, C), 139.91 (s, CH), 149.30 (s, C), 153.06 (s, C), 160.53 (s, 
C), 163.09 (s, C), 189.57 (s, CO); m/z(A?l ES+) 329 (MH+, 100%).
T 4 1 3  r  1)3
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(E)-l-(S,4-Dimethoxyphenyl)-3-(3,5-dimethoxyphenyl)prop-2-en-l-one 243
OMe
MeO
OMe
243
The chalcone 243 was obtained following Protocol A. Using 3,4-dimethoxyacetophenone 
(0.36 g, 3.0 mmol), 2,4,-dimethoxybenzaldehyde (0.33 g, 2.0 mmol) and aqueous sodium 
hydroxide solution (2.0 cm3, 2M) in methanol (3.0 cm3). Recrystallization from methanol 
afforded 243 as white crystals (0.39 g, 1.6 mmol, 62%); m.p. 82 -  84 °C; R f  0.58 (SiC>2 , 
ethyl acetate:hexane 1:1); v^Xcm '1) 2968, 2844, 1652, 1594, 1579, 1510, 1459, 1418, 1286, 
1260, 1162, 1020, 834; 6  'H NMR (400 MHz; CDC13; ppm) 3.83 (6 H, s, OCH3), 3.96 (3H, s, 
OCH3), 3.96 (3H, s, OCH3), 6.51 (1H, t, J2 .0  Hz, H-4” ), 6.78 (2H, d, J2 .0  Hz, H-2” & H- 
6 ” ), 6.92 (1H, d, J  8 . 8  Hz, H-5’), 7.50 (1H, d, J  15.8 Hz, H-2), 7.61 (1H, d, J2 .0  Hz, H-2’), 
7.67 (1H, dd, J2 .0 , 8 . 8  Hz, H-6’),7.71 (1H, d, J  15.8 Hz, H-3); S,3C (100MHz; CDC13; ppm)
55.70 (s, OCH3), 56.28 (s, OCH3), 56.32 (s, OCH3), 102.67 (s, CH), 106.43 (s, CH), 106.53 
(s, CH), 110.18 (s, CH), 111.00 (s, CH), 122.45 (s, CH), 123.30 (s, CH), 131.48 (s, C), 
137.21 (s, C), 144.18 (s, CH), 149.49 (s, C), 153.53 (s, C), 161.27 (s, C), 188.80 (s, CO); 
m/z{API ES+) 329 (MH+, 100%).
(E)-3-(2,6-Dimethoxyphenyl)-l-(3,4-dimethoxyphenyl)prop-2-en-l-one 244
O OMe
244
The chalcone 244 was obtained following Protocol A. Using 2,6-dimethoxyacetophenone 
(0.36 g, 3.0 mmol), 2,4,-dimethoxybenzaldehyde (0.34 g, 2.1 mmol) and aqueous sodium 
hydroxide solution (1.0 cm3, 1M) in methanol (2.0 cm3). Recrystallization from methanol 
afforded 244 as pale cream crystals (0.40 g, 1.2 mmol, 61%); m.p. 119 -  120 °C; R f  0.50 
(SiC>2 , ethyl acetate:hexane 1 :1 ); VmaxXcrn'1) 2932, 2837, 1644, 1593, 1567, 1509, 1478, 
1454, 1435, 1417, 1255, 1238, 1144, 1108, 1022, 1003; 5 'H NMR (400 MHz; CDC13; ppm)
3.92 (6 H, s, OCH3), 3.96 (3H, s, OCH3), 3.97 (3H, s, OCH3), 6.59 (2H, d, J  8.5 Hz, H-3” & 
H-5” ), 6.93 (1H, d , J  8.4 Hz, H-5’), 7.29 (1H, t, J8 .5  Hz, H-4” ), 7.64 (1H, d, J2 .0  Hz, H- 
2’), 7.68(1H, dd, J2 .0 , 8.4 Hz, H-6 ’), 8.00 (1H, d, J  16.2 Hz, H-2), 8.25(1H, d, J  16.2 Hz, H-
3); 8 13C (100MHz; CDC13; ppm) 56.09 (s, OCH3), 56.21 (s, OCH3), 56.27 (s, OCH3), 104.01
Tl nT 1 I
411 MeOMeO
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(s, CH), 110.17 (s, CH), 111.21 (s, CH), 113.30 (s, C), 123.13 (s, CH), 125.02 (s, CH),
131.49 (s, CH), 132.30 (s, C), 135.18 (s, CH), 149.23 (s, C), 152.98 (s, C), 160.53 (s, C),
190.66 (s, CO); m/z(API ES+) 329 (MH+, 100%); HRMS found [MH]+ 329.13849 for 
C 19H21O5, Q 9H21O5 requires [MH]+ 329.13835.
2,3-Dihydro-5,6-dimethoxy-3-(4-methoxyphenyl)inden-l-one 245
MeO'
245 OMe
The indanone 245 was obtained following Protocol C. Using (£)-l-(3,4-dimethoxyphenyl)-3- 
(4-methoxyphenyl)prop-2-en-l-one 235 (0.23 g, 0.77 mmol) in anhydrous trifluoroacetic acid 
(0.3 cm ). Tipped into water (5 cm ), extracted with ethyl acetate ( 2 x 5  cm ) washed with 
saturated aqueous sodium bicarbonate solution (5 cm3). Column chromatography (SiC>2 , 
ethyl acetate:hexane 1:3) afforded 245 as a yellow brown gum (0.016 g, 0.05 mmol, 7%); R f  
0 . 2 2  (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcrn'1) 2933, 2836, 1695, 1590, 1510, 1496, 1463, 
1440, 1418, 1246, 1210, 1044, 1030, 832; 6  *H NMR (400 MHz; CDC13; ppm) 2.59 (1H, dd, 
J  3.3, 19.0 Hz, H-2),3.19 (1H, dd, J  7.7, 19.0 Hz, H-2), 3.80 (3H, s, OCH3), 3.85 (3H, s, 
OCH3), 3.94 (3H, s, OCH3), 4.44 (1H, dd, y  3.3, 7.7 Hz, H-3), 6.63 (1H, s, H-4), 6.85 (2H, d, 
J  8.4 Hz, H-3’ & H-5’), 7.04 (2H, d, J  8.4 Hz, H-2’ & H-6 ’), 7.22 (1H, s, H-7); 5,3C NMR 
(100MHz; CDCI3 ; ppm) 45.68 (s, CH), 47.62 (s, CH2), 55.52 (s, OCH3), 56.38 (s, OCH3), 
56.50 (s, OCH3), 103.84 (s, CH), 107.63 (s, CH), 114.50 (s, CH), 128.77 (s, CH), 130.02 (s, 
C), 136.11 (s, C), 150.02 (s, C), 153.68 (s, C), 155.99 (s, C), 158.76 (s, C), 204.98 (s, CO); 
m/z(APl ES+) 299 (MH+, 100%); HRMS found [MH]+ 299.12734 for C,8H190 4, C,8H ,904 
requires [MH]+ 299.12779.
3-(4-Bromophenyl)-2,3-dihydro-5,6-dimethoxyinden-l-one 246
MeO
246
The indanone 246 was obtained following Protocol C. Using (£)-3-(4-bromophenyl)-l-(3,4- 
dimethoxyphenyl)prop-2-en-l-one 236 (0.23 g, 0.66 mmol) in anhydrous trifluoroacetic acid
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(0.3 cm3). Tipped into water (5 cm3), extracted with ethyl acetate ( 2 * 5  cm3) washed with 
saturated aqueous sodium bicarbonate solution (5 cm3). Column chromatography (SiC>2 , 
ethyl acetate:hexane 1:3) afforded 246 as a yellow solid (0.12 g, 0.35 mmol, 52%); m.p. 106 
-  I l l  °C; Rf 0.21 (Si02, ethyl acetate:hexane 1:3); VmaxXcrn'1) 3062, 3019, 2926, 2854, 
1701, 1689, 1587, 1502, 1488, 1468, 1455, 1434, 1418, 1301, 1283, 1212, 1009, 854, 819; 6 
'H NMR (400 MHz; CDC13; ppm) 2.57 (1H, dd, J  3.5, 18.9 Hz, H-2), 3.20 (1H, dd, J  8.0,
18.9 Hz, H-2), 3.86 (3H, s, OCH3), 3.94 (3H, s, OCH3), 4.45 (1H, dd, J  3.5, 8.0 Hz, H-3), 
6.60 (1H, s, H-4), 7.00 (2H, d, J  8.2 Hz, H-2’ & H-6’), 7.22 (1H, s, H-5), 7.44 (2H, d, J  8.2 
Hz, H-3’ & H-5’); 813C NMR (100MHz; CDC13; ppm) 43.87 (s, CH), 47.25 (s, CH2), 56.40 
(s, OCH3), 56.53 (s, OCH3), 103.97 (s, CH), 107.49 (s, CH), 121.02 (s, C), 129.53 (s, CH),
130.09 (s, C), 132.26 (s, CH), 143.14 (s, C), 150.23 (s, C), 152.63 (s, C), 156.10 (s, C), 
204.25 (s, CO); m/z(API ES+) 347 (MH+, 100%), 349 (MH+, 100%); HRMS found [MH]+ 
347.02820 for C 17H,60 3Br, Ci7Hi60 3Br requires [MH]+ 347.02773.
3-(4-Chlorophenyl)-2,3-dihydro-5,6-dimethoxyinden-l-one 247
MeO‘
247
The indanone 247 was obtained following Protocol C. Using (£)-3-(4-chlorophenyl)-l-(3,4- 
dimethoxyphenyl)prop-2-en-l-one 237 (0.21 g, 0.71 mmol) in anhydrous trifluoroacetic acid 
(0.3 cm ). Tipped into water (5 cm ), extracted with ethyl acetate (2 x 5 cm ) washed with 
saturated aqueous sodium bicarbonate solution (5 cm3). Column chromatography (Si02, 
ethyl acetate:hexane 1:3) afforded 247 as a orange solid (0.073 g, 0.24 mmol, 34%); m.p. 
112- 113 °C; Rf 0.26 (Si02, ethyl acetate:hexane 1:3); VmaxXcnT1) 2923, 1691, 1592, 1501, 
1489, 1469, 1459, 1442, 1402, 1300, 1287, 1046, 818; 5 'H NMR (400 MHz; CDC13; ppm)
2.57 (1H, dd, J  3.4 , 18.9 Hz, H-2), 3.21 (1H, dd, J7 .9 , 18.9 Hz, H-2), 3.86 (3H, s, OCH3),
3.94 (3H, s, OCH3), 4.46 (1H, dd, J  3.4, 7.9 Hz, H-3), 6.60 (1H, s, H-4), 7.05 (2H, d, J  8.6 
Hz, H-2’ & H-6’), 7.23 (1H, s, H-7), 7.29 (2H, d, J  8.6 Hz, H-3’ & H-5’); 813C NMR 
(100MHz; CDC13; ppm) 43.79 (s, CH), 47.29 (s, CH2), 56.38 (s, OCH3), 56.50 (s, OCH3),
103.95 (s, CH), 107.51 (s, CH), 129.15 (s, CH), 129.29 (s, CH), 130.07 (s, C), 132.95 (s, C), 
142.62 (s, C), 150.21 (s, C), 152.72 (s, C), 156.08 (s, C), 204.26 (s, CO); m/z(API ES+) 303 
(MH+, 100%), 305 (MH+, 30%); HRMS found [MH]+ 303.07854 for Ci7Hi60 3C1, 
C,7HI60 3C1 requires [MH]+ 303.07825.
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3-(2,6-Dichlorophenyl)-2,3-dihydro-5,6-dimethoxyinden-l-one 248
MeO
The indanone 248 was obtained following Protocol C. Using (£)-3-(2,6-dichlorophenyl)-l- 
(3,4-dimethoxyphenyl)prop-2-en-l-one 238 (0.26 g, 0.76 mmol) in anhydrous trifluoroacetic 
acid (0.3 cm ). Tipped into water (5 cm ), extracted with ethyl acetate (2><5 cm ) washed 
with saturated aqueous sodium bicarbonate solution (5 cm3). Column chromatography (SiC>2 , 
ethyl acetate:hexane 1:3) afforded 248 as a light brown solid (0.18 g, 0.54 mmol, 71%); m.p. 
140- 143 °C; Rf 0.35 (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcrn'1) 2924, 2853, 1700, 1592, 
1560, 1498, 1465, 1436, 1422, 1292, 1254, 1211, 1115, 773; 6 *H NMR (400 MHz; CDC13; 
ppm) 2.99 (1H, dd, J  4.3, 19.0 Hz, H-2), 3.12 (1H, dd, J  7.7, 19.0 Hz, H-2), 3.85 (3H, s, 
OCH3), 3.94 (3H, s, OCH3), 5.43 (1H, dd, J4 .3 , 7.7 Hz, H-3), 6.52 (1H, s, H-4), 7.23 -  7.16 
(3H, m, H-7, H-4’ & H-3’ or H-5’), 7.43 (1H, dd, J  1.4, 7.8 Hz, H-3’ or H-5’); §,3C NMR 
(100MHz; CDC13; ppm) 40.23 (s, CH), 42.70 (s, CH2), 56.28 (s, OCH3), 56.50 (s, OCH3),
104.41 (s, CH), 106.25 (s, CH), 128.61 (s, CH), 1129.04 (s, CH), 130.34 (s, C), 130.53 (s, 
CH), 135.64 (s, C), 136.59 (s, C), 136.70 (s, C), 149.80 (s, C), 151.61 (s, C), 155.92 (s, C),
203.73 (s, CO); m/z(API ES+) 337 (MH+, 100%), 339 (MH+, 60%); HRMS found [MH]+ 
337.0395 for C n H ^ C h ,  C17H,50 3Cl2requires [MH]+ 337.0392.
2,3-Dihydro-5,6-dimethoxy-3-(3,4,5-trimethoxyphenyl)inden-1 -one 249
MeO‘
OMe
MeO 5’ 
249 OMe
The indanone 249 was obtained following Protocol C. Using (£)-3-(3,4,5-trimethoxyphenyl)- 
l-(3,4-dimethoxyphenyl)prop-2-en-l-one 239 (0.25 g, 0.70 mmol) in anhydrous
trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted with ethyl acetate ( 2 x 5  
cm3) washed with saturated aqueous sodium bicarbonate solution (5 cm3). Column 
chromatography (SiC>2 , ethyl acetate:hexane 1:3) afforded 249 as dark brown solid (0.10 g, 
0.28 mmol, 41%); m.p. 173-175 °C; Rf 0.28 (Si(>2 , ethyl acetate:hexane 1:1); VmaxXcrn'1)
173
Chapter 6 -  Experimental
2957 (s), 2917 (s), 2848, 1690, 1587, 1495, 1462, 1421, 1296, 1259, 1247, 1212, 1110, 1052, 
1008, 835; 8 ‘H NMR (400 MHz; CDC13; ppm) 2.56(1H, dd, J3 .5 , 19.1 Hz, H-2), 3.13 (1H, 
dd, J  7.8, 19.3 Hz,H-2), 3.73 (6H, s, OCH3), 3.77 (3H, s, OCH3), 3.81 (3H, s, OCH3), 3.88 
(3H, s, OCH3), 4.35 (1H, dd,73.5, 7.8 Hz, H-3), 6.24 (2H, s, H-2’ & H-6’), 6.61 (H, s, H-4),
7.16 (H, s, H-7); 8 l3C NMR (100 MHz; CDC13; ppm) 44.59 (s, CH), 47.23 (s, CH2), 56.13 (s, 
OCH3), 56.17 (s, OCH3), 56.40 (s, OCH3), 60.88 (s, OCH3), 103.61 (s, CH), 104.38 (s, CH),
107.41 (s, CH), 129.88 (s, C), 136.76 (s, C), 139.56 (s, C), 149.88 (s, C), 152.86 (s, C),
153.54 (s, C), 155.77 (s, C), 204.57 (s, C=0); m/z (AP+) 359 (MH+, 100%); HRMS found 
[MH]+ 359.1489 for C20H23O6, C20H23O6 requires [MH]+ 359.1489.
3-(3,4-Dichlorophenyl)-2,3-dihydro-5,6-dimethoxyinden-l-one 250215
Me0‘
250
The indanone 250 was obtained following Protocol C. Using (£)-3-(3,4,5-trimethoxyphenyl)- 
l-(3,4-dimethoxyphenyl)prop-2-en-l-one 240 (0.24 g, 0.70 mmol) in anhydrous
trifluoroacetic acid (0.3 cm3). Tipped into water (5 cm3), extracted with ethyl acetate ( 2 x 5  
cm3) washed with saturated aqueous sodium bicarbonate solution (5 cm3). Column 
chromatography (SiC>2 , ethyl acetate:hexane 1:3) afforded 250 as a light brown solid (0.031 g, 
0.09 mmol, 13%); m.p. 144 -  146 °C; R f  0.30 (Si02, ethyl acetateihexane 1:3); VmaxXcnT1) 
2925, 1694, 1588, 1498, 1463, 1417, 1285, 1254, 1211, 1112, 1044, 826; 6 lH NMR (400 
MHz; CDC13; ppm) 2.56 (1H, dd, J3 .5 , 19.1 Hz, H-2), 3.21 (1H, dd, J  7.6, 19.1 Hz, H-2),
3.87 (3H, s, OCH3), 3.94 (3H, s, OCH3), 4.44 (1H, dd, J  3.5, 7.6 Hz, H-3), 6.60 (1H, s, H-6), 
6.84 (1H, dd, J  2.1, 8.4 Hz, H-6’), 7.22 (1H, d, J  2.1 Hz, H-2’), 7.23 (1H, s, H-7), 7.85 (1H, 
d, J  8.4 Hz, H-5’); 6I3C NMR (100MHz; CDC13; ppm) 43.57 (s, CH), 47.10 (s, CH2), 56.43 
(s, OCH3), 56.59 (s, OCH3), 104.07 (s, CH), 107.42 (s, CH), 127.14 (s, CH), 129.85 (s, CH),
130.13 (s, C), 131.16 (s, CH), 131.30 (s, C), 133.16 (s, C), 144.44 (s, C), 150.40 (s, C),
151.93 (s, C), 156.21 (s, C), 203.74 (s, CO); m/z{API ES+) 337 (MH+, 100%), 339 (M H \ 
60%).
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2-Bromo-3,4,5-trimethoxybenzaldehyde 252226-345
The method adopted was that of Beugelmans226 et al. To a stirring solution of 3,4,5- 
trimethoxybenzaldehyde (3.96 g, 20.2 mmol) in chloroform (40 cm3) was added N- 
bromosuccinimide (3.84 g, 21.6 mmol). The reaction was then put under argon and 
re fluxed at 75 °C for 4 hours. The reaction was then left stirring overnight at room 
temperature. The solvent was then evaporated in vacuo, and column chromatography (SiC>2 , 
dichloromethane) afforded 252 as a white solid (4.60 g, 16.7 mmol, 83%); m.p. 69 - 70 °C; 
Rf 0.40 (Si02, DCM); vmax (cm'') 2943, 2866, 1684, 1578, 1564, 1471, 1449, 1426, 1404, 
1383, 1326, 1197, 1165, 1002, 981, 920, 859, 726; 8 'H NMR (400 MHz; CDC13; ppm) 3.91 
(3H, s, OCH3), 3.91 (3H, s, OCH3), 3.98 (3H, s, OCH3), 7.31 (1H, s, H-6’), 10.30 (1H, s, H-
1); 5 l3C NMR (100 MHz; CDC13; ppm) 56.27 (s, OCH3), 61.24 (s, OCH3), 61.31 (s, OCH3),
107.44 (s, CH), 115.69 (s, C), 128.80 (s, C), 148.72 (s, C), 150.79 (s, C), 153.03 (s, C), 
191.15 (s, CHO).
]-(2-Bromo-3,4,5-trimethoxyphenyl)ethanol 253346
To a stirring solution of methylmagnesium chloride in tetrahydrofuran (8.8 cm3, 26.4 mmol, 
3M) in anhydrous tetrahydrofuran (30 cm3) under argon at 0 °C, was slowly added 2-bromo- 
3,4,5-trimethoxybenzaldehyde 252 (4.53 g, 16.5 mmol) in anhydrous tetrahydrofuran (20 
cm3). The reaction was then stirred overnight at room temperature and then poured into 
mixture of concentrated aqueous ammonium chloride solution (100 cm3) and ice, and then 
extracted with ethyl acetate (6 * 20 cm ). The organic fraction was then dried over 
anhydrous magnesium sulfate, filtered and evaporated in vacuo to afforded 253 as a yellow 
oil (4.74 g, 16.3 mmol, 99%); Rf 0.33 (SiC>2 , ethyl acetaterhexane 1:3); VmaxXcm'1) 3476, 
2972, 2939, 1664, 1570, 1478, 1450, 1426, 1391, 1316, 1196, 1160, 1045, 999, 857, 796; 6 
*H NMR (400 MHz; CDC13; ppm) 1.44 (3H, d, J 6 A  Hz, H-2), 2.16 (1H, d, J  1.2 Hz, OH-1), 
3.86 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.88 (3H, s, OCH3), 5.22 (1H, dq, J  1.2 Hz, 6.4 Hz,
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H-l), 6.98 (1H, s, H-6’); 5 l3C NMR (100 MHz; CDCh; ppm) 23.65 (s, CH3), 56.12 (s, 
OCH3), 61.03 (s, OCHj), 61.11 (s, OCH3), 69.23 (s, CHOH), 105.08 (s, CH), 107.64 (s, C),
140.48 (s, C), 142.04 (s, C), 150.41(s, C), 153.10 (s, C); m/z(AP+) 273 (M-H20  100%), 275 
(M-H20 , 90%).
l-(2-Bromo-3,4,5-trimethoxyphenyl)ethanone 251226,346
O
HI J?
MeO^fT^Br
OMe
251
Pyridinium chlorochromate (1.75 g, 8.1 mmol) was added to a stirred solution of l-(2-bromo-
3,4,5-trimethoxyphenyl)ethanol 253 (1.58 g, 5.4 mmol) and silica gel (9.0 g) in 
dichloromethane (20 cm3). The reaction was then put under argon gas and stirred at room 
temperature under argon overnight. The solvent was then evaporated in vacuo. Column 
chromatography (SiC>2 , ethyl acetateihexane 1:9) of the crude product supported on silica 
afforded 251 as a yellow solid (1.30 g, 4.5 mmol, 83%); m.p. 37-38 °C; Rf 0.46 (Si02, ethyl 
acetateihexane 1:3); vmax(cm’') 2937, 2847, 1693, 1580, 1560, 1510, 1480, 1438, 1426, 
1381, 1325, 1265, 1208, 1167, 1152, 992, 933, 856; 5 ‘H NMR (400 MHz; CDC13; ppm) 
2.64 (3H, s, H-2), 3.87 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.91 (3H, s, OCH3), 6.81 (H, s, H- 
6’); 8 l3C NMR (100 MHz; CDC13; ppm) 30.70 (s, CH3), 56.26 (s, OCH3), 61.11 (s, OCH3),
61.20 (s, OCH3), 106.50 (s, CBr), 107.84 (s, CH), 137.29 (s, C), 145.15 (s, C), 151.08 (s, C),
152.83 (s, C), 201.18 (s, CO); m/z(AP+) 289 (MH+, 100%), 291 (MH+, 95%).
(E)-J-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 254
O
MeO
MeO
OMe 254
The chalcone 254 was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 251 (1.00 g, 3.5 mmol),/?-anisaldehyde (0.40 cm3, 3.5 mmol) and 
aqueous sodium hydroxide solution (0.7 cm3, 10M) in methanol (3.0 cm3). Recrystallization 
from methanol afforded 254 as white crystals (1.04 g, 2.6 mmol, 74%); m.p. 98 - 100 °C; Rf 
0.27 (SiC>2 , ethyl acetateihexane 1:3); VmaxXcm'1) 2936, 2837, 1636, 1616, 1600, 1572, 1510, 
1480, 1464, 1455, 1423, 1382, 1344, 1246, 1166, 1021, 1004, 987, 829; 8 'H NMR (400 
MHz; CDC13; ppm) 3.85 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.95 (3H, s,
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OCH3), 6.78 (1H, s, H-6’), 6.92 (2H, d, J  8.8 Hz, H-3” & H-5” ), 6.98 (1H, d, J  16.0 Hz, H-
2), 7.44 (1H, d, J  16.0 Hz, H-3), 7.53 (2H, d, J  8.8 Hz, H-2” & H-6” ); 5 l3C NMR (100 
MHz; CDC13; ppm) 55.47 (s, OCH3), 56.29 (s, OCH3), 61.19 (s, OCH3), 61.23 (s, OCH3), 
106.46 (s, CBr), 107.95 (s, CH), 114.50 (s, CH), 123.85 (s, CH), 127.16 (s, C), 130.48 (s, 
CH), 137.09 (s, C), 144.52 (s, C), 146.15 (s, CH), 151.09 (s, C), 152.99 (s, C), 161.99 (s, C), 
194.17 (s, CO); m/z{AP+) 407 (MH+, 100%), 409 (MH+, 95%); HRMS found [MH]+ 
407.04991.
(E)-J-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-en-l -one 
255
O
OMe 255
To a stirring mixture of Using l-(2-bromo-3,4,5-trimethoxyphenyl)ethanone 251 (2.23 g, 7.7 
mmol) and 3-hydroxy-4-methoxybenzaldehyde (1.18 g, 7.7 mmol) in methanol (13 cm3) was 
added an aqueous sodium hydroxide solution (3.1 cm3, 10M). The mixture was then stirred 
overnight at room temperature forming a red solution; the mixture was then acidified with 
aqueous hydrochloric acid (1 M) till the pH ~ 5 -  6, solution turns yellow. The mixture was 
then extracted with dichloromethane (3 x 30 cm3), the organic fraction was then dried over 
anhydrous magnesium sulfate, filtered and evaporated in vacuo. Recrystallization from 
methanol afforded 255 as cream crystals (2.51 g, 5.9 mmol, 77%); m.p. 157 - 159 °C; Rf 
0.18 (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcm'1) 3459, 3004, 2945, 2846, 1640, 1605, 1564, 
1508, 1482, 1459, 1441, 1385, 1343, 1259, 1217, 1158, 1012, 1002, 906, 810, 760; 6 *H 
NMR (400 MHz; CDC13; ppm) 3.87 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.94 (3H, s, OCH3),
3.94 (3H, s, OCH3), 5.67 (1H, s, OH-3” ), 6.78 (1H, s, H-6’), 6.86 (1H, d, J  8.4 Hz, H-5” ), 
6.96(1 H, d, J  16.0 Hz, H-2), 7.08(1H, dd, J2 .0 , 8.4 Hz, H-6” ), 7.20(1H, d, J2 .0  Hz, H-2” ), 
7.40(1 H, d, J  16.0 Hz, H-3); 6 I3C NMR (100 MHz; CDC13; ppm) 56.07 (s, OCH3), 56.29 (s, 
OCH3), 61.19 (s, OCH3), 61.24 (s, OCH3), 106.52 (s, CBr), 108.00 (s, CH), 110.57 (s, CH),
113.31 (s, CH), 122.85 (s, CH), 124.33 (s, CH), 128.09 (s, C), 137.04 (s, C), 144.58 (s, C),
145.95 (s, C), 146.13 (s, CH), 149.10 (s, C), 151.09 (s, C), 152.98 (s, C), 194.04 (s, CO); 
m/z{AP+) 423 (MH+, 100%), 425 (MH+, 100%); HRMS found [MH]+ 423.04471 for 
C,9H2o06Br, Ci9H2o06Br requires [MH]+ 423.04378; CHN found C 53.56%, H 4.49% CHN 
requires C 53.92%, H 4.52%.
177
Chapter 6 -  Experimental
Protocol D
The method adopted was that of Clark225 et al. To a mixture of the 2’-bromochalcone (1 
mmol) and potassium carbonate (0.350 g, 2.53 mmol) in anhydrous dimethyl formamide (8 
cm3) in a Schlenk tube was added palladium(II) chloride (0.005 g, 0.028 mmol) and 
triphenylphosphine (0.019 g, 0.071 mmol). The Schlenk tube was then degassed by 
evacuation, and put under argon. The reaction was then heated to 110 °C for 30 minutes. 
The reaction was then cooled to room temperature and had water (5 cm3) added to it, and 
stirred overnight. The precipitate was then filtered off, washed with water (2 cm3). The wet 
solid was then dissolved in ethyl acetate (3 cm3), and was heated to 65 °C with an aqueous 
potassium thiocyanate solution (1.5 cm3, 2M) under argon for 1 hour. The mixture was then 
cooled to room temperature and extracted with ethyl acetate ( 2 x 3  cm3), the combined 
organic fractions were then washed with water ( 2 x 3  cm3) and brine (3 cm3) then dried over 
anhydrous magnesium sulfate, filtered and evaporated in vacuo.
4,5,6-Trimethoxy-3-(4-methoxyphenyl)-lH-inden-1 -one 256
MeO‘
256 OMe
The indenone 256 was obtained following Protocol D. Using (£)-l-(2-bromo-3,4,5- 
trimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 254 (0.407 g, 1.00 mmol).
Recrystallization from ethyl acetate and hexane afforded 256 as bright red crystals (0.287 g, 
0.88 mmol, 88%); m.p. 107 -  109 °C; R f  0.63 (SiC>2 , ethyl acetaterhexane 1:3); Vmaxfcrn'1) 
2940, 1696, 1600, 1505, 1463, 1404, 1360, 1247, 1103, 1025, 970, 830; 6 *H NMR (400 
MHz; CDC13; ppm) 3.48 (3H, s, OCH3), 3.79 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.91 (3H, s, 
OCH3), 5.73 (1H, s, H-2), 6.95 (2H, d ,J8 .9  Hz, H-3’ & H-5’), 7.01 (1H, s, H-7), 7.66 (2H, d, 
J  8.9 Hz, H-2’ & H-6’); 8 ,3C NMR (100 MHz; CDC13; ppm) 55.38 (s, OCH3), 56.47 (s, 
OCH3), 61.22 (s, OCH3), 61.64 (s, OCH3), 104.45 (s, CH), 113.269 (s, CH), 122.29 (s, CH),
126.49 (s, CH), 127.21 (s, C), 129.02 (s, C), 129.63 (s, CH), 146.83 (s, C), 149.17 (s, C),
154.54 (s, C), 161.18 (s, C), 164.55 (s, C), 195.93 (s, CO); m/z(AP+) 327 (MH+, 100%); 
HRMS found [MH]+ 327.12425 for C,9HI9 0 5 , C 19H 19O5 requires [MH]+ 327.12270.
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(E)-l-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(3-tert-butyldimethylsilaneoxy-4-methoxy
phenyl)prop-2-en-l-one 257
OMe 257
A mixture of (£)-l-(2-bromo-3,4,5-trimethoxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)prop-
2-en-l-one 255 (1.99 g, 4.7 mmol), imidazole (0.39 g, 5.7 mmol) and tert- 
butylchlorodimethylsilane (0.85 g, 5.6 mmol) in anhydrous dimethyl formamide (10 cm ) 
under argon was stirred at room temperature for 3 days. The mixture was then diluted with 
dichloromethane (15 cm ) and washed with water (2 x 15 cm ), the organic fraction was then 
dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo. Column 
chromatography (SiC>2 , ethyl acetate:hexane 1:3) afforded 257 a yellow oil which solidified 
as a cream solid (2.24 g, 4.2 mmol, 89%); m.p. 53 - 55 °C; R f  0.58 (SiC>2 , ethyl 
acetateihexane 1:3); v^X cm '1) 2937, 2854, 1640, 1618, 1510, 1481, 1439, 1427, 1382, 
1337, 1263, 1106, 1012, 997, 985, 861, 838; 8 'H NMR (400 MHz; CDC13; ppm) 0.16 (6H, 
s, Si(CH3)2), 1.00 (9H, SiC(CH3)3), 3.85 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.93 (3H, s, 
OCH3), 3.95 (3H, s, OCH3), 6.77 (1H, s, H-6’), 6.85 (1H, d, J  8.4 Hz, H-5’), 6.93 (1H, d, J
16.1 Hz, H-2), 7.10 (1H, d, J 2 .\  Hz, H-2” ), 7.14 (1H, dd,./2.1, 8.4 Hz, H-6” ), 7.37 (1H, d, 
J  16.1 Hz, H-3); 8 l3C NMR (100 MHz; CDC13; ppm) -4.59 (s, Si(CH3)2), 18.47 (s, 
SiC(CH3)3), 25.70 (s, SiC(CH3)3), 55.48 (s, OCH3), 56.30 (s, OCH3), 61.18 (s, OCH3), 61.23 
(s, OCH3), 106.49 (s, CBr), 107.97 (s, CH), 111.71 (s, CH), 120.10 (s, CH), 123.95 (s, CH), 
124.11 (s, CH), 127.47 (s, C), 137.06 (s, C), 144.51 (s, C), 145.36 (s, C), 146.42 (s, CH), 
151.08 (s, C), 152.97 (s, C), 153.80 (s, C), 194.20 (s, CO); m/z(AP+) 537 (MH+, 90%), 539 
(MH+, 100%); HRMS found [MH]+ 537.13138 for C25H33B r06Si, C25H33Br06Si requires 
[MH]+ 537.13025; CHN found C 55.78%, H 6.16%, CHN requires C 55.86%, H 6.19%.
(E)-3-(3-(Benzyloxy)-4-methoxyphenyl)-l-(2-bromo-3,4,5-trimethoxyphenyl)prop-2-en-l-one
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The chalcone 258 was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 251 (1.24 g, 4.3 mmol), 3-(benzyloxy)-4-methoxybenzaldehyde
262 (1.06 g, 4.4 mmol) and aqueous sodium hydroxide solution (0.9 cm3, 10M) in methanol 
(3.0 cm3). Recrystallization from methanol afforded 258 as cream crystals (1.85 g, 3.6 mmol, 
84%); m.p. I l l  - 112 °C; Rf0.68 (Si02, ethyl acetate:hexane 1:1); Vmaxfcm'1) 2935, 1629, 
1615, 1593, 1510, 1480, 1444, 1426, 1386, 1342, 1256, 1230, 1157,1132, 1101, 1008, 979, 
805, 702; 6 *H NMR (400 MHz; CDC13; ppm) 3.87 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.93 
(3H, s, OCH3), 3.95 (3H, s, OCH3), 5.18 (2H, s, H -l’” ), 6.77 (1H, s, H-6’), 6.90 (1H, d, J
15.6 Hz, H-2), 6.90 (1H, d, J8 .4  Hz, H-5” ), 7.13 (1H, d, J2 .0  Hz, H-2” ), 7.16 (1H, dd, J  
2.0, 8.4 Hz, H-6” ) 7.29 -  7.48 (6H, m, H-3 & H-2” ” -  H-6” ” ); 5 l3C NMR (100 MHz; 
CDC13; ppm) 56.09 (s, OCH3), 56.30 (s, OCH3), 61.20 (s, OCH3), 61.25 (s, OCH3), 71.04 (s, 
CH2), 106.50 (s, CBr), 107.99 (s, CH), 111.48 (s, CH), 112.67 (s, CH), 123.98 (s, CH),
127.28 (s, CH), 127.37 (s, CH), 128.11 (s, CH), 128.70 (s, CH), 136.55 (s, C), 137.02 (s, C), 
144.56 (s, C), 146.28 (s, CH), 148.38 (s, C), 151.07 (s, C), 152.40 (s, C), 152.99 (s, C), 
194.04 (s, CO) missing CH and C peak; m/z(AP+) 513 (MH+, 95%), 515 (MH+, 100%); 
HRMS found [MH]+ 513.0915 for C26H2606Br, C26H260 6Br requires [MH]+ 513.0907; CHN 
found C 59.65%, H 4.78% CHN requires C 60.83%, H 4.91%.
(E)-l-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(3-isopropoxy-4-methoxyphenyl)prop-2-en-l-one 
259
MeO
MeO
OMe 259
The chalcone 259 was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 251 (1.52 g, 5.3 mmol), 3-isopropoxy-4-methoxybenzaldehyde
263 (1.04 g, 5.4 mmol) and aqueous sodium hydroxide solution (0.9 cm , 12M) in methanol 
(5.0 cm ). Recrystallization from methanol afforded 259 as fine light yellow needles (1.82 g,
3.9 mmol, 74%); m.p. 138 -  140 °C; R f  0.83 (Si02, ethyl acetate:hexane 1:1); v^X cm ’1) 
3087, 2980, 2939, 2836, 1634, 1615, 1591, 1512, 1482, 1470, 1443, 1427, 1388, 1339, 1261, 
1162, 1137,999,977; 6 *H NMR (400 MHz; CDC13; ppm) 1.38 (6H, d, J  6.1 Hz, H-2’” & 
H-3’” ), 3.87 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.94 (3H, s, OCH3),
4.57 (1H, sp, J6.1 Hz, H -l” ’), 6.77 (1H, s, H-6’), 6.88 (1H, d, J8 .3  Hz, H-5’), 6.94 (1H, d, J
16.0 Hz, H-2), 7.12 (1H, d, J  1.9 Hz, H-2” ), 7.15 (1H, dd, J  1.9, 8.3 Hz, H-6” ), 7.39 (1H, d, 
J  16.0 Hz, H-3); 6 13C NMR (100 MHz; CDC13; ppm) 22.02 (s, CH(CH3)2), 56.04 (s, OCH3),
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56.30 (s, OCH3), 61.20 (s, OCH3), 61.24 (s, OCH3), 71.59 (s, CH(CH3)2), 106.46 (s, CBr),
107.95 (s, CH), 111.65 (s, CH), 114.51 (s, CH), 123.63 (s, CH), 123.96 (s, CH), 127.28 (s, 
C), 137.05 (s, C), 144.52 (s, C), 146.57 (s, CH), 147.52 (s, C), 151.07 (s, C), 153.00 (s, C),
153.14 (s, C), 194.19 (s, CO); m/z(API-ES+) 465 (M H\ 100%), 467 (MH+, 100%); HRMS 
found [MH]+ 465.0975 for C22H25B1O 6 , C22H25B1O 6 requires [MH]+ 465.09073; CHN found 
C 56.20%, H 5.31%, CHN requires C 56.78%, H 5.42%.
(E)-l-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(4-methoxy-3-(methoxymethoxy)phenyl)prop-2- 
en-l-one 260
MeO.
4M OMeMeO
OMe
260
The chalcone 260 was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 251 (0.44 g, 1.5 mmol), 4-methoxy-3-(methoxymethoxy) 
benzaldehyde 264 (0.30 g, 1.5 mmol) and aqueous sodium hydroxide solution (1.5 cm3, 2M) 
in methanol (6.0 cm3). Recrystallization from methanol afforded 260 as white crystals (0.48 
g, 1.0 mmol, 69%); m.p. 99 -  100 °C; R f  0.20 (Si02, ethyl acetate:hexane 1:3); VmaxXcm'1) 
3004, 2963, 2939, 2837, 1629, 1595, 1510, 1482, 1466, 1451, 1429, 1248, 1138, 1104, 979, 
828; 6  *H NMR (400 MHz; CDC13; ppm) 3.51 (3H, s, OCH3), 3.86 (3H, s, OCH3), 3.91 (3H, 
s, OCH3), 3.92 (3H, s, OCH3), 3.94 (3H, s, OCH3), 5.24 (2H, s, H-2’” ), 6.75 (1H, s, H-6 ’),
6.90 (1H, d, J  8.5 Hz, H-5’), 6.95 (1H, d, J  16.0 Hz, H-2), 7.22 (1H, dd, J2 .0 , 8.5 Hz, H-6 ” ), 
7.37 (1H, d, J  16.0 Hz, H-3), 7.38 (1H, d, J  2.0 Hz, H-2” ); 513C NMR (100MHz; CDC13; 
ppm) 56.26 (s, OCH3), 56.52 (s, OCH3), 56.57 (s, OCH3), 61.38 (s, OCH3), 61.42 (s, OCH3), 
95.77 (s, OCH20), 106.64 (s, CBr), 108.15 (s, CH), 111.87 (s, CH), 115.82 (s, CH), 124.61 
(s, CH), 124.69 (s, CH), 127.76 (s, C), 137.21 (s, C), 144.75 (s, C), 146.48 (s, CH), 147.06 (s, 
C), 151.31 (s, C), 152.54 (s, C), 153.22 (s, C), 194.42 (s, CO); m/z{API ES+) 467 (MH+, 
100%), 469 (M H \ 100%); HRMS found [MH]+ 467.07094 for C21H23B1O 7, C21H23B1O 7 
requires [MH]+ 467.06999.
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3-(Benzyloxy)-4-methoxybenzaldehyde 262347
3 " '
262
Benzyl bromide (2.3 cm3, 19.4 mmol) was added to a mixture of 3-hydroxy-4- 
methoxybenzaldehyde (2.86 g, 18.8 mmol) and potassium carbonate (10.5 g, 76.0 mmol) in 
anhydrous dimethyl formamide (100 cm3). The mixture was then put under argon and heated 
to 90 °C for 2 hours. The dimethyl formamide was then evaporated in vacuo. The crude 
product was then dissolved in chloroform (300 cm3) and filtered through celite, and washed 
with water (6 * 50 cm ). The organic fraction was then dried over anhydrous magnesium 
sulfate, filtered and evaporated in vacuo, to afforded 262 as a pale yellow solid (4.49 g, 18.5 
mmol, 99%); m.p. 53 -  55 °C; Rf 0.63 (Si02, ethyl acetate:hexane 1:1); VmaxXcrn'1) 2966, 
2934, 2812, 2749, 2718, 1677, 1596, 1582, 1505, 1456, 1431, 1383, 1235, 1128, 1008, 805, 
734, 697; 6 *H NMR (400 MHz; CDC13; ppm) 3.88 (3H, s, OCH3), 5.11 (2H, s, H -l” ), 6.91 
(1H, d, J  8.3 Hz, H-5’), 7.21-7.42 (7H, m, H-2’, H-6’, H-2” ’ -  H-6” ’), 9.74 (1H, s, H-l); 6 
,3C NMR (100 MHz; CDC13; ppm) 56.22 (s, OCH3), 70.82 (s, CH2Ph), 110.75 (s, CH), 
111.23 (s, CH), 126.98 (s, CH), 127.51 (s, CH), 128.16 (s, CH), 128.68 (s, CH), 129.96 (s, 
C), 136.27 (s, C), 148.68 (s, C), 155.03 (s, C), 190.92 (s, CHO).
3-Isopropoxy-4-methoxybenzaldehyde 263227
2" 3”
263
The method adopted was that of Ridley227 et al. A mixture 3-hydroxy-4-methoxy 
benzaldehyde (1.54 g, 10.1 mmol), isopropyl bromide (1.45 cm3, 15.4 mmol) and potassium 
carbonate (2.27 g, 16.5 mmol) in anhydrous dimethyl formamide (8 cm3) was stirred at room 
temperature for 96 hours. The mixture was then poured in water (24 cm3) and extracted with 
diethyl ether (3 * 20 cm ). The organic fraction was then washed with aqueous sodium 
hydroxide solution (3 x 30 cm , 1M), dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. Column chromatography (Si02, ethyl acetate:hexane 1:9) afforded 263 
as a yellow brown oil (1.73 g, 8.9 mmol, 88%); Rf 0.23 (Si02, ethyl acetate:hexane 1:9); 
VmaxCcm'1) 2977, 2935, 2841, 1685, 1582, 1506, 1464, 1432, 1238, 1128, 1109; 8 ‘H NMR
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(400 MHz; CDC13; ppm) 1.40 (6 H, d, J  6.\ Hz, H-2” & H-3” ), 3.94 (3H, s, OCH3), 4.65 
(1H, sp,y6.1 Hz, H -l” ), 6.98 (1H, d, J8 .2  Hz, H-5’), 7.41(1H, d ,J  1.8 Hz, H-2’), 7.44 (1H, 
dd, J  1.8, 8.2 Hz, H-6 ’), 9.84 (1H, s, H-l); 6  l3C NMR (100 MHz; CDC13; ppm) 21.91 (s, 
CH(CH3)2), 56.18 (s, OCH3), 71.26 (s, CH(CH3)2), 110.87 (s, CH), 112.46 (s, CH), 126.55 (s, 
CH), 130.01 (s, C), 147.84 (s, C), 155.60 (s, C), 191.04 (s, CHO); m/z(AP+) 125 (C7H90 2, 
50%), 153 (C9H,30 2, 35%), 195 (MH+, 100%).
4-Methoxy-3-(methoxymethoxy)benzaldehyde 264348
0 , M y,
3 ^ 0 ^ 0 M eJ
OMe 
264
The method was adapted from that of Crombie228 et al. To a stirring solution of sodium 
hydride (0.32 g, 8.0 mmol, 60% dispersion in mineral oil) in anhydrous dimethyl formamide 
(4 cm3) at 0 °C under argon 3-hydroxy-4-methoxybenzaldeyde (1.00 g, 6 . 6  mmol) in 
anhydrous dimethyl formamide (4 cm3) was added slowly drop wise over 20 minutes. The 
reaction was then allowed to warm to room temperature and was stirred at room temperature 
for 30 minutes, before being cooled to 0 °C. Chloromethyl methyl ether (0.60 cm3, 7.9 
mmol) in anhydrous dimethyl formamide (2 cm3) was then added drop wise over 30 minutes 
to the mixture at 0 °C. The mixture was then stirred for 30 minutes at 0 °C and then stirred 
overnight at room temperature. The reaction was then tipped into a mixture of water (10 cm3) 
and ice (10 g), and extracted with dichloromethane (4 * 15cm ). The organic fraction was
washed with an aqueous sodium hydroxide solution (2><15 cm3, 1.0M) and water ( 2  x i 5
■*>
cm ), it was then dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo. 
Purification by column chromatography (Si(>2 , ethyl acetate:hexane 1:3) afforded 264 as a 
cream solid (1.14 g, 5.8 mmol, 8 8 %); m.p. 2 9 -3 1  °C; R f  0.69 (Si0 2 , ethyl acetate:hexane 
1:1); Vrnaxfcm'1) 2952, 2839, 2767, 1678, 1595, 1584, 1507, 1464, 1434, 1231, 1151, 1125, 
1073, 997, 916, 803, 730; 5 !H NMR (400 MHz; CDC13; ppm) 3.53 (3H, s, OCH3), 3.97 
(3H, s, OCH3), 5.29 (2H, s, H-2” ), 7.01 (1H, d, J8 .4  Hz, H-5’), 7.55 (1H, dd, J  1.9,78.4 Hz, 
H-6 ’), 7.67 (1H, d, J  1.9 Hz, H-2’), 9.86 (1H, s, H-l); 8 I3C NMR (100MHz; CDC13; ppm)
56.20 (s, OCH3), 56.42 (s, OCH3), 95.41 (s, OCH20), 111.13 (s, CH), 115.39 (s, CH), 126.78 
(s, CH), 130.17 (s, C), 146.97 (s, C), 155.08 (s, C), 190.77 (s, CHO); m/z{API ES+) 197 
(MH+, 100%).
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3-(3-Tert-butyldimethylsilaneoxy-4-methoxyphenyl)-4,5,6-trimethoxy-lH-inden-1 -one 261
MeO
261 OMe
A mixture of (£)-l-(2-bromo-3,4,5-trimethoxyphenyl)-3-(3-/er/-butyldimethylsilaneoxy-4- 
methoxyphenyl)prop-2-en-l-one 2 5 7  (0.104 g, 0.19 mmol), potassium carbonate (0.075 g, 
0.54 mmol), palladium(II) chloride (0.001 g, 0.0056 mmol) and triphenylphosphine (0.005 g, 
0.019 mmol) was dissolved in anhydrous dimethyl formamide (1.5 cm3) and sealed in a 
pressure-rated reaction vial (10 cm ). The reaction vial was then irradiated in a self-turning 
single-mode CEM Discovery™ Focused Synthesizer. The reaction was maintained at 160 °C 
(power: 150 W) for 15 minutes. The mixture was then rapidly cooled to room temperature,
T _then had water (1.5 cm ) added to it and left at room temperature overnight. The precipitate 
was then filtered off, washed with water (1 cm3). The wet solid was then dissolved in ethyl 
acetate (3 cm3), and was heated to 65 °C with an aqueous potassium thiocyanate solution (1 
cm3, 2M) under argon for 1 hour. The mixture was then cooled to room temperature and 
extracted with ethyl acetate (3 cm3), the combined organic fractions were then washed with 
water ( 2  x 1 cm ) and brine ( 2  x 1 cm ) then dried over anhydrous sodium sulfate, filtered 
and evaporated in vacuo to afford 2 6 1  as a red gum (0.072 g, 0.16 mmol, 81%); R f  0.63 
(Si02, ethyl acetate:hexane 1:3); vmax.(cml) 2930, 2855, 1703, 1597, 1508, 1465, 1415, 
1338, 1262, 1106, 1026, 834; 6  ‘H NMR (400 MHz; CDC13; ppm) 0.19 (6 H, s, Si(CH3)2),
1.01 (9H, s, C(CH3)3), 3.47 (3H, s, OCH3), 3.88 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.90 (3H, 
s, OCH3), 5.71 (1H, s, H-2), 6 . 8 8  (1H, d, J8 .7  Hz, H-5’), 7.00 (1H, s, H-7), 7.21 (1H, d, J2A  
Hz, H-2’), 7.31 (1H, dd, J2 .1 , 8.7 Hz, H-6 ’); S13C NMR (100MHz; CDC13; ppm) 0.00 (s, 
Si(CH3)2), 23.10 (s, C(CH3)3), 30.34 (s, C(CH3)3), 60.11 (s, OCH3), 61.13 (s, OCH3), 65.82 
(s, OCH3), 66.25 (s, OCH3), 109.11 (s, CH), 115.65 (s, CH), 125.31 (s, CH), 126.64 (s, CH),
127.06 (s, CH), 131.50 (s, C), 131.97 (s, C), 133.68 (s, C), 148.95 (s, C), 151.55 (s, C),
153.93 (s, C), 157.41 (s, C), 157.41 (s, C), 159.15 (s, C), 169.15 (s, C), 200.47 (s, CO); 
m/z(API ES+) 457 (MH+, 100%); HRMS found [MH]+ 457.20440 for C2 5H330 6Si, 
C25H330 6Si requires [MH]+ 457.20409.
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3-(3-(Benzyloxy)-4-methoxyphenyl)-4,5,6-trimethoxy-lH-inden-1 -one 266
MeO
MeO'
2 6 6 OMe
The indenone 2 6 6  was obtained following Protocol D .  Using (£)-3-(3-(benzyloxy)-4- 
methoxyphenyl)-l-(2-bromo-3,4,5-trimethoxyphenyl)prop-2-en-l-one 2 5 8  (0.54 g, 1.05 
mmol). Recrystallization from ethyl acetate and hexane afforded 2 6 6  as a Red solid (0.28 g, 
0.65 mmol, 62%); m.p. 107- 109 °C; Rf0.71 (SiC>2 , ethyl acetate:hexane 1:1); VmaxXcrn'1) 
2943, 1696, 1595, 1545, 1505, 1465, 1439, 1418, 1404, 1357, 1275, 1255, 1135, 1023, 836, 
756, 702; 5 'H NMR (400 MHz; CDCI3 ; ppm) 3.40 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.90 
(3H, s, OCH3), 3.96 (3H, s, OCH3), 5.20 (2H, s, H -l” ), 5.67 (1H, s, H-2), 6.94 (1H, d, J  8.2 
Hz, H-5’), 7.00 (1H, s, H-7), 7.29 -  7.48 (7H, m, H-2’, H-6 ’ & H-2’”  -  H-6 ’” ); 8  13C NMR 
(100 MHz; CDC13; ppm) 56.03 (s, OCH3), 56.48 (s, OCH3), 61.26 (s, OCH3), 61.75 (s, 
OCH3), 71.05 (s, CH2), 104.48 (s, CH), 110.70 (s, CH), 113.78 (s, CH), 121.74 (s, CH),
122.47 (s, CH), 126.58 (s, C), 127.14 (s, C), 127.34 (s, CH), 127.99 (s, CH), 128.62 (s, CH),
129.00 (s, C), 136.88 (s, C), 146.84 (s, C), 147.33 (s, C), 149.17 (s, C), 151.37 (s, C), 154.51 
(s, C), 164.50 (s, C), 195.81 (s, CO); m/z(AP+) 433 (MH+, 100%); HRMS found [MH]+ 
433.1649 for C26H250 6, C26H250 6 requires [MH]+ 433.1646.
3-(3-lsopropoxy-4-methoxyphenyl)-4,5,6-trimethoxy-lH-inden-1 -one 2 6 7
MeO.
MeO'
OMe
2 6 7 OMe
The indenone 2 6 7  was obtained following Protocol D. Using (£)-l-(2-bromo-3,4,5- 
trimethoxyphenyl)-3-(3-isopropoxy-4-methoxyphenyl)prop-2-en-l-one 2 5 9  (0.46 g, 1.00 
mmol). Recrystallization from ethyl acetate afforded 2 6 7  as a red powder (0.18 g, 0.48 
mmol, 48%); m.p. 111 — 112 °C; R f  0.83 (Si0 2 , ethyl acetate:hexane 1:1); VmaxXcrn'1) 2992, 
2975, 2937, 1692, 1611, 1590, 1538, 1507, 1464, 1438, 1404, 1368, 1271, 1109, 1020, 1001, 
776; 6  'H NMR (400 MHz; CDC13; ppm) 1.40 (6 H, d, J6.1 Hz, H-2” & H-3” ), 3.45 (3H, s, 
OCH3), 3.90 (6 H, s, OCH3), 3.92 (3H, s, OCH3), 4.57 (1H, sp, J6 .1  Hz, H -l” ), 5.73 (1H, s, 
H-2), 6.91 (1H, d, J9 .0  Hz, H-5’), 7.01 (1H, s, H-7), 7.27 -  7.31 (2H, m, H-2’ & H-6 ’); 513C
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( 1 0 0 MHz; CDC13; ppm) 2 2 . 1 0  (s, CH(CH3)2), 55.97 (s, OCH3), 56.48 (s, OCH3), 61.24 (s, 
OCH3), 61.77 (s, OCH3), 71.55 (s, CH(CH3)2), 104.51 (s, CH), 110.85 (s, CH), 115.34 (s, 
CH), 121.39 (s, CH), 122.46 (s, CH), 126.66 (s, C), 127.25 (s, C), 129.03 (s, C), 146.50 (s, 
C), 146.87 (s, C), 149.22 (s, C), 152.04 (s, C), 154.50 (s, C), 164.67 (s, C), 195.81 (s, CO); 
m/z{AP+) 385 (MH+, 100%); HRMS found [MH]+ 385.16672 for C22H250 6, C22H250 6 
requires [MH]+ 385.16456.
4,5,6-Trimethoxy-3-(4-methoxy-3-(methoxymethoxy)phenyl)-lH-inden-1-one 2 6 5
MeO‘
2 6 5  0 M e
A mixture of (£)-l-(2-bromo-3,4,5-trimethoxyphenyl)-3-(4-methoxy-3-(methoxymethoxy) 
phenyl)prop-2-en-l-one 2 6 0  (0.101 g, 0.22 mmol), potassium carbonate (0.081 g, 0.59 
mmol), pailadium(II) chloride (0.001 g, 0.0056 mmol) and triphenylphosphine (0.005 g, 
0.019 mmol) was dissolved in anhydrous dimethyl formamide (1.5 cm ) and sealed in a 
pressure-rated reaction vial (10 cm3). The reaction vial was then irradiated in a self-turning 
single-mode CEM Discovery™ Focused Synthesizer. The reaction was maintained at 160 °C 
(power: 150 W) for 15 minutes. The mixture was then rapidly cooled to room temperature, 
then had water (1.5 cm ) added to it and left at room temperature overnight. The precipitate 
was then filtered off, washed with water (1 cm3). The wet solid was then dissolved in ethyl 
acetate (1 cm3), and was heated to 65 °C with an aqueous potassium thiocyanate solution 
(0.75 cm3, 2M) under argon for 1 hour. The mixture was then cooled to room temperature 
and extracted with ethyl acetate (3 cm3), the combined organic fractions were then washed 
with water ( 2  x 1 cm3) and brine (2 ^ 3  cm3) then dried over anhydrous sodium sulfate, 
filtered and evaporated in vacuo to afford 2 6 5  as a red solid (0.075 g, 0.19 mmol, 91%).
A mixture of (£)-l-(2-bromo-3,4,5-trimethoxyphenyl)-3-(4-methoxy-3-(methoxymethoxy) 
phenyl)prop-2-en-l-one 2 6 0  (0.264 g, 0.56 mmol), potassium carbonate (0.211 g, 1.53 
mmol), palladium(II) chloride (0.005 g, 0.019 mmol) and triphenylphosphine (0.030 g, 0.11 
mmol) was dissolved in anhydrous dimethyl formamide (4.5 cm3) and sealed in a pressure­
rated reaction vial (10 cm3). The reaction vial was then irradiated in a self-turning single­
mode CEM Discovery™ Focused Synthesizer. The reaction was maintained at 160 °C 
(power: 150 W) for 15 minutes. The mixture was then rapidly cooled to room temperature, 
then had water (4.5 cm3) added to it and left at room temperature overnight. The precipitate
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was then filtered off, washed with water (3 cm3). The wet solid was then dissolved in ethyl 
acetate (3 cm3), and was heated to 65 °C with an aqueous potassium thiocyanate solution (2.5 
cm3, 2M) under argon for 1 hour. The mixture was then cooled to room temperature and 
extracted with ethyl acetate (9 cm ), the combined organic fractions were then washed with 
water ( 2 x 3  cm3) and brine (2 x 9  cm3) then dried over anhydrous sodium sulfate, filtered 
and evaporated in vacuo. Column chromatography (SiC>2 , ethyl acetate:hexane 1:19 to 1:3) 
afforded 265 as a red solid (0.041 g, 0.11 mmol, 19%).
m.p. 109 -  1 1 1  °C; R f  0.15 (SiC>2, ethyl acetate:hexane 1:3); VmaxXcrn'1) 2993, 2934, 2844, 
1691, 1599, 1553, 1506, 1465, 1445, 1432, 1406, 1363, 1262, 1111, 1073, 918, 821; 6  ‘H 
NMR (400 MHz; CDC13; ppm) 3.49 (3H, s, OCH3), 3.53 (3H, s, OCH3), 3.90 (3H, s, OCH3),
3.90 (3H, s, OCH3), 3.95 (3H, s, OCH3), 5.27 (3H, s, H-2” ), 5.75 (1H, s, H-2), 6.94 (1H, d, J
8.7 Hz, H-5’), 7.00 (1H, s, H-7), 7.38 (1H, dd, J2 .1 , 8.7 Hz, H-6 ’), 7.54 (1H, d, J2.1 Hz, H- 
2’); S13C NMR (100MHz; CDC13; ppm) 56.18 (s, OCH3), 56.49 (s, OCH3), 56.70 (s, OCH3), 
61.38 (s, OCH3), 61.84 (s, OCH3), 95.94 (s, OCH20), 104.70 (s, CH), 111.04 (s, CH), 116.88 
(s, CH), 122.87 (s, CH), 122.99 (s, CH), 127.11 (s, C), 127.41 (s, C), 129.16 (s, C), 145.94 (s, 
C), 147.11 (s, C), 149.42 (s, C), 151.72 (s, C), 154.76 (s, C), 164.52 (s, C), 196.01 (s, CO); 
m/z{API ES+) 387 (MH+, 100%); HRMS found [MH]+ 387.14368 for C2 iH230 7, C2 iH230 7 
requires [MH]+ 387.14383.
3-(3-Hydroxy-4-methoxyphenyl)-4,5,6-trimethoxy-1 H-inden-1 -one 2 6 8
MeO.
MeO 5
OH
OMe
2 6 8
To a stirring mixture of 3-(3-ter/-butyldimethylsilaneoxy-4-methoxyphenyl)-4,5,6- 
trimethoxy-1 H-inden-1 -one 2 6 1  (0.040 g, 0.088 mmol) in anhydrous tetrahydrofiiran (1.4 
cm3) at 0 °C under argon was added a solution of tetrabutylammonium fluoride in 
tetrahydrofuran (0.09 cm3, 0.09 mmol, 1 M). The reaction was stirred at 0 °C for 30 minutes, 
the solvent was evaporated in vacuo. Column chromatography (SiC>2 , ethyl acetate:hexane 
1:19 to 1:3) afforded 2 6 8  as a red solid (0.020 g, 0.058 mmol, 6 6 %); m.p. 131 — 133 °C; R f  
0.30 (Si02, ethyl acetate:hexane 1:3); v^X cm '1) 3319, 2931, 1683, 1603, 1556, 1501, 1454, 
1405, 1363, 1285, 1236, 1023, 847, 800; 5 *H NMR (400 MHz; CDC13; ppm) 3.52 (3H, s, 
OCH3), 3.89 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.96 (3H, s, OCH3), 5.67 (1H, br. s, OH-3’),
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5.73 (1H, s, H-2), 6.83 (1H, d, J8 .0  Hz, H-5’), 7.00 (1H, s, H-7), 7.24 -  7.28 (2H, m, H-2’ & 
H-6 ’); S13C NMR (100MHz; CDC13; ppm) 56.22 (s, OCH3), 56.70 (s, OCH3), 61.39 (s, 
OCH3), 61.82 (s, OCH3), 104.69 (s, CH), 110.00 (s, CH), 114.51 (s, CH), 120.68 (s, CH),
122.94 (s, CH), 127.41 (s, C), 127.72 (s, C), 129.16 (s, C), 145.17 (s, C), 147.12 (s, C),
148.35 (s, C), 149.44 (s, C), 154.77 (s, C), 164.68 (s, C), 196.08 (s, CO); m/z(API ES+) 343 
(MPT*, 100%); HRMS found [MH]+ 343.11840 for Ci9 H190 6, C,9H|90 6 requires [MH]+ 
343.11761.
3-(3-Hydroxy-4-methoxyphenyl)-4,5,6-trimethoxy-1 H-inden-1 -one 268 & 2,3-Dihydro-3-(3- 
hydroxy-4-methoxyphenyl)-3,4,5,6-tetramethoxyinden-l -one 269
MeO. MeO
MeO 5 OMe
OH OH
OMe OMe
268 269
The method adopted was that of Wang230 et al. To a stirring solution of 4,5,6-trimethoxy-3- 
(4-methoxy-3-(methoxymethoxy)phenyl)-l H-inden-1-one 265 (0.040 g, 0.10 mmol) in 
methanol (3 cm3) under argon was added aqueous hydrochloric acid (0.6 cm3, 3M). The 
reaction was then heated to reflux at 75 °C for 45 minutes. The reaction was cooled to room 
temperature and tipped into water (3 cm3), it was then extracted with dichloromethane (3><10 
cm3). The organic fraction was then washed dried over anhydrous sodium sulfate, filtered 
and evaporated in vacuo. Column chromatography (SiC>2 , ethyl acetate:hexane 1:19 to 2:3) 
afforded 268 as a red solid (0.004 g, 0.01 mmol, 12%) and then afforded 269 as a yellow gum 
(0 . 0 1 1  g, 0.03 mmol, 30%); Rf 0.12 (SiC>2, ethyl acetate:hexane 1:3); VmaxXcrn'1) 3412, 2938, 
2838, 1708, 1595, 1509, 1467, 1416, 1334, 1019, 762; 6  *H NMR (400 MHz; CDC13; ppm) 
2.92 (1H, d, J  19.2 Hz, H-2), 3.17 (1H, d, J  19.2 Hz, H-2), 3.19 (3H, s, OCH3), 3.48 (3H, s, 
OCH3), 3.87 (3H, s, OCH3), 3.91 (3H, s, OCH3), 3.93 (3H, s, OCH3), 5.55 (1H, s, OH-3’),
6.80 (1H, d, J  8.5 Hz, H-5’), 6 . 8 8  (1H, dd, J2 .0 , 8.5 Hz, H-6 ’), 6.90 (1H, d ,72 .0  Hz, H-2’),
7.08 (1H, s, H-7); 8  13C NMR (100 MHz; CDC13; ppm) 51.73 (s, CH2), 51.86 (s, OCH3), 
56.17 (s, OCH3), 56.51 (s, OCH3), 60.53 (s, OCH3), 61.13 (s, OCH3), 83.01 (s, C), 100.18 (s, 
CH), 110.36 (s, CH), 112.14 (s, CH), 116.89 (s, CH), 133.31 (s, C), 138.43 (s, C), 141.22 (s, 
C), 145.52 (s, C), 145.60 (s, C), 149.32 (s, C), 151.03 (s, C), 156.36 (s, C), 202.7 (s, CO) 
/n/z(API-ES -)  373 ([M]\ 100%); HRMS found [MH]+ 375.14396 for C2oH230 7, C2oH230 7 
requires [MH]+375.14383.
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(E)-l-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(4-methoxy-3-nitrophenyl)prop-2-en- J-one 270
OMe 270
The chalcone 270 was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 251 (1.04 g, 3.6 mmol), 4-methoxy-3-nitrobenzaldehyde 276 
(0.65 g, 3.6 mmol) and aqueous sodium hydroxide solution (0.8 cm3, 10M) in methanol (6.0 
cm3). Recrystallization from methanol afforded 270 as yellow fluffy crystals (1.14 g, 2.5 
mmol, 70%); m.p. 9 5 -1 1 0  °C; R f  0.24 (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcnT1) 2942, 
2845, 1662, 1618, 1600, 1579, 1562, 1532, 1498, 1483, 1459, 1445, 1427, 1415, 1343, 1276, 
1001, 818; 6  *H NMR (400 MHz; CDC13; ppm) 3.88 (3H, s, OCH3), 3.94 (3H, s, OCH3),
3.95 (3H, s, OCH3), 4.02 (3H, s, OCH3), 6.80 (1H, s, H-6 ’), 7.48 (1H, d, J  16.2 Hz, H-2), 
7.14 (1H, d, J  8.7 Hz, H-5” ), 7.44 (1H, d, J  16.2 Hz, H-3), 7.76 (1H, dd, J2 .1 , 8.7 Hz, H- 
6 ” ), 8.06 (1H, d, J  2.1 Hz, H-2” ); 8  ,3C NMR (100 MHz; CDC13; ppm) 56.33 (s, OCH3),
56.85 (s, OCH3), 61.23 (s, OCH3), 61.25 (s, OCH3), 106.60 (s, CBr), 108.07 (s, CH), 113.97 
(s, CH), 125.56 (s, CH), 126.32 (s, CH), 127.21 (s, C), 133.99 (s, CH), 136.47 (s, C), 139.85 
(s, C), 142.39 (s, CH), 144.96 (s, C), 151.13 (s, C), 153.13 (s, C), 154.41 (s, C), 193.29 (s, 
CO); m/z(AP+) 452 (MH+, 100%), 454 (MH+, 100%); HRMS found [MH]+ 452.03438 for 
Ci9Hi90 7NBr, Ci9 Hi90 7NBr requires [MH]+ 452.03394; CHN found C 50.28%, H 3.96%, N 
2.95% CHN requires C 50.46%, H 4.01%, N 3.10%.
(E)-J-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(3-fluoro-4-methoxyphenyl)prop-2-en-l-one 271
O
OMe 271
The chalcone 271 was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 251 (0.93 g, 3.2 mmol), 3-fluoro-4-methoxybenzaldehyde (0.53
3 3g, 3.4 mmol) and aqueous sodium hydroxide solution (0.8 cm , 10M) in methanol (3.0 cm ). 
Recrystallization from methanol afforded 271 as white crystals (1.15 g, 2.7 mmol, 84%); 
m.p. 116 -  117 °C; R f  0.71 (SiC>2 , ethyl acetate:hexane 1:1); VmaxXcrn'1) 2934, 1642, 1611, 
1559, 1511, 1482, 1457, 1437, 1425, 1383, 1345, 1266, 1129, 1019, 1008, 986, 804; 8  'H 
NMR (400 MHz; CDC13; ppm) 3.89 (3H, s, OCH3), 3.95 (6 H, s, OCH3), 3.96 (3H, s, OCH3),
6.80 (1H, s, H-6 ’), 6.97 (1H, t,./8 .5  Hz, H-5” ), 6.99 (1H, d ,J  16.1 Hz, H-2), 7.29-7.33 (1H,
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brd, .79.0 Hz, H-6” ), 7.36 (1H, dd, 72.0 Hz, J  12.0 Hz, H-2” ), 7.41 (1H, d, J  15.5 Hz, H-3); 
8 13C NMR (100 MHz; CDC13; ppm) 56.28 (s, OCH3), 56.30 (s, OCH3), 61.20 (s, OCH3),
61.24 (s, OCH3), 106.52 (s, CBr), 108.00 (s, CH), 113.136 (d, J  2.0 Hz, CH), 115.09 (d, J
18.1 Hz, CH), 124.94 (s, CH), 126.22 (d, J3 .7  Hz, CH), 127.70 (d, J6 .6  Hz, C), 136.82 (s, 
C), 144.57 (d, J2 .9  Hz, CH), 144.71 (s, C), 150.03 (d, J 11.0 Hz, C), 151.09 (s, C), 152.39 (d, 
J  247.2 Hz, CF), 153.62 (s, C), 193.72 (s, CO); m/z(AP+) 425 (MH+, 100%), 427 (MH+, 
100%); HRMS found [MH]+ 425.0388 for C^H^OsBrF, C^H^OsBrF requires [MH]+ 
425.0394; CHN found C 53.70%, H 4.21% CHN requires C 53.66%, H 4.27%.
(E)-l-(2-Bromo-3,4,5-trimethoxyphenyl)-3-phenylprop-2-en-l-one 2 7 2
0
OMe 272
The chalcone 2 7 2  was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 2 5 1  (1.15 g, 4.0 mmol), benzaldehyde (0.4 cm3, 3.9 mmol) and 
aqueous sodium hydroxide solution (0.8 cm3, 10M) in methanol (3.0 cm3). Recrystallization 
from methanol afforded 2 7 2  as white crystals (0.86 g, 2.7 mmol, 71%); m.p. 79 -  80 °C; R f  
0.77 (Si02, ethyl acetate:hexane 1:1); v^X cm '1) 2939, 1643, 1623, 1564, 1479, 1464, 1447, 
1426, 1385 , 1341, 1099, 1005, 907, 778, 689; 5 *H NMR (400 MHz; CDC13; ppm) 3.88 (3H, 
s, OCH3), 3.93 (3H, s, OCH3), 3.95 (3H, s, OCH3), 6.80 (1H, s, H-6’), 7.12 (1H, d, J  16.0 Hz, 
H-2), 7.38 -  7.45 (3H, m, H-3” -  H-5” ), 7.49 (1H, d, J  16.0 Hz, H-3), 7.56 -  7.60 (2H, m, 
H-2” & H-6” ); 8 ,3C NMR (100 MHz; CDC13; ppm) 56.30 (s, OCH3), 61.20 (s, OCH3),
61.25 (s, OCH3), 106.58 (s, CBr), 108.05 (s CH), 126.03 (s CH), 128.64 (s CH), 129.04 (s 
CH), 130.93 (s CH), 134.47 (s, C), 136.79 (s, C), 144.74 (s, C), 146.00 (s CH), 151.12 (s, C),
153.04 (s, C), 194.07 (s, CO); m/z(AP+) 377 (MH+, 100%), 379 (MH+, 100%); HRMS 
found [M H f 377.380 for Ci8Hi80 4Br, Ci8H180 4Br requires [MH]+ 377.0383; CHN found C 
57.35%, H 4.49%, CHN requires C 57.31%, H 4.54%.
(E)-l-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(3,5-dimethoxyphenyl)prop-2-en-J-one 2 7 3
0
OMe 273 OMe
The chalcone 2 7 3  was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 2 5 1  (1.04 g, 3.6 mmol), 3,5-dimethoxybenzaldehyde (0.60 g, 3.6
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mmol) and aqueous sodium hydroxide solution (0.8 cm , 10M) in methanol (3.0 cm ). 
Recrystallization from methanol afforded 273 as white crystals (1.15 g, 2.6 mmol, 73%); 
m.p. 81 -  83 °C; R f  0.74 (Si02, ethyl acetate:hexane 1:1); VmaxXcm'1) 2938, 2833, 1664, 
1594, 1562, 1479, 1467, 1448, 1428, 1337, 1279, 1199, 1164, 1055, 1003, 977, 922, 826, 
669; 6 ‘H NMR (400 MHz; CDC13; ppm) 3.75 (6H, s, OCH3), 3.81 (3H, s, OCH3), 3.87 (3H, 
s, OCH3), 3.88 (3H, s, OCH3), 6.45(1H, t, J 2 A  Hz, H-4” ), 6.64 (2H, d, J 2.4 Hz, H-2” & H- 
6” ), 6.72 (1H, s, H-6’), 7.00 (1H, d, J  16.0 Hz, H-2), 7.33 (1H, d, J  16.0 Hz, H-3); 6 ,3C 
NMR (100 MHz; CDC13; ppm) 55.50 (s, OCH3), 56.31 (s, OCH3), 61.21 (s, OCH3), 61.25 (s, 
OCH3), 103.19 (s, CH), 106.39 (s, CH), 106.59 (s, CBr), 108.06 (s, CH), 126.50 (s, CH),
136.32 (s, C), 136.70 (s, C), 144.75 (s, C), 146.01 (s, CH), 151.09 (s, C), 153.04 (s, C),
161.06 (s, C), 194.05 (s, CO); m/z(AP+) 437 (MH+, 100%), 439 (MH+, 95%); HRMS found 
[MH]+ 437.0598 for C2oH2206Br, C2oH2206Br requires [MH]+ 437.0594;CHN found C 
54.93%, H 4.78% CHN requires C 54.93%, H 4.84%.
(E)-l-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 274
0
OMe
1 3
6O’ Br 51 *
OMe 274 OMe
The chalcone 274 was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 251 (1.02 g, 3.5 mmol), 3,4,5-trimethoxybenzaldehyde (0.71 g,
3.6 mmol) and aqueous sodium hydroxide solution (0.8 cm3, 10M) in methanol (3.0 cm3). 
Recrystallization from methanol afforded 274 as white crystals (1.30 g, 2.8 mmol, 79%); 
m.p. 114 -  115 °C; R f  0.61 (Si02, ethyl acetate:hexane 1:1); VmaxXcm'1) 3005, 2967, 2943, 
1636, 1619, 1578, 1501, 1483, 1466, 1448, 1420, 1388, 1334, 1253, 1122, 1002, 841; 6 *H 
NMR (400 MHz; CDC13; ppm) 3.90 (3H, s, OCH3), 3.90 (6H, s, OCH3), 3.91 (3H, s, OCH3),
3.95 (3H, s, OCH3), 3.97 (3H, s, OCH3), 6.80 (H, s, H-6’), 6.81 (2H, s, H-2” & H-6” ), 7.01 
(2H, d, J  15.9 Hz, H-2), 7.38 (2H, d, J  15.9 Hz, H-3); 6 13C NMR (100 MHz; CDC13; ppm)
56.20 (s, OCH3), 56.32 (s, OCH3), 61.04 (s, OCH3), 61.22 (s, OCH3), 61.25 (s, OCH3),
105.68 (s, CH), 106.47 (s, CBr), 107.97 (s, CH), 125.44 (s, CH), 129.89 (s, C), 136.81 (s, C),
140.62 (s, C), 144.64 (s, C), 146.28 (s, CH), 151.06 (s, C), 153.07 (s, C), 153.49 (s, C),
194.08 (s, CO); m/z(AP+) 467 (MH+, 100%), 469 (MH+, 90%); HRMS found [MH]+ 
467.0705 for C2 iH24 0 7Br, C2 iH24 0 7Br requires [MH]+ 467.0700; CHN found C 53.89%, H 
4.89% CHN requires C 53.97%, H 4.96%.
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(E)-l-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(3,4-dichlorophenyl)prop-2-en-l-one 275
0
OMe 275
The chalcone 275 was obtained following Protocol A. Using l-(2-bromo-3,4,5- 
trimethoxyphenyl)ethanone 251 (1.08 g, 3.7 mmol), 3,4-dichlorobenzaldehyde (0.66 g, 3.7 
mmol) and aqueous sodium hydroxide solution (0.8 cm3, 10M) in methanol (3.0 cm3). 
Recrystallization from methanol afforded 275 as white crystals (1.14 g, 2.6 mmol, 71%); 
m.p. 122 -  124 °C; R f  0.87 (SiC>2, ethyl acetate:hexane 1:1); v^X cm '1) 3055, 2940, 1643, 
1622, 1587, 1552, 1477, 1466, 1426, 1386, 1261, 1202, 1160, 1099, 994, 908, 855, 822; 6 *H 
NMR (400 MHz; CDC13; ppm) 3.90 (3H, s, OCH3), 3.95 (3H, s, OCH3), 3.97 (3H, s, OCH3), 
6.82 (1H, s, H-6’), 7.13 (1H, d, J  16.0 Hz, H-2), 7.39 - 7.46 (2H, m, H-3 & H-6” ), 7.50 (1H, 
d, J 8.4 Hz, H-5” ), 7.67 (1H, d, J2 .0  Hz, H-2” ); 6 13C NMR (100 MHz; CDC13; ppm) 56.32 
(s, OCH3), 61.23 (s, OCH3), 61.26 (s, OCH3), 106.68 (s, CBr), 108.15 (s, CH), 127.40 (s, 
CH), 127.46 (s, CH), 130.06 (s, CH), 131.02 (s, CH), 133.39 (s, C), 134.57 (s, C), 134.72 (s, 
C), 136.39 (s, C), 142.42 (s, CH), 145.04, (s, C), 151.12 (s, C), 153.12 (s, C), 193.27 (s, CO); 
m/z{AP+) 445 (MH+, 50%), 447 (MH+, 100%), 449 (MH+, 50%); HRMS found [MH]+ 
444.9606 for C ig H ^ C h B r, C ig H ^ C h B r requires [MH]+ 444.9605; CHN found C 
48.42%, H 3.32% CHN requires C 48.46%, H 3.39%.
4,5,6-Trimethoxy-3-(4-methoxy-3-nitrophenyl)-lH-inden-1 -one 282
MeO‘
MeO
NO
OMe
282
In 5 individual pressure-rated reaction vial (10 cm3), a mixture of (£)-l-(2-bromo-3,4,5- 
trimethoxyphenyl)-3-(4-methoxy-3-nitrophenyl)prop-2-en-l-one 270 (0.100 g, 0.22 mmol), 
potassium carbonate (0.076 g, 0.55 mmol), palladium(II) chloride (0.001 g, 0.0056 mmol) 
and triphenylphosphine (0.005 g, 0.019 mmol) was dissolved in anhydrous dimethyl 
formamide (1.7 cm3) and sealed. Each reaction vial was then irradiated in a self-turning 
single-mode CEM Discovery™ Focused Synthesizer. The reaction was maintained at 160 °C 
(power: 150 W) for 15 minutes. The vials were then rapidly cooled to room temperature,
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then had water (1.8 cm3) added to each vial and left at room temperature overnight. The 
precipitate from each vial was then filtered off, washed with water (5 x 3 cm ). The 
combined wet solid was then dissolved in ethyl acetate (5 cm ), and was heated to 65 °C with 
an aqueous potassium thiocyanate solution (1.5 cm , 2M) under argon for 1 hour. The 
mixture was then cooled to room temperature and extracted with dichloromethane (30 cm3), 
the combined organic fractions were then washed with water (10 cm ) and brine (2 x 15 cm ) 
then dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. Recrystallization 
from ethyl acetate afforded 282 as dark red crystals (0.127 g, 0.34 mmol, 31%); m.p. 155 -  
159 °C; R f  0.34 (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcm'1) 2958 (m), 1694 (s), 1617 (s), 
1566 (m), 1526 (s), 1497 (s), 1466 (s), 1411 (s), 1356 (s), 1283 (s), 1113 (s), 1027 (s); 5 'H 
NMR (400 MHz; CDC13; ppm) 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.91 (3H, s. OCH3),
4.04 (3H, s, OCH3), 5.79 (1H, s, H-2), 7.02 (1H, s, H-7), 7.14 (1H, d, J  8.4 Hz, H-5’), 7.85 
(1H, dd, J  2.3, 8.4 Hz, H-6’), 8.23 (1H, d, J  2.3 Hz, H-2’); 5I3C NMR (100MHz; CDC13; 
ppm) 56.73 (s, OCH3), 56.94 (s, OCH3), 61.36 (s, OCH3), 61.60 (s, OCH3), 105.02 (s, CH),
113.00 (s, CH), 123.90 (s, CH), 125.76 (s, CH), 126.61 (s, C), 126.79 (s, C), 128.47 (s, C), 
133.91 (s, CH), 139.31 (s, C), 147.14 (s, C), 149.19 (s, C), 154.03 (s, C), 155.18 (s, C),
161.74 (s, C), 195.46 (s, CO); m/r(API ES+) 372 (MH+, 100%); HRMS found [MH]+ 
372.10805 for Ci9H |8N 0 7, C i9Hi8N 07requires [MH]+ 372.10778.
3-(3-Fluoro-4-methoxyphenyl)-4,5,6-trimethoxy-1 H-inden-1-one 277
MeO
MeO
OMe
277
The indenone 277 was obtained following Protocol D. Using (£)-l-(2-bromo-3,4,5- 
trimethoxyphenyl)-3-(3-fluoro-4-methoxyphenyl)prop-2-en-l-one 271 (0.43 g, 1.01 mmol). 
Recrystallization from ethyl acetate and hexane afforded 277 as fine orange crystals (0.24 g, 
0.71 mmol, 70%); m.p. 148-149 °C; R/0.47 (Si02, ethyl acetate:hexane 1:1); vmax. (cm'1) 
2947, 2903, 2850, 1699, 1598, 1514, 1463, 1410, 1376, 1343, 1317; 6!H (400 MHz; CDC13; 
ppm), 3.45 (3H, s, OCH3), 3.84 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3), 5.68 
(1H, s, H-2), 6.91-6.97 (2H, m, H-7 & H-5” ), 7.37-7.44 (2H, m, H-2” & H-6” ); 8,3C 
(100MHz; CDC13; ppm), 56.24 (s ,OCH3), 56.49 (s, OCH3), 61.21 (s, OCH3), 61.56 (s, 
OCH3), 104.59 (s, CH), 112.29 (d, J2 .0  Hz, CH), 116.04 (d, J  19.7 Hz, CH), 123.01 (s, CH),
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124.42 (d, J 3.3 Hz, CH), 126.86 (s, C), 126.94 (d, J6 .9  Hz, C), 128.68 (s, C), 146.89 (s, C),
149.09 (s, C), 149.11 (d, J10.8 Hz, C), 151.48 (d, J245.7 Hz, CF), 154.68 (s, C), 163.18 (s, 
C), 195.64 (s, CO); m/z{AP+) 345 (MH+, 100); HRMS found [MH]+ 345.1136 for Ci9H170 5F, 
C,9H,7 0 5F requires [MH]+ 345.1133.
4,5,6-Trimethoxy-3-phenyl-lH-inden-1-one 278
MeO"
MeO
278
The indenone 278 was obtained following Protocol D. Using (£)-l-(2-bromo-3,4,5- 
trimethoxyphenyl)-3-phenylprop-2-en-l-one 272 (0.31 g, 1.00 mmol). Recrystallization from 
ethyl acetate and hexane afforded 278 as light red crystals (0.15 g, 0.66 mmol, 65%); m.p. 
148 -  149 °C; R f  0.76 (Si0 2 , ethyl acetate:hexane 1:1); V m a x X c n T 1 )  3073, 2935, 1692, 1603, 
1553, 1487, 1460, 1443, 1432, 1402, 1364, 1299, 1099, 1020, 853, 770; 5 *H NMR (400 
MHz; CDC13; ppm) 3.43 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.90 (3H, s, OCH3), 5.76 (1H, s, 
H-2), 7.01 (1H, s, H-7), 7.40 -  7.45 (3H, m, H-3’ -  H-5’), 7.61 -  7.65 (2H, m, H-2’ & H-6 ’); 
6  13C NMR (100 MHz; CDC13; ppm) 56.49 (s, OCH3), 61.19 (s, OCH3), 61.51 (s, OCH3),
104.62 (s, CH), 123.56 (s, CH). 127.43 (s, C), 127.68 (s, CH), 127.88 (s, CH), 128.53 (s, 
CH), 129.87 (s, C), 134.29 (s, CH), 134.29 (s, C), 146.98 (s, C), 149.20 (s, C), 154.62 (s, C), 
164.58 (s, C), 195.98 (s, CO); m/z(AP+) 297 (MH+, 100%); HRMS found [MH]+ 297.11257 
for C 18H 17O4 , C 18H 17O4 requires [MH]+ 297.11214.
4,5,6-Trimethoxy-3-(3,5-dimethoxyphenyl)-!H-inden-1 -one 279
MeO.
MeO'
MeO
OMe
MeO
279
The indenone 279 was obtained following Protocol D. Using (£)-l-(2-bromo-3,4,5- 
trimethoxyphenyl)-3-(3,5-dimethoxyphenyl)prop-2-en-l-one 273 (0.44 g, 1.01 mmol). 
Recrystallization from ethyl acetate and hexane afforded 279 as dark red crystals (0.23 g, 
0.64 mmol, 63%); m.p. 113 - 114 °C; R f  0.20 (SKD2 , ethyl acetate:hexane 1:3); VmaxXcm'1)
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2943, 2842, 1691, 1591, 1551, 1462, 1450, 1423, 1404, 1361, 1307, 1293, 1210, 1156, 1105, 
1025, 836, 822; 6 ‘H NMR (400 MHz; CDC13; ppm) 3.50 (3H, s, OCH3), 3.84 (6H, s, 
OCH3), 3.89 (3H, s, OCH3), 3.91 (3H, s, OCH3), 5.77 (1H, s, H-2), 6.55 (1H, t, J  3.6 Hz, H- 
4’), 6.80 (2H, d, J  3.6 Hz, H-2’ & H-6’), 7.01 (1H, s, H-7); 6 13C NMR (100 MHz; CDC13; 
ppm) 55.52 (s, OCH3), 56.49 (s, OCH3), 61.20 (s, OCH3), 61.77 (s, OCH3), 102.00 (s, CH),
104.62 (s, CH), 105.64 (s, CH), 123.68 (s, CH), 127.35 (s, C), 128.44 (s, C), 136.15 (s, C),
146.99 (s, C), 149.26 (s, C), 154.59 (s, C), 160.26 (s, C), 164.45 (s, C), 195.95 (s, CO); 
m/z(AP+) 357 (MH+, 100%); HRMS found [MH]+ 357.1329 for C2oH2i06, C2oH2i06 requires 
[MH]+ 357.1333.
4,5,6-Trimethoxy-3-(3,4,5-trimethoxyphenyl)-lH-inden-1 -one 280
MeO‘
MeO
OMe
MeO OMe
280
The indenone 280 was obtained following Protocol D. Using (£)-l-(2-bromo-3,4,5- 
trimethoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 274 (0.49 g, 1.04 mmol). 
Recrystallization from ethyl acetate and hexane afforded 280 as fine red crystals (0.22 g, 0.56 
mmol, 54%); m.p. 117 -  118 °C; R f  0.45 (Si02, ethyl acetate:hexane 1:1); VmaxXcm’1) 2936, 
2826, 1698, 1603, 1580, 1554, 1500, 1456, 1413, 1366, 1331, 1234, 1102, 1006, 807; 8 ‘H 
NMR (400 MHz; CDC13; ppm) 3.42 (3H, s, OCH3), 3.84 (6H, s, OCH3), 3.84 (3H, s, OCH3),
3.85 (3H, s, OCH3), 3.86 (3H, s, OCH3), 5.72 (1H, s, CH), 6.89 (2H, s, H-Ar), 6.95 (1H, s, H- 
Ar); 8 l3C NMR (100 MHz; CDC13; ppm) 56.25 (s, OCH3), 56.49 (s, OCH3), 61.06 (s, 
OCH3), 61.24 (s, OCH3), 61.92 (s, OCH3), 104.66 (s, CH), 105.20 (s, CH), 123.14 (s, CH),
127.11 (s, C), 128.71 (s, C), 129.48 (s, C), 139.53 (s, C), 146.95 (s, C), 149.20 (s, C), 152.66 
(s, C), 154.58 (s, C), 164.57 (s, C), 195.73 (s, CO); m/z(AP+) 386 (MH+, 100%); HRMS 
found [MH]+ 387.1439 for C21H22O7, C21H22O7 requires [MH]+ 387.1438.
3-(3,4-Dichlorophenyl)-4,5,6-trimethoxy-1 H-inden-1-one 281
MeO
MeO
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The indenone 281 was obtained following Protocol D. Using (£)-l-(2-bromo-3,4,5- 
trimethoxyphenyl)-3-(3,4-dichlorophenyl)prop-2-en-l-one 275 (0.45 g, 1.00 mmol).
Recrystallization from ethyl acetate and hexane afforded 281 as peach coloured crystals (0.12 
g, 0.32 mmol, 32%); m.p. 147 -  149 °C; Rf 0.61 (SiC>2 , ethyl acetate:hexane 1:1); vmax.(cm' 
') 3074, 2946, 1705, 1606, 1546, 1463, 1409, 1361, 1304, 1028, 973, 817, 664; 5 !H NMR 
(400 MHz; CDC13; ppm) 3.55 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.91 (3H, s, OCH3), 5.77 
(1H, s, H-2), 7.02 (1H, s, H-7), 7.48 (1H, dd, J  1.5,8.4 Hz, H-6’), 7.51 (1H, d, J  8.4 Hz, H- 
5’), 7.75 (1H, d, J  1.5 Hz, H-2’); 6 13C NMR (100 MHz; CDC13; ppm) 56.90 (s, OCH3), 
61.54 (s, OCH3), 61.82 (s, OCH3), 105.22 (s, CH), 124.59 (s, CH), 126.63 (s, C), 127.55 (s, 
CH), 128.44 (s, C), 130.04 (s, CH), 130.31 (s, CH), 132.56 (s, C), 134.17 (s, C), 134.56 (s, 
C), 147.35 (s, C), 149.39 (s, C), 155.29 (s, C), 162.07 (s, C), 195.73 (s, CO); m/z(AP+) 365 
(MH+, 100%), 367 (MH+, 70%); HRMS found [MH]+ 365.03436 for CigH^ChO^ 
C18H 15CI2O4 requires [MH]+ 365.03419.
4-Methoxy-3-nitrobenzaldehyde 276349
O
0 2N
MeO *
276
To stirred mixture of concentrated nitric acid (5.3 cm , 83.0 mmol) and concentrated sulfuric 
acid (150 cm ) at -15 °C, was added p-anisaldehyde (9.8 cm , 80.7 mmol). The reaction was 
then stirred at -15 °C for an hour, the solution turns a golden brown colour. The mixture was 
then tipped into cold water (500 cm3) and chilled to 0 °C for an hour. The cream precipitate
“X  7was then filtered, washed with water (100 cm ). Recrystallization from ethanol (~ 100 cm ) 
afforded 276 as cream crystals (10.06 g, 55.6 mmol, 69%); m.p. 77 -  79 °C; Rf 0.32 (SiC>2 , 
ethyl acetate:hexane 1:3); Vmax c^m'1) 3074, 2873, 1704, 1682, 1610, 1569, 1530, 1497, 1468, 
1446, 1424, 1352, 1280, 1206, 1153, 1001, 684; 5 ]H NMR (400 MHz; CDC13; ppm) 4.07 
(3H, s, OCH3), 7.24 (1H, d, J8 .8  Hz, H-5’), 8.09 (1H, dd, J  2.0, 8.8 Hz, H-6’), 8.35 (1H, d, J
2.0 Hz, H-2’), 9.94 (1H, s, H-l); S,3C NMR (100MHz; CDC13; ppm) 57.31 (s, OCH3),
114.06 (s, CH), 127.65 (s, CH), 129.29 (s, C), 134.94 (s, CH), 157.38 (s, C), 188.96 (s, CO).
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l-(2-Bromo-3,4,5-trimethoxyphenyl)propan-l-ol 284
To a stirring solution of ethylmagnesium chloride in tetrahydrofuran (10.5 cm3, 21.0 mmol, 
2M) in anhydrous tetrahydrofuran (10 cm3) under argon at 0 °C, was slowly added 2-bromo- 
3,4,5-trimethoxybenzaldehyde 252 (3.07g, 11.2 mmol) in anhydrous tetrahydrofuran (20 
cm3). The reaction was then stirred overnight at room temperature and then poured into 
mixture of concentrated aqueous ammonium chloride solution (100 cm3) and ice, and then 
extracted with ethyl acetate (6 x 20 cm3). The organic fraction was then dried over 
anhydrous magnesium sulfate, filtered and evaporated in vacuo. Column chromatography 
(Si02, ethyl acetate:hexane 1:9) afforded 284 as a yellow oil (1.99 g, 6.5 mmol, 58%); R f  
0.71 (Si02, ethyl acetate:hexane 1:1); 8 ‘H NMR (400 MHz; CDC13; ppm) 1.02 (3H, t, J7 .4  
Hz, H-3), 1.62 -  1.70 (1H, m, H-2), 1.76- 1.84 (1H, m, H-2), 1.97 (1H, d, J3 .4  Hz, OH-1), 
3.87 (6H, s, OCH3), 3.89 (3H, OCH3), 4.98 -  5.03 (1H, m, H-l)6.94 (1H, s, H-2’).
l-(2-Bromo-3,4,5-trimethoxyphenyl)propan-l-one 283
O
Pyridinium chlorochromate (2.19 g, 10.2 mmol) was added to a stirred solution of l-(2- 
bromo-3,4,5-trimethoxyphenyl)propan-l-ol 284 (1.99 g, 6.5mmol) in dichloromethane (20 
cm ). The reaction was then put under argon gas and stirred at room temperature under argon 
overnight. It was then filtered through Celite®, dried over anhydrous magnesium sulfate, 
filtered and evaporated in vacuo. Column chromatography (Si02, ethyl acetate:hexane 1:3) 
afforded 283 as cream crystals (1.73 g, 1.9 mmol, 88%); m.p. 62 -  63 °C; R f  0.64 (Si02, 
ethyl acetate:hexane 1:1); vmax.(cnTl) 2972, 2938, 2895, 1698, 1582, 1563, 1482, 1447, 1430, 
1401, 1384, 1351, 1318, 1167,999,857,793; 5 'H NMR (400 MHz; CDC13; ppm) 1.15 (3H, 
t, J  7.2 Hz, H-3), 2.85 (2H, q, J1.2  Hz, H-2), 3.80 (3H, s, OCH3), 3.83 (3H, s, OCH3), 3.84 
(3H, s, OCH3), 6.63 (1H, s, H-6’); 8 13C NMR (100 MHz; CDC13; ppm) 8.29 (s, CH3), 36.23 
(s, CH2), 56.27 (s, OCH3), 61.12 ( s , OCH3), 61.18 (s, OCH3), 105.65 (s, CBr), 107.10(s, CH), 
137.81 (s, C), 144.62 (s, C), 151.07 (s, C), 152.96 (s, C), 204.99 (s, CO); m/z(AP+) 303(MH+,
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100%), 305 (M H \ 80%); HRMS found [MH]+ 303.02254 for C,2H16Br0 4 , Ci2Hi6Br04 
requires [MH]+ 303.02265.
(E)-l-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl)-2-methylprop-2-en-l -one 285
0
MeO”
OMe OMe285
The method adopted was that of Edwards72 et al. A solution of l-(2-bromo-3,4,5- 
trimethoxyphenyl)propan-l-one 283 (0.92 g, 3.0 mmol), /?-anisaldehyde (0.35 cm3, 3.1
*> T Tmmol), piperidine (1.2 cm ) and acetic acid (0.6 cm ) in ethanol (3.5 cm ) was heated at 
reflux at 110 °C under argon for 7 days. The mixture was then cooled to room temperature 
and diluted with dichloromethane (30 cm3) and washed with water (3 * 10 cm3). The 
aqueous fraction was then extracted with dichloromethane (3 x 10 cm3). The organic 
fractions were then combined and dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. Column chromatography (Si02, ethyl acetate:hexane 1:3) afforded a 
mixture of 283 and /?-anisaldehyde (2.9:1), the mixture was shaken in deuterated chloroform 
(15 cm3) in the presence of the scavenger agent PS-trisamine (1.18 g, 5.36 mmol) at room 
temperature for 2 hours, reaction monitored by *H NMR. The mixture was , filtered and 
evaporated in vacuo to afforded 285 as yellow oil (0.78 g, 1.8 mmol, 61%); Rf 0.32 (Si02, 
ethyl acetate:hexane 1:1); VmaxXcrn'1) 2937, 2839, 1648, 1599, 1565, 1509, 1479, 1462, 1426, 
1382, 1333, 1251, 1174, 1005, 828; 8 !H NMR (400 MHz; CDC13; ppm) 2.25 (3H, s, CH3),
3.84 (3H, s, OCH3), 3.86 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.94 (3H, s, OCH3), 6.65 (1H, s, 
H-6’), 6.93 (2H, d, J  8.8 Hz, H-3” & H-5” ), 7.09 (1H, s, H-3), 7.40 (2H, d, J  8.8 Hz, H-2” 
& H-6” ); 8 13C NMR (100 MHz; CDC13; ppm) 12.87 (s, CH3), 55.35 (s, OCH3), 56.25 (s, 
OCH3), 61.18 (s, OCH3), 106.24 (s, CBr), 107.46 (s, CH), 114.01 (s, CH), 128.111 (s, C),
131.99 (s, CH), 134.44 (s, C), 137.08 (s, C), 143.69 (s, C), 145.41 (s, CH), 150.90 (s, C),
152.96 (s, C), 160.39 (s, C), 198.13 (s, CO); m/z{AP+) 421 (MH+, 100%), 423 (MH+, 100%); 
HRMS found [MH]+ 421.06569 for C20H22BrO5, C20H22BrO5 requires [MH]+ 421.06451; 
CHN found C 55.78%, H 6.16%, CHN requires C 55.86%, H 6.19%.
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l-(2-(Allyloxy)-4-methoxyphenyl)ethanone 330262
O
MeO'4 6'
330
The method adopted was that of Anjaneyulu262 et al.To a stirring solution of 2-hydroxy-4- 
methoxyacetophenone (1.66 g, 10.0 mmol),and potassium carbonate (5.00 g, 36.2 mmol) in
*2 “ Xacetone (10cm ) at room temperature, was added allyl bromide (1.72 cm , 19.9 mmol). The 
mixture was then put under argon and heated to reflux overnight at 75 °C. The reaction was 
then cooled to room temperature and filtered to remove the potassium carbonate, and then the 
acetone was evaporated in vacuo. The crude product was then diluted with ethyl acetate (30 
cm3) and washed with an aqueous sodium hydroxide solution (3 x20 cm3, 1.3 M) and water 
(3 *20 cm3). The organic fraction was then dried over anhydrous magnesium sulfate, filtered 
and evaporated in vacuo to afforded 330 as a white solid (2.05g, 10.0 mmol, 99%); m.p. 36 -  
37 °C; R f  0.36 (Si02, ethyl acetaterhexane 1:3); Vmaxfcrn'1) 3090, 2988, 2928, 2846, 1647, 
1597, 1572, 1501, 1480, 1465, 1465, 1439, 1419, 1326, 1201, 1010, 923, 827; 6 ‘H NMR 
(400 MHz; CDC13; ppm) 2.59 (3H, s, H-2), 3.83 (3H, s, OCH3), 4.60 (2H, td, J  1.5, 5.3 Hz, 
H -l” ), 5.32 (1H, dq, J  10.6, 1.5 Hz, cis H-3” ), 5.44 (1H, dq, J  17.2, 1.5 Hz, trans H-3” ), 
6.18 (1H, tdd, J  5.3, 10.6, 17.2 Hz, H-2” ), 6.43 (1H, d, J2 .4  Hz, H-3’), 6.51 (1H, dd, J2 .4 ,
8.9 Hz, H-5’), 7.83 (1H, d, J  8.9 Hz, H-6’); 513C NMR (100MHz; CDC13; ppm) 32.28 (s, 
CH3), 55.74 (s, OCH3), 69.66 (s, OCH2), 99.60 (s, CH), 105.57 (s, CH), 118.53 (s, CH2), 
121.65 (s, C), 132.74 (s, CH), 132.90 (s, CH), 160.25 (s, C), 164.59 (s, C), 197.98 (s, CO); 
m/z{API ES+) 207 (MH+, 100%).
l-(3-Allyl-2-hydroxy-4-methoxyphenyl)ethanone 326262
OH O
MeO 4'
326
The method was adapted from that of Anjaneyulu262 et al. l-(2-(allyloxy)-4-methoxyphenyl) 
ethanone 330 (0.50 g, 2.4 mmol) was dissolved in A^^A-dimethylaniline (5 cm3) and sealed in 
a pressure-rated reaction vial (10 cm3). The reaction vial was then irradiated in a self-turning 
single-mode CEM Discovery™ Focused Synthesizer. The reaction was maintained at 260 °C 
(power: 250 W) for 12 minutes. The mixture was then rapidly cooled to room temperature
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and poured into hydrochloric acid (50 cm , 2M) and extracted with ethyl acetate ( 5x10  cm ). 
The organic fraction as then washed with hydrochloric acid (5 x 10 cm3, 2M) and saturated 
sodium bicarbonate aqueous solution (10 cm ), it was then dried over anhydrous sodium 
sulfate, filtered and evaporated in vacuo. Purification by column chromatography (Si02, 
ethyl acetateihexane 1:9) afforded 326 as a cream solid (0.33g, 1.6 mmol, 66%); m.p. 49 -  
51 °C; R f  0.48 (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcm'1) 3002, 2949, 2914, 2842, 1608, 
1496, 1466, 1414, 1366, 1268, 1123, 1070, 995, 918, 818; 6 lH NMR (400 MHz; CDC13; 
ppm) 2.57 (3H, s, H-2), 3.42 (2H, td, J  1.7, 6.1 Hz, H -l” ), 3.89 (3H, s, OCH3), 4.93 -  4.98 
(1H, dm, J  10.1 Hz, cis-H-3” ), 4.97 -  5.04 (1H, dm, J  17.0 Hz, trans-H-3” ), 5.95 (1H, ddt, J
10.1, 17.0, 6.1 Hz, H-2” ),6.47 (1H, d, J  8.8 Hz, H-5’), 7.64 (1H, d, J  8.8 Hz, H-6’), 12.77 
(1H, s, OH-2’); 813C NMR (100MHz; CDC13; ppm) 26.49 (s, CH3), 26.77 (s, CH2), 56.07 (s, 
OCH3), 102.31 (s, CH), 144.58 (s, C), 144.70 (s, CH2), 115.68 (s, C), 130.86 (s, CH), 136.10 
(s, CH), 162.09 (s, C), 163.59 (s, C), 203.13 (s, CO).
l-(3-Allyl-4-methoxy-2-(methoxymethoxy)phenyl)ethanone 331
MeO 4'
331
To a stirring solution of l-(3-allyl-2-hydroxy-4-methoxyphenyl)ethanone 326 (l.OOg, 4.8 
mmol) in anhydrous tetrahydrofuran (10 cm ) at 0 °C under argon, sodium hydride (0.29 g,
7.3 mmol, 60% dispersion in mineral oil) was added. The reaction was then stirred for 5 
minutes at 0 °C, before adding Chloromethyl methyl ether (0.56 cm3, 7.4 mmol) to the 
mixture. The reaction was then stirred for a further 10 minutes at 0 °C. The reaction was 
then heated to 65 °C for 18 hours. The reaction was then allowed to cool to room 
temperature; it was then tipped into water (10 cm3) and extracted with ethyl acetate ( 3 x 1 5  
cm ). The organic fraction was then washed with water (2 x 10 cm ) and dried over 
anhydrous sodium sulfate, filtered and evaporated in vacuo. Purification by column 
chromatography (SiC>2 , ethyl acetate:hexane 1:9) afforded 331 as a yellow oil (0.52 g, 2.1 
mmol, 43%); R f  0.54 (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcm*1) 2941, 2840, 1675, 1588, 
1482, 1465, 1427, 1264, 972, 921, 806; 6 'H NMR (400 MHz; CDC13; ppm) 2.58 (3H, s, H- 
2), 3.48 (2H, td, J  1.6, 5.6 Hz, H -l” ), 3.52 (3H, s, H-4” ’), 3.89 (3H, s, OCH3), 4.96 (2H, s, 
H-2” ’), 4.95 -  5.01 (2H, m, H-3” ), 5.92 -  6.03 (1H, m, H-2” ), 6.71 (1H, d, J  8.8 Hz, H-5’), 
7.57 (1H, d, J  8.8 Hz, H-6’); 813C NMR (100MHz; CDC13; ppm) 28.46 (s, CH2), 30.25 (s,
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CH), 56.09 (s, OCH3), 58.07 (s, OCH3), 101.60 (s, 0CH20), 115.12 (s, CH2), 122.86 (s, C),
127.06 (s, C), 129.65 (s, CH), 136.51 (s, CH), 156.00 (s, C), 161.83 (s, C), 199.59 (s, CO); 
m/z{API ES+) 251 (MH+, 100%); HRMS found [MH]+ 251.12800 for C14H19O4 , C14H19O4 
requires [MH]+ 251.12779.
4-(Methoxymethoxy)benzaldehyde 3 3 2 350
0 OMe
3 3 2
The method was adapted from that of Crombie228 et al. To a stirring solution of sodium 
hydride (0.81 g, 20.3 mmol, 60% dispersion in mineral oil) in anhydrous dimethyl formamide 
(10 cm3) at 0 °C under argon 4-methoxybenzaldeyde (2.00 g, 16.4 mmol) in anhydrous 
dimethyl formamide (10 cm3) was added slowly drop wise over 20 minutes. The reaction 
was then allowed to warm to room temperature, before being cooled to 0 °C. Chloromethyl 
methyl ether (1.5 cm , 19.7 mmol) in anhydrous dimethyl formamide (4 cm ) was then added 
drop wise over 20 minutes to the mixture at 0 °C. The mixture was then stirred for 30 
minutes at 0 °C and then stirred overnight at room temperature. The reaction was then tipped 
into a mixture of water (20 cm ) and ice (20 g), and extracted with ethyl acetate (4 x 30cm ).
'i
The organic fraction was washed with an aqueous sodium hydroxide solution (2 xlO cm ,0.1 
M) and water (2 xlO cm ), it was then dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. Purification by column chromatography (SiC>2 , ethyl acetate:hexane 1:9 
to 1:1) afforded 3 3 2  as a pale yellow oil (2.30 g, 13.8 mmol, 84%); R f  0.46 (Si02, ethyl 
acetate:hexane 1:3); vmax(cm'‘) 2903, 2829, 2741, 1684, 1597, 1578, 1508, 1444, 1427, 1237, 
1213, 1201, 1079, 974, 921, 831; 8 'H NMR (400 MHz; CDC13; ppm) 3.49 (3H, s, OCH3), 
5.25 (2H, s, H-2” ), 7.15 (2H, d, J8 .6  Hz, H-3’ & H-5’), 7.84 (2H, d, J8 .6  Hz, H-2’ & H-6’),
9.90 (1H, s, H-l); 8 l3C NMR (100 MHz; CDC13; ppm) 56.58 (s, CH3), 94.33 (s, OCH20), 
116.50 (s, CH), 130.97 (s, C), 132.10 (s, CH), 162.43 (s, C), 191.12 (s, CHO).
(E)-l-(3-Allyl-2-hydroxy-4-methoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1 -one 3 2 9
3 2 9
To a stirring solution of l-(3-allyl-4-methoxy-2-(methoxymethoxy)phenyl)ethanone 3 3 1  
(0.150 g, 0.60 mmol) and 4-(methoxymethoxy)benzaldehyde 3 3 2  (0.100 g, 0.60 mmol) in
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"X  "Xmethanol (1.8 cm ) was added an aqueous solution of sodium hydroxide (0.6 cm , 2M) and 
the mixture stirred at room temperature overnight. The mixture was then extracted with
3 3dichloromethane (3 * 5 cm ), the organic fraction was then washed with water (3 x 5 cm ), 
dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. The crude product
"X *1was then dissolved in methanol (12 cm ), and had hydrochloric acid (2.4 cm , 3M) added to 
it. The reaction under argon was then heated to reflux at 75 °C for 45 minutes. The reaction 
was then cooled to room temperature and tipped into water (12 cm3), it was then extracted 
with ethyl acetate ( 3 x 1 2  cm3). The organic fraction was then washed with water (2 x 10 
cm3) and brine (10 cm3), dried over anhydrous sodium sulfate, filtered and evaporated in 
vacuo. Purification by column chromatography (SiC>2 , ethyl acetate:hexane 1:9 to 1:1) 
afforded 3 2 9  as a yellow solid (0.150 g, 0.48 mmol, 81%); m.p. 140 -  142 °C; R f  0.39 (SiC>2, 
ethyl acetate:hexane 1:3); VmaxXcm'1) 3166, 2903, 1666, 1628, 1605, 1582, 1543, 1511, 1490, 
1458, 1413, 1280, 1236, 1210, 1165, 1120, 783; 6 *H NMR (400 MHz; CDC13; ppm) 3.45 
(2H, td, J  1.8, 6.2 Hz, H -l’” ), 3.91 (3H, s, OCH3), 4.98 (1H, dq, J  10.0, 1.8 Hz, cis-H-3’” ),
5.04 (1H, dq, J  17.1, 1.8 Hz, trans-H-3’” ), 5.65 (1H, br. s, OH-4” ), 5.98 (1H, ddt, J  10.0,
17.1, 6.2 Hz, H-2” ’), 6.52 (1H, d, J  9.2 Hz, H-5’), 6.89 (2H, d, J  8.8 Hz, H-3” & H-5” ),
7.47 (1H, d, J  15.0 Hz, H-2), 7.55 (2H, d, J  8.8 Hz, H-2” & H-6” ), 7.83 (1H, d, J9.2  Hz, H- 
6’), 7.84 (1H, d, J  15.0 Hz, H-3), 13.50 (1H, br. s, OH-2’); 513C NMR (100MHz; CDC13; 
ppm) 26.89 (s, CH2), 56.09 (s, OCH3), 102.35 (s, CH), 114.73 (s, CH2), 114.85 (s, C), 115.95 
(s, C), 116.25 (s, CH), 118.29 (s, CH), 127.96 (s, C), 129.82 (s, CH), 130.80 (s, CH), 136.15 
(s, CH), 144.40 (s, CH), 158.27 (s, C), 163.33 (s, C), 163.64 (s, C), 192.64 (s, CO); m/z(API 
ES+) 311 (MH+, 100%), 333 (MNa+, 50%); HRMS found [MH]+ 311.12800 for C19H19O4, 
C19Hi90 4 requires [MH]+ 311.12779.
(E)-l-(3-Allyl-2-hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 3 3 6
OH O
OMe 
3 3 6
To a stirring solution of l-(3-allyl-4-methoxy-2-(methoxymethoxy)phenyl)ethanone 3 3 1  
(0.025 g, 0.10 mmol) and /?-anisaldehyde in methanol (0.1 cm3, 1M), in methanol (0.1 cm3) 
was added an aqueous solution of sodium hydroxide (0.1 cm3, 2M) and the mixture stirred at 
room temperature overnight. The mixture was then extracted with chloroform ( 3 x 3  cm ), 
the organic fraction was then evaporated in vacuo. The crude product was then dissolved in 
methanol (3 cm ), and had hydrochloric acid (0.6 cm , 3M) added to it. The reaction under
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argon was then heated to reflux at 75 °C for 45 minutes. The reaction was then cooled to 
room temperature and tipped into water (3 cm3), it was then extracted with chloroform (3 x 
10 cm ). The organic fraction was then dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. Purification by column chromatography (SiC>2 , ethyl acetate:hexane 1 :9 
to 1:1) afforded 336 as yellow needle crystals (0.023 g, 0.07mmol, 72%); m.p. 94 -  95 °C; 
R f  0.48 (SiC>2 , ethyl acetateihexane 1:3); VmaxXcnT1) 3004, 2978, 2908, 2841, 1633, 1603, 
1584, 1559, 1510, 1491, 1461, 1442, 1415, 1281, 1235, 1183, 1112, 1076, 856, 825; 6  *H 
NMR (400 MHz; CDC13; ppm) 3.45 (2H, td, J  1.7, 6.2 Hz, H -l’” ), 3.87 (3H, s, OCH3), 3.91 
(3H, s, OCH3), 4.97 (1H, dq, J9.9, 1.7 Hz, cis-H-3” ’), 5.03 (1H, dq, J  17.2, 1.7 Hz, trans-H- 
3’” ), 5.98 (1H, ddt, J  9.9, 17.2, 6.2 Hz, H-2” ), 6.52 (1H, d, J  9.0 Hz, H-5’), 6.95 (2H, d, J
8 . 6  Hz, H-3”  & H-5” ), 7.49 (1H, d, J  15.4 Hz, H-2), 7.62 (2H, d, J 8 . 6  Hz, H-2” & H-6 ” ),
7.84 (1H, d, J  9.0 Hz, H-6 ’), 7.87 (1H, d, J  15.4 Hz, H-3), 13.52 (1H, s, OH-2’); 8 13C NMR 
(100MHz; CDC13; ppm) 26.90 (s, CH2), 55.66 (s, OCH3), 56.08 (s, OCH3), 102.25 (s, CH), 
114.69 (s, CH + CH2), 114.89 (s, C), 115.90 (s, C), 118.26 (s, CH), 127.84 (s, C), 129.73 (s, 
CH), 130.55 (s, CH), 136.19 (s, CH), 144.34 (s, CH), 161.98 (s, C), 163.36 (s, C), 163.53 (s, 
C), 192.50 (s, CO); m/z(API ES+) 325 (MH+, 100%); HRMS found [MH]+ 325.14338 for 
C20H21O4 , C20H21O4 requires [MH]+ 325.14344.
Protocol E
To a stirring mixture of the allyl compound, 2-methybut-2-ene and anhydrous 
dichloromethane in a Schlenk tube under an argon atmosphere, was added a quantity of 
Grubbs catalyst, 2nd generation. The mixture was then degassed, put under an argon 
atmosphere and heated to reflux at 50 °C for 12 hours. The dichloromethane was then 
evaporated in vacuo. Purification by column chromatography (SiC>2 , ethyl acetate:hexane 1:9 
to 1 :1 ).
(E)-l-(2-Hydroxy-4-methoxy-3-(3-methylbut-2-enyl)phenyl)-3-(4-hydroxyphenyl)prop-2-en- 
1-one 317
OH O
MeO 4- OH
317
The chalcone 317 was obtained following Protocol E using (£)-l-(3-allyl-2-hydroxy-4- 
methoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one 329 (0.050 g, 0.16 mmol), 2- 
methybut-2-ene (0.33 cm3, 3.1 mmol) and Grubbs catalyst, 2nd generation (0.003 g, 0.0035 
mmol) in anhydrous dichloromethane (2.3 cm ). Purification by column chromatography
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(Si02, ethyl acetate:hexane 1:9 to 1:1) afforded 317 as a yellow solid (0.036 g, 0.11 mmol, 
66%); m.p. 130 -  131 °C; R f  0.15 (SiC>2, ethyl acetate:hexane 1:3); V m a x X c m ' 1 )  3282,2924, 
1622, 1603, 1579, 1548, 1513, 1489, 1435, 1408, 1365, 1279, 1244, 1218, 1167, 1119, 833, 
794; 5 'H NMR (400 MHz; CDC13; ppm) 1.68 (3H, s, CH3), 1.80 (3H, s, CH3), 3.36 (2H, d, J  
6.5 Hz, H -l’” ), 3.91 (3H, s, OCH3), 5.23 (1H, br. d, J  6.5 Hz, H-2’” ) 5.41 (1H, br. s, OH- 
4” ), 6.50 (1H, d, J  9.2 Hz, H-5’), 6.88 (2H, d, J  8.2 Hz, H-3”  & H-5” ), 7.47 (1H, d, J  15.4 
Hz, H-2), 7.56 (2H, d, J  8.2 Hz, H-2”  & H-6” ), 7.79 (1H, d, J  9.2 Hz, H-6’), 7.83 (1H, d, J
15.4 Hz, H-3), 13.46 (1H, s, OH-2’); 8 l3C NMR (100 MHz; CDC13; ppm) 18.05 (s, CH3), 
21.96 (s, CH2), 26.05 (s, CH3), 56.01 (s, OCH3), 102.31 (s, CH), 114.89 (s, C), 116.22 (s, 
CH), 117.81 (s, C), 118.45 (s, CH), 122.25 (s, CH), 128.07 (s, C), 129.35 (s, CH), 130.75 (s, 
CH), 132.17 (s, C), 144.15 (s, CH), 158.13 (s, C), 163.23 (s, C), 163.47 (s, C), 192.56 (s, 
CO).
1-(3-AllyI-2,4-dimethoxyphenyl)ethanone 346351
346
To a stirring solution of l-(3-allyl-2-hydroxy-4-methoxyphenyl)ethanone 326 (1.29g, 6.3 
mmol) in anhydrous tetrahydrofuran (50 cm ) at 0 °C under argon, sodium hydride (0.39 g,
9.8 mmol, 60% dispersion in mineral oil) was added. The reaction was then stirred for 5 
minutes at 0 °C, before adding dimethyl sulfate (0.91 cm3, 9.6 mmol) to the mixture. The 
reaction was then stirred for a further 10 minutes at 0 °C and then heated to 65 °C for 18 
hours. The reaction was then allowed to cool to room temperature; it was then tipped into 
water (80 cm ) and extracted with ethyl acetate (6 x 40 cm ). The organic fraction was then 
dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. Purification by 
column chromatography (SiC>2 , ethyl acetate:hexane 1:9) afforded 346 as a yellow oil (1.32 g,
6.0 mmol, 96%); R f  0.40 (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcm'1) 3079, 2941, 2840, 
1672, 1638, 1586, 1482, 1457, 1408, 1232, 1115, 1091, 1071, 808; 6 ‘H NMR (400 MHz; 
CDC13; ppm) 2.61 (3H, s, H-2), 3.44 (2H, td, J  1.6, 6.0 Hz, H -l” ), 3.75 (3H, s, OCH3), 3.87 
(3H, s, OCH3), 4.95 -  5.01 (2H, m, H-3” ), 5.98 (1H, ddt, J9 .5 , 17.8, 6.0 Hz, H-2” ), 6.71 
(1H, d, J  8.8 Hz, H-5’), 7.63 (1H, d, J  8.8 Hz, H-6’); 6 13C NMR (100 MHz; CDC13; ppm)
28.11 (s, CH3), 30.23 (s, CH2), 56.09 (s, OCH3), 63.33 (s, OCH3), 106.51 (s, CH), 115.05 (s, 
CH2), 122.49 (s, C), 126.15 (s, C), 130.09 (s, CH), 136.75 (s, CH), 159.53 (s, C), 162.15 (s, 
C), 199.33 (s, CO).
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J-(2,4-Dimethoxy-3-(3-methylbut-2-enyl)phenyl)ethanone 347352
MeO 0
MeO 4’
3 4 7
The acetophenone 3 4 7  was obtained following Protocol E. Using l-(3-allyl-2,4- 
dimethoxyphenyl)ethanone 3 4 6  (1.0 g, 4.5 mmol), 2-methybut-2-ene (9.1 cm3, 85.6 mmol) 
and Grubbs catalyst, 2nd generation (0.077 g, 0.0905 mmol) in anhydrous dichloromethane 
(65 cm ). Purification by column chromatography (SiC>2 , ethyl acetate:hexane 1:19 to 1:3) 
afforded 3 4 7  as a light brown oil (1.1 g, 4.5 mmol, 98%); R f  0.47 (SiC>2 , ethyl acetate:hexane 
1:3); vmax.(cm-') 2939, 1671, 1586, 1482, 1455, 1409, 1265, 807; 8 'H NMR (400 MHz; 
CDCh; ppm) 1.68 (3H, d ,J  1.2 Hz, CH3), 1.78 (3H, s, CH3), 2.61 (3H, s, H-2), 3.37 (2H, d, J
6.9 Hz, H -l” ), 3.74 (3H, s, OCH3), 3.87 (3H, s, OCH3), 5.13 -  5.20 (1H, tm, J  6.9 Hz, H- 
2” ), 6.69 (1H, d, J  8.6 Hz, H-5’), 7.60 (1H, d, J  8.6 Hz, H-6’); 5 13C NMR (100 MHz; 
CDC13; ppm) 18.08 (s, CH3), 23.06 (s, CH2), 25.97 (s, CH3), 30.23 (s, CH3), 56.04 (s, OCH3),
63.05 (s, OCH3), 106.47 (s, CH), 122.79 (s, CH), 124.37 (s, C), 126.09 (s, C), 129.65 (s, CH),
131.97 (s, C), 159.39 (s, C), 162.14 (s, C), 199.36 (s, CO).
ProtocolF
To a stirring solution of substituted acetophenone and substituted benzaldehyde in methanol 
was added a quantity of an aqueous solution of sodium hydroxide and the mixture stirred at 
room temperature overnight. The mixture was then extracted with ethyl acetate or chloroform 
or dichloromethane, the organic fraction was then washed with water, dried over anhydrous 
sodium sulfate, filtered and evaporated in vacuo. The chalcone was then isolated by column 
chromatography or recrystallization.
(E)-l-(3-Allyl-2,4-dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one 3 4 8
3 4 8
The chalcone 3 4 8  was obtained by following Protocol F. Using l-(3-allyl-2,4- 
dimethoxyphenyl)ethanone 3 4 6  (0.087 g, 0.39 mmol), /7-anisaldehyde in methanol (0.39 cm3, 
1M), and aqueous sodium hydroxide solution (0.39 cm3, 2M) in methanol (1.2 cm3). The 
mixture was extracted with ethyl acetate (2 x 5 cm3) and washed with water ( 2 * 5  cm3).
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Purification by column chromatography (Si02, ethyl acetate:hexane 1:9) afforded 3 4 8  as a 
yellow oil (0.082 g, 0.24 mmol, 62%); R f  0.30 (Si02, ethyl acetate:hexane 1:3); VmaxXcrn'1) 
2937, 1655, 1638, 1587, 1571, 1509, 1482, 1458, 1421, 1408, 1235, 1170,1076, 804; 8  *H 
NMR (400 MHz; CDC13; ppm) 3.48 (2H, td, J  1.5, 6.0 Hz, H -l’” ), 3.71 (3H, s, OCH3), 3.85 
(3H, s, OCH3), 3.88 (3H, s, OCH3), 4.97 -  5.03 (2H, m, H-3” ’), 6.01 (1H, ddt„ J  9.6,17.6,
6.0 Hz, H-2’” ), 6.74 (1H, d, J 8 . 6  Hz, H-5’), 6.92 (2H, d, J 8 . 8  Hz, H-3” & H-5” ), 7.42 (1H, 
d, J  15.8 Hz, H-2), 7.58 (2H, d, J  8 . 8  Hz, H-2” & H-6 ” ), 7.63 (1H, d, J  8 . 6  Hz, H-6 ’), 7.70 
(1H, d, J  15.8 Hz, H-3); 8  13C NMR (100 MHz; CDC13; ppm) 24.04 (s, CH2), 55.63 (s, CH3),
56.12 (s, CH3), 63.53 (s, CH3), 106.61 (s, CH), 114.58 (s, CH), 144.94 (s, CH2), 122.23 (s, 
C), 124.23 (s, CH), 126.60 (s, C), 128.10 (s, C), 130.25 (s, CH), 130.41 (s, CH), 136.91 (s, 
CH), 143.39 (s, CH), 159.20 (s, C), 161.66 (s, C), 161.67 (s, C), 191.91 (s, CO); m/z(API 
ES+) 399 (MH+, 100%); HRMS found [MH]+ 339.15954 for C21H230 4, C2 iH230 4 requires 
[MH]+ 339.15909.
(E)-l-(3-Allyl-2,4-dimethoxyphenyl)-3-(3-fluoro-4-methoxyphenyl)prop-2-en-l-one 3 4 9
3 4 9
The chalcone 3 4 9  was obtained by following Protocol F .  Using l-(3-allyl-2,4- 
dimethoxyphenyl)ethanone 3 4 6  (0.110 g, 0.50 mmol), 3-fluoro-4-methoxybenzaldehyde 
(0.076 g, 0.50 mmol), and aqueous sodium hydroxide solution (0.50 cm , 2M) in methanol
■i o  ^
(2.0 cm ). The mixture was extracted with chloroform (2 x 5 cm ) and washed with water (2 
x 5 cm3). Purification by column chromatography (Si02, ethyl acetate:hexane 1:9) afforded 
3 4 9  as a yellow solid (0.148 g, 0.42 mmol, 84%); m.p. 77 -  79 °C; R f  0.25 (Si02, ethyl 
acetate:hexane 1:3); vmax.(cm'1) 2939, 1651, 1616, 1584, 1514, 1484, 1456, 1436, 1411, 
1276, 1262, 1242, 1209, 1096; 8  *H NMR (400 MHz; CDC13; ppm) 3.48 (2H, td, J  1.5, 6.0 
Hz, H -l’” ), 3.70 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.93 (3H, s, OCH3), 4.97 -  5.03 (2H, m, 
H-3’” ), 6.01 (1H, ddt, J 9.6, 17.6, 6.0 Hz, H-2’” ), 6.75 (1H, d, J8 .7  Hz, H-5’), 6.97 (1H, t, J
8.5 Hz, H-5” ), 7.33 (1H, br. d, J  8.5 Hz, H-6 ” ), 7.39 (1H, dd, J  2.0 Hz, J  12.1 Hz, H-2” ),
7.42 (1H, d, J  15.6 Hz, H-2), 7.64 (1H, d, J8 .7  Hz, H-6 ’), 7.65 (1H, br. d, J  15.6 Hz, H-3); 8  
,3C NMR (100 MHz; CDC13; ppm) 28.03 (s, CH2), 56.14 (s, CH3), 56.49 (s, CH3), 63.61 (s, 
CH3), 106.71 (s, CH), 113.38 (d, J2 .2  Hz, CH), 115.01 (s, CH2), 115.11 (d, J21.3 Hz, CH),
122.32 (s, C), 125.41 (s, CH), 126.09 (d, J  2.9 Hz, CH), 126.37 (s, C), 128.75 (d, J 1 A  Hz, 
C) 130.37 (s, CH), 136.84 (s, CH), 142.03 (d, J 2.9 Hz, CH), 149.74 (s, C), 152.66 (d, .7245.4
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Hz, CF), 159.34 (s, C), 161.89 (s, C), 191.43 (s, CO); m/z(API ES+) 357 (MH+, 100%); 
HRMS found [MH]+ 357.15081 for C21H22O4F, C21H22O4F requires [MH]+ 357.14966.
(E)-3-(4-Carboxymethoxyphenyl)-l-(3-allyl-2,4-dimethoxyphenyl)prop-2-en-1-one 350
MeO O
MeO 4’ 0  C 02H
350
To a stirring solution of l-(3-allyl-2,4-dimethoxyphenyl)ethanone 346 (0.110 g, 0.50 
mmol),and 4-formyl phenoxyacetic acid (0.090 g, 0.50 mmol) in methanol (2.0 cm3), was 
added an aqueous sodium hydroxide solution (1 cm3, 2M) and the mixture stirred at room 
temperature overnight. The mixture was then acidified with hydrochloric acid (until pH = 1, 
1M), and extracted with ethyl acetate (3><5 cm3). The organic fraction was then washed with 
water (2 x 5 cm ) dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo. 
Recrystallization from methanol afforded 350 as cream crystals (0.136 g, 0.36 mmol, 71%); 
m.p. 173 -  175 °C; R f  0.26 (SiC>2 , methanol:ethyl acetate 1:9); vmax.(cm *) 2938, 2559, 1735, 
1703, 1645, 1574, 1561, 1505, 1467,1453, 1417,1225, 1173, 1079, 1015, 987, 917, 834; 5 
lH NMR (400 MHz; CD3OD; ppm) 3.45 (2H, td, J  1.4, 6.1 Hz, H -l’” ), 3.67 (3H, s, OCH3), 
3.89 (3H, s, OCH3), 4.72 (2H, s, H-2” ” ), 4.93 -  5.01 (2H, m, H’3’” ), 5.96 (1H, ddt, J  
10.2,17.0, 6.1 Hz, H-2’” ), 6.87 (1H, d, J  8.7 Hz, H-5’), 6.99 (2H, d, J  8.7 Hz, H-3” & H- 
5” ), 7.42(1 H, d, J  15.9 Hz, H-2), 7.58 (1H, d, J  8.7 Hz, H-6 ’), 7.62 (2H, d, JS . l  Hz, H-2” & 
H-6 ” ), 7.63 (1H, d, J  15.9 Hz, H-3); 6  13C NMR (100 MHz; CD3OD; ppm) 27.54 (s, CH2),
55.26 (s, OCH3), 62.67 (s, OCH3), 64.65 (s, OCH20), 106.41 (s, CH), 113.97 (s, CH2),
115.03 (s, CH), 122.27 (s, C), 124.10 (s, CH), 125.95 (s, C), 128.50 (s, C), 129.90 (s, CH), 
130.15 (s, CH), 136.64 (s, CH), 143.88 (s, CH), 159.11 (s, C), 160.38 (s, C), 161.99 (s, C),
171.03 (C02H), 192.82 (s, CO); m/z(API ES+) 383 (MH+, 100%); HRMS found [MH]+ 
383.15032 for C22H23O6 , C22H23O6 requires [MH]+ 383.14891.
(E)-J-(3-Allyl-2,4-dimethoxyphenyl)-3-(3,4-dichlorophenyl)prop-2-en- 1-one 351
351
The chalcone 351 was obtained by following Protocol F. Using 1-(3-ally 1-2,4- 
dimethoxyphenyl)ethanone 346 (0.110 g, 0.50 mmol), 3,4-dichlorobenzaldehyde (0.088 g,
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0.50 mmol), and aqueous sodium hydroxide solution (0.50 cm3, 2M) in methanol (2.0 cm3). 
The mixture was extracted with dichloromethane (3 x 5 cm ) and washed with water ( 2x15 
cm ). Recrystallization from methanol afforded 351 as pale yellow crystals (0.130 g, 0.35 
mmol, 69%); m.p. 78 -  79 °C; Rf 0.52 (Si02, ethyl acetate:hexane 1:3); VmaxXcm'1) 2940, 
1655, 1638, 1603, 1583,1551, 1469, 1454, 1408,1321, 1268, 1258, 1228, 1215, 1119, 1077, 
976, 917, 823; 6  *H NMR (400 MHz; CDC13; ppm) 3.48 (2H, td, J  1.4, 6.0 Hz, H -l” ’), 3.70 
(3H, s, OCH3), 3.90 (3H, s, OCH3), 4.97 -  5.03 (2H, m, H-3’” ), 6.00 (1H, ddt, J  11.1, 16.1,
6.0 Hz, H-2’” ), 6.76 (1H, d, J 8.7 Hz, H-5’), 7.44 (1H, dd, J  1.8, 8.3 Hz, H-6 ” ), 7.47 (1H, d, 
J8.3 Hz, H-5” ), 7.54 (1H, d ,J  15.8 Hz, H-2), 7.63 (1H, d, J  15.8 Hz, H-3), 7.67 (1H, d, J8.7 
Hz, H-6 ’), 7.69 (1H, d, J  1.8 Hz, H-2” ); 8  13C NMR (100 MHz; CDC13; ppm) 28.02 (s, 
CH2), 56.18 (s, OCH3), 63.75 (s, OCH3), 106.88 (s, CH), 115.08 (s, CH2), 122.42 (s, C),
126.02 (s, C), 127.64 (s, CH), 127.93 (s, CH), 130.03 (s, CH), 130.56 (s, CH), 131.09 (s, 
CH), 133.43 (s, C), 134.20 (s, C), 135.54 (s, C), 136.73 (s, CH), 140.21 (s, CH), 159.53 (s, 
C), 162.24 (s, C), 190.91 (s, CO); m/z(API ES+) 377 (MH+, 100%), 379 (MH+, 70%); 
HRMS found [MH]+ 377.07085 for C20Hi9O3C12, C20Hi9O3C12 requires [MH]+ 377.07058.
(E)-l-(3-Allyl-2,4-dimethoxyphenyl)-3-(2,4-dichlorophenyl)prop-2-en- 1-one 352
MeO
MeO 41
352
The chalcone 352 was obtained following Protocol A using l-(3-allyl-2,4- 
dimethoxyphenyl)ethanone 346 (0.110 g, 0.50 mmol), 2,4-dichlorobenzaldehyde (0.088 g, 
0.50 mmol) and aqueous sodium hydroxide solution (0.5 cm3, 2M) in methanol (2.0 cm3). 
Recrystallization from methanol afforded 352 as pale yellow crystals (0.155 g, 0.41 mmol, 
82%); m.p. 91 -  92 °C; Rf 0.56 (Si02, ethyl acetate:hexane 1:3); VmaxXcrn’1) 2941, 1645, 
1601, 1590, 1462, 1409, 1327, 1271, 813; 8  !H NMR (400 MHz; CDC13; ppm) 3.47 (2H ,td,J
1.4, 5.9 Hz, H -l” ’), 3.70 (3H, s, OCH3), 3.89 (3H, s, OCH3), 4.97 -  5.03 (2H, m, H-3’” ),
6.00 (1H, ddt, J  9.4,17.8, 5.9 Hz, H-2’” ), 6.77 (1H, d, J  8.7 Hz, H-5’), 7.27 (1H, dd, J  2.1, 
8.7 Hz, H-5” ), 7.45 (1H, d, J2.1 Hz, H-3” ), 7.52 (1H, d, J  15.8 Hz, H-2), 7.67 (1H, d, J8.7 
Hz, H-6 ’), 7.68 (1H, d, J  8.4 Hz, H-6 ” ), 8.06 (1H, d, J  15.8 Hz, H-3); 8  13C NMR (100 
MHz; CDC13; ppm) 28.01 (s, CH2), 56.17 (s, OCH3), 63.76 (s, OCH3), 106.87 (s, CH),
115.06 (s, CH2), 122.36 (s, C), 126.04 (s, C), 127.72 (s, CH), 128.67 (s, CH), 129.09 (s, CH), 
130.23 (s, CH), 130.62 (s, CH), 132.32 (s, C), 136.23 (s, C), 136.32 (s, C), 136.73 (s, CH), 
137.49 (s, CH), 159.53 (s, C), 162.20 (s, C), 190.94 (s, CO); m/z(API ES+) 377 (MH+,
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100%), 379 (MH+, 70%); HRMS found [MH]+ 377.07103 for C 2 0 H 19O 3 C I 2 ,  C 2 0 H 19O 3C I 2  
requires [MH]+ 377.07058.
(E)-l-(3-Allyl-2,4-dimethoxyphenyl)-3-(4-(methoxymethoxy)phenyl)prop-2-en-1-one 3 5 3
MeO 0
O OMeMeO 4'
3 5 3
The chalcone 3 5 3  was obtained by following Protocol F. Using l-(3-allyl-2,4- 
dimethoxyphenyl)ethanone 3 4 6  (0.110 g, 0.50 mmol), 4-(methoxymethoxy)benzaldehyde 
3 3 2  (0.084 g, 0.50 mmol), and aqueous sodium hydroxide solution (0.50 cm3, 2M) in 
methanol (2.0 cm3). The mixture was extracted with dichloromethane ( 2 x 5  cm3) and 
washed with water (5 cm3). Purification by column chromatography (SiC>2 , ethyl 
acetate:hexane 1:19 to 1:4) afforded 3 5 3  as a yellow oil (0.142 g, 0.39 mmol, 77%); R f  0.29 
(SiC>2 , ethyl acetate:hexane 1:3); Vmax c^m'1) 2938, 1655, 1638, 1589, 1508, 1482, 1456, 
1421, 1408, 1272, 1232, 1151, 1075, 807; 6  *H NMR (400 MHz; CDC13; ppm) 3.45 -  3.49 
(2H, m, H -l’” ), 3.49 (3H, s, OCH3), 3.70 (3H, s, OCH3), 3.88 (3H, s, OCH3), 4.97 -  5.03 
(2H, m, H-3’” ), 5.21 (2H, s, H-2” ” ), 6.01 (1H, ddt,,/9.6, 17.6, 6.0 Hz, H-2’” ), 6.75 (1H, d, 
J 8.7 Hz, H-5’), 7.06 (2H, d, J 8.7 Hz, H-3” & H-5” ), 7.44 (1H, d, J  15.8 Hz, H-2), 7.57 (2H, 
d, JS . l  Hz, H-2” & H-6 ” ), 7.63 (1H, d, J8 .7  Hz, H-6 ’), 7.70 (1H, d, J15.8 Hz, H-3); 6  13C 
NMR (100 MHz; CDC13; ppm) 28.04 (s, CH2), 56.12 (s, OCH3), 56.39 (s, OCH3), 63.55 (s, 
OCH3), 94.42 (s, OCH20), 106.63 (s, CH), 114.96 (s, CH2), 116.69 (s, CH), 122.25 (s, C),
124.68 (s, CH), 126.54 (s, C), 129.15 (s, C), 130.31 (s, CH), 136.89 (s, CH), 143.17 (s, CH),
159.20 (s, C), 159.26 (s, C), 161.72 (s, C), 191.84 (s, CO); m/z(API ES+) 369 (MH+, 100%); 
HRMS found [MH]+ 369.17007 for C22H25O5, C22H25O5 requires [MH]+ 369.16965.
(E)-l-(3-Allyl-2,4-dimethoxyphenyl)-3-(3-methoxy-4-(methoxymethoxy)phenyl)prop-2-en-l- 
one 3 5 4
MeO O
0 OMe
3 5 4
The chalcone 3 5 4  was obtained by following Protocol F. Using l-(3-allyl-2,4- 
dimethoxyphenyl)ethanone 3 4 6  (0.110 g, 0.50 mmol), 3-methoxy-4-(methoxymethoxy) 
benzaldehyde 3 6 5  (0.098 g, 0.50 mmol), and aqueous sodium hydroxide solution (0.50 cm3,
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2M) in methanol (2.0 cm ). The mixture was extracted with dichloromethane (2 x 5 cm ) and 
washed with water (5 cm3). Purification by column chromatography (Si02, ethyl 
acetate:hexane 1:9 to 1:5) afforded 3 5 4  as a yellow oil (0.177 g, 0.45 mmol, 89%); R f  0.21 
(Si02, ethyl acetate:hexane 1:3); VmaxXcm'1) 2937, 1655, 1638, 1588, 1508, 1482, 1463, 
1409, 1216, 1155, 1118, 1075,978,806; 6 !H NMR (400 MHz; CDC13; ppm) 3.48 (2H, td, J
1.5, 6.0 Hz, H -l’” ), 3.52 (3H, s, OCH3), 3.71 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.94 (3H, 
s, OCH3), 4.98 -  5.04 (2H, m, H-3’” ), 5.28 (2H, s, H-2” ” ), 6.01 (1H, ddt, J  9.6, 17.7, 6.0 
Hz, H-2’” ), 6.75 (1H, d, J8 .7  Hz, H-5’), 7.15 (1H, d, J  1.7 Hz, H-2” ), 7.16 (1H, d, J8.3 Hz, 
H’5” ), 7.19 (1H, dd, J  1.7, 8.3 Hz, H-6” ), 7.40 (1H, d, J  15.8 Hz, H-2), 7.62 (1H, d, J  8.7 
Hz, H-6’), 7.67 (1H, d, J  15.8 Hz, H-3); 6 13C NMR (100 MHz; CDC13; ppm) 28.05 (s, 
CH2), 56.13 (s, OCH3), 56.23 (s, OCH3), 56.58 (s, OCH3), 63.55 (s, OCH3), 95.42 (s, 
OCH20), 106.61, 111.18, 114.97 (s, CH2), 116.08 (s, CH), 122.27 (s, C), 122.72 (s, CH),
125.00 (s, CH), 126.51 (s, C), 129.75 (s, C), 130.25 (s, CH), 136.89 (s, CH), 143.55 (s, CH), 
148.79 (s, C), 150.02 (s, C), 159.19 (s, C), 161.72 (s, C), 191.94 (s, CO); m/z(API ES+) 399 
(MH+, 100%); HRMS found [MH]+ 399.18062 for C23H2706, C23H2706 requires [MH]+ 
399.18022.
(E)-l-(3-Allyl-2,4-dimethoxyphenyl)-3-(4-methoxy-3-(methoxymethoxy)phenyl)prop-2-en-l- 
one 3 5 5
Q  3 „ 1"" 3""
Me0^ 4>Nj; 6' 6"^fx>Me
3 5 5
The chalcone 3 5 5  was obtained by following Protocol F. Using l-(3-allyl-2,4- 
dimethoxyphenyl)ethanone 3 4 6  (0.110 g, 0.50 mmol), 4-methoxy-3-(methoxymethoxy) 
benzaldehyde 2 6 4  (0.098 g, 0.50 mmol), and aqueous sodium hydroxide solution (0.50 cm3, 
2M) in methanol (2.0 cm3). The mixture was extracted with dichloromethane (2 x 10 cm3) 
and washed with water ( 2 x 1 0  cm3). Purification by column chromatography (Si02, ethyl 
acetate:hexane 1:9 to 1:1) afforded 3 5 5  as a yellow oil (0.145 g, 0.37 mmol, 73%); R f  0.18 
(Si02, ethyl acetate:hexane 1:3); VmaxXcnT1) 2937, 1654, 1637, 1588, 1508, 1482, 1461, 
1442, 1407, 1075, 993, 804; 6 *H NMR (400 MHz; CDC13; ppm) 3.48 (2H, td, ./cl.4, 6.1 Hz, 
H -l’” ), 3.54 (3H, s, OCH3), 3.71 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.93 (3H, s, OCH3),
4.97 -  5.04 (2H, m, H-3’” ), 5.27 (2H, s, H-2” ” ), 6.01 (1H, ddt, J 9.5, 17.7, 6.1 Hz, H-2’” ),
6.74 (1H, d, J8 .7  Hz, H-5’), 6.91 (1H, d, J8.5 Hz, H-5” ), 7.29 (1H, d d ,J  1.9, 8.5 Hz, H-6” ), 
7.36 (1H, d, J  15.8 Hz, H-2), 7.42 (1H, d, J  1.9 Hz, H-2” ), 7.60 (1H, d, J8 .7  Hz, H-6’), 7.64
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(1H, d, J  15.8 Hz, H-3); 8  13C NMR (100 MHz; CDC13; ppm) 28.06 (s, CH2), 56.12 (s, 
OCH3), 56.23 (s, OCH3), 56.56 (s, OCH3), 63.48 (s, OCH3), 95.86 (s, OCH20), 106.54 (s, 
CH), 111.87 (s, CH), 114.96 (s, CH2), 116.25 (s, CH), 122.28 (s, C), 124.17 (s, CH), 124.81 
(s, CH), 126.50 (s, C), 128.49 (s, C), 130.15 (s, CH), 136.92 (s, CH), 143.64 (s, CH), 146.90 
(s, C), 152.05 (s, C), 159.14 (s, C), 161.62 (s, C), 192.07 (s, CO); m/z(API ES+) 399 (MH+, 
100%); HRMS found [MH]+ 399.18047 for C23H270 6, C23H270 6 requires [MH]+ 399.18022.
(1 E,4E)-1,5-Bis(4-methoxy-3-(methoxymethoxy)phenyl)penta-l,4-dien-3-one 366
n
MeO. .0 .3 ' 3 . 0 .  .OMe
4'
OMe
(l£,4J£)-l,5-bis(4-methoxy-3-(methoxymethoxy)phenyl)penta-l,4-dien-3-one 366 was also 
isolated from the column chromatography of (E)-1 -(3-allyl-2,4-dimethoxyphenyl)-3-(4- 
methoxy-3-(methoxymethoxy)phenyl)prop-2-en-1-one 355. Purification by column 
chromatography (Si02, ethyl acetate:hexane 1:9 to 1:1) afforded 366 as yellow solid (0.18 g, 
0.04 mmol, 17%); m.p. 105 - 107 °C; R f  0.07 (Si02, ethyl acetateihexane 1:3); VmaxXcrn'1) 
3002, 2919, 2839, 1646, 1622, 1584, 1507, 1466, 1441, 1429, 1401, 1260, 1155, 1126, 1076, 
974, 919, 799; 8  'H NMR (400 MHz; CDC13; ppm) 3.56 (6 H, s, OCH3), 3.94 (6 H, s, OCH3),
5.30 (4H, s, H-2” ), 6.92 (2H, d, JS .4  Hz, H-5’), 6.95 (2H, J  15.8 Hz, H-2), 7.27 (2H, dd, J
1.9, 8.4 Hz, H-6 ’), 7.47 (2H, d, J  1.9 Hz, H-2’), 7.67 (2H, J  15.8 Hz, H-3); 8  13C NMR (100 
MHz; CDC13; ppm) 56.24 (s, OCH3), 56.57 (s, OCH3), 95.79 (s, OCH20), 111.85 (s, CH),
115.35 (s, CH), 124.14 (s, CH), 124.66 (s, CH), 128.26 (s, C), 143.03 (s, CH), 147.06 (s, C),
152.13 (s, C), 188.92 (s, CO); m/z{API-ES +) 415 ([MH]+, 100%); HRMS found [MH]+ 
415.17558 for C23H270 7, C23H270 7requires [MH]+ 415.17513.
3-Methoxy-4-(methoxymethoxy)benzaldehyde 365353
0
~ 3^0Me
H 1
The method was adapted from that of Crombie228 et al. To a stirring solution of sodium 
hydride (0.16 g, 4.0 mmol, 60% dispersion in mineral oil) in anhydrous dimethyl formamide 
(2 cm3) at 0 °C under argon 4-hydroxy-3-methoxybenzaldeyde (0.50 g, 3.3 mmol) in 
anhydrous dimethyl formamide (2 cm3) was added slowly drop wise over 20 minutes. The 
reaction was then allowed to warm to room temperature, before being cooled to 0 °C.
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Chloromethyl methyl ether (0.30 cm , 3.9 mmol) in anhydrous dimethyl formamide (1 cm ) 
was then added drop wise over 30 minutes to the mixture at 0 °C. The mixture was then 
stirred for 30 minutes at 0 °C and then stirred overnight at room temperature. The reaction 
was then tipped into a mixture of water (5 cm3) and ice (5 g), and extracted with ethyl acetate 
(4><6 cm3). The organic fraction was washed with an aqueous sodium hydroxide solution (2 
x3 cm3, 0 .1 M) and water ( 2  x3  cm3), it was then dried over anhydrous sodium sulfate, filtered 
and evaporated in vacuo. Purification by column chromatography (SiC>2 , ethyl acetate:hexane 
1:9 to 1:3) afforded 3 6 5  as pale yellow oil (0.51 g, 2.6 mmol, 80%); R f  0.22 (Si02, ethyl 
acetate-.hexane 1:3); vmax{c m l) 2956, 2932, 2872, 2829, 1680, 1596, 1586, 1506, 1466, 
1451, 1442, 1421, 1259, 1230, 1150, 1126, 1082,919, 8 6 8 , 817, 728; 8 NMR (400 MHz; 
CDC13; ppm) 3.53 (3H, s, OCH3), 3.96 (3H, s, OCH3), 5.37 (3H, s, H-2” ), 7.28 (1H, d, J 8 . 8  
Hz, H-5’), 7.42 -  7.45 (2H, m, H-2’ & H-6 ’), 9.88 (1H, s, H-l); 5 13C NMR (100 MHz; 
CDC13; ppm) 56.27 (s, OCH3), 56.76 (s, OCH3), 95.24 (s, OCH20), 109.73 (s, CH), 114.91 
(s, CH), 126.67 (s, CH), 131.30 (s, C), 150.30 (s, C), 152.23 (s, C), 191.24 (s, CHO).
(E)-l-(2,4-Dimethoxy-3-(3-methylbut-2-enyl)phenyl)-3-(4-methoxyphenyl)prop-2-en-l-one 
3 5 6
MeO O
OMeMeO 4'
3 5 6
The chalcone 3 5 6  was obtained by following Protocol F. Using l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)ethanone 3 4 7  (0.087 g, 0.35 mmol), / 7-anisaldehyde in methanol 
(0.35 cm3, 1M), and aqueous sodium hydroxide solution (0.35 cm3, 2M) in methanol (1.4 
cm ). The mixture was extracted with dichloromethane (2 x 5 cm ) and washed with water (5 
cm3). Purification by column chromatography (Si02, ethyl acetate:hexane 1:9) afforded 3 5 6  
as a pale yellow oil (0.069 g, 0.19 mmol, 54%); R f  0.35 (Si02, ethyl acetate:hexane 1:3); 
VmaxXcnf1) 2934, 1655, 1588, 1571, 1509, 1481, 1456, 1421, 1409, 1235, 1170, 802; 8 *H 
NMR (400 MHz; CDC13; ppm) 1.69 (3H, d, J  1.2 Hz, CH3), 1.79 (3H, s CH3), 3.40 (2H, d, J
6.9 Hz, H -l’” ), 3.69 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.88 (3H, s, OCH3), 5.15 -  5.22 
(1H, tm, J  6.9 Hz, H-2’” ), 6.72 (1H, d, J  8 . 6  Hz, H-5’), 6.92 (2H, d, J  8 . 8  Hz, H-3” & H- 
5” ), 7.42 (1H, d, J  15.8 Hz, H-2), 7.58 (2H, d, J 8 . 8  Hz, H-2” & H-6 ” ), 7.59 (1H, d, J  8 . 6  
Hz, H-6 ’), 7.70 (1H, d, J  15.8 Hz, H-3); 5 13C NMR (100 MHz; CDC13; ppm) 18.10 (s, CH3),
23.02 (s, CH2), 26.02 (s, CH3), 55.53 (s, OCH3), 56.07 (s, CH3), 63.29 (s, CH3), 106.56 (s, 
CH), 114.57 (s, CH), 122.92 (s, CH), 124.12 (s, C), 124.34 (s, CH), 126.56 (s, C), 128.16 (s,
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C), 129.80 (s, CH), 130.39 (s, CH), 131.85 (s, C), 143.28 (s, CH), 159.09 (s, C), 161.64 (s, 
C), 191.95 (s, CO); m/z(API ES+) 367 (MH+, 100%); HRMS found [MH]+ 367.19117 for 
C23H27O4 , C23H27O4 requires [MH]+ 367.19039.
(E)-3-(3-Fluoro-4-methoxyphenyl)-I-(2,4-dimethoxy-3-(3-methylbut-2-enyl)phenyl)prop-2- 
en-l-one 357
MeO O
MeO 4' OMe
357
The chalcone 357 was obtained by following Protocol F. Using l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)ethanone 347 (0.087 g, 0.35 mmol), 3-fluoro-4-
methoxybenzaldehyde (0.053 g, 0.35 mmol), and aqueous sodium hydroxide solution (0..35 
cm3, 2M) in methanol (1.4 cm3). The mixture was extracted with dichloromethane ( 2 x 5  
cm3) and washed with water (5 cm3). Purification by column chromatography (Si02, ethyl 
acetate:hexane 1:19) afforded 357 as a yellow solid (0.100 g, 0.26 mmol, 75%); m.p. 64 -  6 6  
°C; Rf 0.29 (Si02, ethyl acetate:hexane 1:3); vmax(c m l) 2911, 1647, 1583, 1514,1468,1438, 
1407,1274, 1254, 1086, 976, 761; 6  *H NMR (400 MHz; CDC13; ppm) 1.69 (3H, d, J  0.8 Hz, 
CH3), 1.80 (3H, s CH3), 3.40 (2H, d, J  6.9 Hz, H -l’” ), 3.69 (3H, s, OCH3), 3.89 (3H, s, 
OCH3), 3.93 (3H, s, OCH3), 5.15 -  5.22 (1H, tm, J6 .9  Hz, H-2’” ), 6.73 (1H, d, J8 .4  Hz, H- 
5’), 6.96 (1H, t, J  8.4 Hz, H-5” ), 7.33 (1H, br. d, J  8.4 Hz, H-6 ” ), 7.39 (1H, dd, J  2.2 Hz, J
11.8 Hz, H-2” ), 7.42 (1H, d, J 16.2 Hz, H-2), 7.60 (1H, d J8 .4  Hz, H-6 ’), 7.64 (1H, d, J 16.2 
Hz, H-3); 6  13C NMR (100 MHz; CDC13; ppm) 18.11 (s, CH3), 23.01 (s, CH2), 26.01 (s, 
CH3), 56.08 (s, OCH3), 56.48 (s, OCH3), 63.36 (s, OCH3), 106.67 (s, CH), 113.38 (d, J  22  
Hz, CH), 115.09 (d, J  18.3 Hz, CH), 122.84 (s, CH), 124.20 (s, C), 125.51 (s, CH) 126.08 (d, 
J3 .0  Hz, CH), 126.32 (s, C), 128.80 (d, J 6 . 6  Hz, C), 129.91 (s, CH), 131.93 (s, C), 141.91 
(d, J2 .2  Hz, CH), 149.65 (d, J  11.0 Hz, C), 153.66 (d, J 245.4 Hz, CF), 159.23 (s, C), 161.87 
(s, C), 191.46 (s, CO); m/z(API ES+) 385 (MFT, 100%); HRMS found [MH]+ 385.18150 for 
C23H260 4F, C23H260 4F requires [MH]+ 385.18096.
(E)-3-(4-Carboxymethoxyphenyl)-l-(2,4-dimethoxy-3-(3-methylbut-2-enyl)phenyl) prop-2-en- 
1-one 358
MeO O
358
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To a stirring solution of l-(2,4-dimethoxy-3-(3-methylbut-2-enyl)phenyl)ethanone 3 4 7  (0.087 
g, 0.35 mmol),and 4-formyl phenoxyacetic acid (0.063 g, 0.35 mmol) in methanol (1.4 cm3), 
was added an aqueous sodium hydroxide solution (0.70 cm3, 2M) and the mixture stirred at 
room temperature overnight. The mixture was then acidified with hydrochloric acid (until pH 
= 1, 2M), and extracted with ethyl acetate ( 4 x 5  cm3). The organic fraction was then washed 
with water ( 2 x 5  cm3) dried over anhydrous magnesium sulfate, filtered and evaporated in 
vacuo. Recrystallization from methanol afforded 3 5 8  as pale brown crystals (0.119 g, 0.29 
mmol, 85%); m.p. 148 -  150 °C; R f  0.14 (Si02, methanohethyl acetate 1:4); VmaxXcnT1) 
2909, 1736, 1705, 1645, 1591, 1561, 1506, 1453, 1417, 1227, 1173, 808; 6  *H NMR (400 
MHz; C D 3 O D ;  ppm) 1.67 (3H, d, J 0.8 Hz, C H 3 ) ,  1.78 (3H, s, C H 3 ) ,  3.38 (2H, d, J 6.9 Hz, H- 
1’” ), 3.65 (3H, s, O C H 3 ) ,  3.89 (3H, s, O C H 3 ) ,  4.72 (2H, s, H-2” ” ), 5.11 -  5.19 (1H, tm, J
6.9 Hz, H-2’” ), 6.85 (1H, d, J  8 . 8  Hz, H-5’), 6.98 (2H, d, J  8 . 6  Hz, H-3” & H-5” ), 7.42 (1H, 
d, J  16.6 Hz, H-2), 7.54 (1H, d, J  8 . 8  Hz, H-6 ’), 7.61 (2H, d, J  8 . 6  Hz, H-2” & H-6 ” ), 7.63 
(1H, d, J  16.6 Hz, H-3); 6  ,3C NMR (100 MHz; C D 3 O D ;  ppm) 16.80 (s, CH3), 22.43 (s, 
CH2), 24.74( s, CH3), 55.22 (s, CH3), 62.29 (s, C H 3 ) ,  64.62 (s, C H 2 ) ,  106.37 (s, CH), 115.02 
(s, CH), 122.72 (s, CH), 124.00 (s, C), 124.12 (s, CH), 125.89 (s, C), 128.51 (s, C), 129.50 (s, 
CH), 130.15 (s, CH), 131.13 (s, C), 143.80 (s, CH), 158.98 (s, C), 160.35 (s, C), 161.97 (s, 
C), 171.02 (s, C 0 2H), 192.83 (s, CO); m/z(API ES+) 411 (MH+, 100%); HRMS found 
[MH]+ 411.18079 for C24H270 6, C24H270 6 requires [MH]+ 411.18022.
(E)-3-(3,4-Dichlorophenyl)-l-(2,4-dimethoxy-3-(3-methylbut-2-enyl)phenyl)prop-2-en-l-one 
3 5 9
MeO O
MeO 4'
3 5 9
The chalcone 3 5 9  was obtained by following Protocol F. Using l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)ethanone 3 4 7  (0.087 g, 0.35 mmol), 3,4-dichlorobenzaldehyde 
(0.062 g, 0.35 mmol), and aqueous sodium hydroxide solution (0.35 cm3, 2M) in methanol 
(1.4 cm3). The mixture was extracted with dichloromethane (2 x 5  cm3) and washed with 
water (5 cm3). Purification by column chromatography (Si02, dichloromethane:hexane 3:1) 
afforded 3 5 9  as a yellow oil (0.037g, 0.09 mmol, 25%); R f  0.42 (Si02, 
dichloromethane:hexane 3:1); VmaxXcrn’1) 2934, 1659, 1586, 1552, 1470, 1410, 1322, 1270, 
805; 6  lH NMR (400 MHz; CDC13; ppm) 1.70 (3H, d, J  1.2 Hz, CH3), 1.80 (3H, s, CH3), 
3.40 (2H, d, J6 .9  Hz, H -l” ’), 3.68 (3H, s, OCH3), 3.90 (3H, s, OCH3), 5.15 -  5.21 (1H, tm, J
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6.9 Hz, H-2” ’), 6.75 (1H, d , J 8 . 8  Hz, H-5’), 7.44 (1H, dd, J  1.7, 8.3 Hz, H-6 ” ), 7.47 (1H, d,
78.3 Hz, H-5” ), 7.55 (1H, d, J  16.0 Hz, H-2), 7.62 (1H, d, J  16.0 Hz, H-3), 7.63 (1H, d, 78.8 
Hz, H-6 ’), 7.69 (1H, d, 7  1.7 Hz, H-2” ); 5 ,3C NMR (100 MHz; CDC13; ppm) 18.12 (s, 
CHj), 22.99 (s, CH2), 26.00 (s, CH3), 56.12 (s, OCH3), 63.49 (s, OCH3), 106.84 (s, CH),
122.74 (s, CH), 124.31 (s, C), 125.97 (s, C), 127.62 (s, CH), 128.03 (s, CH), 130.03 (s, CH), 
130.11 (s, CH), 131.08 (s, CH), 132.04 (s, C), 133.41 (s, C), 134.15 (s, C), 135.60 (s, C), 
140.10 (s, CH), 159.40 (s, C), 162.23 (s, C), 196.96 (s, CO); m/z(API ES+) 405 (MH+, 
100%), 407 (MH*. 60%); HRMS found [MH]+ 405.10242 for C22H23C120 3, C22H23C120 3 
requires [MH]+ 405.10188.
(E)-3-(2,4-Dichlorophenyl)-l-(2,4-dimethoxy-3-(3-methylbut-2-enyl)phenyl)prop-2-en-l-one
360
MeO O , Cl
1 y  II 3
I I 2
6
5' 5"
360
The chalcone 360 was obtained by following Protocol F. Using l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)ethanone 347 (0.087 g, 0.35 mmol), 2,4-dichlorobenzaldehyde 
(0.062 g, 0.35 mmol), and aqueous sodium hydroxide solution (0.35 cm3, 2M) in methanol 
(1.4 cm3). The mixture was extracted with dichloromethane (2><5 cm3) and washed with 
water (5 cm ). Purification by column chromatography (Si02, ethyl acetate:hexane 1:9) 
afforded 360 as a yellow oil (0.126 g, 0.31 mmol, 89%); Rf 0.56 (Si02, ethyl acetate:hexane 
1:3); VmaxXcrn'1) 2937, 1657, 1583, 1466, 1410, 1272, 1256, 806; 6  'H NMR (400 MHz; 
CDC13; ppm) 1.69 (3H, d, J  1.2 Hz, CH3), 1.79 (3H, s, CH3), 3.40 (2H, d, J 6.9 Hz, H -l’” ),
3.69 (3H, s, OCH3), 3.90 (3H, s, OCH3), 5.14 -  5.20 (1H, tm, J6 .9  Hz, H-2’” ), 6.75 (1H, d, J
8 . 8  Hz, H-5’), 7.27 (1H, dd, J  1.7, 8.4 Hz, H-5” ), 7.45 (1H, d, J  1.7 Hz, H-3” ), 7.53 (1H, d, 
J  15.8 Hz, H-2), 7.64 (1H, d, J  8 . 8  Hz, H-6 ’), 7.68 (1H, d, J  8.4 Hz, H-6 ” ), 8.05 (1H, d, J
15.8 Hz, H-3); 5 13C NMR (100 MHz; CDC13; ppm) 18.11 (s, CH3), 22.98 (s, CH2), 26.00 (s, 
CH3), 56.11 (s, OCH3), 63.51 (s, OCH3), 106.82 (s, CH), 122.75 (s, CH), 124.26 (s, C), 
125.99 (s, C), 127.72 (s, CH), 128.67 (s, CH), 129.19 (s, CH), 130.17 (s, CH), 130.23 (s, 
CH), 132.00 (s, C), 132.38 (s, C), 136.21 (s, C), 136.27 (s, C), 137.39 (s, CH), 159.41 (s, C), 
162.19 (s, C), 191.00 (s, CO); m/z(API ES+) 405 (MH+, 100%), 407 (MH+, 70%); HRMS 
found [MH]+ 405.10239 for C22H23C12 0 3, C22H23C120 3 requires [MH]+ 405.10188.
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(E)-l-(2,4-Dimethoxy-3-(3-methylbut-2-enyl)phenyl)-3-(4-(methoxymethoxy)phenyl) prop-2-
en-l-one 361
MeO O
0 OMe
3 6 1
The chalcone 3 6 1  was obtained by following Protocol F. Using l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)ethanone 3 4 7  (0.087 g, 0.35 mmol), 4-(methoxymethoxy) 
benzaldehyde 3 3 2  (0.059 g, 0.35 mmol), and aqueous sodium hydroxide solution (0.35 cm , 
2M) in methanol (1.4 cm ). The mixture was extracted with dichloromethane (2 x 5 cm ) and 
washed with water (5 c m ). Purification by column chromatography (SiC>2 , ethyl 
acetate:hexane 1:19) afforded 3 6 1  as a yellow oil (0.120, 0.30 mmol, 8 6 %) R f  0.37 (SiC>2 , 
ethyl acetatethexane 1:3); VmaxXcrn'1) 2933, 1655, 1590, 1508, 1481, 1455, 1421, 1409, 1232, 
1151, 982; 6  *H NMR (400 MHz; CDC13; ppm) 1.69 (3H, d, J  0.8 Hz, CH3), 1.79 (3H, s, 
CH3), 3.40 (2H, d, J  6.7 Hz, H -l’” ), 3.48 (3H, s, OCH3), 3.69 (3H, s, OCH3), 3.89 (3H, s, 
OCH3), 5.16 -  5.22 (1H, tm, J 6.1 Hz, H-2’” ), 5.21 (2H, s, H-2” ” ), 6.73 (1H, d, J 8 . 8  Hz, H- 
5’), 7.06 (2H, d , J 8 . 8  Hz, H-3” & H-5” ), 7.44 (1H, d, J16.0 Hz, H-2), 7.57 (2H, d, J 8 . 8  Hz, 
H-2” & H-6 ” ), 7.60 (1H, d, J 8 . 8  Hz, H-6 ’), 7.69 (1H, d, J  16.0 Hz, H-3); 5 ,3C NMR (100 
MHz; CDC13; ppm) 18.10 (s, CH3), 23.02 (s, CH2), 26.02 (s, CH3), 56.07 (s, OCH3), 56.39 (s, 
OCH3), 63.30 (s, OCH3), 94.43 (s, OCH20), 106.58 (s, CH), 116.69 (s, CH), 122.90 (s, CH),
124.13 (s, C), 124.78 (s, CH), 126.50 (s, C), 129.21 (s, C), 129.84 (s, CH), 130.29 (s, CH),
131.87 (s, C), 143.06 (s, CH), 159.13 (s, C), 159.17 (s, C), 161.69 (s, C), 191.90 (s, CO); 
m/z{API ES+) 397 (MH+, 100%); HRMS found [MH]+ 397.20159 for C24H29O5, C24H29O5 
requires [MH]+ 397.20095.
(E)-l-(2,4-Dimethoxy-3-(3-methylbut-2-enyl)phenyl)-3-(3-methoxy-4-(methoxymethoxy) 
phenyl prop-2-en-l-one 3 6 2
MeO O
0 OMe
3 6 2
The chalcone 3 6 2  was obtained by following Protocol F. Using l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)ethanone 3 4 7  (0.087 g, 0.35 mmol), 3-methoxy-4-
(methoxymethoxy)benzaldehyde 3 6 5  (0.069 g, 0.35 mmol), and aqueous sodium hydroxide
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solution (0.35 cm3, 2M) in methanol (1.4 cm3). The mixture was extracted with 
dichloromethane ( 2><5 cm3) and washed with water (5 cm3). Purification by column 
chromatography (SiC>2 , ethyl acetate:hexane 1:19) afforded 362 as a yellow oil (0.128 g, 0.30 
mmol, 85%); R f  0.25 (Si02, ethyl acetate:hexane 1:3); VmaxXcm'1) 2934, 1655, 1588, 1507, 
1482, 1453, 1410, 1217, 1088, 978, 806; 8  *H NMR (400 MHz; CDC13; ppm) 1.69 (3H, d, J  
0.8 Hz, CH3), 1.80 (3H, s, CH3), 3.41 (2H, d, J6 .9  Hz, H -l’” ), 3.52 (3H, s, OCH3), 3.69 (3H, 
s, OCH3), 3.89 (3H, s, OCH3), 3.94 (3H, s, OCH3), 5.16 - 5.22 (1H, tm, J  6.9 Hz, H-2’” ), 
5.28 (2H, s, H-2” ” ), 6.73 (1H, d, J  8 . 8  Hz, H-5’), 7.15 (1H, d, J  1.7 Hz, H-2” ), 7.17 (1H, d, 
J  8.3 Hz, H-5” ), 7.20 (1H, dd, J  1.7, 8.3 Hz, H-6 ” ), 7.41 (1H, d, J 15.6 Hz, H-2), 7.59 (1H, 
d, J  8 . 8  Hz, H-6 ’), 7.66 (1H, d, J 15.6 Hz, H-3); 8  ,3C NMR (100 MHz; CDC13; ppm) 18.10 
(s, CH3), 23.03 (s, CH2), 26.02 (s, CH3), 56.07 (s, OCH3), 56.23 (s, OCH3), 56.57 (s, OCH3),
63.30 (s, OCH3), 95.42 (s, OCH20), 106.57 (s, CH), 111.19 (s, CH), 116.09 (s, CH), 122.66 
(s, CH), 122.88 (s, CH), 124.15 (s, C), 125.13 (s, CH), 126.48 (s, C), 129.78 (s, CH), 129.81 
(s, C), 131.89 (s, C), 143.41 (s, CH), 148.74 (s, C), 150.02 (s, C), 159.06 (s, C), 161.68 (s, C),
192.01 s, CO); m/z(API ES+) 427 (MH+, 100%); HRMS found [MH]+ 427.21192 for 
C25H3 i0 6, C25H3 i0 6 requires [MH]+ 427.21152.
(E)-l-(2,4-Dimethoxy-3-(3-methylbut-2-enyl)phenyl)-3-(4-methoxy-3-(methoxymethoxy) 
phenyl)prop-2-en-l-one 363
MeO
OMe
OMeMeO 4'
363
The chalcone 363 was obtained by following Protocol F. Using l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)ethanone 347 (0.087 g, 0.35 mmol), 4-methoxy-3-
(methoxymethoxy)benzaldehyde 264 (0.069 g, 0.35 mmol), and aqueous sodium hydroxide 
solution (0.35 cm3, 2M) in methanol (1.4 cm3). The mixture was extracted with 
dichloromethane (2 x 5  cm3) and washed with water (5 cm3). Purification by column 
chromatography (Si02, ethyl acetate:hexane 1:19) afforded 363 as a pale yellow oil (0.136 g, 
0.32 mmol, 91%); R f  0.20 (Si02, ethyl acetate:hexane 1:3); VmaxXcrn'1) 2934, 1655, 1588, 
1509, 1482, 1442, 1409, 1218, 1154, 1132, 1088, 996, 804; 8  !H NMR (400 MHz; CDC13; 
ppm) 1.69 (3H, d, J0 .8  Hz, CH3), 1.80 (3H, s, CH3), 3.41 (2H, d, J6 .9  Hz, H -l’” ), 3.54 (3H, 
s, OCH3), 3.70 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.92 (3H, s, OCH3), 5.16 - 5.22 (1H, tm, J
6.9 Hz, H-2” ’), 5.27 (2H, s, H-2” ” ), 6.73 (1H, d, J 8 . 8  Hz, H-5’), 6.91 (1H, d ,J8 .3  Hz, H- 
5” ), 7.28 (1H, dd, J2 .0  Hz, J8 .3  Hz, H-6 ” ), 7.37(1H, d, J  16.0 Hz, H-2), 7.43 (1H, d,J2 .0
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Hz, H-2” ), 7.57 (1H, d, J  8 . 8  Hz, H-6 ’), 7.63 (1H, d, J 15.6 Hz, H-3); 8  13C NMR (100 
MHz; CDCh; ppm)18.09 (s, CH3), 23.04 (s, CH2), 26.02 (s, CH3), 56.07 (s, OCH3), 56.23 (s, 
OCH3), 56.55 (s, OCH3), 63.22 (s, OCH3), 95.87 (s, OCH20), 106.50 (s, CH), 111.87 (s, 
CH), 116.24 (s, CH), 122.91 (s, CH), 124.15 (s, C), 124.17 (s, CH), 124.94 (s, CH), 126.47 
(s, C), 128.55 (s, C), 129.69 (s, CH), 131.85 (s, C), 143.51 (s, CH), 146.91 (s, C), 152.01 (s, 
C), 159.01 (s, C), 161.58 (s, C), 192.14 (s, CO); m/z(APl ES+) 427 (MH+, 100%); HRMS 
found [M H f 427.21212 for C25H3 i0 6, C25H3 i0 6 requires [M H f 427.21152.
Protocol G
The method adopted was that of Wang230 et al. To a stirring solution of MOM-protected 
compound in methanol under argon was added hydrochloric acid (3M). The reaction was 
then heated to reflux at 75 °C for 45 minutes. The reaction was cooled to room temperature 
and tipped into water ( 6  cm3), it was then extracted with ethyl acetate (3><6 cm3). The 
organic fraction was then washed with water ( 2  x 5  cm ), dried over anhydrous sodium 
sulfate, filtered and evaporated in vacuo. Purified by column chromatography or 
recrystallization.
(E)-l-(3-Allyl-2,4-dimethoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-l-one 367
367
The chalcone 367 was obtained by following Protocol G. Using (£)-l-(3-allyl-2,4- 
dimethoxyphenyl)-3-(4-(methoxymethoxy)phenyl)prop-2-en-l-one 353 (0.134 g, 0.36 
mmol), methanol (7.3 cm3) and hydrochloric acid (1.3 cm3, 3M). Purification by column 
chromatography (SiC>2 , ethyl acetate:hexane 1:9 to 1:4) afforded 367 as a yellow oil (0 . 1 1 2  g, 
0.35 mmol, 95%); R f  0.13 (Si0 2 , ethyl acetate:hexane 1:3); VmaxXcm'1) 3232, 2938, 1638, 
1576, 1510, 1483, 1438, 1408, 1272, 1216, 1095, 808; 8  ]H NMR (400 MHz; CDC13; ppm)
3.47 (2H, td, J  1.5, 6.0 Hz, H -l’” ), 3.71 (3H, s, OCH3), 3.88 (3H, s, OCH3), 4.97 -  5.03 (2H, 
m, H-3’” ), 5.93 (1H, s, OH-4” ), 6.00 (1H, ddt, J9.6, 17.6, 6.0 Hz, H-2’” ), 6.75 (1H, d, J8 .7  
Hz, H-5’), 6 . 8 8  (2H, d, J  8 . 6  Hz, H-3” & H-5” ), 7.41 (1H, d, J  15.8 Hz, H-2), 7.52 (2H, d, J
8 . 6  Hz, H-2” & H-6 ” ), 7.63 (1H, d, J  8.7 Hz, H-6 ’), 7.70 (1H, d, J  15.8 Hz, H-3); 8  13C 
NMR (100 MHz; CDC13; ppm) 26.04 (s, CH2), 56.13 (s, OCH3), 65.56 (s, OCH3), 106.65 (s, 
CH), 114.97 (s, CH2), 116.18 (s, CH), 122.29 (s, C), 124.06 (s, CH), 126.44 (s, C), 128.03 (s, 
C), 130.29 (s, CH), 130.68 (s, CH), 136.85 (s, CH), 143.75 (s, CH), 158.19 (s, C), 159.24 (s,
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C), 161.77 (s, C), 192.30 (s, CO); m/z(API ES+) 325 (MH+, 100%); HRMS found [MH]+ 
325.14524 for C20H21O4 , C20H21O4 requires [MH]+ 325.14344.
(E)-l-(3-Allyl-2,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-l-one 368
The chalcone 368 was obtained by following Protocol G. Using (£)-l-(3-allyl-2,4- 
dimethoxyphenyl)-3-(3-methoxy-4-(methoxymethoxy)phenyl)prop-2-en-l-one 354 (0.152 g, 
0.38 mmol), methanol (7.6 cm3) and hydrochloric acid (1.4 cm3, 3M). Purification by 
column chromatography (Si0 2 , ethyl acetate:hexane 1:9 to 1:3) afforded 368 as a yellow oil 
(0.134 g, 0.38 mmol, 99%); R f  0.13 (SiC>2 , ethyl acetate:hexane 1:3); VmaxXcm*1) 3355, 2937, 
1638, 1583, 1508, 1482, 1454, 1427, 1408, 1207, 1117, 1076, 807; 6  *H NMR (400 MHz; 
CDCI3 ; ppm) 3.48 (2H, td, J  1.5, 6.0 Hz, H -l’” ), 3.71 (3H, s, OCH3), 3.88 (3H, s, OCH3), 
3.94 (3H, s, OCH3), 4.97 -  5.03 (2H, m, H-3’” ), 5.91 (1H, s, OH-4” ), 6.00 (1H, ddt, J9 .4 , 
17.7, 6.0 Hz, H-2” ), 6.74 (1H, d, J8 .7  Hz, H-5’), 6.93 (1H, d, J8.3Hz, H-5” ), 7.04 (1H, d, J  
1.8, H-2” ), 7.18 (1H, dd J  1.8, 8.3 Hz, H-6 ” ), 7.36 (1H, d, J  15.8 Hz, H-2), 7.61 (1H, d, J8 .7  
Hz, H-6 ’), 7.66 (1H, d, J  15.8 Hz, H-3); 8  ,3C NMR (100 MHz; CDC13; ppm) 28.05 (s, CH2), 
56.12 (s, OCH3 ), 56.25 (s, OCH3), 63.53 (s, OCH3), 106.58 (s, CH), 110.17 (s, CH), 114.94 
(s, CH2), 115.00 (s, CH), 122.22 (s, C), 123.57 (s, CH), 124.20 (s, CH), 126.58 (s, C), 127.93 
(s, C), 130.18 (s, CH), 136.90 (s, CH), 143.96 (s, CH), 146.97 (s, C), 148.25 (s, C), 159.10 (s, 
C), 161.62 (s, C), 192.01 (s, CO); m/z(API ES+) 355 (MH+, 100%); HRMS found [MH]+ 
355.15441 for C21H23O5 , C21H23O5 requires [MH]+ 355.15400.
(E)-l-(3-Allyl-2,4-dimethoxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-en-l-one 369
The chalcone 369 was obtained by following Protocol G. Using (£)-l-(3-allyl-2,4- 
dimethoxyphenyl)-3-(4-methoxy-3-(methoxymethoxy)phenyl)prop-2-en-l-one 355 (0.137 g, 
0.34 mmol), methanol (6.9 cm3) and hydrochloric acid (1.3 cm3, 3M). Purification by 
column chromatography (Si0 2 , ethyl acetate:hexane 3:17 to 1:3) afforded 369 as a yellow 
solid (0.120 g, 0.34 mmol, 98%); m.p. 91 -  94 °C; R f  0.15 (Si0 2 , ethyl acetate:hexane 1:3);
MeO 0
368
MeO O
369
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VmaxXcm"1) 3377, 2937, 2839, 1638, 1583, 1508, 1483, 1456, 1439, 1211, 1118, 1076; 5 'H 
NMR (400 MHz; CDC13; ppm) 3.47 (2H, td, J  1.4, 6.0 Hz, H -l” ’), 3.70 (3H, s, OCH3), 3.88 
(3H, s, OCH3), 3.93 (3H, s, OCH3), 4.97 -  5.03 (2H, m, H-3’” ), 5.66 (1H, s, OH-3” ), 6.00 
(1H, ddt, J  9.5, 17.7, 6.0 Hz, H-2” ), 6.74 (1H, d, J  8.7 Hz, H-5’), 6.86 (1H, d, J  8.4Hz, H- 
5” ), 7.12 (1H, dd, J  2.0, 8.4Hz, H-6” ), 7.26 (1H, d, J2.Q Hz, H-2” ), 7.41 (1H, d, J  15.7 Hz, 
H-2), 7.63 (1H, d, J  8.7 Hz, H-6’), 7.66 (1H, d, J  15.7 Hz, H-3); 5 13C NMR (100 MHz; 
CDC13; ppm) 28.04 (s, CH2), 56.11 (s, OCH3), 56.24 (s, OCH3), 63.52 (s, OCH3), 106.60 (s, 
CH), 110.75 (s, CH), 113.38 (s, CH), 114.96 (s, CH2), 122.26 (s, C), 122.69 (s, CH), 124.76 
(s, CH), 126.53 (s, C), 129.06 (s, C), 130.27 (s, CH), 136.88 (s, C), 143.39 (s, CH), 146.06 (s, 
C), 148.76 (s, C), 159.28 (s, C), 161.70 (s, C), 191.75 (s, CO); m/z(API ES+) 355 (MH+, 
100%); HRMS found [MH]+ 355.15431 for C2|H230 5, C2,H230 5 requires [MH]+ 355.15400.
(E)-3-(4-Hydroxyphenyl)-l-(2,4-dimethoxy-3-(3-methylbut-2-enyl)phenyl)prop-2-en-l-one
370
MeO O
OHMeO 4'
370
The chalcone 370 was obtained by following Protocol G. Using (£)-l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)-3-(4-(methoxymethoxy)phenyl) prop-2-en-l-one 361 (0.101 g, 
0.25 mmol), methanol (5.1 cm3) and hydrochloric acid (0.9 cm3, 3M). Purification by 
column chromatography (SiC>2, ethyl acetate:hexane 3:17) afforded 370 as a pale yellow solid 
(0.080 g, 0.23 mmol, 89%); m.p. 131 -  132 °C; Rf 0.13 (SiC>2, ethyl acetaterhexane 1:3); 
Vm axXcm '1)  3362, 2935, 1651, 1589, 1557, 1541, 1483, 1436, 1273, 1244, 1068, 811; 6 'H 
NMR (400 MHz; CDC13; ppm) 1.69 (3H, d, J  1.0 Hz, CH3), 1.79 (3H, s, CH3), 3.40 (2H, d, J
6.7 Hz, H -l’” ), 3.70 (3H, s, OCH3), 3.88 (3H, s, OCH3), 5.16 -  5.20 (1H, tin, J 6.1 Hz, H- 
2’” ), 6.49 (1H, s, OH-4” ), 6.73 (1H, d, J  8.7 Hz, H-5’), 6.89 (2H, d, J  8.5 Hz, H-3”  & H- 
5” ), 7.42 (1H, d, J  15.8 Hz, H-2), 7.51 (2H, d, J  8.5 Hz, H-2”  & H-6” ), 7.60 (1H, d, J  8.7 
Hz, H-6’), 7.70 (1H, d, J  15.8 Hz, H-3); 8 l3C NMR (100 MHz; CDC13; ppm) 18.10 (s, CH3), 
23.02 (s, CH2), 26.00 (s, CH3), 56.08 (s, OCH3), 63.33 (s, OCH3), 106.63 (s, CH), 116.23 (s, 
CH), 122.84 (s, CH), 123.98 (s, CH), 124.22 (s, C), 126.34 (s, C), 127.87 (s, C), 129.86 (s, 
CH), 130.71 (s, CH), 131.91 (s, C), 144.02 (s, CH), 158.47 (s, C), 159.13 (s, C), 161.81 (s, 
C), 192.63 (s, CO); m/z(API ES+) 353 (MH+, 100%); HRMS found [MH]+ 353.17624 for 
C22H250 4, C22H250 4 requires [MH]+ 353.17474.
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(E)-3-(4-Hydroxy-3-methoxyphenyl)-l-(2,4-dimethoxy-3-(3-methylbut-2-enyl)phenyl)prop-2-
en-l-one 371
MeO O
3;OMe
OHMeO 4-
371
The chalcone 371 was obtained by following Protocol G. Using (£)-l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)-3-(3-methoxy-4-(methoxymethoxy)phenylprop-2-en-1 -one 362
(0.104 g, 0.24 mmol), methanol (4.9 cm3) and hydrochloric acid (0.9 cm3, 3M). Purification 
by recrystallization from methanol afforded 371 as light yellow crystals (0.067 g, 0.17 mmol, 
72%); m.p. 91 -  92 °C; R f  0.13 (Si02, ethyl acetate:hexane 1:3); VmaxXcm'1) 3455, 2936, 
1647, 1584, 1509, 1456, 1429, 1411, 1085, 1062, 810; 6  *H NMR (400 MHz; CDC13; ppm)
1.69 (3H, d, J  1.1 Hz, CH3), 1.79 (3H, s, CH3), 3.41 (2H, d, J6 .9  Hz, H -l’” ), 3.70 (3H, s, 
OCH3), 3.89 (3H, s, OCH3), 3.94 (3H, s, OCH3), 5.16 -  5.21 (1H, tm, J6 .9  Hz, H-2’” ), 5.94 
(1H, s, OH-4” ), 6.73 (1H, d, J8 .7  Hz, H-5’), 6.94 (1H, d, J 8.2 Hz, H-5” ), 7.11 (1H, d, J  1.9 
Hz, H-2” ), 7.18 (1H, dd, J  1.9, 8.2 Hz, H-6 ” ), 7.37 (1H, d, J  15.8 Hz, H-2), 7.58 (1H, d, J
8.7 Hz, H-6 ’), 7.65 (1H, d, J  15.8 Hz, H-3); 5 13C NMR (100 MHz; CDC13; ppm) 18.10 (s, 
CH3), 23.02 (s, CH2), 26.01 (s, CH3), 56.06 (s, OCH3), 56.23 (s, OCH3), 63.28 (s, OCH3),
106.53 (s, CH), 110.20 (s, CH), 115.00 (s, CH), 122.90 (s, CH), 123.50 (s, CH), 124.10 (s, 
C), 124.32 (s, CH), 126.55 (s, C), 127.98 (s, C), 129.71 (s, CH), 131.85 (s, C), 143.85 (s, 
CH), 146.97 (s, C), 148.21 (s, C), 158.96 (s, C), 161.58 (s, C), 192.08 (s, CO); m/z(API ES+) 
383 (M H \ 100%); HRMS found [MH]+ 383.18531 for C23H2 7 0 5, C23H270 5 requires [MH]+ 
383.18530.
(E)-3-(3-Hydroxy-4-methoxyphenyl)-l-(2,4-dimethoxy-3-(3-methylbut-2-enyl)phenyl)prop-2- 
en-l-one 372
MeO O
3iOH
OMeMeO 4'
372
The chalcone 372 was obtained by following Protocol G. Using (£)-l-(2,4-dimethoxy-3-(3- 
methylbut-2-enyl)phenyl)-3-(4-methoxy-3-(methoxymethoxy)phenylprop-2-en-l-one 363 
(0.123 g, 0.29 mmol), methanol (5.8 cm3) and hydrochloric acid (1.1 cm3, 3M). Purification 
by column chromatography (Si02, ethyl acetate:hexane 1:4) followed by recrystallization
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from methanol afforded 372 as light yellow needles (0.065g, 0.17 mmol, 59%); m.p. I l l  -  
113 "C; Rf 0.17 (Si02, ethyl acetate:hexane 1:3); vraax(cm'') 3483, 2938, 1647, 1584, 1510, 
1481, 1451, 1440, 1267, 1089, 1010,805; 8 'H NMR (400 MHz; CDC13; ppm) 1.69 (3 H, d, 7
1.0 Hz, CH3), 1.80 (3H, s CH3), 3.40 (2H, d, 76.9 Hz, H -l” ’), 3.69 (3H, s, OCH3), 3.88 (3H, 
s, OCH3), 3.93 (3H, s, OCH3), 5.16 -  5.21 (1H, tm, 7 6.9 Hz, H-2’” ), 5.68 (1H, s, OH-3” ), 
6.72 (1H, d, 78.8 Hz, H-5’), 6 . 8 6  (1H, d ,78.4  Hz, H-5” ), 7.12 (1H, dd, 72.0, 8.4 Hz, H-6 ” ),
7.27 (1H, d, 72.0 Hz, H-2” ), 7.42 (1H, d, 715.7 Hz, H-2), 7.60 (1H, d, 7 8 . 8  Hz, H-6 ’), 7.65 
(1H, d, 7 15.7 Hz, H-3); 8  l3C NMR (100 MHz; CDC13; ppm) 18.10 (s, CH3), 23.01 (s, CH2),
26.00 (s, CH3), 56.05 (s, OCH3), 56.24 (s, OCH3), 63.27 (s, OCH3), 106.56 (s, CH), 110.75 
(s, CH), 113.35 (s, CH), 122.69 (s, CH), 122.89 (s, CH), 124.14 (s, C), 124.85 (s, CH), 
126.49 (s, C), 129.12 (s, C), 129.83 (s, CH), 131.83 (s, C), 143.27 (s, CH), 146.06 (s, C),
148.74 (s, C), 159.17 (s, C), 161.68 (s, C), 191.77 (s, CO); m/z(API ES+) 383 (MH+, 100%); 
HRMS found [MH]+ 383.18547 for C23H270 5, C23H270 5 requires [MH]+ 383.18530.
l-(4-Methoxy-2-(methoxymethoxy)phenyl)ethanone 374354
MeO 4'
374
To a stirring solution of 2-hydroxy-4-methoxyacetopheone (1.66g, 10.0 mmol) in anhydrous 
tetrahydrofuran (3.5 cm3) at 0 °C under argon, sodium hydride (0.60 g, 15.0 mmol, 60% 
dispersion in mineral oil) was added. The reaction was then stirred for 5 minutes at 0 °C, 
before adding Chloromethyl methyl ether (1.14 cm3, 15.0 mmol) to the mixture. The reaction 
was then stirred for a further 10 minutes at 0 °C. The reaction was then heated to 65 °C for 18 
hours. The reaction was then allowed to cool to room temperature; it was then tipped into
'X 1water (5 cm ) and extracted with ethyl acetate (3 x 10 cm ). The organic fraction was then 
washed with brine (2 x 1 0  cm3) and dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. Purification by column chromatography (SiC>2 , ethyl acetate:hexane 1:9 
to 1:4) afforded 374 as a pale yellow oil (1.37 g, 6.5 mmol, 65%); R f  0.50 (Si0 2 , ethyl 
acetate:hexane 1:3); vmax(cm ') 2944, 2840, 1664, 1596, 1573, 1499, 1449, 1217, 1153, 
1134, 1064, 984, 921, 833; 8  'H NMR (400 MHz; CDC13; ppm) 2.61 (3H, s, H-2), 3.52 (3H, 
s, OCH3), 3.84 (3H, s, OCH3), 5.28 (2H, s, H-2” ), 6.58 (1H, dd, 7 2.4, 8 . 8  Hz, H-5’), 6.70 
(1H, d, 7 2.4 Hz, H-3’), 7.82 (1H, d, 7  8 . 8  Hz, H-6 ’); 8  l3C NMR (100 MHz; CDC13; ppm) 
31.98 (s, CH3), 55.76 (s, OCH3), 56.67 (s, OCH3), 94.69(s, OCH20), 101.09 (s, CH), 107.10 
(s, CH), 121.93 (s, C), 132.63 (s, CH), 158.82 (s, C), 164.49 (s, C), 197.94 (s, CO); m/z(APl
222
Chapter 6 -  Experimental
ES+) 211 (MH+, 100%), 233 (MNa+); HRMS found [MH]+ 211.09654 for CiiH150 4, 
C11H15O4 requires [MH]+ 211.09649.
(E)-l-(4-Methoxy-2-(methoxymethoxy)phenyl)-3-(4-(methoxymethoxy)phenyl)prop-2-en-l- 
one 375
0 OMeMeO 4'
375
The chalcone 375 was obtained by following Protocol F. Using l-(4-methoxy-2- 
(methoxymethoxy)phenyl)ethanone 374 (0.100 g, 0.48 mmol), 4-(methoxymethoxy) 
benzaldehyde 332 (0.079 g, 0.47 mmol), and aqueous sodium hydroxide solution (0.96 cm3, 
2M) in methanol (1.0 cm3). The mixture was extracted with ethyl acetate ( 3 x 5  cm3). 
Purification by column chromatography (SiC>2 , ethyl acetate:hexane 1:19 to 3:7) afforded 375 
as a yellow oil (0.129 g, 0.36 mmol, 62%); R f  0.23 (SiC>2 , ethyl acetate.hexane 1:3); vmax.(cm' 
]) 2936, 2828, 1687, 1650, 1598, 1572, 1508, 1443, 1422, 1238, 1210, 1150, 1076, 920, 830, 
807; 5 NMR (400 MHz; CDC13; ppm) 3.48 (3H, s, OCH3), 3.50 (3H, s, OCH3), 3.86 (3H, 
s, OCH3), 5.21 (3H, s, H-2” ” ), 5.25 (3H, s, H’” ), 6.63 (1H, dd, J2 .3 , 8 . 8  Hz, H-5’), 6.73 
(1H, d, J2 .3  Hz, H-3’), 7.05 (2H, d, J 8 . 6  Hz, H-3” & H-5” ), 7.38 (1H, d, J 16.0 Hz, H-2),
7.53 (2H, d, J 8 . 6  Hz, H-2” & H-6 ” ), 7.63 (1H, d, J 16.0 Hz, H-3), 7.70 (1H, d, J 8 . 8  Hz, H- 
6 ’); 6  ,3C NMR (100 MHz; CDC13; ppm) 55.79 (s, OCH3), 56.39 (s, OCH3), 56.72 (s, 
OCH3), 94.44 (s, OCH2O), 95.24 (s, OCH20), 101.86 (s, CH), 107.35 (s, CH), 116.72 (s, 
CH), 123.41 (s, C), 125.63 (s, CH), 129.33 (s, C), 130.09 (s, CH), 132.58 (s, CH), 142.41 (s, 
CH), 157.94 (s, C), 159.10 (s, C), 163.92 (s, C), 191.29 (s, CO); m/z(API ES+) 358 (MH+, 
100%); HRMS found [MH]+ 359.14959 for C20H23O6 , C20H23O6 requires [MH]+ 359.14891.
(E)-l-(2-Hydroxy-4-methoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-l-one 373355
OH O
OHMeO 4'
373
The method adopted was that of Wang230 et al. To a stirring solution of (£)-l-(4-methoxy-2- 
(methoxymethoxy)phenyl)-3-(4-(methoxymethoxy)phenyl)prop-2-en-l-one 375 (0.039 g, 
0.14 mmol) in methanol (3 cm3) under argon was added hydrochloric acid (1.0 cm3, 3M). 
The reaction was then heated to reflux at 75 °C for 45 minutes. The reaction was cooled to 
room temperature and tipped into water (3 cm3), it was then extracted with chloroform (3 *
223
Chapter 6 -  Experimental
10 cm ). The organic fraction was then dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. Purification of the crude residue by column chromatography (SiCh, 
ethyl acetateihexane 1:9 to 1:4) afforded 373 as a yellow solid (0.012 g, 0.04 mmol, 41%); 
m.p. 151 - 156 °C; Rf 0.18 (SiC>2 , ethyl acetate:hexane 1:19 to 1:3); Vmaxfcm'1) 3227, 2922, 
2851, 1626, 1607, 1589, 1543, 1505, 1456, 1441, 1417, 1368, 1280, 1215, 1163, 1128, 1021, 
997, 959, 790; 6 *H NMR (400 MHz; CDC13; ppm) 3.87 (3H, s, OCH3), 4.99 (1H, s, OH- 
4” ), 6.47 -  6.51 (2H, m, H-3’ & H-5’), 6.89 (2H, d, J8 .8  Hz, H-3” & H-5” ), 7.46 (1H, d, J
15.4 Hz, H-2), 7.58 (2H, d, J8 .8  Hz, H-2” & H-6” ), 7.83 (1H, d, J9.2  Hz, H-6’), 7.86 (1H, 
d, J 15.4 Hz, H-3), 13.54 (1H, s, OH-2’); 6 13C NMR (100 MHz; CDC13; ppm) 55.83 (s, 
OCH3), 101.31 (s, CH), 107.93 (s, CH), 114.36 (s, C), 116.25 (s, CH), 118.15 (s, CH), 127.98 
(s, C), 130.83 (s, CH), 131.38 (s, CH), 144.47 (s, CH), 158.24 (s, C), 166.34 (s, C), 166.84 (s, 
C), 192.19 (s, CO); m/z(API-ES+) 271 (MH+, 100%), 293 (MNa+, 10%); HRMS found 
[MH]+ 271.09700 for Ci6Hi50 4, Ci6Hi50 4 requires [MH]+ 271.09649.
2,3-Dihydro-2-(4-hydroxyphenyl)-7-methoxychromen-4-one 376281
MeO 7
376 6 OH
2,3-Dihydro-2-(4-hydroxyphenyl)-7-methoxychromen-4-one 376 was also isolated from the 
column chromatography of (£)-l-(2-hydroxy-4-methoxyphenyl)-3-(4-hydroxyphenyl)prop-2- 
en-l-one 373. Purification by column chromatography (Si02, ethyl acetate:hexane 1:19 to 
1:3) afforded 376 as yellow cube crystals (0.010 g,0.04 mmol, 34%); m.p. 181 - 182 °C; Rf 
0.16 (Si02, ethyl acetate:hexane 1:3); Vmaxfcrn'1) 3253, 2923, 2850, 1652, 1594, 1573, 1516, 
1441, 1251, 1200, 1161, 1115,834,815; 6 *H NMR (400 MHz; CDC13; ppm) 2.81 (1H, dd, 
J  2.9 Hz, J  16.9 Hz, H-3), 3.06 (1H, dd, J  13.2, 16.9 Hz, H-3), 3.83 (3H, s, OCH3), 5.41 (lh, 
dd, J2 .9 , 13.2 Hz, H-2), 5.50 (1H, s, OH-4’), 6.48 (1H, d, J2 .4  Hz, H-8), 6.62 (1H, dd, J2.4,
8.7 Hz, H-6), 6.90 (2H, d, J  8.4 Hz, H-3’ & H-5’), 7.35 (2H, d, J  8.4 Hz, H-2’ & H-6’), 7.87 
(1H, d, J  8.7 Hz, H-5); 8 ,3C NMR (100 MHz; CDC13; ppm) 44.14 (s, CH2), 55.65 (s, OCH3), 
79.73 (s, CH), 100.92 (s, CH), 110.26 (s, CH), 114.80 (s, C), 115.66 (s, CH), 127.98 (s, CH), 
128.78 (s, CH), 131.02 (s, C), 156.07 (s, C), 163.63 (s, C), 166.24 (s, C), 190.94 (s, CO); 
m/z(API-ES+) 271 (MH+, 100%).
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(E)-3-(4-Carboxymethoxyphenyl)-l-(3,4-dichlorophenyl)prop-2-en-l-one 318253
O
318
To a stirring solution of 3,4-dichloroacetophenone (0.95 g, 5.0 mmol),and 4-formyl 
phenoxyacetic acid (0.90 g, 5.0 mmol) in methanol (10cm3), was added an aqueous sodium 
hydroxide solution (2 cm3, 10M) and the mixture stirred at room temperature overnight. The 
mixture was then acidified with hydrochloric acid (until pH = 1, 1M), and extracted with 
ethyl acetate (3 * 100cm3). The organic fraction was then dried over anhydrous magnesium 
sulfate, filtered and evaporated in vacuo. Recrystallization from methanol afforded 318 as a 
yellow crystals (1.16 g, 3.3 mmol, 66%); m.p. 208 -  209 °C; Rf 0.18 (SiC>2 , ethyl 
acetate:methanol 19:1); Vmaxfcrn'1) 2560, 1732, 1702, 1659, 1594, 1574, 1509, 1433, 1421, 
1290, 1243, 1202, 1176, 987, 820, 681; 6 *H NMR (400 MHz; d6-DMSO; ppm) 4.76 (2H, s, 
H-2’” ), 6.99 (2H, d, J  8.6 Hz, H-3” & H-5” ), 7.74 (1H, d, J  15.4 Hz, H-2), 7.81 (1H, d, J
8.5 Hz, H-5’), 7.83 (1H, d, J  15.4 Hz, H-3), 7.87 (2H, d, J  8.6 Hz, H-2” & H-6” ), 8.08 (1H, 
dd, J2 .1 , 8.5 Hz, H-6’), 8.37 (1H, d, J2A  Hz, H-2’), 13.08 (1H, broad s, C02H); 6 13CNMR 
(100 MHz; CDC13; ppm) 65.22 (s, OCH20), 115.61 (s, CH), 119.79 (s, CH), 128.31 (s, C),
129.13 (s, CH), 131.00 (s, CH), 131.74 (s, CH), 131.77 (s, CH), 132.59 (s, C), 136.48 (s, C),
138.63 (s, C), 145.74 (s, CH), 160.78 (s, C), 170.55 (s, C 02H), 187.52 (s, CO).
(E)-l-(3,4-Dichlorophenyl)-3-(4-chlorophenyl)prop-2-en-l -one 383356
O
383
The chalcone 383 was obtained following Protocol A using 3,4-dichloroacetophenone (0.38 
g, 2.0 mmol), 4-chlorobenzaldehyde (0.28 g, 2.0 mmol) and aqueous sodium hydroxide 
solution (1 cm3, 4M) in methanol (2 cm3). Recrystallization from methanol afforded 383 as 
light yellow crystals (0.41 g, 1.3 mmol, 66%); m.p. 141 - 143 °C; Rf 0.83 (Si02, ethyl 
acetate:hexane 1:3); VmaxXcrn'1) 1659, 1601, 1577, 1552, 1490, 1459, 1405, 1207, 1049, 
1030, 1012, 984, 830, 736; 6 !H NMR (400 MHz; CDC13; ppm) 7.41 (2H, d, J 8.6 Hz, H-3” 
& H-5” ), 7.42 (1H, d, J  15.6 Hz, H-2), 7.59 (2H, d, J  8.6 Hz, H-2” & H-6” ), 7.59 (1H, d, J
8.5 Hz, H-5’), 7.79 (1H, d, J  15.6 Hz, H-3), 7.85 (1H, dd, J2 .1 , 8.5 Hz, H-6’), 8.09 (1H, d ,J
2.1 Hz, H-2’); 5 ,3C NMR (100 MHz; CDC13; ppm) 121.48 (s, CH), 127.72 (s, CH), 129.60
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(s, CH), 129.98 (s, CH), 130.68 (s, CH), 131.05 (s, CH), 133.19 (s, C), 133.61 (s, C), 137.18 
(s, C), 137.74 (s, C), 137.81 (s, C), 144.75 (s, CH), 187.91 (s, CO).
(E)-l,3-Bis(3,4-dichlorophenyl)prop-2-en-l-one 384357
O
384
The chalcone 384 was obtained following Protocol A using 3,4-dichloroacetophenone (0.38 
g, 2.0 mmol), 3,4-dichlorobenzaldehyde (0.35 g, 2.0 mmol) and aqueous sodium hydroxide 
solution (1 cm3, 4M) in methanol (2 cm3). Recrystallization from methanol afforded 384 as 
cream crystals (0.57 g, 1.6 mmol, 83%); m.p. 161 -  163 °C; Rf 0.56 (SiC>2 , ethyl 
acetaterhexane 1:3); vmax{ c m ]) 3061, 1660, 1604, 1578, 1553, 1472, 1394, 1310, 1206, 
1027, 989, 768; 6 *H NMR (400 MHz; CDC13; ppm) 7.43 (1H, d, J  15.2 Hz, H-2), 7.47 (1H, 
dd, J2 .0 , 8.4 Hz, H-6” ), 7.51 (1H, d, J8 .4  Hz, H-5” ), 7.60 (1H, d, J8.5 Hz, H-5’), 7.72 (1H, 
d, J  15.2 Hz, H-3), 7.74 (1H, d, J2 .0  Hz, H-2” ), 7.85 (1H, dd, J 2.1, 8.5 Hz, H-6’), 8.10 (1H, 
d, J  2.1 Hz, H-2’); 8 13C NMR (100 MHz; CDC13; ppm) 122.50 (s, CH), 127.73 (s, CH),
127.88 (s, CH), 130.12 (s, CH), 130.70 (s, CH), 131.10 (s, CH), 131.28 (s, CH), 133.69 (s, 
C), 134.72 (s, C), 135.12 (s, C), 137.52 (s, C), 137.96 (s, C), 143.30 (s, CH), 187.54 (s, CO).
(E)-3-(2,6-Dichlorophenyl)- J-(3,4-dichlorophenyl)prop-2-en-l-one 385
0 Cl
f t V i , 12"
5'
ii
C l^ 5"
385
The chalcone 385 was obtained following Protocol A using 3,4-dichloroacetophenone (0.38 
g, 2.0 mmol), 2,6-dichlorobenzaldehyde (0.35 g, 2.0 mmol) and aqueous sodium hydroxide 
solution (1 cm3, 4M) in methanol (2 cm3). Recrystallization from methanol afforded 385 as 
fluffy light yellow crystals (0.46g, 1.3 mmol, 66%); m.p. 100 -  101 °C; Rf 0.57 (Si02, ethyl 
acetaterhexane 1:3); VmaxXcnT1) 3088, 1668, 1609, 1580, 1553, 1466, 1437, 1426, 1298, 
1205, 1027, 732; 8 'H NMR (400 MHz; CDC13; ppm) 7.24 (1H, t, J  8.1 Hz, H-4” ), 7.40 (2H, 
d, J  8.1 Hz, H-3”  & H-5” ), 7.59 (1H, d, J  16.0 Hz, H-2), 7.60 (1H, d, J  8.5 Hz, H-5’), 7.85 
(1H, dd, J  2.0, 8.5 Hz, H-6’), 7.88 (1H, d, J  16.0 Hz, H-3), 8.10 (1H, d, J2 .0  Hz, H-2’); 8 
,3C NMR (100 MHz; CDC13; ppm) 127.94 (s, CH), 129.18 (s, CH), 129.69 (s, CH), 130.41 
(s, CH), 130.93 (s, CH), 131.08 (s, CH), 132.44 (s, C), 133.67 (s, C), 135.48 (s, C), 137.43 (s,
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C), 137.96 (s, C), 139.25 (s, CH), 188.14 (s, CO); m/z(API-ES +) 345 ([MH]+, 75%), 347 
([MH]+, 100%), 349 ([MH]+, 50%); HRMS found [MH]+ 344.94037 for C 15H 19CI4O, 
C 15H 19CI4O requires [MH]+ 344.94020.
(E)-3-(4-Bromophenyl)-l-(3,4-dichlorophenyl)prop-2-en-l-one 386
0
386
The chalcone 386 was obtained following Protocol A using 3,4-dichloroacetophenone (0.38 
g, 2.0 mmol), 4-bromobenzaldehyde (0.37 g, 2.0 mmol) and aqueous sodium hydroxide 
solution (1 cm3, 4M) in methanol (2 cm3). Recrystallization from methanol afforded 386 as 
cream crystals (0.40 g, 1.1 mmol, 56%); m.p. 154 - 155 °C; Rf 0.77 (SiC>2, ethyl 
acetate:hexane 1:3); vmax.(cm'') 1660, 1600, 1577, 1553, I486, 1464, 1401, 1209, 1030, 984, 
829, 735; 8  ‘H N M R (400 MHz; CDC13; ppm) 7.43 (1H, d, J  15.6 Hz, H-2), 7.51 (2H, d, J 8 .6  
Hz, H-2”  & H-6 ” ), 7.57 (2H, d, J  8 .6  Hz, H-3”  & H-5” ), 7.59 (1H, d, J  8.5 Hz, H-5’), 7.77 
(1H, d, J  15.6 Hz, H-3), 7.84 (1H, dd, J  2.1 Hz, J  8.5 Hz, H-6 ’), 8.09 (1H, d, J  2.1 Hz, H-2’); 
8  13C NMR (100 MHz; CDC13; ppm) 121.58 (s, C), 125.58 (s, C), 127.73 (s, CH), 130.18 (s, 
CH), 130.69 (s, CH), 131.05 (s, CH), 132.56 (s, CH), 133.62 (s, C), 137.76 (s, C), 137.79 (s, 
C), 144.81 (s, CH), 187.90 (s, CO); m/z(API-ES +) 355 ([MH]+, 65%), 357 ([M H ]\ 90%), 
359 ([MH]+, 45%); HRMS found [MH]+ 354.92885 for C i5H |0BrCl2O, C i5Hi0BrCl2O 
requires [MH]+ 354.92866.
(E)-l-(3,4-Dichlorophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-l-one 387
O OMe
OMe 
387
The chalcone 387 was obtained following Protocol A using 3,4-dichloroacetophenone (0.38 
g, 2.0 mmol), 2,4-dimethoxybenzaldehyde (0.33 g, 2.0 mmol) and aqueous sodium hydroxide 
solution (1 cm3, 4M) in methanol (2 cm3). Recrystallization from methanol afforded 387 as 
fluffy bright yellow crystals (0.48 g, 1.4 mmol, 72%); m.p. 129 - 130 °C; Rf 0.47 (SiC>2, 
ethyl acetate:hexane 1:3); VmaxXcnT1) 2836, 1662, 1589, 1578, 1504, 1472, 1434, 1413, 1300, 
1280, 1209, 807; 6  'H  NMR (400 MHz; CDC13; ppm) 3.87 (3H, s, OCH3), 3.91 (3H, s, 
OCH3), 6.48 (1H, d, J 2.4 Hz, H-3” ), 6.54 (1H, dd, J  2.4, 8.7 Hz, H-5” ), 7.45 (1H, d, J  15.6
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Hz, H-2), 7.56 (1H, d, J  8.7 Hz, H-6 ” ), 7.57 (1H, d, J  8.1 Hz, H-5’), 7.82 (1H, dd, J2.0, 8.1 
Hz, H-6 ’), 8.06 (1H, d, J  15.6 Hz, H-3), 8.08 (1H, d, J  2.0 Hz, H-2’); 8  13C NMR (100 MHz; 
CDClj; ppm) 55.76 (s, OCH3), 55.82 (s, OCH3), 98.68 (s, CH), 105.78 (s, CH), 117.00 (s, C), 
119.43 (s, CH), 127.71 (s, CH), 130.65 (s, CH), 130.80 (s, CH), 131.52 (s, CH), 133.27 (s, 
C), 136.89 (s, C), 138.72 (s, C), 142.04 (s, CH), 160.86 (s, C), 163.67 (s, C), 188.86 (s, CO); 
m/z(API-ES +) 337 ([MH]+, 100%), 339 ([MH]\ 65%); HRMS found [MH]+ 337.03974 for 
CnHisCbOj, C |7Hi5C120 3 requires [MH]+ 337.03928.
(E)-l-(3,4-Dichlorophenyl)-3-(3,5-dimethoxyphenyl)prop-2-en-l-one 388
O
Cl 
Cl
The chalcone 388 was obtained following Protocol A using 3,4-dichloroacetophenone (0.38 
g, 2.0 mmol), 3,5-dimethoxybenzaldehyde (0.33 g, 2.0 mmol) and aqueous sodium hydroxide 
solution (1 cm3, 4M) in methanol (2 cm3). Recrystallization from methanol afforded 388 as 
fluffy yellow crystals (0.47g, 1.4 mmol, 70%); m.p. 114 — 115 °C; R f  0.60 (SiC>2, ethyl 
acetate:hexane 1:3); v^X cm '1) 2963, 1661, 1590, 1557, 1466, 1449, 1425, 1283, 1160, 
1065, 978, 834, 825, 806, 667; 5 lH NMR (400 MHz; CDC13; ppm) 3.85 (6 H, s, OCH3), 
6.55 (1H, t, J  2.3 Hz, H-4” ), 6.77 (2H, d, J2 .3  Hz, H-2” & H-6 ” ), 7.38 (1H, d, J  15.6 Hz, 
H-2), 7.58 (1H, d, J  8.4 Hz, H-5’), 7.74 (1H, d, J 15.6 Hz, H-3), 7.84 (1H, dd, J2 .0 , 8.4 Hz, 
H-6 ’), 8.09 (1H, d, J  2.0 Hz, H-2’); 6  13C NMR (100 MHz; CDC13; ppm) 55.75 (s, OCH3), 
103.33 (s, CH), 106.75 (s, CH), 121.63 (s, CH), 127.76 (s, CH), 130.70 (s, CH), 130.99 (s, 
CH), 133.538 (s, C), 136.56 (s, C), 137.58 (s, C), 137.93 (s, C), 146.30 (s, CH), 161.34 (s, C),
188.22 (s, CO); m/z{API-ES +) 337 ([MH]+, 100%), 339 ([MH]+, 65%); HRMS found 
[MH]+ 337.04019 for Ci7H 14Cl2 0 3, Ci7H,4C120 3 requires [MH]+ 337.03928.
(E)-l-(3,4-Dichlorophenyl)-3-(2,3,4-tr imethoxyphenyl)pr op-2-en-1-one 389
0 OMe
389
The chalcone 389 was obtained following Protocol A using 3,4-dichloroacetophenone (0.38 
g, 2.0 mmol), 2,3,4-trimethoxybenzaldehyde (0.39 g, 2.0 mmol) and aqueous sodium
' X  'Xhydroxide solution (1 cm , 4M) in methanol (2 cm ). Recrystallization from methanol
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afforded 389 as fluffy white crystals (0.60 g, 1.8 mmol, 90%); m.p. 121 -  122 °C; Rf 0.47 
(SiC>2 , ethyl acetate:hexane 1:3); Vmaxfcrn'1) 2946, 1631, 1592, 1552, 1498, 1460, 1418, 
1299, 1281, 1255, 847, 797; 6  *H NMR (400 MHz; CDC13; ppm) 3.90 (3H, s, OCH3), 3.93 
(3H, s, OCH3), 3.96 (3H, s, OCH3), 6.73 (1H, d, J  8 . 6  Hz, H-5” ), 7.40 (1H, d, J  8 . 6  Hz, H- 
6 ” ), 7.47 (1H, d, J  16.0 Hz, H-2), 7.58 (1H, d, J  8.3 Hz, H-5’), 7.84 (1H, dd, J  2.0, 8.3 Hz, 
H-6 ’), 8.02 (1H, d, J  16.0 Hz, H-3), 8.09 (1H, d, J  2.0 Hz, H-2’); 6  13C NMR (100 MHz; 
CDC13; ppm) 56.35 (s, OCH3), 61.17 (s, OCH3), 61.68 (s, OCH3), 107.85 (s, CH), 120.39 (s, 
CH), 121.82 (s, C), 124.39 (s, CH), 127.73 (s, CH), 130.67 (s, CH), 130.89 (s, CH), 133.37 
(s, C), 137.16 (s, C), 138.44 (s, C), 141.69 (s, CH), 142.70 (s, C), 154.23 (s, C), 156.45 (s, C), 
188.64 (s, CO); m/z{API-ES +) 367 ([MH]+, 100%), 369 ([MH]\ 70%); HRMS found [MH]+ 
367.04975 for QgH^ChO^ C,gH,7Cl2 0 4  requires [MH]+ 367.04984.
(E)-l-(3,4-Dichlorophenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-l-one 390
O
390
The chalcone 390 was obtained following Protocol A using 3,4-dichloroacetophenone (0.38 
g, 2.0 mmol), 2,3,4-trimethoxybenzaldehyde (0.39 g, 2.0 mmol) and aqueous sodium 
hydroxide solution (1 cm , 4M) in methanol (2 cm ). Recrystallization from methanol 
afforded 390 as yellow crystals (0.35 g, 0.9 mmol, 48%); m.p. 129 - 130 °C; Rf 0.40 (SiC>2, 
ethyl acetate:hexane 1:3); vmax (cnTl) 3086, 2941, 2836, 1662, 1597, 1579, 1551, 1503,1465, 
1453, 1435, 1417, 1284, 1207, 1131, 1033, 976, 770; 8  *H NMR (400 MHz; CDC13; ppm) 
3.92 (3H, s, OCH3), 3.94 (6 H, s, OCH3), 6.87 (2H, s, H-2” & H-6 ” ), 7.31 (1H, d, J  15.6 Hz, 
H-2), 7.59 (1H, d, J8 .5  Hz, H-5’), 7.75 (1H, d, J  15.6 Hz, H-3), 7.85 (1H, dd, J2 .1 , 8.5 Hz, 
H-6 ’), 8.09 (1H, d, J  2.1 Hz, H-2’); 8  13C NMR (100 MHz; CDC13; ppm) 56.51 (s, OCH3),
61.27 (s, OCH3), 106.11 (s, CH), 120.43 (s, CH), 127.76 (s, CH), 130.14 (s, C), 130.65 (s, 
CH), 130.99 (s, CH), 133.49 (s, C), 137.48 (s, C), 138.10 (s, C), 141.10 (s, C), 146.51 (s, 
CH), 153.77 (s, C), 188.21 (s, CO); m/z(API-ES +) 367 ([MH]+, 100%), 369 ([MH]+, 70%); 
HRMS found [MH]+ 367.04985 for C,gHi7Cl20 4 , C ig H ^ C ^  requires [MH]+ 367.04984.
(E)-l-(3,4-Dichlorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1 -one 391:1224
391
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The method adopted was that of Wang230 et al. To a stirring solution of (£)-l-(3,4-dichloro 
phenyl)-3-(4-(methoxymethoxy)phenyl)prop-2-en-l-one 3 9 2  (0.100 g, 0.30 mmol) in 
methanol ( 6  cm3) under argon was added hydrochloric acid (1.2 cm3, 3M). The reaction was 
then heated to reflux at 75 °C for 45 minutes. The reaction was cooled to room temperature 
and tipped into water ( 6  cm3), it was then extracted with dichloromethane (3><10 cm3). The 
organic fraction was then dried over anhydrous magnesium sulfate, filtered and evaporated in 
vacuo. Purification of the crude residue by column chromatography (Si02, ethyl 
acetate:hexane 1:9 to 1:4) afforded 3 9 1  as a bright yellow solid (0.09g, 0.30mmol, 99%); 
m.p. 193 - 196 °C; R f  0.31 (Si02, ethyl acetate:hexane 1:3); Vmaxfcrn'1) 3220, 2924, 1646, 
1591, 1559, 1544, 1516, 1444, 1286, 1219, 1170, 1051, 1029, 988; 6  *H NMR (400 MHz; 
CD3OD; ppm) 6.75 (2H, d, J 8 . 8  Hz, H-3” & H-5” ), 7.45 (1H, d, J  15.4 Hz, H-2), 7.55 (2H, 
d, J  8 . 8  Hz, H-2” & H-6 ” ), 7.60 (1H, d, J  8.4 Hz, H-5’), 7.69 (1H, d, J  15.4 Hz, H-3), 7.90 
(1H, dd, J  1.6, 8.4 Hz, H-6 ’), 8.10 (1H, d, J  1.6 Hz, H-2’); § ,3C NMR (100 MHz; CDC13; 
ppm) 116.51 (s, CH), 118.42 (s, CH), 126.33 (s, C), 129.05 (s, CH), 130.91 (s, CH), 131.74 
(s, CH), 132.10 (s, CH), 132.54 (s, C), 136.32 (s, C), 138.77 (s, C), 146.40 (s, CH), 161.16 (s, 
C), 187.39 (s, CO).
(E)-l-(3,4-Dichlorophenyl)-3-(4-(methoxymethoxy)phenyl)prop-2-en-l-one 3 9 2
O OMe
3 9 2
The chalcone 3 9 2  was obtained following Protocol A using 3,4-dichloroacetophenone (0.57 
g, 3.0 mmol), 4-(methoxymethoxy)benzaldehyde 3 3 2  (0.50 g, 3.0 mmol) and aqueous sodium 
hydroxide solution (3 cm3, 2M) in methanol (7 cm3). Recrystallization from methanol 
afforded 3 9 2  as yellow needles (0.67 g, 2.0 mmol, 6 6 %); m.p. 109 -  110 °C; R f  0.50 (Si02, 
ethyl acetate:hexane 1:3); VmaxXcrn’1) 1661, 1594, 1572, 1509, 1425, 1211, 1174, 1155, 
1070, 1038, 981, 728; 6  !H NMR (400 MHz; CDC13; ppm) 3.50 (3H, s, OCH3), 5.24 (2H, s, 
H-2’” ), 7.09 (2H, d, J  8 . 8  Hz, H-3” & H-5” ), 7.34 (1H, d, J  15.4 Hz, H-2), 7.59 (1H, d, J
8.4 Hz, H-5’), 7.61 (2H, d, J  8 . 8  Hz, H-2” & H-6 ” ), 7.81 (1H, d, J  15.4 Hz, H-3), 7.84 (1H, 
dd, J2 .1 , 8.4 Hz, H-6 ’), 8.09 (1H, d, J2.1 Hz, H-2’); 8  13C NMR (100 MHz; CDC13; ppm) 
56.45 (s, OCH3), 94.43 (s, OCH20), 116.83 (s, CH), 119.26 (s, CH), 127.68 (s, CH), 128.47 
(s, C), 130.60 (s, CH), 130.64 (s, CH), 130.93 (s, CH), 133.46 (s, C), 137.32 (s, C), 138.28 (s, 
C), 145.99 (s, CH), 159.83 (s, C), 188.20 (s, CO); m/z(API-ES +) 337 ([MH]+, 100%), 339
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([MH]\ 60%), 359 ([MNa]+, 35%), 361 ([MNa]\ 20%); HRMS found [MH]+ 337.03980 for 
C17H15O3CI2 , C ,7Hl50 3 Cl2 requires [MH]+ 337.03928.
I-Acetylpyrrolidin-2-one 398323
4 5
398
To a stirring solution of 2-pyrrolidinone (2.50 cm3, 32.9 mmol) in anhydrous tetrahydrofuran 
(20 cm3) at -20 °C under argon was slowly added a butyllithium solution in hexane (13.30 
cm3, 2.5 M). The mixture was then stirred at -20 °C for a further 20 minutes, and then chilled 
to -78 °C before adding acetyl chloride (2.56 cm3, 36.0 mmol) in anhydrous tetrahydrofuran 
(30 cm3). The mixture was then left stirring overnight allowing it to warm to room 
temperature. It was then tipped into water (100 cm3) and extracted with ethyl acetate ( 6  x 30 
cm3). The organic fraction was dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. To give a yellow oil (2.97 g, 23.4 mmol, 71%); Rf 0.52 (Si02, ethyl 
acetate:hexane 1:1); v^Xcm*1) 2986, 2901, 1736, 1687, 1485, 1463, 1419, 1359, 1245, 
1228, 1191; 6  *H NMR (400 MHz; CDC13; ppm) 1.97 (2H, quintet, J l . l  Hz, H-4), 2.43 (3H, 
s, H-2’), 2.54 (2H, t, J  8.1 Hz, H-3), 3.74 (2H, t, J  7.2 Hz, H-5); 6  13C NMR (100 MHz; 
CDC13; ppm) 17.13 (s, CH2), 24.92 (s, CH3), 33.54 (s, CH2), 45.30 (s, CH2), 171.37 (s, CO), 
175.58 (s, CO).
(E)-3-((Benzo[d][1,3]dioxol-6-yl)methylene)pyrrolidin-2-one 397321
■i3"
397
The method adopted was that of Zimmer321 et al. To a stirring solution of sodium hydride 
(4.82 g, 120.5 mmol, 60% dispersion in mineral oil) in anhydrous tetrahydrofuran (50 cm ) at 
0 °C under argon, a mixture of piperonal (5.94 g, 39.6 mmol) and 1-acetylpyrrolidin-2-one 
398 (5.09 g, 40.1 mmol) in anhydrous tetrahydrofuran (50 cm3) was added slowly drop wise 
over an hour. The reaction was then stirred at 0 °C for a further hour. Methanol (15 cm3) was 
then added to the mixture at 0 °C to quench any remaining sodium hydride. The mixture was 
then tipped into ice, acidified with Sulfuric acid (6 M), and extracted with chloroform (10 x 
30 cm3). The organic fraction was dried over anhydrous magnesium sulfate, filtered and 
evaporated in vacuo. Recrystallization from 2-propanol afforded 397 as a cream powder
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solid (2.32 g, 10.7 mmol, 27%); m.p. 246-248 °C; Rf0.23 (Si02, ethyl acetate); VmaxXcm'1) 
3174, 3051, 2898, 1678, 1639, 1601, 1495, 1444, 1266, 1240, 1038, 810; 6 NMR (400 
MHz; CDC13; ppm) 3.12 (2H, td, J6 .5 , 2.8 Hz, H-4), 3.56 (2H, t, J6 .5  Hz, H-5), 6.01 (2H, s, 
H-2” ), 6.45 (1H, br. S, H-l), 6.86 (1H, d, J7 .9  Hz, H-4” ), 6.97 -  7.02 (2H, m, H-5” & H- 
7” ), 7.28 (1H, t, J2 .8  Hz, H -l’); 5 13C NMR (100 MHz; CDC13; ppm) 26.36 (s, CH2), 39.38 
(s, CH2), 102.01 (s, CH2), 109.29 (s, CH), 109.42 (s, CH), 124.99 (s, CH), 128.37 (s, CH),
130.63 (s, C), 131.10 (s, C), 148.00 (s, C), 148.35 (s, C), 171.39 (s, CO); m/z{AP+) 218 
(M H\ 100%); HRMS found [MH]+ 218.0812 for Ci2H120 3N, Ci2H,20 3N requires [MH]+ 
218.0812.
(E)-3-((Benzo[d][1,3]dioxol-5-yl)methylene)-2-oxopyrrolidine-l-carbaldehyde 396
396
The method adopted was that of Rigo322 et al. A mixture of (£)-3-((benzo[d][l,3]dioxol-6- 
yl)methylene)pyrrolidin-2-one 397 (1.64 g, 7.6 mmol) in neat formic acid (27 cm3) was 
heated to reflux at 105 °C for 18 hours. The mixture was then cooled to room temperature 
and evaporated in vacuo. Purification of the crude residue by column chromatography (Si02, 
ethyl acetate:CHCl3 1:4) afforded 396 as a white solid (1.02 g, 4.2 mmol, 55%); m.p. 197 -  
198 "C; Rf 0.56 (S i02, ethyl acetate:CHCl3 1:4); vmax.(cm'') 2915, 1724, 1684, 1634, 1600, 
1505, 1493, 1451, 1440, 1342, 1310, 1229, 1039, 718; 8 'H NMR (400 MHz; CDC13; ppm)
3.09 (2H, dt, J  2.8 Hz J  7.3 Hz, H-4), 3.82 (2H, t, J  7.3 Hz, H-5), 6.03 (2H, s, H-2” ), 6.88 
(1H, d, J  8.0 Hz, H-4” ), 7.00 (1H, d, J  1.6 Hz, H-7” ), 7.06 (1H, dd, J  1.6, 8.0 Hz, H-5” ),
7.53 (1H, t, J2.Z Hz, H -l’), 9.24 (1H, s, H -l’” ); 8 l3C NMR (100 MHz; CDC13; ppm) 23.78 
(s, CHcHtNH), 39.59 (s, CHcmNH), 101.78 (s, OCHjO), 108.93 (s, CH), 109.36 (s, CH),
126.22 (s, C), 126.67 (s, CH), 128.94 (s, C), 136.06 (s, CH), 148.34 (s, C), 149.31 (s, C), 
161.21 (s, CHO), 170.17 (s, CO); m/z{AP+) 246 (MH+, 100%); HRMS found [MH]+ 
246.0758 for Ci3Hi2 0 4 N, Cj3Hi20 4 N requires [MH]+ 246.0761.
Protocol H
The method adopted was that of Zimmer321 et al. To a stirring solution of sodium hydride 
(0.36 g, 9.0 mmol, 60% dispersion in mineral oil) in anhydrous tetrahydrofuran (5 cm3) at 0 
°C under argon, a mixture of benzaldehyde and rhodanine in anhydrous tetrahydrofuran was 
added slowly drop wise over 20 minutes. The reaction was then stirred at 0 °C for a further 
hour. Methanol (3 cm3) was then added to the mixture at 0 °C to quench any remaining
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sodium hydride. The mixture was then tipped into ice, acidified with Sulfuric acid (10 cm3, 
1M). The precipitate was then filtered off and recrystallized from acetone.
(Z)-5-((Benzo[d][l,3Jdioxol-6-yl)methylene)-2-thioxothiazolidin-4-one 402358
0
The KNK analogue 402 was obtained following Protocol H using piperonal (0.45 g, 3.0 
mmol) and rhodanine (0.40 g, 3.0 mmol) in anhydrous tetrahydrofuran (5 cm3). 
Recrystallization from acetone afforded 402 as a yellow powder (0.52 g, 1.95 mmol, 65%); 
m.p. 292 - 293°C; R f  0.10 (Si02, ethyl acetate:hexane 1:1); VmaxXcm'1) 3158 (broad m), 3051 
(m), 2913 (m), 2833, 1691, 1582, 1501, 1431, 1371, 1264, 1223, 1035, 920, 803, 665; 6 !H 
NMR (400 MHz; d6-DMSO; ppm) 6.13 (2H, s, H-2” ), 7.08 (1H, d, J  8.0 Hz, H-4” ), 7.11 
(1H, d, J  1.9 Hz, H-7” ), 7.15 (1H, dd, J  1.9 Hz, J  8.0 Hz, H-5” ), 7.56 (1H, s, H -l’), 13.81 
(1H, br. s, NH-3); 8,3C (100MHz; d6-DMSO; ppm) 102.84 (s, CH2), 110.01 (s, CH), 110.19 
(s, CH), 123.57 (s, C), 127.39 (s, CH), 127.84 (s, C), 132.60 (s, CH), 149.00 (s, C), 150.36 (s, 
C), 170.05 (s, CO), 196.04 (s, CS).
(Z)-5-(2,4-Dichlorobenzylidene)-2-thioxothiazolidin-4-one 403359
The KNK analogue 403 was obtained following Protocol H using 2,4-dichlorobenzaldehyde 
(0.53 g, 3.0 mmol) and rhodanine (0.40 g, 3.0 mmol) in anhydrous tetrahydrofuran (5 cm3). 
Recrystallization from acetone afforded 403 as a light orange solid (0.38 g, 1.3 mmol, 44%); 
m.p. 230 -  231 °C; R f  0.37 (Si02, ethyl acetate:hexane 1:3); Vmaxfcrn'1) 3100, 2924, 2847, 
1734, 1592, 1578, 1467, 1444, 1412, 1234, 1153, 1108,803,773,734,684,669; 6*HNMR 
(400 MHz; d6-DMSO; ppm) 7.51 (1H, d, J  8.7 Hz, H-6” ), 7.58 (1H, dd, J  1.9, 8.7 Hz, H- 
5” ), 7.64 (1H, s, H -l’), 7.82 (1H, d, J  1.9 Hz, H-3” ); 5,3C (100MHz; d6-DMSO; ppm) 
125.38 (s, CH), 129.17 (s, CH), 130.53 (s, C), 130.60 (s, C), 130.70 (s, CH), 131.08 (s, CH),
136.30 (s, C), 136.38 (s, C), 169.99 (s, CO), 196.04 (s, CS).
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(Z)-5-(5-Bromo-2-methoxybenzylidene)-2-thioxothiazolidin-4-one 404
OMe
404
The KNK analogue 404 was obtained following Protocol H using 5-bromo-2- 
methoxybenzaldehyde (0.64 g, 3.0 mmol) and rhodanine (0.40 g, 3.0 mmol) in anhydrous 
tetrahydrofuran (5 cm3). Recrystallization from acetone afforded 404 as orange flakes (0.51 
g, 1.6 mmol, 52%); m.p. 262 - 263°C; R f  0.22 (Si02, ethyl acetate:hexane 1:3); VmaxXcm'1) 
3140, 3029, 2857, 1694, 1577, 1478, 1454, 1253, 1229, 1186, 815; 6 *H NMR (400 MHz; 
d6-DMSO; ppm) 3.90 (3H, s, OCH3), 7.13 (1H, d, J 8.4 Hz, H-3” ), 7.48 (1H, d, J2 .5  Hz, H- 
6” ), 7.62 -  7.68 (2H, m, H-4” & H -l’) 13.85 (1H, br s, NH-3); 5,3C (100MHz; d6-DMSO; 
ppm) 56.82 (s, CH3), 113.5 (s, C), 114.99 (s, CH), 124.35 (s, C), 125.77 (s, CH), 128.15 (s, 
C), 132.37 (s, CH), 135.55 (s, CH), 157.76 (s, C), 170.24 (s, CO), 196.52 (s, CS); m/z(API- 
ES+) 330 (MH+, 100%), 332 (MH+, 100%); HRMS found [MH]+ 329.92554 for 
C,iH9BrN02S2, Ci,H9BrN02S2requires [MH]+ 329.92526.
(Z)-5-(4-Methoxybenzylidene)-2-thioxothiazolidin-4-one 405324,360
405
The KNK analogue 405 was obtained following Protocol H using /?-anisaldehyde (0.34 cm ,
3.0 mmol) and rhodanine (0.40 g, 3.0 mmol) in anhydrous tetrahydrofuran (5 cm3). 
Recrystallization from acetone afforded 405 as light orange crystals (0.50 g, 2.0 mmol, 66%); 
m.p. 254 -  255 °C; R f  0.22 (Si02, ethyl acetate:hexane 1:3); Vmax^cm'1) 3127, 2923, 2851, 
1683, 1582, 1563, 1507, 1443, 1421, 1258, 1237, 1197, 1168, 821; 5 *H NMR (400 MHz; 
d6-DMSO; ppm) 3.83 (3H, s, OCH3), 7.11 (2H, d, J  9.0 Hz, H-3” & H-5” ), 7.56 (2H, d, J
9.0 Hz, H-2” & H-6” ), 7.61 (1H, s, H -l’), 13.75 (1H, br. s, NH-3); 513C (100MHz; d6- 
DMSO; ppm) 56.25 (s, CH3), 115.78 (s, CH), 122.97 (s, C), 126.17 (s, C), 132.52 (s, CH), 
133.37 (s, CH), 162.01 (s, C), 170.21 (s, CO), 196.24 (s, CS).
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(Z)-5-(3,5-Dimethoxybenzylidene)-2-thioxothiazolidin-4-one 406
NH3
MeO 406
The KNK analogue 406 was obtained following Protocol H using 3,5-dimethoxybenzaldehde 
(0.50 g, 3.0 mmol) and rhodanine (0.40 g, 3.0 mmol) in anhydrous tetrahydrofuran (5 cm3). 
Recrystallization from acetone afforded 406 as a orange solid (0.53 g, 1.9 mmol, 63%); m.p. 
257 -  259°C; R f  0.22 (Si02, ethyl acetate:hexane 1:3); VmaxXcrn’1) 3190, 3140, 3065, 2833, 
1712, 1597, 1482, 1439, 1204, 1156, 981, 740; 5 *H NMR (400 MHz; d6-DMSO; ppm) 3.79 
(6H, s,OCH3), 6.63(1 H , t , J 2.1 Hz H-4” ), 6.71 (2H ,d,J2.1 Hz, H-2” & H-6” ), 7.55 (1H, 
s, H -l’), 13.82 (1H, br. s, NH-3); 813C (100MHz; d6-DMSO; ppm) 56.15 (s, CH3), 103.48 (s, 
CH), 108.74 (s, CH), 126.95 (s, C), 132.17 (s, CH), 135.52 (s, C), 161.56 (s, C), 170.16 (s, 
CO), 196.36 (s, CS); m/z(API-ES+) 282 (MH+, 100%); HRMS found [MH]+ 282.02487 for 
Ci2H12N 03S2, Ci2Hj2N 03S2 requires [MH]+ 282.02531.
(Z)-5-(3,4,5-Trimethoxybenzylidene)-2-thioxothiazolidin-4-one 407361
MeO 4
The KNK analogue 407 was obtained following Protocol H using 3,4,5- 
trimethoxybenzaldehde (0.59 g, 3.0 mmol) and rhodanine (0.40 g, 3.0 mmol) in anhydrous 
tetrahydrofuran (5 cm3). Recrystallization from acetone afforded 407 as orange crystals (0.37 
g, 1.2 mmol, 40%); m.p. 192 -  194 °C; R f  0.15 (Si02, ethyl acetate:hexane 1:3); VmaxXcrn*1) 
3140,2923,2853, 1687, 1595, 1571, 1498, 1454, 1416, 1299, 1216, 1128, 1067,991,823; 5 
‘H NMR (400 MHz; d6-DMSO; ppm) 3.71 (3H, s, OCH3), 3.82 (6H, s, OCH3), 6.88 (2H, s, 
H-2” & H-6” ), 7.57 (1H, s, H -l’), 13.80 (1H, br. s, NH-3); 8,3C (100MHz; d6-DMSO; 
ppm) 56.71 (s, CH3), 60.91 (s, CH3), 108.62 (s, CH), 125.04 (s, C), 129.13 (s, C), 132.69 (s, 
CH), 140.41 (s, C), 153.94 (s, C), 170.03 (s, CO), 196.19 (s, CS).
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(Z)-5-(2,4,6-Trimethoxybenzylidene)-2-thioxothiazolidin-4-one 408
408
The KNK analogue 408 was obtained following Protocol H using 2,4,6- 
trimethoxybenzaldehde (0.59 g, 3.0 mmol) and rhodanine (0.40 g, 3.0 mmol) in anhydrous 
tetrahydrofuran (10 cm3). Recrystallization from acetone afforded 408 as a light 
orange/brown solid (0.76 g, 2.4 mmol, 81%); m.p. 260 -  262 °C; R f  0.12 (SiC>2 , ethyl 
acetate-.hexane 1:3); VmaxXcrn'1) 3055, 2977, 2935, 2852, 1704, 1682, 1607, 1561, 1461, 
1440, 1202, 1179, 1157, 1121; 6 !H NMR (400 MHz; d6-DMSO; ppm) 3.84 (3H, s, OCH3), 
3.86 (6H, s, OCH3), 6.29 (2H, s, H-3”  & H-5” ), 7.79 (1H, s, H -l’), 13.37 (1H, br. s, NH-3); 
813C (100MHz; d6-DMSO; ppm) 56.51 (s, CH3), 91.77 (s, CH), 104.4 (s, C), 123.02 (s, C),
126.47 (s, CH), 160.67 (s, C), 165.65 (s, C), 170.61 (s, CO), 197.92 (s, CS); m/z(API-ES+) 
312 (MH+, 100%); HRMS found [MH]+ 312.03590 for C i 3 H 1 4 N 0 4 S 2 ,  C i 3 H i 4 N 0 4 S 2  requires 
[MH]+312.03588.
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0 ( 4 )
C(9)'
0 C ( 1 8 )£ ( 6 )
C (1)C(5) C(11x :(io ] lc ( 17)0 ( 3 ) (^12) ,C (19)
C (1 3 f
|C (2) 0 (1 6 )0 (1 4 ]C (20) 0 ( 5 )0 ( 4 ) C (25)|
»(2 )0 ( 8]
-(2 1 )
0 (2 4 ]
C(22)0 (7 )'
0 (2 3 )'
0 (6)
C (26)
T able 1. Crystal data and structure refin em ent 
Identification cod e  
Em pirical form ula  
Form ula w eigh t 
Temperature 
W avelength  
Crystal system  
Space G roup  
U nit ce ll d im en sion s
V olu m e
Z
D ensity  (calcu lated) 
A bsorption coe ffic ien t  
F (0 0 0 )
Crystal s ize
Theta range for data co llec tio n  
Index ranges 
R eflection  co llec ted  
Independent reflections  
A bsorption  correction  
R efinem ent m ethod  
Data /  restraints /  param etres 
G o o d n ess-o f-fit  on  FA2  
Final R in d ices [I> 2sigm a  (I)] 
R in d ices (a ll data)
E xtinction  co e ff ic ien t  
Largest d iff. peak  and h o le
for 03L aw rence4  (1 7 3 )
03L aw rence4
C 26  H 26 0 6
4 3 4 .4 7
150 (2 ) K
0 .7 1 0 7 3
M on oclin ic
P 2 ( l ) / c
a =  1 5 .8047  (4 ) A  alpha =  90  deg. 
b =  6 .8 7 2 5  (2 )  A  beta = 103 .7263  (1 0 ) deg. 
c =  2 1 .6 2 9 5  ( 8 ) A  gam m a =  90  deg. 
2 2 8 2 .2 5 (1 2 )  A A3 
4
1 .264  M g/m A3 
0 .0 8 9  m m A- l  
9 2 0
0 .3 0  x 0 .1 0  x 0 .0 8  mm  
3 .1 2  to  2 7 .5 2  deg.
-2 0 < = h < = 2 0 , - 8 < = k < = 8 , -27<=1<=28  
16881
5191 [R (int) =  0 .0 7 4 6 ]
'm ulti-scan'
Full-m atrix least-squares on FA2
5 1 9 1 / 0 / 2 9 5
1.039
R1 = 0 .0 5 1 7 , w R 2 =  0 .1221  
R1 = 0 .0 8 8 5 ,  w R 2 =  0 .1 4 0 0  
0 .0 2 0 3  (1 9 )
0 .2 3 6  a n d -0.221 e .A A-3
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T able 1
0 (4 ) ,0(18)
£ ( 12) £ ( 1 7 )
W 16 > 0 (5 )
£ 0°)£(9)
C(13)
0 (5 ) ’0(11)’0 ( 1)
0 (1 5 ) £ ( 1 9 )
|y—o
.14)0 ( 3 )
.0 (20 )C(8)|
■574) t ( 3 )
0 (2 5 )
0 (2 )
.0 (2 4 )
'C(23)
lN(D
■0(27)
0 (2 6 }
Crystal data and structure refinem ent 
Identification  cod e  
Em pirical form ula  
Form ula w eigh t  
Tem perature 
W avelength  
Crystal system  
Space G roup  
U nit c e ll d im en sion s
V olu m e
Z
D en sity  (ca lcu lated) 
A bsorption  co effic ien t  
F(000)
C rystal s ize
T heta range for data co llec tion  
Index ranges 
R eflection  co llec ted  
Independent reflection s  
M ax. and m in. transm ission  
R efinem ent m ethod  
D ata /  restraints /  param etres 
G ood n ess-o f-fit on FA2 
Final R in d ices [I> 2sigm a (I)] 
R ind ices (a ll data)
A bsolu te structure parametre 
E xtinction  coe ffic ien t  
Largest d iff. peak and hole
for 03L aw rence2 (1 7 5 )  
s92
C 27 H 29 N 0 5
447.51
150(2) K
0 .7 1 0 7 3
Orthorhom bic
P2 ( 1 ) 2 ( 1 ) 2 ( 1 )
a =  7 .2683  (2 ) A  alpha =  9 0  deg.
b =  1 3 .9 3 1 7 (4 )  A  beta =  90  deg.
c  =  2 2 .9 0 5 5  (7 )  A  gam m a = 90  deg.
2319 .41  (1 2 ) A A3
4
1.282 M g/m A3 
0 .0 8 8  m m A- l  
952
0 .3 8  x  0 .35  x  0 .3 0  m m
2 .9 2  to  2 7 .4 9  deg.
-7< = h < 9 , -1 7 < = k < 1 8 , -29<=1<29  
12133
5 0 7 8  [R (int) =  0 .0 7 4 3 ]
0 .9741  and 0 .9673  
Full-m atrix least-squares on FA2 
5078  /  0 / 3 0 5  
1.021
R1 = 0 .0 5 6 4 , w R 2 =  0 .1 1 6 4  
R1 = 0 .0 9 1 9 ,  w R 2 =  0 .1 3 0 8  
-0 . 1( 12)
0.0111  (15 )
0 .2 2 7  and -0 .272  e .A A-3
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0 (4 )
C(20)
SC(6)
( 10,
C(5’ fC(11)
0 (3 ) C(1)
C ( 1 2 j X ^ y  S>LC(181C(2)C(4V
C(17)
C(8)i C(3) C(14)O 0(2)
c<15)ooT 0(19)
(^7)
Table 1. Crystal data and structure refinem ent 
Identification code  
Em pirical form ula  
Formula w eigh t  
Temperature 
W avelength  
Crystal system  
Space Group  
U nit ce ll d im ensions
V olum e
Z
D ensity  (calcu lated) 
A bsorption coeffic ien t  
F (0 0 0 )
C rystal size
Theta range for data co llec tion  
Index ranges 
R eflection  co llec ted  
Independent reflections  
M ax. and m in. transm ission  
R efinem ent m ethod  
Data /  restraints /  parametres 
G o o d n ess-o f-fit on FA2 
Final R in d ices [I> 2sigm a (I)] 
R ind ices (all data)
E xtinction  coe ffic ien t  
Largest d iff. peak and hole
for 03 L aw rence 1 (1 8 2 )  
s92
C 27 H 29  N  0 5
447 .51  
150(2) K 
0 .7 1 0 7 3  
O rthorhom bic 
P2 ( 1 ) / c
a =  1 1 .5 1 0 6 (3 )  A  
b =  14.2603  (4 ) A
alpha =  90  deg. 
beta =  93 .263  (2 ) deg.
c  =  10 .5117  (3 ) A  gam m a =  90  deg. 
1722 .64  ( 8 ) A A3 
4
1 .320  M g/m A3 
0 .0 9 4  m m A- l  
728
0 . 2 2  x  0 . 2 0  x  0 .1 8  m m  
2 .93  to  2 7 .4 6  deg.
-1 4 < = h < 1 4 , -1 8 < = k < 1 8 , -13<=1<13  
18706
3905  [R (int) =  0 .0828 ]
0 .9 8 3 2  and 0 .9675  
Full-m atrix least-squares on FA2 
3905  /  0 /  232  
1.019
R1 = 0 .0 4 8 6 , w R 2 =  0 .1 1 7 8  
R1 = 0 .0 7 8 4 , w R 2 =  0 .1 3 5 2  
0 .0 1 9 (2 )
0 .263  and -0 .326  e .A A-3
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Table 3. Bond length [A] and angles [deg] for 03Lawrencel (182)
0 (1 ) -C (3 ) 1 .366  (2 ) 0 (1 ) -C (7 ) 1 .4 2 9 (2 )
0 (2 ) -C (4 ) 1.382 (2 ) 0 (2 ) -C (8 ) 1.420 (2)
0 (3 ) -C (5 ) 1 .370  (2 ) 0 (3 ) -C (9 ) 1 .4 2 8 (2 )
O (4 )-C (10 ) 1 .2 3 0 (2 ) 0 (5 ) -C (1 6 ) 1.375 (2)
0 (5 ) -C (1 9 ) 1.421 (2 ) C (l) -C (2 ) 1.393 (2)
C ( l) -C ( 6 ) 1 .394  (2 ) C (l) -C (1 0 ) 1.507 (2)
C (2 )-C (3 ) 1.393 (2 ) C (3)-C (4) 1.398 (2)
C (4 )-C (5 ) 1 .393 (2 ) C (5)-C (6) 1.391 (2)
C ( 1 0 ) - C ( l l ) 1 .479 (2 ) C (1 1 )-C ( 12) 1.345 (2)
C (1 1 )-C (2 0 ) 1 .5 1 2 (2 ) C (12 )-C (13 ) 1 .466 (2)
C (1 3 )-C (1 8 ) 1 .394 (2 ) C (13 )-C (14 ) 1.406 (2)
C (1 4 )-C (1 5 ) 1.378 (3 ) C (15 )-C (16 ) 1.390 (2)
C (1 6 )-C (1 7 ) 1.393 (2 ) C (17 )-C (18 ) 1.389 (2)
C (3 ) -0 ( l) - C ( 7 ) 1 1 7 .8 4 (1 3 ) C (4 )-0 (2 )-C (8 ) 1 1 4 .2 9 (1 3 )
C (5 )-G (3 )-C (9 ) 1 1 7 .8 7 (1 3 ) C (1 6 )-0 (5 )-C (1 9 ) 1 1 8 .1 9 (1 4 )
C (2 )-C (l)-C (6 ) 1 2 0 .9 4 (1 5 ) C (2 )-C (l)-C (1 0 ) 120.43 (15)
C (6 )-C ( 1 )-C ( 10) 1 1 8 .3 0 (1 4 ) C (3 )-C (2 )-C (l) 1 1 9 .1 7 (1 5 )
0 (1 ) -C (3 )-C (2 ) 124.91 (15 ) 0 (1 )-C (3 )-C (4 ) 1 1 4 .8 9 (1 4 )
0 (2 ) -C (3 )-C (4 ) 1 2 0 .2 0 (1 5 ) 0 (2 )-C (4 )-C (5 ) 1 1 9 .0 9 (1 5 )
0 (2 ) -C (4 )-C (3 ) 1 2 0 .7 7 (1 5 ) C (5 )-C (4 )-C (3 ) 120.05 (14)
0 (3 ) -C (5 )-C (6 ) 1 2 4 .9 2 (1 5 ) 0 (3 )-C (5 )-C (4 ) 1 1 5 .0 7 (1 4 )
C (6 )-C (5 )-C (4 ) 120.01 (15 ) C (5 )-C (6 )-C (l) 1 1 9 .5 6 (1 5 )
0 (4 ) -C (  10)-C ( 11) 1 2 0 .6 0 (1 5 ) O (4 )-C (1 0 )-C (l) 1 1 7 .8 0 (1 5 )
C ( l l ) -C (1 0 ) - C ( l ) 1 2 1 .6 0 (1 4 ) C (1 2 )-C (l 1)-C (10) 1 1 9 .0 5 (1 4 )
C (1 2 )-C (l 1)-C (20) 1 2 4 .9 3 (1 6 ) C (1 0 )-C (l 1 )-C (20) 115.41 (14)
C (1 1 )-C ( 12 )-C ( 13) 1 2 7 .9 4 (1 5 ) C (1 8 )-C (1 3 )-C (1 4 ) 1 1 6 .9 2 (1 6 )
C (18 )-C (1 3 )-C (1 2 ) 1 2 4 .3 2 (1 5 ) C (1 4 )-C (1 3 )-C (1 2 ) 1 1 8 .7 2 (1 5 )
C (1 5 )-C (1 4 )-C (1 3 ) 1 2 1 .7 2 (1 6 ) C (1 4 )-C (1 5 )-C (1 6 ) 1 2 0 .2 0 (1 6 )
0 (5 ) -C (1 6 )-C (1 5 ) 1 1 5 .7 9 (1 5 ) 0 (5 )-C (1 6 )-C (1 7 ) 124.41 (16)
C (1 5 )-C (1 6 )-C (1 7 ) 1 1 9 .7 7 (1 6 ) C (1 8 )-C (1 7 )-C (1 6 ) 1 1 9 .3 3 (1 6 )
C (1 7 )-C (1 8 )-C (1 3 ) 1 2 2 .1 7 (1 5 )
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C(3)
0(5)0(3)
C(19)
C(15)kC(7)
,0 (6)£(14)
C(8)C(6)
rC(16)
,C(9)0(5),
0(1 C(12)C(10)C(4)
C(18)
0 (1) 0(4)
Table l. Crystal data and structure
Identification code
Empirical formula
Formula w eight
Temperature
W avelength
Crystal system
Space group
Unit cell dim ensions
Volum e
Z
Density (calculated)
Absorption coefficient 
F(OOO)
Crystal size
Theta range for data collection  
Index ranges 
Reflections collected  
Independent reflections 
Com pleteness to theta =  27.50°  
Absorption correction  
M ax. and min. transmission
Refinem ent method
Data /  restraints /  parametres
G oodness-of-fit on F^
Final R indices [I>2sigm a(I)]
R indices (all data)
Largest diff. peak and hole
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refinement for njl0403 (209).
njl0403
C 19 H 18 0 6  
342.33  
150(2) K 
0.71073 A 
M onoclinic 
P 21/n
a =  10.1965(4) A a = 90°.
b =  6 .5167(2) A (3= 101.484(2)°
c =  24 .6468(9) A y = 90°.
1604.93(10) A3 
4
1.417 M g/m 3
0.106  mm'*
720
0.18 x 0.18 x 0 . 1 0  mm 3
2.92 to 27.50°.
-13<=h<= 12, -7<=k<=8, -31 <=1<=31 
11803
3664  [R(int) =  0.0911]
99.1 %
Semi-empirical from equivalents 
0.9895 and 0.9812
Full-matrix least-squares on F^
3664 / 0 / 2 2 9
1.014
R1 = 0 .0 6 1 5 , wR2 =  0.1411 
R1 = 0 .1 1 2 4 , wR2 =  0.1664
0.313 and -0 .3 1 2 e .A -3
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Table 2. A tom ic coord inates ( x  1 0 ^ ) and equivalent isotropic d isplacem ent parametres (A ^x 1(P ) 
for nj10403 (209 ). U (eq ) is d efined  as one third o f  the trace o f  the orthogonalized  LJO tensor.
X y z U (eq )
C (1) 6 3 1 7 (3 ) -1 3 0 1 9 (4 ) 10158(1) 2 6 (1 )
C (2) 2 5 9 9 (3 ) -1 2 4 6 6 (4 ) 880 4 (1 ) 31 (1 )
C (3) 3 5 8 3 (3 ) -7 2 0 2 (4 ) 7 7 2 9 (1 ) 34 (1 )
C (4) 6 5 5 6 (2 ) -9 6 0 6 (3 ) 9 4 9 6 (1 ) 2 1 ( 1 )
C (5) 5 6 1 9 (2 ) -1 1 1 4 7 (3 ) 9 3 2 2 (1 ) 2 0 ( 1 )
C (6 ) 4 7 1 2 (2 ) -1 0 9 4 8 (3 ) 881 9 (1 ) 2 0 ( 1 )
C (7 ) 4 6 8 2 (2 ) -9 1 3 9 (3 ) 8 5 1 3 (1 ) 2 1 ( 1 )
C ( 8 ) 5 6 2 9 (2 ) -7 6 1 2 (3 ) 8 6 7 8 (1 ) 2 1 ( 1 )
C (9) 6 5 7 6 (2 ) -78 6 2 (3 ) 9 1 7 0 (1 ) 2 0 ( 1 )
C (10) 7 6 4 7 (2 ) -6 3 1 5 (3 ) 9 3 7 5 (1 ) 2 1 ( 1 )
C ( l l ) 7 9 1 6 (2 ) -4 6 3 7 (3 ) 9 0 0 9 (1 ) 23 (1 )
C (12) 8 8 6 3 (2 ) -3 2 5 2 (3 ) 9 1 8 7 (1 ) 2 2 ( 1 )
C ( 13) 9 2 3 0 (2 ) -1 4 8 3 (3 ) 8 8 8 5 (1 ) 2 0 ( 1 )
C( 14) 8 7 7 9 (2 ) -1 2 5 3 (3 ) 8 3 0 9 (1 ) 2 3 (1 )
C (15) 9 1 1 9 (2 ) 5 11 (3 ) 8 0 7 4 (1 ) 2 2 ( 1 )
C (16) 9 8 6 9 (2 ) 2 0 4 7 (3 ) 8 3 7 8 (1 ) 2 4 (1 )
C ( 17) 1 0 333 (3 ) 1878(4) 8 9 3 8 (1 ) 2 5 (1 )
C (18) 10004 (2 ) 70 (4 ) 9 1 8 4 (1 ) 2 4 (1 )
C (19) 9 5 3 9 (3 ) 2 9 4 1 (4 ) 7 4 9 0 (1 ) 3 5 (1 )
0 ( 1 ) 5 5 1 0 (2 ) -1 2 8 9 8 (2 ) 9 6 1 2 (1 ) 2 5 (1 )
0 ( 2 ) 3 8 5 7 (2 ) -1 2 5 4 4 (2 ) 8 6 2 4 (1 ) 2 5 (1 )
0 ( 3 ) 3 6 9 6 (2 ) -9 0 5 0 (2 ) 8 0 4 4 (1 ) 2 6 (1 )
0 ( 4 ) 8 3 1 2 (2 ) -6 4 8 8 (2 ) 9 8 4 8 (1 ) 2 7 (1 )
0 ( 5 ) 8 7 7 1 (2 ) 1 1 1 2 ( 2 ) 7 5 2 4 (1 ) 32 (1 )
0 ( 6 ) 10025(2 ) 3 6 6 9 (3 ) 8 0 3 9 (1 ) 3 4 (1 )
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Table 3. Bond lengths [A] and angles [°] for nj10403 (209).
C (1 )-0 (1 ) 1 .433 (3 )
C (1)-H (1A ) 0 .9 8 0 0
C (1)-H (1B ) 0 .9 8 0 0
C (1)-H (1C ) 0 .9 8 0 0
C (2 )-0 (2 ) 1 .438(3 )
C (2)-H (2A ) 0 .9 8 0 0
C (2 )-H (2B ) 0 .9 8 0 0
C (2)-H (2C ) 0 .9 8 0 0
C (3 )-0 (3 ) 1 .425(3 )
C (3 )-H (3 A ) 0 .9 8 0 0
C (3 )-H (3 B ) 0 .9 8 0 0
C (3)-H (3C ) 0 .9 8 0 0
C (4 )-C (5 ) 1 .393(3 )
C (4)-C (9) 1 .394(3 )
C (4)-H (4) 0 .9 5 0 0
C ( 5 ) - 0 ( l ) 1 .363(3 )
C (5)-C (6) 1 .397(3 )
C (6 ) -0 (2 ) 1 .380(3 )
C (6)-C (7) 1 .397(3 )
C (7 )-0 (3 ) 1 .374(3 )
C (7)-C (8) 1 .390(3 )
C (8)-C (9) 1 .400(3 )
C ( 8 )-H ( 8 ) 0 .9 5 0 0
C (9 )-C (10 ) 1 .498(3 )
C (10 )-O (4 ) 1 .231(3)
C (1 0 ) -C ( l l ) 1 .478(3 )
C (1 1 )-C ( 12) 1 .330(3 )
C (1 1 )-H ( 1 1 ) 0 .9 5 0 0
C (12 )-C (13 ) 1 .460(3)
C (12)-H (12) 0 .9 5 0 0
C (13 )-C (18 ) 1 .399(3 )
C (13 )-C (14 ) 1 .412(3 )
C (14)-C (15) 1 .362(3 )
C (14 )-H (14 ) 0 .9 5 0 0
C (15 )-C (16 ) 1 .385(3 )
C (1 5 )-0 (5 ) 1 .387(3 )
C (16 )-C (17 ) 1 .372(3 )
C (1 6 )-0 (6 ) 1 .376 (3 )
C (17 )-C (18 ) 1 .396(3 )
C (17 )-H (17 ) 0 .9 5 0 0
C (18 )-H (18 ) 0 .9 5 0 0
C (1 9 )-0 (6 ) 1 .426(3 )
C (1 9 )-0 (5 ) 1 .438(3 )
C ( 19)-H ( 19A ) 0 .9 9 0 0
C (1 9 )-H (1 9 B ) 0 .9 9 0 0
0 (1 ) -C (1 )-H (1 A ) 109.5
0 (1 ) -C (1 )-H (1 B ) 109.5
H(1 A )-C (1 )-H (1 B ) 109.5
0 (1 )-C (1 )-H (1 C ) 109.5
H (1A )-C (1 )-H (1C ) 109.5
H (1B )-C (1)-H (1C ) 109.5
0 (2 )-C (2 )-H (2 A ) 109.5
0 (2 )-C (2 )-H (2 B ) 109.5
H (2A )-C (2)-H (2B ) 109.5
0 (2 )-C (2 )-H (2 C ) 109.5
H (2A )-C (2)-H (2C ) 109.5
H (2B )-C (2)-H (2C ) 109.5
0 (3 )-C (3 )-H (3 A ) 109.5
0 (3 )-C (3 )-H (3 B ) 109.5
H (3A )-C (3)-H (3B ) 109.5
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0 (3 )-C (3 )-H (3 C ) 109.5
H (3A )-C (3)-H (3C ) 109.5
H (3B )-C (3)-H (3C ) 109.5
C (5)-C (4)-C (9) 119 .9 (2 )
C (5)-C (4)-H (4) 1 2 0 . 1
C (9)-C (4)-H (4) 1 2 0 . 1
0 (1 )-C (5 )-C (4 ) 124 .4 (2 )
0 (1 )-C (5 )-C (6 ) 115 .7 (2 )
C (4 )-C (5 )-C (6 ) 119 .9 (2 )
0 (2 ) -C (6 )-C (5 ) 1 1 9 .94 (19 )
0 (2 ) -C (6 )-C (7 ) 120 .3 (2 )
C (5 )-C (6 )-C (7 ) 119 .8 (2 )
0 (3 ) -C (7 )-C (8 ) 124 .5(2)
0 (3 ) -C (7 )-C (6 ) 115 .0 (2 )
C (8 )-C (7 )-C (6 ) 120 .5 (2 )
C (7 )-C (8 )-C (9 ) 119 .3(2)
C (7 )-C (8 )-H (8 ) 120.3
C (9 )-C (8 )-H (8 ) 120.3
C (4 )-C (9 )-C (8 ) 120 .4 (2 )
C (4)-C (9)-C ( 10) 116 .6 (2 )
C (8)-C (9)-C ( 10) 123 .0 (2 )
O (4 )-C (1 0 )-C (l 1) 1 2 0 .8 ( 2 )
O (4 )-C (10 )-C (9 ) 119 .0 (2 )
C ( ll) -C (1 0 )-C (9 ) 120 .16(19)
C (1 2 )-C (l 1 )-C (10) 1 2 0 .8 (2 )
C ( 12 )-C ( 11 )-H ( 11) 119.6
C (1 0 )-C (l 1 )-H (1 1) 119.6
C (1 1 )-C (12 )-C (13 ) 127 .7 (2 )
C (1 1 )-C (12 )-H (12 ) 116.2
C (13 )-C (12 )-H (12 ) 116.2
C (18 )-C (13 )-C (14 ) 119 .3(2)
C ( 18)-C ( 13)-C ( 12) 118 .6 (2 )
C (14 )-C (13 )-C (12 ) 1 2 2 . 1 ( 2 )
C (15 )-C (14 )-C (13 ) 117 .2 (2 )
C (15 )-C (14 )-H (14 ) 121.4
C (1 3 )-C (14 )-H (14 ) 121.4
C( 14)-C ( 15)-C ( 16) 122 .7 (2 )
C (1 4 )-C (1 5 )-0 (5 ) 128 .0 (2 )
C (1 6 )-C (1 5 )-0 (5 ) 109 .2(2)
C (1 7 )-C (1 6 )-0 (6 ) 127 .9 (2 )
C ( 17)-C ( 16)-C ( 15) 121 .9(2)
0 (6 )-C (1 6 )-C (1 5 ) 1 1 0 .2 ( 2 )
C (16 )-C (17 )-C (18 ) 116.1(2)
C (16 )-C (17 )-H (17 ) 121.9
C (18 )-C (17 )-H (17 ) 121.9
C (17 )-C (18 )-C (13 ) 1 2 2 .8 ( 2 )
C (17 )-C (1 8 )-H (1 8 ) 118.6
C (1 3 )-C (1 8 )-H (1 8 ) 118.6
0 (6 ) -C ( 1 9 ) -0 ( 5 ) 108 .01(19)
0 (6 ) -C (  19)-H ( 19A ) 1 1 0 . 1
0 (5 ) -C (  19)-H ( 19A ) 1 1 0 . 1
0 (6 ) -C (  19)-H ( 19 B ) 1 1 0 . 1
0 (5 ) -C (  19 )-H ( 19 B ) 1 1 0 . 1
H( 19 A )-C ( 19 )-H ( 19 B ) 108.4
C (5 )-0 (  1 )-C ( 1) 116.55(18)
C (6 )-0 (2 )-C (2 ) 114.03(17)
C (7 )-0 (3 )-C (3 ) 117.37(18)
C( 15 )-0 (5 )-C ( 19) 104.84(17)
C (1 6 )-0 (6 )-C (1 9 ) 105.08(18)
Sym m etry transform ations used  to generate equivalent atoms:
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Table 4. A nisotropic d isp lacem en t param etres (A 2 x 103 )for njl0403 (209 ). T he anisotropic 
displacem ent factor exp on en t takes the form: -2 : 2 [ h2 a*2 LJl * + ... + 2  h k a* b* u l 2  ]
u n U 2 2 u 3 3 u 2 3 U * 3 u i 2
C (1) 3 0 (2 ) 2 4 (1 ) 2 2 ( 1 ) 3 (1) 2 ( 1 ) -3 (1 )
C (2) 2 5 (2 ) 3 5 (1 ) 35 (2 ) - 1 ( 1 ) 9 (1 ) -7 (1 )
C (3) 4 1 (2 ) 2 9 (1 ) 2 9 (1 ) 8 ( 1 ) -4 (1 ) 0 ( 1 )
C (4) 2 0 ( 1 ) 2 1 ( 1 ) 2 1 ( 1 ) 0 ( 1 ) 4 (1 ) 0 ( 1 )
C (5) 2 1 ( 1 ) 17(1) 2 5 (1 ) H O 1 1 ( 0 3 (1 )
C ( 6 ) 19(1) 19(1) 2 4 (1 ) -4 (1 ) 7 (1 ) - 1 ( 1 )
C (7) 2 0 ( 1 ) 2 2 ( 1 ) 2 1 ( 1 ) - 1 ( 1 ) 5 (1 ) 2 ( 1 )
C ( 8 ) 2 5 (1 ) 17(1) 2 2 ( 1 ) 1 ( 0 7 ( 0 0 ( 1 )
C (9) 2 1 ( 1 ) 2 0 ( 1 ) 2 0 ( 1 ) - 1 ( 1 ) 6 ( 1 ) 2 ( 1 )
C (10) 2 0 ( 1 ) 2 0 ( 1 ) 2 1 ( 1 ) 0 ( 1 ) 4 (1 ) 2 ( 1 )
C ( l l ) 2 4 (1 ) 2 2 ( 1 ) 2 2 ( 1 ) 3 ( 0 5 ( 0 1 ( 0
C ( 12) 2 4 (1 ) 2 2 ( 1 ) 2 0 ( 1 ) 0 ( 1 ) 5 ( 0 K O
C (13) 18(1) 2 0 ( 1 ) 2 3 (1 ) 2 ( 1 ) 5 (1 ) 0 ( 1 )
C ( 14) 2 0 ( 1 ) 2 2 ( 1 ) 2 6 (1 ) - 2 ( 1 ) 4 (1 ) - 2 ( 1 )
C (15) 2 1 ( 1 ) 2 4 (1 ) 2 1 ( 1 ) 3 ( 0 4 (1 ) 2 ( 1 )
C (16) 2 4 (1 ) 19(1) 30 (1 ) 5 ( 0 9 (1 ) -K O
C (17) 2 6 (1 ) 2 2 ( 1 ) 2 7 (1 ) -3 (1 ) 3 ( 0 -3 (1 )
C (18 ) 2 3 (1 ) 2 6 (1 ) 2 3 (1 ) - 1 ( 1 ) 4 (1 ) K O
C (19) 3 3 (2 ) 3 5 (2 ) 3 3 (1 ) 1 0 ( 1 ) 1 ( 0 - 1 0 ( 1 )
0 ( 1 ) 2 8 (1 ) 2 0 ( 1 ) 2 6 (1 ) 4 (1 ) 3 ( 0 -5 (1 )
0 ( 2 ) 2 4 (1 ) 2 1 ( 1 ) 3 0 (1 ) -4 (1 ) 7 (1 ) -4 (1 )
0 ( 3 ) 2 8 (1 ) 2 4 (1 ) 2 3 (1 ) 3 ( 0 - 2 ( 1 ) -K O
0 ( 4 ) 2 8 (1 ) 2 7 (1 ) 2 4 (1 ) 4 (1 ) - 1 ( 1 ) -4 (1 )
0 ( 5 ) 3 7 (1 ) 3 1 (1 ) 2 4 (1 ) 9 (1 ) 1 ( 0 - 8 ( 1 )
0 ( 6 ) 4 3 (1 ) 2 6 (1 ) 3 2 (1 ) 8 ( 0 6 ( 1 ) - 8 ( 1 )
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T able 5. Hydrogen coord inates ( x  IO"*) and isotropic d isplacem ent parametres (A ^x 1(P ) 
for nj 10403 (209).
X y z U (eq)
H (1A ) 7 2 6 4 -13088 10133 38
H (1B ) 6075 -14251 10344 38
H (1C ) 6 1 6 4 -1 1800 10370 38
H (2A ) 2 7 6 0 -12521 92 0 9 47
H (2 B ) 2 0 4 6 -1 3638 8650 47
H (2C ) 2 135 -11187 8675 47
H (3 A ) 3 4 4 9 -6043 7966 51
H (3B ) 2 8 1 8 -7304 7419 51
H (3C ) 4 4 0 4 -6987 7587 51
H (4) 7179 -9743 9 8 3 6 25
H (8) 5633 -6410 8460 26
H( 11) 7407 -4547 8642 27
H (12) 93 5 8 -3436 9553 26
H (14) 8259 -2285 8094 27
H (17) 10848 2931 9 147 30
H (18) 10319 -113 9 5 7 0 29
H (19A ) 10298 2632 7 307 42
H (19B ) 8972 3998 7 269 42
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